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Abstract  
Human papillomavirus (HPV) infection is common in England. Persistent HPV 
infection can cause cervical and other HPV-related cancers. In clinical trials, HPV 
vaccination was found to have very high efficacy against HPV infection and early 
HPV-related disease. The National HPV Immunisation Programme, using HPV16/18 
vaccine, was introduced in the UK in September 2008 for females aged up to 18 
years old. This thesis aims to evaluate the equity and coverage of HPV vaccination 
in England and the population-level impact of the vaccination programme on 
infection and early disease outcomes in young females. 
In this thesis, serological surveillance confirmed high coverage of HPV vaccination 
in the targeted female population. However, surveillance among women at higher 
risk of HPV infection indicated lower coverage among those born outside of the UK, 
from more deprived areas or with a previous diagnosis of chlamydia infection.  
The same higher-risk population was used to investigate a previous ecological 
observation of reduced genital warts diagnoses since the vaccination was 
introduced. I designed and conducted a case-control study to estimate the 
effectiveness of HPV16/18 vaccination against genital warts (which are largely 
caused by HPV6/11). This study found no evidence that HPV16/18 vaccination 
offered cross-protection against warts (adjusted odds ratio (95% CI):1.02 (0.72-
1.45)). 
My analyses of HPV infection surveillance data within the post-vaccination period 
(2010-2016) demonstrated substantial declines in prevalence of HPV16/18 infection 
in 16-18 year olds (8.2% in 2010/2011 compared to 1.6% in 2016) and of 
HPV31/33/45 (6.5% to 0.6%). This work provides evidence of substantial direct 
protection against HPV16/18 and some type-specific cross-protection. It also shows 
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a strong herd protection effect of vaccination. Reassuringly, there was no evidence 
of other non-vaccine types becoming more common.  
The results of this thesis will inform future decisions about changes to the National 
HPV Immunisation Programme and the UK Cervical Screening Programme.  
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Chapter 1: Introduction 
Human papillomavirus (HPV) infection is very common in both men and women in 
England, particularly among younger age-groups. Although a large proportion of 
HPV infections clear on their own without manifesting symptoms, HPV-related 
cancers and genital warts still cause substantial ill health and reduced quality of life 
in those affected. Since effective vaccines became available in 2007, HPV 
vaccination programmes have been introduced in many high-income countries. In 
England, the National HPV Immunisation Programme was introduced in 2008 with 
the primary aim to reduce the incidence of cervical cancer in women. Vaccination is 
offered routinely to females in Year Eight of schooling (those aged 12 years on the 
previous 1st September). Females remain eligible for vaccination up to age 18 years 
old and, in the first two years of the programme, there was also a catch-up 
campaign specifically targeting these older females. In Chapter 2 of this PhD, I 
describe in more detail the epidemiology of HPV infection and related diseases prior 
to the introduction of HPV vaccination. I also describe the licensed HPV vaccines 
and give further details about the roll-out of HPV vaccination in the UK and in other 
parts of the world. 
At the time of the introduction of these vaccination programmes, a reduction in the 
prevalence of the HPV vaccine types was expected to be seen over the following 
years and many countries established surveillance systems to monitor this. 
Evidence of these changes has begun to emerge, and can be used to evaluate past 
decisions and performance and to inform future decisions and implementation. This 
PhD focuses on the impact at a population level of the National HPV Immunisation 
Programme in England. After the Background (Chapter 2), the thesis is separated 
broadly into two parts. In the first part (Chapters 3, 4, 5 and 6) I explore changes in 
the prevalence of HPV infection. In the second part (Chapters 7 and 8) I study the 
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serological response to the vaccine HPV types as a biological marker to estimate 
vaccination coverage. The chapters are summarised briefly below: 
Chapter 3 comprises an international systematic review and meta-analysis of 
changes in non-vaccine HPV types since the introduction of HPV vaccination 
programmes. Through this work I explored whether reductions in vaccine types 
were associated with increases in other HPV types. 
Chapter 4 provides details of the HPV infection surveillance established in England 
to monitor and evaluate the National HPV Immunisation Programme. In this chapter, 
I describe the strengths and limitations of the surveillance data and methods I 
adopted as part of this PhD to strengthen this surveillance and facilitate accurate 
interpretation of the results.  
Chapter 5 details methods to collect individual HPV vaccination records for a subset 
of women included in the HPV infection surveillance. I also present results of a 
validation study to compare vaccination status from different data collection 
systems. 
Chapter 6 presents the results of the HPV infection surveillance described in 
Chapter 4, in which I investigated changes in the prevalence of HPV infection in 
young women in England since the introduction of HPV vaccination.  
In Chapter 7, I describe the data sources and methods used for two surveillance 
studies to monitor HPV antibodies in residual sera specimens and methods to 
ascertain HPV vaccination status using these data. This chapter also includes the 
methods of a nested case-control study which I designed and conducted as part of 
this PhD. This study was designed to explore a previous unexpected ecological 
observation of reductions in the incidence of genital warts associated with 
HPV16/18 coverage. 
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In Chapter 8, I report the analyses of data from these two serology surveillance 
studies to validate HPV vaccination coverage in England and explore variations in 
subgroups of the populations studied. I also present the results and further 
discussion of the nested case-control study that was conducted to estimate the 
effect of vaccination on the incidence of genital warts. 
The final chapter, Chapter 9, includes a discussion of the public health importance 
of these first results showing an impact of HPV vaccination in England. I discuss the 
strengths and limitations of using surveillance data to evaluate HPV vaccination, 
and how this thesis addressed some of these limitations. Finally, I discuss the 
implications of the results and how they inform future public health policies. 
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Chapter 2: Background 
In this chapter I describe the biology and natural history of human papillomavirus 
(HPV) infection and progression from infection to disease. I review the epidemiology 
of HPV and related diseases in the UK. I then describe current HPV vaccines and, 
specifically, the National Immunisation Programme in England. Finally, I explore the 
rationale and methods proposed to monitor and evaluate this national vaccination 
programme.  
2.1. Biology and natural history of HPV infection 
 Human papillomavirus 2.1.1
The Human papillomavirus (HPV) is a non-enveloped, double-stranded DNA virus 
which consists of six early genes (E1, E2, E4, E5, E6 and E7), two late genes (L1 
and L2), and a non-coding long control region (LCR). The HPV genome is circular 
with a capsid, around 55-60 nanometres in size, formed of the L1 proteins 
assembled as 72 star-shaped pentamers (Figure 2.1).  
 
 
Figure 2.1: Structure of human papillomavirus (HPV)  
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There are over 100 types (or strains) of HPV which are grouped into species which 
identify closely related types. These species are further grouped into five genera 
(Alpha-papillomavirus, Beta-papillomavirus, Gamma-papillomavirus, Mu-
papillomavirus and Nu-papillomavirus) (Table 2.1)[1].  
Table 2.1: Classification of human papillomaviruses within genera and 
species 
Genus Species HPV types 
Alpha-papillomavirus 1 32, 42 
 
2 3, 10, 28, 29, 77, 78, 94 
 
3 61, c62, 72, 81, 83, 84, c86, c87, c89 
 
4 2, 27, 57 
 
5 26, 51, 69, 82 
 
6 30, 53, 56, 66 
 
7 18, 39, 45, 59, 68, 70, c85 
 
8 7, 40, 43, c91 
 
9 16, 31, 33, 35, 52, 58, 67 
 
10 6, 11, 13, 44, 55, 74, CCPV, PcPV 
 
11 34, 73 
 
12 RhPV1 
 
13 54 
 
14 c90 
 
15 71 
   Beta-papillomavirus 1 5, 8, 12, 14, 19, 20, 21, 24, 25, 36, 47, 93 
 
2 9, 15, 17, 22, 23, 37, 28, 80 
 
3 49, 75, 76 
 
4 92 
 
5 96 
   Gamma-papillomavirus 1 4, 65, 95 
 
2 50 
 
3 48 
 
4 60 
 
5 88 
   Mu-papillomavirus 1 1 
 
2 63 
   Nu-papillomavirus - 41 
Adapted from de Villiers et al [1] 
25 
 
Since the early 1980s, novel HPV types have been identified using a sequential 
numbering system. Of the HPV types described, approximately 40 infect the genital 
tract. These genital HPV types have been classified by the International Agency for 
Research on Cancer (IARC) into four categories: high-risk, probably high-risk, 
possibly high-risk and low-risk, according to their association with cervical cancer. 
There are 13 HPV types which have been classified as high-risk (16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59) or probably high-risk (68) with a further seven types 
classified as possibly high-risk (26, 53, 66, 67, 70, 73, 82) [2]. Other HPV types, 
classified as low-risk, are associated with genital warts (types 6 and 11; Section 
2.4.3) as well as plantar warts and common and flat warts.  
 Transient and persistent HPV infection 2.1.2
Genital HPV infection is common in both men and women and individuals can be 
infected with a single HPV type or with multiple types. HPV is predominantly 
sexually transmitted, although penetrative intercourse is not essential for 
infection[3]. HPV exclusively infects the epithelium cells of the skin and mucous 
membranes and is thought to infect the basal epithelial cells through micro-
abrasions or other epithelial trauma which expose sections of the basal cells[4]. 
Genital HPV types are found in the cervix, vulva, vagina, penis, anus and rectum. 
The genital types can also invade the mucous membranes of the mouth, tongue and 
throat.  
A current HPV infection can be detected using molecular testing (Section 2.2). HPV 
infection cannot be treated but the majority of men and women infected with HPV 
will be asymptomatic and the infection will clear on its own. Previous studies have 
shown that approximately 50% of high-risk HPV infections will clear within 6 months 
of the initial infection, with 80-90% clearing within 24 months[5-7]. Whilst there is no 
clear biological definition of what constitutes persistent HPV infection, it has been 
shown that women with a high-risk HPV infection which does not clear within 6 
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months are at an increased risk of HPV-related disease, hence this is generally the 
definition used. Persistent high-risk HPV infection of mucosal epithelium can 
progress to intraepithelial neoplasia. If left untreated, intraepithelial neoplasia can 
further progress to high-grade abnormalities and potentially cancer (Section 2.4). 
 Immune response to natural HPV infection 2.1.3
Not all individuals who have a natural HPV infection will seroconvert (i.e. 
subsequently have detectable antibodies) for that particular HPV type. The life cycle 
of HPV infection is limited to the epithelium and there is no viraemia, hence the level 
of HPV in lymphatic channels is very low. Furthermore, as there is no cytolysis or 
necrosis HPV does not cause inflammation and so HPV infections may not provoke 
an antibody response. Seroconversion following a natural HPV infection is more 
common in women than in men. In women, around 50-70% of transient HPV-16 
infections will produce antibodies to the HPV16 L1 protein [8-11] albeit often only a 
weak antibody response. The proportion that seroconverts after a persistent HPV 
infection is higher; one study conducted in a cohort of 588 women showed around 
80% seroconverted after persistent HPV DNA infection with type 16 and 60% with 
HPV 18 [9]. In men, a smaller proportion seroconverts. A study of 156 men showed 
that only 7% with a transient HPV-16 infection and around 20% with a persistent 
HPV-16 infection seroconverted for that HPV type[12]. 
When antibodies are detected after HPV infection, it can take between 3 and 48 
months before this occurs and there is poor correlation between seropositivity and 
current HPV infection [9, 13]. This suggests that these relatively weak antibody 
responses following natural infection are not a key factor in the clearance of the 
infection. Furthermore, it is unclear whether antibody responses elicited from a 
natural HPV infection are sufficient to protect against future reinfection from the 
same type[14, 15] or infections with other closely related types[16].  
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2.2. Testing to detect current HPV infection 
Several technologies are available to detect a current HPV infection. Tests to detect 
high-risk HPV types can be broadly separated by objective into research tests and 
clinical tests. Tests used for research (and/or surveillance) are generally required to 
have a low detection threshold in order to determine HPV presence (and/or to 
identify HPV genotypes) in a particular sample. Clinical tests aim to identify samples 
with high HPV DNA copy numbers, which have been shown to be associated with 
progression to high-grade cervical disease (Section 2.4).   
In this thesis, I focus on research tests for surveillance to monitor HPV prevalence 
in the population. There are two main approaches to detecting specific HPV types, 
which both use polymerase chain reaction (PCR) techniques to amplify HPV DNA 
present in biological specimens.  
(i) Consensus PCR assays (otherwise known as broad spectrum assays) aim 
to amplify multiple mucosal HPV types by targeting a conserved L1 gene. 
Such methods for HPV detection in specimens use various different 
consensus primers with varying sensitivity and specificity. However, in 
specimens with multiple HPV infections these consensus assays may miss 
under-represented HPV types (i.e. those with lower HPV DNA copy 
numbers), as these are masked by types with higher HPV DNA copy 
numbers [17, 18]; the implications of this are explored further in Section 
2.7.3. Following consensus PCR techniques, individual HPV types can be 
identified by sequencing of the amplified DNA. 
(ii) Type-specific PCR assays amplify DNA using a type-specific primer and 
therefore have a higher sensitivity for individual HPV types, even in the 
presence of multiple infections. However, these assays are more expensive 
and laborious, especially if considering testing for many HPV types and, 
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therefore, are not necessarily a suitable approach for large epidemiological 
studies or infection surveillance. 
2.3. HPV infection prevalence and risk factors  
Studies conducted prior to the introduction of HPV vaccination in high-income 
countries have shown prevalence of high-risk HPV infection of 35-45% in the 
younger sexually active age-groups (under 25 years of age) and decreasing 
prevalence with increasing age[19-22]. This age-specific pattern of HPV infection is 
confirmed with data from seroprevalence surveys, which although not accurately 
reflecting the proportion of women with a current infection (Section 2.1.3), show 
exposure to HPV from the age of 14-16 years with an initial peak at around 22-24 
years[23]. Data from other countries have shown worldwide variations in these age-
specific patterns of HPV prevalence, with some Central and South American 
countries having a second peak in HPV prevalence at an older age, and other 
countries having high prevalence across all ages[24].  
As genital HPV infection is almost entirely sexually transmitted, risk factors 
associated with HPV infection of the genital tract tend to be similar to risk factors 
associated with other sexually transmitted infections. Results from a national survey 
of sexual attitudes and lifestyles (Natsal-3) conducted among 16-45 year olds in 
Britain between 2010 and 2012 showed infection with high-risk HPV types in women 
was associated with younger age, not living with a partner, lower socio-economic 
status, increased number of sexual partners, attendance at a Genitourinary 
Medicine (GUM) clinic and/or having a previous sexually transmitted infection (STI) 
diagnosis, smoking and increased alcohol consumption[25]. Another UK study, 
conducted among 2,369 sexually active young women attending for chlamydia 
screening, showed increased HPV prevalence was associated with multiple sexual 
partners and that those with Chlamydia trachomatis infection were more likely to be 
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infected with a high-risk HPV type[19]; the latter finding was not surprising as the 
two infections have been shown to have very similar risk factors[26]. High-risk HPV 
infection has also been shown to be associated with ethnicity. Specifically, in the 
USA, a national survey of 4,150 women aged 14–59 years which was conducted 
between 2003 and 2006, showed non-Hispanic black women had a higher 
prevalence of HPV infection compared to non-Hispanic white women [20] although 
there was less evidence of this after adjustment with other factors (including number 
of sexual partners and poverty index) suggesting that variations in HPV infection by 
ethnicity may be partly explained by differences in sexual behaviour. A national 
survey of 2,569 women conducted in the UK between 2010 and 2012, showed high-
risk HPV prevalence was lower in women of Asian ethnicity[25].  
2.4. HPV-related disease 
 Cervical cancer  2.4.1
Persistent infection with one of the high-risk HPV types is a necessary, but not 
sufficient, cause of cervical cancer [27]. In the cervix, following infection of the basal 
epithelium cells, there is expression of the early HPV genes (E1, E2, E4, E5, E6 and 
E7). As the virus replicates and moves to the surface layer of the epithelium the late 
genes L1 and L2 are expressed. This causes the production of virions which are 
shed internally at the skin surface. Progression to cancer is associated with 
integration of the HPV genome into the host chromosome which causes disruption 
of E2 and leads to overexpression of E6 and E7 oncogenes[28], which in turn 
inactivates the host’s anti-oncogenes p53 and retinoblastoma protein (pRB)[29, 30].  
Progression from a persistent HPV infection to cervical cancer takes many years 
with gradual progression from pre-cancerous low-grade lesions to high-grade 
lesions and eventually to cervical cancer. The median time from high-grade lesion to 
cancer is estimated to be over 20 years[31] although not all pre-cancerous lesions 
progress; some regress without treatment. A large proportion of HPV infections 
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found in cervical cancer are from one of two species of HPV types; α7 and α 9 (α7 
includes HPV18, HPV39, HPV45, HPV59 and HPV 68; α9 includes HPV16, HPV31, 
HPV33, HPV35, HPV52 and HPV58) (Section 2.1.1). HPV16 and 18 are associated 
with at least 70-80% of all cervical cancers[32, 33], 50-65% of all high-grade 
cervical lesions[32, 34] (Figure 2.2) and 25-35% of low-grade cervical lesions[35].  
Figure 2.2: HPV prevalence among cervical cancers and high-grade cervical 
lesions, in England (cases collected between 20001 and 2008[32]) 
 
  SCC = Squamous cell carcinoma; ADC = Adeno and adeno-squamous carcinoma; CGIN = Cervical 
glandular intraepithelial neoplasia; CIN; cervical intraepithelial neoplasia 
1: A small proportion (4%) of cervical cancer cases were collected between 1986 and 2000 
 
Worldwide, cervical cancer is the 4th most common cancer among women with an 
estimated 528,000 new cases of invasive cervical cancer and 266,000 deaths in 
2012[36]. In the UK, the incidence of cervical cancer is lower and is the 13th most 
common cancer among women, with 2,517 cases in 2015 (9.2 cervical cancers per 
100,000 women) and a peak incidence around 25-29 years of age[37] . These data 
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represent cervical cancer incidence prior to any effect of HPV vaccination. The 
lower incidence in the UK and some other high income countries is largely due to 
effective cervical screening (Section 2.5). The introduction of HPV vaccination 
programmes, largely in adolescent women, is expected to reduce the incidence of 
cervical cancer even further as vaccinated females reach the ages at which cervical 
cancer could be diagnosed. 
 Other HPV-related cancers 2.4.2
HPV has also been shown to be associated with, although not a necessary cause 
of, cancers at other sites and it is estimated that around 643,000 (~5%) of all 
cancers worldwide in 2012 were associated with HPV (530,000 from cervical 
cancer, 113,000 other HPV-related cancers)[38] . These cancers include cancer of 
the vulva, vagina, penis, anus and some sites of the upper aerodigestive tract[38-
45]. The population attributable fractions associated with HPV at these sites are 
shown in Figure 2.3. Cancers of the vulva, vagina and penis are less common than 
cervical cancer with 1,081, 197 and 519 cases diagnosed respectively in the UK in 
2015, with a much smaller proportion of these cancers attributable to HPV[37]. 
Cancer of the anus is more common but still has a lower incidence than cervical 
cervical cancer with 853 cases diagnosed in females and 403 cases diagnosed in 
males in the UK in 2015[37]. However, there has been a 130% increase in the 
incidence of anal cancer reported since the mid-1970s[46]. The incidence of anal 
cancer is disproportionately high in men who have sex with men (MSM) with an 
estimated annual incidence of around 5.1 per 100,000 for HIV-negative MSM[47] 
and 45.9 per 100,000 for HIV positive MSM[47]. Finally, data have shown that the 
incidence of cancers of the aerodigestive tract (including oral cavity, oropharynx, 
tonsil and larynx) has also been increasing up to 2015[37]. It has been suggested 
that the cancers which are HPV-related (between 20-30%[44]) are largely 
responsible for this increase[48, 49].  
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Figure 2.3: Proportion of cancers which are related to high-risk HPV infection, 
by cancer site 
 
Penis: Global estimates from systematic review of articles published between 1986 and 2008[41]; 
Anus: cases diagnosed in Europe between 1986 and 2011[40];                                               
Oropharynx (includes cancer of oropharynx and tonsil): cases diagnosed in the UK between 2002 and 
2011[43];                                                                                                                                           
Larynx (includes cancers of the larynx and hypopharynx): European estimates from systematic review 
of articles published up to 2004[44];                                                                                                     
Oral cavity (includes cancer of tongue, gum, floor of mouth, and palate): European estimates from 
systematic review of articles published up to 2004[44];                                                                    
Vulva: Proportion attributable to HPV from global estimates from systematic review of articles 
published between 1986 and 2008[42] / Proportion of HPV positive attributable to HPV16/18 from a 
different systematic review of articles published up to 2007[45];                                                    
Vagina: Proportion attributable to HPV from global estimates from systematic review of articles 
published between 1986 and 2008[42] / Proportion of HPV positive attributable to HPV16/18 from a 
different systematic review of articles published up to 2007[45] 
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2.4.3. Genital warts and recurrent respiratory papillomatosis 
Two low-risk HPV types, types 6 and 11, cause the vast majority of genital warts. 
Whilst genital warts are not usually associated with severe morbidity the demand on 
health services and the loss of patients’ quality of life is considerable. In England, 
there were 35,374 and 27,342 new cases of genital warts diagnosed in 2016 in 
males and females respectively[50]. One study of genital warts seen in sexual 
health clinics (otherwise known as GUM clinics) estimated a quality-adjusted life 
year (QALY) loss equivalent to 6.6 days of healthy life lost per episode of genital 
warts, with an average cost of £94 per episode[51]. 
HPV6 and 11 also cause the rarer but more serious condition of recurrent 
respiratory papillomatosis (RRP), characterised by warty growths in the respiratory 
tract which can lead to breathing difficulties and chronic coughing. Treatment for 
moderate or severe disease has historically been with surgery to debulk the warty 
growths although more recently the use of intralesional cidofovir has been a major 
advance in non-surgical treatment of RRP[52]. A cross-sectional study conducted in 
the UK in 2015 estimated the prevalence of RRP requiring management in 
secondary or tertiary health sector to be approximately 1.4 per 100,000 
population[53]. RRP has a bimodal age distribution. Juvenile onset RRP (JORRP) is 
usually diagnosed in children under 5 years old and is thought to be a caused by 
vertical transmission of HPV. Adult onset RRP (AORRP) is less common and less 
severe. AORRP is usually diagnosed in those aged 30-40 years old and is more 
common in men than women.  
2.5. Secondary prevention: Cervical screening  
Cervical screening programmes have been adopted in many countries, and those 
that have introduced a cervical screening programme which is adequately organised 
(e.g. that includes training for cervical sample takers, quality assurance of the 
programme, call/recall systems to invite women at specified time intervals rather 
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than opportunistic testing) have seen dramatic reductions in the incidence and 
mortality associated with cervical abnormalities and cancer[54-56]. In high-income 
countries, screening programmes have almost exclusively relied on use of the 
Papanicolaou smear test (Pap smear). Subsequent advances have seen the 
introduction of liquid-based cytology (LBC) across many screening programmes 
which involve the collected cells being placed in a preservative rather than on a 
slide. Both Pap smears and LBC aim to detect nuclear abnormalities in the cells of 
the cervix. Even more recently, the use of HPV testing as the primary test in the 
cervical screening programme has been piloted at sites across England and 
recommended to be fully implemented by 2019. HPV testing for high-risk HPV types 
has been shown to be more sensitive than cytology to detect high-grade cervical 
abnormalities, although it is considerably less specific, especially in younger 
women[57, 58]. 
The National Health Service (NHS) Cervical Screening Programme was established 
in England in 1964 with a call/recall system established in 1988 which allowed 
District Health Authorities to invite all eligible women for screening. Women aged 
20-49 were invited for screening at 3-yearly intervals and those ages 50-64 at 5-
yearly intervals. From 2003, the age women were invited for their first cervical 
screen in England was raised from 20 to 25 years. The introduction of HPV testing 
could allow the interval between screens to be extended due to the high long-term 
negative predictive value of the test[59]. 
2.6. Primary prevention: HPV vaccination 
2.6.1. HPV vaccines 
There are currently three prophylactic HPV vaccines which have been licensed by 
the European Medicines Agency (EMA) for use in Europe; Cervarix® 
(GlaxoSmithKlein; GSK) is a bivalent vaccine containing the two high-risk HPV 
types 16 and 18; Gardasil® (MSD Merck) is a quadrivalent vaccine which contains 
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these two high-risk types and additionally against the low-risk types 6 and 11; and 
Gardasil® 9 (MSD Merck) which is a nonavalent vaccine which contains the same 
types as the quadrivalent vaccine as well as an additional 5 high-risk types (31, 33, 
45, 52 and 58).  
These vaccines work in a similar way; the L1 proteins which form the HPV capsid 
are re-produced using insect or yeast cells. These synthesised proteins then form 
L1 pentamers which self-assemble into virus-like particles (VLPs). These VLPs are 
not infectious or oncogenic as they contain no viral DNA but when inoculated 
intramuscularly, elicit a type-specific antibody response which is far greater than 
that elicited by natural infection[60] and is sufficient to protect against future 
infection of these HPV types (Section 2.6.2). As these HPV vaccines are relatively 
new, the duration of the immune response following vaccination is as yet unknown. 
However, data from clinical trials show that HPV antibodies remain for at least 10 
years after vaccination with the bivalent vaccine[61] and 8.5 years after vaccination 
with the quadrivalent vaccine[62] with high antibody levels suggesting that these 
vaccines will generate a longer term immune response. The duration of protection 
for Gardasil 9 is not yet known although data from clinical trials have demonstrated 
non-inferior immune responses for the HPV types included in the quadrivalent 
vaccine[63]. The reason for the enhanced immunogenicity after vaccination 
compared to natural infection is thought to be due to the adjuvants used, the optimal 
dosing schedules and the fact that the vaccines are delivered intramuscularly so 
VLPs can access the lymphatic system and activate B cells and dendritic cells.  
2.6.2. Efficacy of HPV vaccines 
For both the bivalent and quadrivalent vaccine, phase III clinical trials have 
demonstrated 100% vaccine efficacy against HPV16- and HPV18-related pre-
cancerous lesions when administered to HPV-naïve women (i.e. women who were 
HPV DNA negative and seronegative at baseline) compared to a placebo [60, 64]. 
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The quadrivalent vaccine has also been shown to provide almost 100% protection 
against HPV6- and HPV11-associated anogenital warts in HPV naïve males and 
females (with vaccine efficacy of 91.6% against HPV-6 related lesions and 100% 
against HPV-11 related lesions)[65]. The nonavalent vaccine additionally has a high 
vaccine efficacy (96.7% in the per protocol analysis) against HPV-31, 33, 45, 52, 58 
related cervical, vulvar and vaginal disease[63]. 
For all three vaccines, nearly 100% of women will seroconvert after vaccination with 
high HPV antibody titres[63, 66, 67]. However, the vaccine efficacy against disease 
depends on current and previous exposure to HPV infection. HPV vaccination of 
women with a current HPV DNA infection has not been shown to have any effect on 
clearance of the existing infection or reducing progression to disease progression. It 
is not clear whether vaccination has an impact on re-infection with the same HPV 
type among those who were infected at the time of receiving the vaccine. There is 
also some evidence of a slightly reduced protective effect of HPV vaccination 
against pre-cancerous abnormalities among young women currently not infected 
with HPV but with serological evidence of previous exposure[68, 69].  Whilst any 
serological correlates of protection for HPV have yet to be determined, it is thought 
that high concentrations of neutralising antibodies to HPV which are elicited by HPV 
vaccination play an important role in protecting against future HPV infection. 
Serological assays to monitor other immune responses (e.g. IgG antibodies or 
binding antibodies to proteins) following vaccination can be used as a proxy for 
assays measuring HPV-neutralising antibodies and have the benefit of being less 
complex than the neutralising assays and allow high throughput testing.  
Clinical trials with disease endpoints have largely been conducted in young adult 
women receiving a 3-dose schedule of vaccine. Clinical endpoints for women 
vaccinated at younger ages will require longer follow-up, given the time between 
HPV infection and presentation with cervical abnormalities. However, other clinical 
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trials have demonstrated non-inferior immune responses (compared to 3-doses in 
older women) for younger women aged 9-15 years old at vaccination receiving 3 
vaccine doses or 2 vaccine doses (given at least 6 months apart). These 
immunogenicity studies (“immunological bridging studies”) have the benefit of 
shorter follow-up as they consider the endpoint of immune responses following 
vaccination rather than disease outcomes which may not occur for years following 
vaccination. Such studies[70, 71] have been the basis for extending the European 
licence of HPV vaccination to a 2-dose schedule for females aged under the age of 
15 years old at the time of the first dose (with 3-doses still recommended for older 
women) and have led to similar recommendations by the World Health Organisation 
(WHO)[70, 72].  
2.6.3. Cross-protection against closely related HPV types 
Phase III studies have also demonstrated evidence that both the bivalent and 
quadrivalent vaccine provide a level of cross-protection against some closely-
related HPV types (Table 2.1) not included in the vaccines.  
Evidence for cross-protection from the clinical trials is summarised in Table 2.2. To 
summarise, among HPV-naïve women at vaccination, vaccine efficacy for the 
bivalent vaccine against 6-month persistent infection with HPV types 31, 33 and 45 
was 77.1% (95% CI: 67.2-84.4), 43.1% (95% CI: 19.3-60.2) and 79.0% (95% CI: 
61.3-89.4) respectively[73]. Furthermore, a post-hoc analysis of one trial showed an 
unexpected moderate cross-protective efficacy against HPV6 [74] which is 
discussed and explored in more detail in the case-control study reported in Section 
8.4. For the quadrivalent vaccine, there is less evidence of cross-protection from the 
published clinical trials, with only HPV type 31 showing an appreciable vaccine 
efficacy of 46.2% (95% CI: 15.3-66.4)[75]. It has been suggested that the reason for 
the difference in cross-protection between the bivalent and quadrivalent vaccine 
could be due to the different adjuvants used for the two vaccines[76]. 
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Table 2.2: Evidence from Phase III studies for cross-protection against 
persistent infection (at 6- or 12-months) of non-vaccine HPV types 
HPV type HPV vaccine Study 
Vaccine efficacy   
(95% CI) 
High-risk HPV types 
HPV31 
Bivalent PATRICIA
1
 77.1% (67.2-84.4) 
Quadrivalent FUTURE I/II
2
 46.2% (15.3-66.4) 
HPV33 
Bivalent PATRICIA
1
 43.1% (19.3-60.2) 
Quadrivalent FUTURE I/II
2
 28.7% (-45.1-65.8) 
HPV45 
Bivalent PATRICIA
1
 79.0% (61.3-89.4) 
Quadrivalent FUTURE I/II
2
 7.8% (-67.0-49.3) 
HPV51 
Bivalent PATRICIA
1
 25.5% (12.0-37.0) 
Quadrivalent FUTURE I/II
2
 Not available 
HPV52 
Bivalent PATRICIA
1
 18.9% (3.2-32.2) 
Quadrivalent FUTURE I/II
2
 18.4% (-20.6-45.0) 
HPV58 
Bivalent PATRICIA
1
 -6.2% (-44.0-21.6) 
Quadrivalent FUTURE I/II
2
 5.5% (-54.3-42.2) 
Low-risk HPV types 
HPV6 
Bivalent PATRICIA
3
 34.9% (11.3-51.8) 
Quadrivalent 
 
Not applicable 
HPV11 
Bivalent PATRICIA
3
 30.3% (-45.0-67.5) 
Quadrivalent 
 
Not applicable 
1: Total vaccinated cohort naïve (TVC-naïve) analysis included 5427 vaccinated vs 5399 
control subjects. Participants were women aged 15-25 years.[73] 
2: Restricted modified intention to treat (RMITT) analysis included 1036 vaccinated vs 1032 
control subjects. Participants were women aged 16-26 years.[75] 
3: TVC-naïve post-hoc analysis included 5259 vaccinated vs 5249 control subjects. 
Participants were women aged 15-25 years.[74]  
 Both TVC naïve and RMITT analyses included women without evidence of high-risk HPV 
infection at baseline 
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2.6.4. HPV vaccination programmes  
A survey at the end of 2014 found that since 2006, 64 countries had implemented a 
national HPV vaccination programme, four countries had introduced a programme 
sub-nationally and 12 overseas territories had implemented vaccination[77]. In 
England (as throughout the rest of the UK), the National HPV Immunisation 
Programme was introduced in September 2008 with a 3-dose schedule for all girls 
aged 12-13 years old, using the bivalent vaccine Cervarix®. A catch-up campaign 
for all girls up to age 18 was offered in the first two years of the programme (as 
outlined in Chapter 1). Routine vaccination of 12-13 year olds has continued, 
although from September 2012 there was a change in the vaccine offered from 
Cervarix® to the quadrivalent vaccine Gardasil®. Following emergence of 
immunological evidence (Section 2.6.2) it was reconsidered that from September 
2014, routinely vaccinated girls need receive only two doses of the vaccine; the 
second dose being given at least 6- and at most 24-months following the first dose. 
In England, vaccination for the routine programme has almost entirely been 
provided at schools. However, for the older girls, both school-based and GP-based 
vaccination was offered. There has been consistently high vaccination coverage for 
the routine cohorts, with administration data reporting national coverage above 85% 
for one dose and above 80% for all three doses since the introduction of the 
programme[78-81]. Among the catch-up cohorts, coverage has been lower, with 3-
dose coverage ranging from 39% to 76% and a larger proportion of women 
receiving partial vaccination (between 2.3% and 6.8% receiving only 1-dose and 
between 3.9% and 11.9% only 2-doses)[78-80]. Ecological analysis of HPV 
vaccination coverage suggests that area-level deprivation has little impact on 
vaccination coverage for school-based vaccination delivery, although there was 
some evidence of inequality of uptake among the girls vaccinated at an older age, 
with lower recorded vaccination coverage in areas with higher deprivation[82].  
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2.7. Surveillance to monitor HPV in England 
2.7.1. The role of Public Health England and UK health departments 
The Joint Committee on Vaccination and Immunisation (JCVI) is an independent 
Departmental committee of experts which advises the UK health departments on 
vaccination for the prevention of infections and/or disease. Following a 
recommendation from JCVI, it is the obligation of the Secretary of State to ensure 
that such a vaccination programme is implemented. The Department of Health and 
Social Care is responsible for determining the Immunisation policy in England. 
However, much of the implementational and operational aspects of national 
immunisation programmes are delegated to Public Health England (PHE) which is 
an executive agency of the Department of Health and Social Care.  
An important requirement of implementing national immunisation programmes is 
conducting surveillance to monitor the coverage and impact of vaccination on 
infection and/or disease. Monitoring vaccination in an unselected population (and 
under public health conditions of vaccine storage, handling, and administration) 
provides important information that is not available from clinical trials. Such 
surveillance identifies whether a programme is working well and potentially informs 
any changes to existing programmes. It is the responsibility of PHE to carry out 
surveillance to evaluate and inform national immunisation programmes and to report 
back to JCVI. 
2.7.2. Monitoring the coverage of the HPV vaccination programme 
National monitoring of vaccination coverage data provides the first evidence of the 
success of the programme to deliver HPV vaccine to the targeted cohorts and can 
identify subgroups of the population with lower coverage. 
Individual-level vaccination status should be recorded on the local Child Health 
Information System (CHIS) and in GP clinical records of eligible girls. In addition, 
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HPV vaccination details should be uploaded on to the National Health Applications 
and Infrastructure Services (NHAIS) system (otherwise known as Open Exeter) so 
that these records can be linked to cervical screening records once women become 
eligible for the NHS Cervical Screening programme. Full details of how these data 
are recorded are provided in Section 5.1.1.  
In addition, annual reports of area-level HPV vaccination coverage are produced by 
the Immunisation Department at PHE. These data are collected via the ImmForm 
website, using a manual online data submission by NHS England Area Teams 
(ATs). ATs are notified of their individual denominators (i.e. the Area’s ‘responsible 
population’ which is derived from the relevant school roll, or from the Child Health 
Information system for cohorts/areas not using a school-based delivery) prior to the 
start of the academic year to provide the opportunity to amend these where 
appropriate. Numerator data on HPV vaccine doses given in schools or GP 
surgeries are then collated by ATs and entered onto ImmForm. Data provided are 
aggregate counts by year of age and area. Coverage by other characteristics (e.g. 
ethnicity and deprivation) is not available from this national data collection. I 
summarise the results of studies which have investigated variations in HPV 
vaccination uptake and completion (Table 7.1, Section 7.2.2). In Chapter 7, I also 
describe work I have done in this PhD to monitor and validate HPV vaccine 
coverage data using biological markers of vaccination. Vaccine-induced antibodies 
are elicited in almost all vaccinated women and these are substantially higher than 
those following natural infection (Section 2.6.1). Therefore, dual seropositivity for 
both HPV16 and HPV18 with high antibody concentrations strongly suggests a 
vaccine-induced response. In this thesis, I present two seroprevalence surveys, 
conducted among: 
(i) Young women (aged 15 to 19 years old) undergoing routine microbiological 
or biochemical blood tests through participating laboratories across 
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England. A total of 3,772 residual serum specimens were collected 
between 2010 and 2013. 
(ii) Young women (aged 16 to 20 years old) attending sexual health clinics in 
England who are likely to be at an increased risk of high-risk HPV infection. 
These residual serum specimens were linked to data on ethnicity, country 
of birth, other STI diagnoses and area-level deprivation before being 
anonymised prior to HPV antibody testing. A total of 3,959 samples were 
collected and tested between 2011 and 2015.  
These data have three important functions. Firstly, they allow validation of vaccine 
coverage estimated by Public Health England using ImmForm collection. Secondly, 
they help identification of population subgroups with lower vaccination coverage. 
Finally, they inform vigilance for changes in immunogenicity over time following 
vaccination (i.e. antibody waning). Further details of both serological surveillance 
studies are provided in Chapters 7 and 8.  
2.7.3. Evaluation of the HPV vaccination programme  
One of the first measurable effects of a national HPV vaccination programme is on 
HPV infections in young women. Based on the data from clinical trials, it is 
anticipated that, following the introduction of the programme there will be: 
(i) a large reduction in the population-level prevalence of HPV16 and HPV18 
infections, and a smaller reduction in the prevalence of closely-related HPV 
types against which the vaccines were shown to have some cross-
protection;  
(ii) a lower prevalence of the vaccine and cross-protective HPV types among 
vaccinated women compared to unvaccinated women (i.e. evidence of 
vaccine effectiveness against these HPV types); 
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(iii) a lower prevalence of vaccine HPV types in unvaccinated women 
compared to women prior to the introduction of HPV vaccination, due to the 
herd protection effect (i.e. with less HPV infections in the population, there 
will be less opportunity to infect unvaccinated women); 
(iv) no change in the prevalence of other non-vaccine HPV types. 
Regarding the last point, whilst it is not expected that there will be a change in the 
other non-vaccine HPV types, there are two possible reasons to observe increases 
in the prevalence of non-vaccine HPV types as a result of HPV vaccination. The first 
is the concern that reductions in the vaccine-related HPV types could lead to other, 
less common, HPV types filling their ecological niche and becoming more common; 
this is known as type-replacement. Although there was no evidence of HPV type 
competition from natural history studies conducted prior to the introduction of HPV 
vaccination, pneumococcal serotype replacement was seen following 7-valent 
pneumococcal vaccination in England and Wales[83]. Therefore, the prevalence of 
other HPV types is being monitored to remain vigilant for any potential increases in 
non-vaccine HPV types. The second possible cause of an apparent increase in 
these types is an unmasking effect, an entirely artificial increase which is an artefact 
of the HPV tests used (as alluded to in Section 2.2). In other words, it may appear 
that there is an increase in non-vaccine HPV types due to the higher sensitivity of 
broad spectrum assays to detect non-vaccine HPV types in a post-vaccination 
population with less HPV16 and HPV18. Quantification of any potential type-
replacement is complicated by this unmasking effect. I explore this further in 
Chapter 3 and Section 4.1. 
At the start of this PhD, there was no routine testing of young women for HPV in 
clinical practice as this is largely an asymptomatic, transient infection with no 
recommended treatment. In England, a survey was established by PHE in 2008 to 
determine type-specific HPV DNA prevalence among sexually active 16-24 year old 
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women[19]. This made use of residual samples from women undergoing chlamydia 
screening. In this PhD, I compare pre-vaccination findings with type-specific HPV 
prevalence in 2010 to 2016 following the introduction of HPV vaccination in 
England. This surveillance, although not population-based, offers a large source of 
suitable samples from young sexually active women. This PhD includes results of 
HPV testing of 15,463 samples collected following the introduction of HPV 
vaccination (for comparison with 2,369 samples which were collected and tested 
prior to the introduction of HPV vaccination). Further details of this surveillance, 
including consideration of type-replacement and potential unmasking effects, are 
provided in Chapters 4, 5 and 6. 
Another effect of HPV vaccination that I consider is the impact on early disease 
outcomes, including genital warts. An ecological analysis conducted prior to this 
PhD suggested an unexpected moderately protective effect of the bivalent vaccine 
against genital warts in England[84]. In this PhD, I conducted further analyses, 
using data from an epidemiological study I designed to investigate this association 
(Chapter 7). The impact of HPV vaccination on other disease related to high-risk 
HPV types (i.e. HPV-related pre-cancer and cancer) will be established at PHE at a 
future date. It will take longer to see such an effect, given the delay between 
infection and disease onset, hence this falls outside the scope of this PhD.  
2.8. PhD rationale and objectives 
2.8.1. Rationale 
Following the introduction of a vaccination programme, measuring the impact on 
infection and disease is an effective way to monitor progress and to inform changes 
and/or advocate continuation of the programme (as described in Section 2.7.3). 
National surveillance to monitor HPV vaccination programmes in England and 
elsewhere often compares the changing epidemiology of HPV infection and disease 
over time using repeat cross-sectional studies. Such surveillance studies provide 
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useful estimates for the population-level impact of HPV vaccination. However, this 
approach is subject to issues with continuity of patient selection (e.g. changing 
service provision affecting patient attendances at certain clinic types) and changing 
HPV detection methods over time, hence interpretation of changes are complicated. 
In this thesis, I describe my role in the design, management and analysis of several 
surveillance activities established to monitor different aspects of the HPV 
vaccination programme in England. As a further objective of this PhD, I aimed to 
address some of the issues with interpretation of national surveillance data in two 
ways. Firstly, I developed and applied novel techniques to enable accurate 
interpretation of changes in type-specific HPV infection and HPV seroprevalence 
data. Secondly, I collected additional data and designed and conducted additional 
epidemiological studies to calculate directly the effects of HPV vaccination on HPV 
infection and early disease outcomes.  Using these methods, I assessed throughout 
this PhD the early impact of HPV16/18 vaccination on the epidemiology of HPV 
infection in vaccinated and unvaccinated individuals in England. These analyses will 
inform further use of HPV vaccines and potential changes to the national cervical 
screening in the UK and in other countries with high vaccination coverage in young 
females. In addition, these data could inform introduction of vaccination in countries 
yet to implement a national programme.  
2.8.2.  PhD research questions 
Type-specific HPV infection and HPV seroprevalence data from PHE’s HPV 
Surveillance programme have been analysed to address the following questions in 
the first eight years of the National HPV Immunisation Programme: 
Research question 1: What is the effect of national HPV vaccination with the 
bivalent vaccine on infection with HPV16 and/or HPV18? This includes estimation of 
the population-level impact of the vaccination programme among young women as 
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well as direct calculation of the vaccine effectiveness against HPV16 and/or 18 
infection. 
Research question 2: What is the effect of national HPV vaccination with the 
bivalent vaccine on infection with other high-risk HPV types? This research question 
comprises investigation of reductions in the prevalence of closely related HPV types 
(i.e. cross protection) and potential changes in other non-vaccine HPV types (either 
decreases due to cross-protection or increases due to potential type-replacement). 
For non-vaccine types, I look at the population-level impact in young women and 
vaccine effectiveness, similar to research question 1. 
Research question 3: What is the evidence for a herd protection effect of the HPV 
vaccination programme on women known to be unvaccinated?  
Research question 4: What is the prevalence of biological markers of HPV 
vaccination coverage in vaccinated populations? To answer this research question, 
I initially investigate whether monitoring the antibody response to HPV vaccine 
types is a suitable marker to monitor HPV vaccination coverage. I then use this 
approach to estimate HPV vaccination coverage among vaccinated women and to 
explore variations in coverage in different population subgroups. Finally, I 
investigate whether there is evidence of HPV antibodies waning over time since 
vaccine introduction.  
In addition, I designed and conducted an epidemiological study (case-control) to 
address the following question: 
Research question 5: To what extent does the bivalent HPV vaccine offer protection 
against genital warts?  
Further detail about the data sources used for each question, and in which Chapters 
of the thesis each question is addressed, is included in Figure 2.4.
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Figure 2.4: PhD research questions and relevant data sources 
48 
 
Chapter 3: Systematic review to investigate 
changes in non-vaccine HPV types following HPV 
vaccination 
3.1. Introduction 
In this chapter, I present a systematic review and meta-analysis which I conducted 
to investigate the population-level impact of national HPV vaccination on non-
vaccine HPV types (Figure 2.4; research question 2). Originally, at the start of this 
PhD, I had intended to conduct a review to compare the prevalence of high-risk 
HPV infection (including vaccine HPV types and cross-protective types) between 
the pre- and post-vaccination time periods. After developing the research question, 
search strategy and inclusion criteria for this systematic review, I learned that 
another research group (Université Laval, Canada) were conducting a similar 
systematic review of the population level impact of HPV vaccination on infection and 
early disease outcomes. I agreed to provide data from England to inform their 
review and I was invited to be an author. This group were investigating changes in 
the combined prevalence of any high-risk HPV type, the combined prevalence of 
vaccine HPV types and the combined prevalence of cross-protective HPV types. 
The group were not considering changes in individual HPV types. I therefore 
amended my research question slightly to examine the evidence for changes in 
HPV infection with individual non-vaccine high-risk HPV types. I also adapted my 
inclusion criteria slightly to agree with those being used by Université Laval so that 
these systematic reviews would complement each other (Table A1 in the Appendix). 
I assessed the eligibility of studies that were identified using my original search 
criteria; as a result one additional study was included in the systematic review being 
led by Université Laval. 
The manuscript below published in Emerging Infectious Diseases in 2016 provides 
the results of this systematic review and meta-analysis which I conducted and 
49 
 
analysed to investigate changes in non-vaccine HPV types after HPV vaccine 
introduction. The supplementary material for this publication is included in Appendix 
B. As the published review was based on a search conducted in February 2016, I 
re-ran the systematic review in December 2017 for the purposes of this thesis. I 
summarise the findings of this update at the end of this Chapter.  
 
 


-
-
-
-
-
Persistent infection with a high-risk human papillo-mavirus (HPV) genotype is necessary for develop-
ment of cervical cancer (1). Two high-risk types, HPV16 
2–4). 
The HPV vaccines currently available commercially have 
-
high-risk HPV types: bivalent and quadrivalent vaccines 
against HPV16 and HPV18 and the new nonavalent vac-
cine against HPV31, HPV33, HPV45, HPV52, and HPV58 
(5–7). Clinical trial data for the bivalent and quadrivalent 
vaccines have shown low-to-moderate protection (i.e., 
cross-protection) against other high-risk HPV types that 
are phylogenetically related to HPV16 and HPV18 (8,9).
Many countries have now introduced HPV vaccination 
programs (10). A recently published systematic review and 
meta-analysis assessed population-level effects of HPV 
vaccination on vaccine HPV types and showed strong evi-
dence that HPV vaccination is highly effective against in-
11). 
The review also examined closely related HPV types as a 
single group and found evidence of cross-protection over-
all in a population-based setting (11). However, assess-
ment of changes in the prevalence of closely related HPV 
types combined may not provide full evidence of the ef-
fects of a national vaccination program because examining 
the types as a single group potentially conceals decreases 
or increases in the prevalence of individual types. Group-
ing HPV types together limits the possibility of examining 
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tecting changes in other individual nonvaccine types. For 
example, a theoretical concern is that reduced prevalences 
of infection with HPV16 and HPV18 could lead to other 
high-risk HPV types occupying those niches and becoming 
more common causes of disease. Although type replace-
ment was not observed in the clinical trials (12), moni-
toring for possible type replacement in population-based 
settings after the introduction of national HPV vaccination 
programs is important. Furthermore, because nonvaccine 
HPV types are far less common than vaccine HPV types, a 
single study may have limited scope to determine whether 
type replacement has occurred. Combining data from sev-
eral reports improves the ability to investigate type replace-
ment. We aimed to investigate population-level effects of 
HPV vaccination programs that used bivalent or quadri-
caused by individual nonvaccine high-risk HPV types.
Methods
Objectives
Using data from surveys conducted before an HPV vacci-
nation program was introduced and data from surveys after 
the program was introduced, we compared HPV prevalenc-
es for similar populations within the same country. We con-
ducted a systematic literature search to determine changes 
in HPV prevalence for each nonvaccine high-risk HPV 
type. At the time of our search, any eligible study would 
have considered vaccination that used bivalent or quadri-
valent vaccines; consequently, high-risk HPV types used 
only in the nonavalent vaccine were considered nonvaccine 
HPV types. Each individual type was presented separately 
in our analysis. We included HPV types for which some 
cross-protection had been demonstrated in clinical trials 
(HPV31 and HPV33, which are phylogenetically related 
to HPV16, and HPV45, which is phylogenetically related 
to HPV18) (8,9,13); other high-risk HPV types included in 
the nonavalent vaccine (HPV52 and HPV58); other high-
risk and probably high-risk HPV types (HPV35, HPV39, 
HPV51, HPV56, HPV59, and HPV68); and other possibly 
high-risk HPV types (HPV26, HPV53, HPV70, HPV73, 
for Research on Cancer (14). This systematic review and 
meta-analysis was reported in accordance with PRISMA 
guidelines (15).
Search Strategy and Selection Criteria
Using Embase, Medline, LILACS, and African Index Me-
dicus databases, we searched for eligible publications pub-
programs were introduced, through February 19, 2016. To 
identify relevant studies that mentioned both vaccination 
and HPV infection or a related disease (such as HPV-re-
lated precancerous lesions, cancers, and genital warts), the 
search strategy incorporated MeSH terms from the PubMed 
database (http://www.ncbi.nlm.nih.gov/mesh) and relevant 
words found in the title or abstract (online Technical Ap-
pendix, http://wwwnc.cdc.gov/EID/article/22/10/16-0675-
Techapp1.pdf). The search had no language restrictions.
Eligible studies were those that assessed population-
level effects of HPV vaccination over time by comparing 
of HPV DNA in patient samples) during a prevaccination 
period with the prevalence during a postvaccination period. 
We excluded studies comparing HPV infection in vaccinat-
ed persons with HPV infection in unvaccinated persons as 
part of an individually randomized trial because such stud-
ies would not measure population-level effects. Similarly, 
we excluded studies in which HPV infection was compared 
only between unvaccinated and vaccinated persons in the 
postvaccination period. We also excluded studies in which 
only a small proportion (<2%) of the postvaccination study 
population was vaccinated (i.e., studies conducted in large-
ly unvaccinated populations). One author (D.M.) initially 
reviewed titles and abstracts of studies for eligibility; we 
reviewed in full those studies that appeared to address 
changes in HPV prevalence after introduction of HPV vac-
cination programs. We also compared search results with 
11), which com-
pared prevaccination and postvaccination periods for high-
risk vaccine types (HPV16 and HPV18), cross-protected 
types (HPV31, HPV33, and HPV45), and all high-risk 
HPV nonvaccine types combined.
Data Extraction and Data Quality
For each study, we extracted data on study design and 
country of study. Then, for both prevaccincation and post-
vaccination periods, we extracted data on year(s) of sample 
collection, study setting and population, sample size, speci-
men type, assay used for HPV DNA testing, HPV geno-
types included in the assay, demographic and sexual behav-
ior data collected, and the measure of effect (and method 
used to determine any effect). For the postvaccination pe-
riod, we also extracted data on the method used to ascertain 
estimated vaccination coverage.
In addition, we assessed the potential bias in each 
study by considering the comparability of the study popula-
tions in the prevaccination versus postvaccination periods 
(i.e., similar setting and population demographics); the ex-
tent of adjustment for potential confounders; the suitability 
of the specimen type to assess HPV DNA infection; the 
suitability of the assay used for accurate HPV DNA testing 
(and whether the suitability of assays differed between the 
prevaccination and postvaccination periods); and the meth-
od used to estimate HPV vaccination coverage. To assess 
external validity, we considered whether the study samples 
were population based. Each of these factors was scored as 
either low risk or high risk.
When published data on HPV prevalence and preva-
lence ratios (PRs) for individual high-risk HPV types 
were unavailable, we contacted authors to request the 
-
tion and postvaccination periods and the PRs for the 2 
periods for each nonvaccine high-risk HPV type. We 
requested PRs adjusted for demographic and sexual be-
havior data or the unadjusted PRs if data on confounders 
were unavailable; we calculated unadjusted PRs if au-
thors provided raw data. By using data from a previously 
conducted validation study, 1 study included adjusted 
odds ratios rather than PRs to adjust for the change in 
assay used during the prevaccination and postvaccina-
tion periods (16).
Data Analysis
We used estimates weighted to account for selection pro-
cesses if that data were available from authors unweighted 
numbers, as shown in online Technical Appendix Table 1). 
<19 and 20–24 
years of age) because of expected lower rates of vaccina-
tion coverage and lower vaccine effectiveness in those 
vaccinated at older ages. Consequently, for each study, 
we requested data from authors for the same 2 age groups. 
One study included data for girls <13 years of age, so we 
requested data restricted to those 16–19 years of age (17).
To enable calculation of a PR for a prevalence of 0 
during either the prevaccination or postvaccination period, 
we used a continuity correction of 0.5. When prevalence 
was 0 for both the prevaccination and postvaccination pe-
riods, we excluded the study from the meta-analysis for 
the relevant age group and HPV type. Results were fur-
quadrivalent). PRs within each subgroup were combined 
if data were not shown to be heterogeneous; lack of het-
erogeneity was determined by a p value >0.10 calculated 
with the Cochrane Q test or by an I2 value <25% (18). 
Sensitivity analyses were restricted to studies that used 
cervical, vulval, or vaginal swabs as specimen type be-
cause urine samples have lower sensitivity for detecting 
HPV DNA infection (19).
Results
Included Studies
unique articles in searches from all 4 databases (Figure 
1). An initial search of title and abstracts of these articles 
excluded 4,508 (97.0%) because of ineligibility. For the 
remaining 140 articles, we examined the full text to determine 
-
gible studies (Figure 1). Of these 10 studies, 1 met all eli-
from authors (20). Therefore, we included 9 studies in the 
systematic review and meta-analysis (16,17,21–27). All 
eligible studies were repeat cross-sectional studies that 
compared changes in prevalence in populations before 
and after introduction of a national HPV vaccination pro-
gram (online Technical Appendix Table 1). Because only 
1 study considered changes in HPV infection among male 
and female populations, we considered only female popula-
tions in the analysis. Two studies were population-based 
national surveys (23,26); 3 studies were conducted among 
young women obtaining chlamydia screening (16,17,27); 2 
studies comprised young women attending a primary care 
clinic, community health center, or hospital-based adoles-
cent clinic (21,22); and 2 studies comprised women obtain-
ing cervical screening (24,25) (online Technical Appendix 
Table 1). The included studies contained data on 13,886 
girls and women <19 years of age and 23,340 women 20–
24 years of age.
The studies varied in methodologic quality on the basis 
of potential bias (Table 1). Most studies collected some de-
mographic and sexual behavior data to enable appropriate 
Figure 1.
adjustment of the relative risks, although the number of 
factors collected was limited in some studies (16,17,24,25) 
(Table 1; online Technical Appendix Table 1). 
HPV Types Included in Nonavalent HPV Vaccines 
HPV Types with Prior Evidence for Cross-Protection 
We found evidence of reduced prevalence of HPV31 (Fig-
ure 2; Table 2) among girls and women <19 years of age 
(PR 0.73, 95% CI 0.58–0.91) but found little evidence of 
changed prevalences for HPV33 or HPV45 among this age 
group (PR 1.04, 95% CI 0.78–1.38 for HPV33; PR 0.96, 
95% CI 0.75–1.23 for HPV45). Results were heteroge-
neous for HPV31, HPV33, and HPV45 in women 20–24 
years of age; consequently, we did not calculate summary 
PRs (Figure 2; Table 2).
Other HPV Types 
We found evidence of increased prevalence of HPV52 in 
those <19 years of age (PR 1.34, 95% CI 1.13–1.59) (Figure 
3; Table 2), but because of heterogeneity, we did not calcu-
late summary PRs for those 20–24 years of age. We found 
no evidence of a changed prevalence for HPV58 among the 
younger age group (PR 1.01, 95% CI 0.80–1.26) but found 
borderline evidence of an increase for those 20–24 years of 
age (PR 1.14, 95% CI 0.99–1.31).
Other High-Risk and Possibly High-Risk HPV Types
No consistent patterns appeared across the studies for oth-
er HPV vaccine types not used in the nonavalent vaccine 
(Table 2; online Technical Appendix Figure 1). We found 
evidence of increased prevalences from the prevaccination 
period to the postvaccination period in those <19 years 
of age for HPV39 (PR 1.27, 95% CI 1.05–1.54), HPV53 
(PR 1.51, 95% CI 1.10–2.06), and HPV73 (PR 1.36, 95% 
CI 1.03–1.80). For women 20–24 years of age, evidence 
indicated increased prevalence for HPV39 (PR 1.13, 95% 
CI 1.00–1.28).
Sensitivity Analysis
As a sensitivity analysis, we performed 3 additional analy-
bivalent or quadrivalent); by potential bias of the original 
-
tors indicating high risk of bias; or relatively high potential 
>3 factors indicating high risk of bias) (Ta-
ble 1); and by vaccination coverage (i.e., low <50%; high 
>50%). For studies in settings that used the bivalent vac-
cine, we found evidence of increased prevalence between 
the prevaccination period and postvaccination periods 
among those <19 years of age for HPV52, HPV53, HPV56, 
and HPV70 (online Technical Appendix Table 2, Figures 
2–4). Prevalence of HPV53 among women 20–24 years of 
age also increased. For the quadrivalent vaccine, evidence 
showed increased prevalences of HPV39, HPV51, and 
HPV59 for those <19 years of age. Among those 20–24 
years of age, evidence indicated increased prevalence of 
HPV52 and HPV70 (online Technical Appendix Table 2, 
Figures 2–4).
bias of the included studies had results similar to those in 
-
ble 3). However, among those <19 years of age, studies 
with a relatively low potential bias showed no evidence of 
increased prevalence for HPV52 or HPV39, although evi-
-
ies with relatively high potential bias, among this younger 
age group, evidence showed increased prevalences of 
HPV51 and HPV70, although these increases were not 
of age, evidence showed decreased prevalence for HPV33 
in those studies with a relatively low potential bias. No 
Table 1 -
 
 
 
16  
-
17  21  22  23  24  25  26  27  
-
samples† 
H H H H     H 
Comparative populations† H H       H 
 
H H    H H   
 
    H     
accuracy 
         
Identical HPV assays† H         
 
H H   H   H H 
 
†For both prevaccination and postvaccination periods. 
 
-
sis because of heterogeneity of data. Studies with a rela-
tively high potential bias showed evidence of increased 
prevalences of HPV52 and HPV58 among women 20–24 
years of age. Among this older age group, evidence ex-
isted for decreased prevalence of HPV82 in those studies 
with both relatively high potential bias and relatively low 
potential bias, although those studies with relatively high 
potential bias had a larger decrease. Again, no summary 
of heterogeneity.
Vaccination coverage was high for the younger age 
group in all studies (online Technical Appendix Table 4). 
For the older age group, studies with high vaccination cov-
erage showed decreased prevalence for HPV31. No sum-
because of heterogeneity. For the older age group, we 
found evidence of increased prevalences for HPV39 and 
but only in studies with low vaccination coverage. Al-
evidence of an increased prevalence for HPV70 in low-
coverage studies and borderline evidence of an increased 
prevalence for HPV26 in high-coverage studies. No sum-
because of heterogeneity.
Discussion
Comprehensive postvaccination surveillance should not 
-
tion and associated disease but should also assess any other 
potential effects of reductions of targeted infections. We 
assessed changes in nonvaccine HPV types to determine 
evidence of cross-protection for individual HPV types 
and to investigate the potential concern that reductions in 
certain HPV types after the introduction of HPV vaccina-
tion in a population could create a niche that enables other 
nonvaccine high-risk HPV types to become more common 
(i.e., type replacement). We found evidence of a reduction 
in the prevalence of HPV31 among girls and women <19 
years of age. Our main analysis showed increases in other 
nonvaccine HPV types (HPV39, HPV52, HPV53, HPV58, 
and HPV73), but these increases were inconsistent for the 
2 age groups examined and the vaccines used.
A previous systematic review evaluated changes in 
high-risk HPV types combined and found evidence of a 
reduction in the prevalence of HPV types closely related 
to vaccine types (HPV31, HPV33, and HPV45) when 
they were considered as a single group (PR 0.72, 95% 
CI 0.54–0.96 for girls and women 13–19 years of age) 
(11). Our review provides evidence of reduced prevalence 
for HPV31 but little evidence of reduced prevalence for 
HPV33 or HPV45.
Figure 2.
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Comparing HPV prevalence in a prevaccination period 
to prevalence in a similar population in a postvaccination 
period enables consideration of population-level effects 
of HPV vaccination on HPV prevalence. However, these 
repeat cross-sectional study designs have limitations. Al-
though all studies addressed similar populations in the pre-
vaccination and postvaccination periods, these populations 
may have undergone temporal changes that are indepen-
dent of HPV vaccination over time and that possibly affect 
HPV prevalence. For example, increases in diagnoses of 
other sexually transmitted infections have occurred during 
the same period as that of HPV vaccination programs (28). 
Furthermore, incidence of genital warts increased in many 
countries before vaccine introduction (29–31) and has con-
tinued to increase postvaccination in persons ineligible for 
vaccination (11
we observed in some HPV types are possibly associated 
with broad increases in sexual risk over time. We consid-
ered changes in demographics and sexual behavior for the 
populations over time when information was available, but 
unrecorded population changes or other temporal changes 
affecting the relative proportions of high-risk HPV types 
likely occurred over time (32,33). Also, more geographic 
variation exists in the relative frequency of nonvaccine 
HPV types in populations compared with the prevalence of 
HPV16, which, before the vaccination programs, was the 
most frequent high-risk type observed in almost all popula-
tions (34).
Furthermore, the change in assay used during the pre-
vaccination and postvaccination periods was a potential 
source of bias in 1 study (16), which calculated odds ratios 
(ORs) adjusted for differences in diagnostic accuracy. This 
adjusted OR could not be converted to a PR by using the 
log-binomial model and was included as an OR. However, 
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given the low prevalence of individual HPV types, the use 
of an OR instead of a PR for this study was unlikely to have 
affected the results substantially.
Another limitation is that the broad-spectrum as-
says used in these studies (and in baseline prevaccination 
evaluations globally) can lack sensitivity for detecting 
individual HPV types when multiple types are present, 
particularly if another HPV type with a higher viral load 
is present. In the postvaccination period, in the absence 
of HPV16 and HPV18, this lack of sensitivity could lead 
because these types were underestimated in the prevac-
cine period because of the predominance of HPV16 or 
HPV18. Studies have shown this potential unmasking ef-
fect (35,36); some increases in nonvaccine types that we 
observed could result from unmasking.
Given the low prevalence of some nonvaccine HPV 
types, assessing changes in prevalence for individual types 
since the introduction of HPV vaccination has been chal-
lenging. By combining data from several studies, we en-
hanced our power to consider changes in individual HPV 
types. However, even with data from 13,886 girls and 
women <19 years of age and 23,340 women 20–24 years of 
age, we still had limited power to consider changes in very 
rare HPV types or to investigate reasons for the heterogene-
-
tween age groups and the 2 (i.e., bivalent and quadrivalent) 
vaccines. Conversely, type 1 errors can occur with multiple 
testing, so modest evidence for increases should be inter-
preted with caution.
We decided against performing random-effects meta-
analyses in the presence of between-study heterogeneity 
because, in most instances, inconsistency occurred in the 
direction of effect, making a summary estimate (i.e., the 
average value of these opposing effects) uninformative 
(37). Exploring the causes of heterogeneity could provide 
further insight into the reasons for these increases, so we 
performed 3 subgroup analyses by vaccine used, potential 
potential bias suggested that increased PRs for some HPV 
types may have been reported more often in the studies with 
relatively high potential bias. However, for all 3 subgroup 
sensitivity analyses, the small number of studies in each 
stratum limited the interpretation of the analyses. Similarly, 
we were limited to only 8 studies for each age group and 
(because meta-regression should generally not be consid-
ered for <10 studies) (37). As further data accrue, a useful 
future analysis would be exploring the association between 
reductions in the HPV vaccine types and any increases (not 
resulting from unmasking) in nonvaccine HPV types. If in-
creases result from type replacement, then we would expect 
to see increasing prevalences of nonvaccine HPV types as 
prevalences of vaccine HPV types decrease.
HPV type is encouraging. However, the results of this sys-
tematic review and meta-analysis provide no clear evidence 
Figure 3.
25
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for type replacement because the data are unclear about the 
extent to which any observed increases result from other 
temporal changes, changes in the study populations, or an 
unmasking effect of broad spectrum HPV assays. Large-
scale epidemiologic analyses that use various designs have 
not detected evidence of any interactions between high-risk 
types, and the known high evolutionary stability of these 
viruses lessens the risk that type replacement will be a 
problem (38,39).
Most women included in the surveillance studies were 
those vaccinated at older ages (i.e., potentially vaccinated 
after HPV exposure), and some studies included popula-
tions with relatively low coverage, compared with nation-
ally reported vaccination coverage for routine cohorts. 
Future studies should continue to monitor population-lev-
el prevalences of these HPV types. In particular, studies 
should consider populations vaccinated at young ages and 
having high vaccination coverage and, perhaps more im-
portant, should examine the absolute prevalence of cervical 
intraepithelial neoplasia 3 lesions attributed to each high-
risk HPV type.
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3.3. Update to previous analysis 
The database search for this systematic review and meta-analysis presented in the 
previous section was conducted in February 2016. I re-ran the database searches 
on 4th December 2017 using the same search criteria with the exception that I 
restricted to publications in 2015, 2016 and 2017. I included 2015 to identify any 
publications which were published in 2015 but had not been updated on Medline or 
Embase in February 2016 when the previous search was conducted. To ensure that 
publications were not included multiple times, I first deduplicated between Embase 
and Medline, as before, and then deduplicated with the previous search conducted 
in February 2016. A total of 1,243 new and unique publications were identified for 
eligibility screening (Figure 3.1).  
Eligibility criteria were identical to those used for the published systematic review. I 
searched all titles/abstracts and identified 46 potentially eligible publications for a full 
paper search. Of these, four publications were eligible for inclusion (three of which 
were updated versions of publications included in the previous review conducted in 
February 2016). I provide the reasons for exclusion in Figure 3.1 and details of the 
included papers in Table 3.1. 
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2,091 papers published between 2015 and 2017  
identified from Medline, Embase, AIM and Lilacs 
1,243 unique papers 
identified 
Duplicated in previous search 
(February 2016): 848 
46 for full paper review 
Ineligible after examining 
title/abstract: 1,197 
 4 additional studies identified 
Ineligible: 
Unvaccinated population1 12 
Data from RCT  2 
Disease outcomes only 3 
Updated data later published  4 
Only vaccine HPV types 2 
Only post-vaccination period 18 
Cohort of vaccinated women 1 
1: Includes studies where the vast majority of the population were unvaccinated 
Figure 3.1: Flow chart for eligible studies included in the update of the systematic 
review (conducted 4th December 2017) 
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Table 3.1: Characteristics of studies selected for systematic review 
Study Country 
(vaccine 
type) 
Years of 
specimen 
collection 
Number of 
specimens 
tested 
Study population 
and setting 
Specimen 
type 
Assay for HPV 
DNA testing 
Demographic and 
sexual behaviour 
data collected 
Vaccination 
status 
Studies included in original systematic review (conducted February 2016) 
Cameron et al[85] 
See Technical Appendix Table 1 in Appendix B 
Chow et al[86] 
Cummings et al[87] 
Kahn et al[88] 
Markowitz et al[89] 
Mesher et al[90] 
Söderlund-Strand et 
al[91] 
Sonnenberg et al[26] 
Tabrizi et al[92] 
Studies identified in initial systematic review (conducted February 2016) but excluded as type-specific data were not available 
Dunne et 
al[93] 
USA 
(quadrivalent) 
Pre-vacc: 
2007    
Post-vacc: 
2012-2013 
Pre-vacc: 
4,138   
Post-vacc: 
4,171 
Women aged 20-
29 years old 
attending for 
routine cervical 
cancer screening 
at a clinic in 
Northwest USA 
Residual LBC 
specimen 
Linear Array 
HPV Genotyping 
test 
Age at first dose, race, 
ethnicity, family poverty, 
tested for chlamydia in 
past year, tested 
positive for chlamydia in 
past year, tested for 
HIV in past year, tested 
for pregnancy in past 6 
months 
Extracted from 
electronic 
medical 
record 
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Study Country 
(vaccine 
type) 
Years of 
specimen 
collection 
Number of 
specimens 
tested 
Study population 
and setting 
Specimen 
type 
Assay for HPV 
DNA testing 
Demographic and 
sexual behaviour data 
collected 
Vaccination 
status 
Updated data from studies included in initial systematic review 
Kahn et 
al[94] 
(update of 
Kahn et 
al[88]) 
USA 
(quadrivalent) 
Pre-vacc: 
2006-2007 
Post-vacc: 
2009-2010 
2013-2014 
Pre-vacc: 
371 
Post-vacc: 
409 
400 
Females (aged 13-
26 years old) who 
had history of 
sexual intercourse, 
recruited from 
hospital based 
adolescent clinic 
and a community 
health centre 
Cervicovaginal 
swabs by 
clinician or 
self-collected 
swab 
Linear Array 
HPV Genotyping 
test 
Age, race, health care 
insurance, knowledge 
about HPV vaccines, 
smoking status, 
gynaecologic history 
(number of 
pregnancies, history of 
STIs), sexual 
behaviours (age at first 
sex, number of male 
lifetime partners, 
number of male 
partners in previous 3 
months, anal sex, 
condom use) 
 
Comparisons were 
adjusted for propensity 
score to account for 
confounding  
Self-
administered 
questionnaire 
Kavanagh et 
al[95] 
(update of 
Cameron et 
al[85]) 
UK: Scotland 
(Bivalent) 
Pre-vacc: 
2009-2010 
Post-vacc: 
2011-2015 
Pre-vacc: 
2,757 
Post-vacc: 
5,827 
Females (aged 20-
21 years old) 
attending for 
cervical screening 
as part of national 
cervical screening 
programme. 
Residual LBC 
specimen 
Multimetrix HPV 
assay 
Scottish Index of 
Multiple Deprivation, 
month/year of birth, age 
at vaccination 
 
Data linked 
from Scottish 
Immunisation 
Recall System 
65 
 
Study Country 
(vaccine 
type) 
Years of 
specimen 
collection 
Number of 
specimens 
tested 
Study population 
and setting 
Specimen 
type 
Assay for HPV 
DNA testing 
Demographic and 
sexual behaviour data 
collected 
Vaccination 
status 
Updated data from studies included in initial systematic review (continued) 
Oliver et 
al[96] 
(update of 
Markowitz et 
al[89]) 
USA 
(Quadrivalent) 
Pre-vacc: 
2003-2006 
Post-vacc: 
2009-2012 
Pre-vacc: 
1,795 
Post-vacc: 
2,424 
Females (aged 14-
24 years old) 
participating in 
population based 
NHANES survey 
Self-collected 
cervicovaginal 
sample 
Linear Array 
HPV Genotyping 
test 
Ethnicity, poverty index 
and, for those reported 
ever having sex; age at 
first sex, lifetime 
number of partners, 
number of partners in 
the previous 12 months. 
 
Prevalence ratios were 
adjusted for 
race/ethnicity, poverty 
index, and number of 
lifetime partners 
Self-reported 
New studies identified from update of systematic review 
Grun et 
al[97] 
Sweden 
(majority 
quadrivalent) 
Pre-vacc: 
2008-2011 
Post-vacc: 
2013-2015 
Pre-vacc: 
615 
Post-vacc: 
338 
Females (aged 15-
23 years old) 
attending a youth 
health clinic in 
Sweden 
Cervical 
samples by 
professional or 
self-test 
Multiplex 
polymerase 
chain reaction 
and Luminex 
technology 
Age. No other data 
reported 
Self-reported 
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To summarise, three of the four additional papers reported updates to results that 
were included in the original review. Kahn et al compared HPV prevalence at three 
separate time points (2006-2007 (prior to HPV vaccination); 2009-2010 and 2013-
2014) among 13-26 year old women in the USA[94]. This was an update of a 
previous paper by Kahn et al published in 2012 which compared HPV prevalence 
for the first two time periods only and showed a reduction in the prevalence of HPV 
vaccine types but a slight increase in non-vaccine HPV types[88]. In the updated 
publication, the authors demonstrated a continued decline in the vaccine-types but, 
contrary to the previous publication, the prevalence of non-vaccine HPV types in 
2013-2014 was similar to the prevalence in 2006-2007. This updated publication did 
not include investigation of changes in any individual HPV types. Kavanagh et al[95] 
published an update of a previous analysis published by Cameron et al[85], which 
was conducted among 20-21 year old women attending for cervical screening in 
Scotland between 2009 and 2013. The previous analysis demonstrated a decrease 
in HPV16, 18, 31, 33 and 45 but a non-significant increase in HPV51. In the 
updated publication, extended to 2015, these results were strengthened as the 
authors demonstrated declines in prevalence of vaccine types from 28.9% in 2009 
to 4.8% in 2015 and substantial declines in HPV31, 33 and 45 over the same time 
period (13.0% to 3.0%). Despite these clear declines in later birth cohorts for 
HPV16, 18, 31, 33 and 45, there was no evidence of any trends in the prevalence of 
other high-risk HPV types which would suggest type-replacement (the authors 
presented graphically the prevalence of individual HPV types by birth cohort in the 
online appendix). Oliver et al[96], updated a previous paper published by 
Markowitz[89], considering HPV prevalence among women included in the National 
Health and Nutrition Examination Survey (NHANES), an ongoing series of cross-
sectional surveys which are designed to be nationally representative of the US 
population (this was a separate population from the one considered by Kahn et al 
above).  The previous analysis, which compared pre-vaccination HPV prevalence 
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(specimens collected between 2003 and 2006) to post-vaccination HPV prevalence 
(specimens collected between 2009 and 2012), demonstrated reductions in the 
HPV vaccine types but no significant changes in other HPV types. The updated 
analysis extended post-vaccination data collection to 2014 and demonstrated a 
decline in vaccine types from 11.5% in 2003-2006 to 3.3% in 2011-2014. This 
publication included individual changes in the prevalence of 12 high-risk HPV types 
and a further 21 other HPV types. The authors concluded that there was little 
evidence of corresponding increases in non-vaccine types among 14-19 year olds. 
For 20-24 year olds there was an increase in HPV73 only. Finally, Grun et al (the 
only eligible study which was not an update of a previous publication) considered 
HPV prevalence in cervical samples collected from young women attending a youth 
clinic in Sweden. The authors reported declines in the prevalence of HPV16 from 
34.7% in 2008-2011 to 18% in 2013-2015. Changes in the prevalence of individual 
HPV types were presented graphically and there was little evidence of increases 
between the pre-vaccination and post-vaccination period. 
The data that were available from the publications included in this updated review 
continue to support the finding that there is no clear evidence for type-replacement 
following introduction of HPV vaccination. Following the publication of the previous 
systematic review and meta-analysis, it was agreed that the team from Université 
Laval (Section 3.1) would lead future data collection for both the systematic review 
on vaccine types and non-vaccine types. Therefore, I did not contact authors for 
data on changes in individual HPV types because the group at Université Laval will 
be contacting these authors when data are requested for an updated publication. As 
most changes in individual HPV types were not included in the four additional 
publications (or were only presented graphically), the meta-analysis and forest plots 
were not updated in this thesis.  
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There were several publications excluded from this updated review either because, 
(i) the analyses compared HPV prevalence among vaccinated and unvaccinated 
women within the post-vaccination period[98-112], (ii) the analyses were restricted 
to measuring HPV infection at a single time point in the post-vaccination period and 
did not stratify by vaccine status[113], or (iii) the analyses were restricted to 
comparing HPV prevalence over time within the post-vaccination period[114, 115]. 
In Section 4.2, I describe the advantages and disadvantages of considering 
changes within the post-vaccination period only rather than comparing prevalence 
between the pre- and post-vaccination period. For this analysis, the focus was on 
assessing relatively small changes in the prevalence of non-vaccine types rather 
than the larger direct protection of vaccination on vaccine types. Therefore, it was 
more appropriate to consider the population-level effect rather than limiting 
comparisons to vaccinated and unvaccinated women which may be affected by 
inequalities in who is being vaccinated. However, as the time since vaccine 
introduction increases, there could be an argument that future reviews could include 
changes in non-vaccine HPV prevalence over time within the post-vaccination 
period. 
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Chapter 4: Methods for HPV infection surveillance 
to evaluate the National HPV Immunisation 
programme  
In this chapter, I describe the methods of repeat cross-sectional surveillance of HPV 
infection in young sexually active women attending for chlamydia screening which 
was established to evaluate the HPV Immunisation Programme. I first consider the 
expected changes in HPV prevalence following the introduction of HPV vaccination 
and the strengths and limitations of using surveillance data to monitor such 
changes. I then describe the study population and my role in this surveillance 
including the data and specimen collection, data linkage and statistical methods to 
inform research questions 1, 2 and 3 of this thesis (Figure 2.4). I also describe 
additional methodology that I developed to improve interpretation of changes in 
HPV prevalence. 
4.1. Expected changes in the prevalence of HPV infection 
following national HPV16/18 vaccination 
4.1.1.  Reductions in vaccine HPV types 
Given the high efficacy of HPV vaccines and the high coverage achieved by the 
vaccination programme, it was expected that there would be large declines in the 
HPV vaccine types following the introduction of vaccination. To predict the likely 
scale of these declines, a simplistic approach would be simply to multiply the 
vaccine efficacy from the clinical trials with the vaccine coverage in the population. 
However, the reductions in HPV vaccine-type infections in a population-based 
surveillance study will likely differ from those seen in the clinical trials for several 
reasons. Firstly, the proportion of women vaccinated who had a prior HPV infection 
will vary depending on the population and age at vaccination. As the vaccine has no 
efficacy against clearance of an existing infection, this will reduce the impact of HPV 
vaccination. Secondly, there may be some inequalities in who receives vaccination. 
For example, if vaccinated women are those at a lower risk of infection (either at the 
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time of vaccination or subsequently) then this could affect the expected population-
level impact of the vaccine (the methods and results of surveillance to investigate 
inequities in HPV vaccination coverage are described in Chapter 7 and Chapter 8). 
Finally, in a population with high vaccine coverage, we would expect some herd 
protection among unvaccinated women, which would increase the impact of 
vaccination compared to results seen in individually randomised pre-licensure 
clinical trials.  
4.1.2. Reductions in phylogenetically related HPV types (cross-protection) 
As described in Section 2.6.3, the results from the clinical trials of the bivalent 
vaccine provided evidence of cross-protection against persistent infection with 
HPV31, HPV33 and HPV45, three of the high-risk types which are phylogenetically 
closely related to the HPV vaccine types. There was also some evidence of cross-
protection against HPV51 (not included in either the α7 or α9 species group which 
include the vaccine types; Table 2.1)[73]. Therefore, moderate declines in the cross-
protective HPV types were expected. As described in the previous section, the scale 
of these declines is also dependent on the vaccination coverage, the risk of 
exposure to HPV prior to vaccination and herd protection effects.  
4.1.3.  Potential increases in other high-risk HPV types (type-replacement) 
With the declines in HPV vaccine types and closely related types, there has been 
some concern that this could lead to other HPV types filling an ecological niche and 
taking their place (known as type-replacement). I described this in detail in Chapter 
3 along with results of the systematic review to investigate changes in the non-
vaccine HPV types following the introduction of national HPV vaccination. Although 
these data provide no clear evidence for increases in the HPV non-vaccine types to 
date, it is prudent to remain vigilant for such changes. If type-replacement was to 
occur, this could have a serious effect on the potential impact of HPV vaccination on 
the incidence of cervical pre-cancer and cancer. Such information is required to 
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inform effectiveness and cost-effectiveness models that will inform changes in the 
HPV vaccination programme (for example, the choice of vaccine used in the 
national programme). Therefore, if increases in non-vaccine HPV types were seen, 
it would be imperative to explore, and rule out, other possible reasons for such 
changes before concluding that this was due to type-replacement.  
4.1.4.  How to interpret changes in HPV prevalence 
One of the challenges of interpreting national surveillance data is to ascertain what 
are the true effects of HPV vaccination (i.e. effectiveness against the vaccine-types, 
effectiveness against the closely related HPV types, type-replacement) and what 
are the effects not related to HPV vaccination (i.e. effects of chance, changes in the 
surveillance population unrelated to vaccination, the change in the HPV assay over 
time, unmasking effect). 
In Section 4.4 and Chapter 5, I describe the methods that I developed to 
disentangle the true effects of HPV vaccination from other changes, unrelated to 
vaccination. 
4.2. National surveillance of HPV DNA infection: Aims and 
background  
4.2.1. Aims of national surveillance of HPV infection 
As previously described, national HPV infection surveillance is required to monitor 
the population-level impact of the National HPV Immunisation Programme. There 
are two distinct approaches to such surveillance, which offer different benefits and 
challenges. 
The first option is to compare the prevalence of HPV infection over time and explore 
how changes are associated with vaccination coverage. In the simplest example, 
HPV prevalence in a survey conducted prior to the introduction of HPV vaccination 
is compared to prevalence in a similar survey conducted following vaccine 
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introduction. This estimates the population-level changes in HPV infection that 
incorporates the direct effect of vaccination and indirect effect of herd protection 
among both vaccinated and unvaccinated individuals. However, this analysis is 
subject to bias if there are other changes over time that affect HPV infection in the 
population but are unrelated to HPV vaccination.  
The second option is to compare the prevalence of HPV infection in vaccinated 
women compared to unvaccinated women in the post-vaccination period. This 
requires data on individuals’ vaccination status and allows direct calculation of 
vaccine effectiveness. However, the effectiveness estimate may be confounded by 
risk factors for HPV infection that may be inequitably distributed among vaccinated 
and unvaccinated females. For example, if those being vaccinated are those at 
lower risk for HPV infection then we would overestimate the true vaccine 
effectiveness.  
Ideally, any surveillance would incorporate both the above options to explore fully 
the impact of the vaccination programme on HPV infection.  
4.2.2. My role in this surveillance 
Prior to the start of this PhD, a survey of HPV prevalence had been conducted by 
PHE in the pre-vaccination period and post-vaccination surveillance had been 
established.  
My role was to lead the PHE evaluation of the HPV Immunisation Programme in 
England and this, together with extended work, formed this section of this PhD. I 
continued to lead the collection of samples from the post-vaccination period and I 
designed and conducted all analyses on changes in the prevalence of HPV infection 
within the post-vaccination period compared to the pre-vaccination period.  
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Prior to the start of this PhD, there was also an intention to collect HPV vaccination 
status on women included in this surveillance. This was more complex than initially 
expected given the lack of a single national immunisation database. Therefore, as 
part of my role at PHE and forming part of this PhD, I established methods and 
conducted data collection of HPV vaccination status for a subset of women included 
in the post-vaccination surveillance (Section 4.3.6). This allowed two important 
additional analyses. Firstly, as described above, this enabled direct calculation of 
the vaccine effectiveness in this population. Secondly, I compared the prevalence of 
HPV vaccine-types among unvaccinated women in the post-vaccination period with 
the prevalence among women in the pre-vaccination period to provide an estimate 
of the herd protection effect. I also describe work I devised and conducted as part of 
this PhD to adjust for the change in assay over time when comparing HPV 
prevalence between the pre- and post-vaccination periods (Section 4.4).   
My role in this surveillance is further clarified in the cover sheets for the publications 
in Chapter 6 of the thesis. 
4.2.3.  Source of routine samples for HPV testing 
It was announced in 2016 that HPV primary screening would be introduced in 
England (Section 2.5). However, cervical screening in England does not start until 
age 25 years old and primary HPV screening had yet to be introduced at the time of 
this PhD. Therefore, it was necessary to find a source of routinely collected residual 
samples originally obtained for other purposes that could be tested for HPV 
infection. These samples should ideally be collected from younger sexually active 
women to be able to demonstrate an effect of HPV vaccination as early as possible. 
Such samples also needed to be suitable to identify a current HPV DNA infection. 
Urine specimens lack sensitivity to detect HPV infection and swabs taken from the 
cervix or vagina are more suitable to determine a current HPV DNA infection with 
high sensitivity[116]. 
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As cervical screening is not offered in England until young women reach the age of 
25 years, the first cohort of vaccinated women would not attend for cervical 
screening for at least seven years following the introduction of HPV vaccination. To 
obtain an alternative source of cervical or vaginal swabs taken from younger, 
sexually active women, PHE made use of residual samples collected from young 
women attending for chlamydia screening using a vulva-vaginal swab (VVS) 
specimen (Section 4.2.4).  
4.2.4.  The National Chlamydia Screening Programme (NCSP) 
Chlamydia is the most commonly diagnosed bacterial sexually transmitted infection 
in England and is particularly prevalent among young men and women[50]. The 
majority of chlamydia infections are asymptomatic hence most infected individuals 
will be unaware of their infection. However, if left untreated, chlamydia infection can 
lead to pelvic inflammatory disease (PID) which can in turn lead to long-term pelvic 
pain, infertility and ectopic pregnancy. Consequently, chlamydia screening in 
England is recommended annually and on sexual partner change for all sexually 
active men and women aged 24 years old and under[117] in order to control 
chlamydia infection and disease sequelae.   
In England, there was a phased introduction of the National Chlamydia Screening 
Programme (NCSP) from 2003 to 2008. Chlamydia screening is offered 
opportunistically when eligible individuals attend a range of different venues 
(including both clinical and non-clinical settings).  
Since the introduction of the NCSP, systems were established by PHE to collect 
individual-level data from chlamydia tests carried out through the programme. More 
recently, this has been expanded to collect data on all chlamydia tests undertaken 
in England at NHS laboratories, local authorities and NHS-commissioned 
laboratories using the Chlamydia Testing Activity Dataset (CTAD) (described in 
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Section 4.2.5). Data from 2016 reported that over 1.4 million chlamydia tests were 
carried out in 15-24 year olds in England (representing around 30% of females and 
12% males in the target population tested if we assume one test per person per 
year) with 128,098 chlamydia diagnoses [118]. These samples are usually self-
taken[119]. Patient instructions vary slightly by area and collection device but for 
women, the sample is generally collected by inserting the swab around two inches 
into the vagina and gently rotating for between 10 and 30 seconds. The patient is 
then instructed to insert the swab into a tube and seal this before either returning to 
the health practitioner or returning directly to the testing laboratory. 
4.2.5. Data collection for the NCSP  
Between 2003 and March 2012, all data on chlamydia tests and diagnoses 
conducted as part of the NCSP were compiled to produce the NCSP dataset. These 
data were submitted to PHE quarterly from all testing venues participating in the 
NCSP. Data collected included patient sociodemographic data, sexual behaviour 
data and information about the chlamydia test performed (Figure 4.1 and Table 4.1).  
In April 2012, there was a substantial change to the way that chlamydia testing data 
were reported. The introduction of the Chlamydia Testing Activity Dataset (CTAD) 
meant that data were submitted directly from the testing laboratories rather than the 
testing venues where patients were seen (Figure 4.1). Each laboratory reports 
individual-level data, based on the information provided from the clinic, when the 
sample is sent for testing. These data are submitted quarterly but some of the data 
collected differs from the NCSP dataset. As before, data are collected on 
sociodemographics and the chlamydia test result although there are some 
differences in the data completeness (for example, ethnicity is more often missing in 
CTAD). However, CTAD collects no data on sexual behaviour and does not record 
the reason for the test. Full details of the comparison between the two datasets are 
provided in Table 4.1.
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Figure 4.1: Collection of data from women undergoing chlamydia screening in England since 2003 
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Table 4.1: Data fields available in the National Chlamydia Screening 
Programme (NCSP) database and Chlamydia Testing Activity Dataset (CTAD) 
  Data field 
NCSP database 
(2003 - March 2012) 
CTAD 
(April 2012 - date) 
  Identifiers 
       Patient identifier (NCSP/CTAD) Data completeness 98% Data completeness 91% 
     NHS number Data completeness 8% Data completeness 30% 
  Socio-demographic data   
     Date of birth Data completeness 100% Data completeness 100% 
     Gender Data completeness 100% 
1  Male 
2  Female 
Data completeness 100% 
1  Male 
2  Female 
9  Indeterminate 
     Ethnicity Data completeness 73% 
Patient ethnicity based on 
ONS classification
1
 
Data completeness 19% 
Patient ethnicity based on 
ONS classification
1
 
     Postcode of residence Data completeness 88%
2
 Data completeness 60% 
     Postcode of GP Not collected Data completeness 47% 
     Postcode of testing service Not collected Data completeness 90% 
  Sexual behaviour data   
     Did the patient report two or more                                           
sexual partners in previous 12 months? 
Data completeness 54% 
1  Yes 
2  No 
 
Not collected 
     Did the patient report a new sex 
partner in the last 3 months? 
Data completeness 56% 
1  Yes 
2  No 
 
Not collected 
  Details of chlamydia test   
     Reason for test Data completeness 99% 
A03  Chlamydia screening 
A04  Diagnostic testing 
A08  Contact of chlamydia 
positive 
A11  Reports symptoms of STI 
Not collected 
     Testing service type Data completeness 100% 
01 Gynaecology and fertility 
02 Outreach 
03 Antenatal 
04 Occupational Health 
05 Pharmacy 
06 Community Sexual Health 
Services 
07 General Practice 
08 Accident and Emergency 
09 Remote testing 
10 Military 
11 Prisons and YOI 
12 Chlamydia Screening 
Office 
13 Termination of Pregnancy  
14 Education 
15 Youth 
Data completeness 99% 
01  GUM services 
02  Community Sexual 
Health Services 
3  General Medicine 
Practitioner Practice 
04  Pharmacy Premises 
05  TOP Services 
06  Internet 
XX  Other 
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     Specimen type Data completeness 99% 
1  Urine sample 
2  Cervical swab 
3  Vulva/vaginal swab 
4  Urethral swab 
5  Other 
Data completeness 100% 
1  Urine 
2  Genital 
3  Rectal 
4  Pharyngeal 
     Specimen date Data completeness 100% Data completeness 98% 
     Result of chlamydia test Data completeness 100% 
1  Positive 
2  Negative 
3  Equivocal 
4  Insufficient Specimen 
5  Inhibitory result 
Data completeness 100%  
01  Positive 
02  Negative 
03  Equivocal 
04  Insufficient Specimen 
05  Inhibitory result 
XX  Other 
1: Ethnicity in CTAD categorised as: White: British, Irish, any other White background; Mixed: White 
and Black Caribbean, White and Black African, White and Asian, Any other mixed background; Asian: 
Indian, Pakistani, Bangladeshi, any other Asian background; Black or Black British; Caribbean, African, 
any other Black background; Other Ethnic Groups: Chinese, Any other ethnic group, not stated. 
2: Postcode of residence was available but was not linked prior to anonymisation for pre-vaccination 
surveillance. Therefore IMD could not be calculated in the pre-vaccination period and was only 
available in the post-vaccination period (see Section 4.3.12). 
 
4.3. National surveillance of HPV DNA infection: Methods 
4.3.1.  HPV surveillance study population 
A small subset of laboratories conducting chlamydia screening tests was selected to 
participate in the national HPV infection surveillance. Prior to the start of this PhD, 
laboratories were recruited from across the country and from a mix of urban and 
rural areas. The recruitment of these laboratories was also based on their 
throughput of eligible specimens (at least 700 specimens over a 6-month period). 
PHE requested that laboratories identify a target number of residual VVS samples 
from eligible women (based on information provided from the testing venue) for the 
purposes of national HPV infection surveillance. Eligible women were defined as 
those; 
· Aged 16 to 24 years old  
· Having a sample taken for opportunistic chlamydia screening (i.e. not a 
symptomatic test or partner notification test). This criterion was to exclude 
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those with a far higher risk of chlamydia who were also likely to have a higher 
risk of HPV infection.  
· Being screened at either a General Practice, a Youth Clinic or Sexual and 
Reproductive Health Clinics (also known as Community Sexual Health 
Services, Contraceptive Sexual Health Services or Family Planning Clinics). 
This criterion was applied to maintain a more stable population over time that 
was less subject to bias from changes in attendance patterns at other settings.  
The national HPV surveillance was established at six testing laboratories in 2008 for 
the pre-vaccination period. The collection of post-vaccination period specimens was 
established at 10 testing laboratories in 2010 (the same six laboratories as the pre-
vaccination period as well as an additional four laboratories in order to increase the 
number of samples collected in the post-vaccination period). The process of data 
and sample collection and data linkage are shown in Figure 4.2 and described in 
detail in Sections 4.3.3 to 4.3.5. These processes were in place prior to my 
involvement with this surveillance. As highlighted in Section 4.2.2, I have been the 
lead on this surveillance since October 2011, and I have conducted (or overseen) all 
these processes. The pre-vaccination prevalence data were published prior to the 
start of this PhD but I designed and conducted all analyses of post-vaccination data. 
Sections 4.3.6, 4.3.7 and 4.3.10 to 4.3.17 describe the methods that I established 
for this surveillance. 
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Figure 4.2: Methods to request and collect residual specimens from 10 
chlamydia testing laboratories across England who participated in the HPV 
surveillance study 
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4.3.2. Ethics 
This surveillance to monitor the impact of HPV vaccination using residual chlamydia 
samples was initially reviewed and approved by the South East Research Ethics 
Committee (REC reference: 10/H1102/7). Patient identifiable data were used to 
assess eligibility and also to enable linkage with chlamydia results and HPV 
vaccination status. Prior to HPV testing, all patient identifiable data were irreversibly 
deleted. Individual patient consent was not required as this study tested these 
anonymised specimens (with patient-identifiable data deleted prior to testing) as 
part of Public Health Surveillance conducted to monitor the HPV vaccination 
programme.  
In September 2014, this surveillance was reclassified as Public Health Monitoring 
as part of PHE’s national remit and therefore was withdrawn from the Research 
Ethics Committee.   
4.3.3.  Collection of residual samples 
Pre-vaccination era specimens were collected between January 2008 and 
September 2008, prior to the introduction of HPV vaccination. Post-vaccination era 
specimen collection started in October 2010 and this PhD includes results from 
samples collected up to December 2016. All women included in these analyses will 
have been offered the HPV16/18 vaccine as part of the National HPV Immunisation 
Programme. 
Sample collection for the pre- and post-vaccination surveillance was identical. Each 
year of the surveillance, The HPV surveillance team at PHE (either me or overseen 
by me) sent updated instructions to each laboratory to request the target number of 
samples from each age-group. Laboratories were asked to send the following to the 
Virus Reference Department (VRD) at PHE: 
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· A minimum of 2ml of residual sample after the chlamydia test had been 
performed refrigerated (not frozen) prior to sending. 
· Anonymised sample tubes labelled only with a unique barcode (duplicate 
barcode labels were provided by PHE). All other patient identifiers removed 
from the sample tubes prior to sending.  
Chlamydia testing laboratories were asked not to select samples based on the 
chlamydia test result, in order to collect a representative sample of chlamydia 
negative and chlamydia positive specimens.  
4.3.4.  Data collection for residual samples 
Along with the specimen, the laboratories were also asked to complete a data 
collection form (blank versions were provided by PHE). Chlamydia testing 
laboratories were asked to attach the duplicate of the barcode that was attached to 
the residual sample alongside the corresponding patient information, which 
included: 
· The date of sample collection 
· The date the sample was sent to VRD 
· Patient’s date of birth 
· NCSP/CTAD identifier  
· NHS number, when available 
These data collection forms were sent securely to the HPV surveillance team at 
Public Health England (separately from the sample tubes). Data from the data 
collection forms were entered onto a secure Access database designed specifically 
for this surveillance study. Data were entered by two separate individuals and any 
discrepancies were checked with the original list. Any obvious errors on data 
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collection forms (e.g. dates in the future or 8-digit NHS numbers) were checked with 
the chlamydia testing laboratories.  
4.3.5. Linkage of HPV surveillance data to the NCSP database and CTAD 
Using Stata version 12 (StataCorp LP), I linked the HPV surveillance data with the 
NCSP database or CTAD database depending on the year of sample collection. 
This linkage was performed to confirm eligibility of samples (as outlined in Section 
4.3.1) as well as obtain some additional information reported at the time of the 
chlamydia screen (as described in Table 4.1).  
The patient identifiers included on the data collection forms were used for linkage. 
When possible, I used the NCSP/CTAD identifier that uniquely identifies an 
individual chlamydia test. However, for some laboratories, this identifier was not 
available and therefore could not be provided on the data collection forms. If 
NCSP/CTAD identifiers were unavailable, the patient’s date of birth and the date of 
the specimen were used to link to the relevant laboratory’s data. Ten percent of 
residual samples could not be matched to NCSP/CTAD data suggesting that; (i) the 
testing venue and/or laboratory had not submitted this chlamydia test to the NCSP 
database or CTAD in error, (ii) incorrect data had been submitted to the NCSP 
database or CTAD, or, (iii) incorrect data had been entered to the data collection 
form for the HPV surveillance. These samples were not released for HPV testing. 
Further details of this linkage are provided in Figure 4.3. 
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Figure 4.3: Algorithm to link the NCSP/CTAD dataset with the HPV surveillance 
specimens and data 
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For samples which were linked using an NCSP/CTAD identifier, I verified that the 
date the sample was taken and date of birth in the NCSP/CTAD database matched 
the data on the data collection forms.  
I calculated the age of the women at testing using their date of birth and the date the 
specimen was taken. Ineligible samples were identified using the eligibility criteria 
given in Section 4.3.1, specifically; 
· Out of eligible age-range for the surveillance 
· Invalid reason for test (as recorded in NCSP dataset – not available in CTAD 
dataset) 
· Invalid venue type (as recorded in NCSP/CTAD dataset) 
· Invalid specimen type (as recorded in NCSP/CTAD dataset) 
· Sample not taken from a female (as recorded in NCSP/CTAD dataset) 
Twenty-one percent of samples were ineligible according to the above criteria and 
were not released for HPV testing. 
4.3.6.  Linkage of HPV surveillance data to HPV vaccination records 
As part of the national HPV surveillance, I aimed to obtain retrospectively the HPV 
vaccination status for all eligible women in the post-vaccination period. Briefly, 
vaccination records were collected using two approaches:  
1. Collected directly from the chlamydia testing laboratory using the chlamydia-
test request form (based on self-reported vaccination status)  
2. I contacted the Child Health Record Departments for each relevant local 
authority (this comprised between 1 and 7 local authorities for each testing 
laboratory). I requested HPV vaccination records for eligible women, defined as 
women included in the HPV surveillance, who had:  
o a valid NHS number  
86 
 
o a known local authority of residence (based on postcode) 
o a date of birth on or after 1st September 1990 (i.e. those who would 
have been eligible to receive the HPV vaccine as part of the National 
HPV vaccination Programme) 
On receipt, I linked these HPV vaccination data to the HPV infection 
surveillance database to allow further analyses of the post-vaccination data (see 
Sections 4.2.1 and 4.3.15). I describe the methods to collect HPV vaccination 
records from Child Health Records Department in further detail in Section 5.2. 
4.3.7. Estimated vaccination coverage 
As described in the Background (Section 2.7.2), national HPV vaccination data are 
collated and published by PHE, using local area-level data collected using the 
ImmForm website.  
For those women for whom it was not possible to link to HPV vaccination status 
(Section 4.3.6), I estimated HPV vaccination coverage using these nationally 
reported data to analyse the association between HPV vaccination coverage and 
changes in HPV prevalence (as described in Section 4.3.14). Specifically, I 
attributed the national reported vaccination coverage data for the relevant birth 
cohort to each individual record, summed these and divided by the total number of 
records (i.e. a weighted average). An example is given in Table 4.2. 
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Table 4.2: An example calculation of estimated HPV vaccination coverage in 
the HPV surveillance population 
Patient 
Vaccination 
status 
National 
coverage
1
 
Individual 
contribution 
1 Vaccinated 0.784 1 
2 Unvaccinated 0.784 0 
3 Unknown 0.784 0.784 
4 Vaccinated 0.784 1 
5 Unknown 0.784 0.784 
6 Unknown 0.784 0.784 
7 Unknown 0.784 0.784 
8 Vaccinated 0.784 1 
9 Vaccinated 0.784 1 
Sum 7.136 
Estimated coverage (sum/total number of patients) 0.793 
1: for relevant birth cohort 
   
The vaccinated birth cohorts by date of birth are given in Table 4.3 with the national 
coverage. I calculated 1-dose and 3-dose coverage which included vaccination in 
the year the vaccine was offered and mop-up vaccination (i.e. vaccine doses given 
to girls who either started or completed their vaccination late). Women recorded as 
vaccinated but with an unknown number of doses were assumed to be fully 
vaccinated in the main analysis; this was considered further in the sensitivity 
analysis (Section 6.3).  
4.3.8. Anonymisation of HPV surveillance data  
Following linkage of the HPV surveillance data with the NCSP/CTAD databases 
(and HPV vaccination data for relevant specimens), I irreversibly deleted all 
personal identifiable patient data prior to releasing samples for HPV testing 
(including all identifiable data collected on the data collection forms and held in the 
Access database), keeping the barcode number. Therefore, it was not possible, at 
any stage to link HPV infection result back to an individual.                                                                                                             
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Table 4.3: Vaccination cohorts of eligible women included in HPV infection surveillance 
Year HPV 
vaccination first 
offered 
Date of birth Vaccination 
cohort 
Age first 
offered HPV 
vaccination 
National vaccination coverage
1
 
1 or more 
doses (%) 
2 or more 
doses (%) 
All 3 doses 
(%) 
2008/09 01/09/1995 - 31/08/1996 Routine 12-13 years old 89.4 87.7 84.4 
2008/09 01/09/1990 - 31/08/1991 Catch-up 17-18 years old 66.1 59.3 47.4 
2009/10 01/09/1996 - 31/08/1997 Routine 12-13 years old 85.9 84.1 80.9 
2009/10 01/09/1994 - 31/08/1995 Catch-up 14-15 years old 81.9 79.6 75.7 
2009/10 01/09/1993 - 31/08/1994 Catch-up 15-16 years old 78.4 75.8 70.8 
2009/10 01/09/1992 - 31/08/1993 Catch-up 16-17 years old 59.8 55.9 48.1 
2009/10 01/09/1991 - 31/08/1992 Catch-up 17-18 years old 55.6 50.3 38.9 
2010/11 01/09/1997 - 31/08/1998 Routine 12-13 years old 88.9 87.5 84.2 
2011/12 01/09/1998 - 31/08/1999 Routine 12-13 years old 90.6 89.6 86.8 
2012/13 01/09/1999 - 31/08/2000 Routine 12-13 years old 90.9 89.6 86.1 
2013/14 01/09/2000 - 31/08/2001 Routine 12-13 years old 91.1 89.8 86.7 
2014/15 01/09/2001 - 31/08/2002 Routine 12-13 years old 89.4 85.1
2
  
2015/16 01/09/2002 - 31/08/2003 Routine 12-13 years old 87.0 83.1
2
  
2016/17 01/09/2003 - 31/08/2004 Routine 12-13 years old 87.2 Pending
2
  
1: Includes mop-up vaccination performed after the year vaccination was first offered  
 2: The National HPV Immunisation Programme moved to a 2-dose schedule from September 2014. In some local areas, vaccine doses were given 12 months 
apart. Data are collated and published annually hence data on full 2-dose coverage are not available until 2 years after the first dose is given
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4.3.9. HPV testing 
The assay used for HPV testing changed between the pre- and post-vaccination 
periods.  
Specimens collected in the pre-vaccination period were initially tested by the Hybrid 
Capture 2 (HC2) HPV DNA test, using the Combined Probe Cocktail Method to 
detect high-risk and possible high-risk types (as above) and five low-risk types (6, 
11, 42, 43 and 44). Relative light units/cut off (RLU/CO) greater than 1 were 
considered positive. Samples which were HC2 positive were then genotyped by the 
Linear Array HPV Genotyping test (Roche Molecular Systems). DNA was extracted 
using the automated BioRobot Universal platform (Qiagen, UK) and then amplified 
using PGMY primers. The LA test identified 37 HPV types (6, 11, 16, 18, 26, 31, 33, 
35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 
72, 73 (MM9), 81, 82 (MM4), 83 (MM7), 84 (MM8), IS39, and CP6108)  
Specimens collected in the post-vaccination period were tested for type-specific 
HPV DNA to detect 13 high-risk types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59 and 68), five possible high-risk types (HPV26, 53, 70, 73 and 82) and two 
low-risk types (HPV6 and 11), using an in-house multiplexed PCR and Luminex-
based genotyping test. DNA was extracted from residual VVS for use in a 
multiplexed, block-based PCR with HPV-specific oligonucleotides and two 
`housekeeping’ gene oligonucleotides. The result was reported as inadequate if the 
samples were negative for both HPV and the housekeeping gene, pyruvate 
dehydrogenase (PDH).  
All the high-risk HPV types which were detectable by the pre-vaccination test were 
also included in the post-vaccination test. However, there may well have been 
differences in the detection rates of the two testing methods. A validation study was 
conducted by the VRD to compare the two tests and I describe this, along with the 
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potential implications of the assay change, in more detail in Section 4.4 and Chapter 
6.  
The following Sections (4.3.10 to 4.3.17) describe the data analysis which I 
designed and conducted to address research questions 1, 2 and 3 of this thesis 
(Figure 2.4).  
4.3.10. Data coding and descriptive analysis 
I linked HPV test results with the anonymised HPV surveillance dataset, using the 
unique barcode number.  
Samples with an inadequate HPV result were excluded from the analysis. HPV 
prevalence was calculated for each specific HPV type. I also calculated combined 
HPV prevalence, restricted to types included in both the pre-vaccination and post-
vaccination assays, for (i) any high-risk HPV type; (ii) the HPV vaccine types 
(HPV16 and/or 18); (iii) the additional high-risk HPV types included in the 
nonavalent HPV vaccine (HPV31, 33, 45, 52 and/or 58); (iv) the HPV types for 
which there is evidence of cross-protection from clinical trials: HPV31, 33 and/or 45 
(HPV51 was not included here as the evidence of potential cross-protection against 
this type was not consistent in the clinical trial; see Sections 2.6.3 and 4.1.2) and (v) 
the non-vaccine high-risk HPV types (i.e. any high-risk type not including HPV16 or 
18).  
I divided the post-vaccination period into separate time periods with broadly similar 
time since vaccination, vaccination coverage and age at vaccination; 2010–2011, 
2012-2013, 2014-2015 and 2016. 
I categorised ethnicity as white (including white, white British, white Irish and any 
other white background), black (including black or black British, black Caribbean, 
black African, white and black Caribbean, white and black African and any other 
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black background), Asian (including Asian or Asian British, white and Asian, Indian, 
Pakistani, Bangladeshi and any other Asian background) and Other (including 
Chinese, any other mixed background and any other ethnic group). The chlamydia 
test results were recorded as positive, negative or unknown (if there was an 
inconclusive result). 
I compared differences in ethnicity, sexual behaviour, sample collection venue, and 
chlamydia test results between the pre- and post-vaccination period and over time 
within the post-vaccination period to explore whether there were changes in the 
study population attending for chlamydia screening. HPV prevalence was calculated 
for each individual HPV type and groups, as defined above.  
4.3.11.  Stratification of results by age at sample and age at vaccination 
All analyses comparing HPV prevalence over time (see Sections 4.3.12 to 4.3.14) 
were stratified by three age-groups, denoting the age at which the sample was 
taken (16-18 years old, 19-21 years old and 22-24 years old). As previously 
described (Section 2.3), HPV prevalence varies by age, hence considering changes 
in HPV prevalence in a specific age-group provided a more stable population for 
comparison over time with differences more likely to be due to HPV vaccination.  
Table 4.4 describes the association between age at sample collection, year of 
sample collection and age at vaccination. Age at vaccination is closely related to 
both vaccination coverage (coverage is higher at younger ages) and the expected 
effectiveness of the vaccine, largely due to a higher risk of exposure to HPV before 
vaccination in those vaccinated at older ages (and hence lower vaccine 
effectiveness). Therefore, analyses of vaccine effectiveness (described in Section 
4.3.15) were stratified by the age that vaccination would have been offered as part 
of the national programme (offered vaccination at 12-15 years old vs. offered 
vaccination at 16-17 years old).  
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Table 4.4: Age at which HPV vaccination would have been offered as part of the National HPV Immunisation Programme, by age at 
sample collection and year of sample collection  
Age at sample 
collection 
(years) 
Age first offered vaccination 
Pre-vaccination period   Post-vaccination period (by year) 
2008   2010 2011 2012 2013 2014 2015 2016 
16 
All samples collected 
prior to HPV 
vaccination 
 
14-16 12-15 12-14 12 12 12 12 
17 
 
15-17 14-16 12-15 12-14 12 12 12 
18 
 
16-17 15-17 14-16 12-15 12-14 12 12 
19 
 
17 16-17 15-17 14-16 12-15 12-14 12 
20 
 
17 17 16-17 15-17 14-16 12-15 12-14 
21 
 
NA
1
 17 17 16-17 15-17 14-16 12-15 
22 
 
NA
1
 NA
1
 17 17 16-17 15-17 14-16 
23 
 
NA
1
 NA
1
 NA
1
 17 17 16-17 15-17 
24   NA
1
 NA
1
 NA
1
 NA
1
 17 17 16-17 
1: Women born before 1st September 1990 were not eligible to receive the HPV vaccine in the national 
programme 
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4.3.12. Comparison of HPV prevalence between the pre- and post-
vaccination period 
These analyses were conducted on samples collected between 2008 and April 
2013.  
Changes in the prevalence of HPV between the pre-vaccination and post-
vaccination periods were compared using prevalence ratios (PRs), calculated using 
a log binomial regression model in Stata. The corresponding 95% confidence 
intervals were calculated using a Wald test. Trends over time were assessed by 
including the three time periods (pre-vaccination, 2–3 years post-vaccination, 4–5 
years post-vaccination) as an ordered categorical variable. I similarly calculated 
odds ratios (ORs) using a logistic regression model in Stata. The reason for 
calculating odds ratios in addition to prevalence ratios is described in Section 4.4 
along with further detail regarding the adjustment for the change in assay between 
the pre- and post-vaccination periods. 
Data on sexual behaviour were only collected for samples reported through the 
NCSP dataset and not for samples reported via CTAD (see Section 4.2.5). In the 
NCSP dataset, there was a high proportion of missing data for this variable (~20% 
of sexual behaviour data were missing in the pre-vaccination period and >50% in 
the post-vaccination period). Furthermore, ethnicity was poorly recorded in both the 
NCSP and CTAD dataset (although there were more missing data in CTAD) and 
this varied by area and year of data collection. Given the very high proportion of 
missingness for sexual behaviour data and ethnicity, it was not appropriate to 
perform any multiple imputation methods[120]. Thus, these variables were not 
included in the multivariable regression; although they were included in descriptive 
analyses but should be interpreted with caution. Furthermore, IMD was only 
available in the post-vaccination period as patient postcode was not linked in the 
pre-vaccination period and hence IMD was also not included in this multivariable 
94 
 
regression model. Therefore, there were relatively few variables which could be 
considered for multivariable regression analysis: testing venue type, age and 
chlamydia test result which was used as a proxy for high-risk sexual behaviour. For 
both PRs and ORs, all variables were kept in the model.  
4.3.13. Sensitivity analyses for comparison of HPV prevalence between the 
pre- vs post-vaccination period 
A further three sub-analyses were conducted using the above approach, as follows: 
Analyses restricted to HPV positive samples: Due to the limited number of 
demographic variables for inclusion in the multi-variable regression model and to go 
some way towards addressing concerns about changes in prevalence of HPV over 
time which were unrelated to HPV vaccination (e.g. changes in sexual behaviour 
which are not fully addressed by adjustment of chlamydia result), I also analysed 
data restricted to specimens with at least one HR-HPV type detected. This enabled 
me to consider changes in the relative, rather than absolute, prevalence of specific 
HPV types. As an example, if 20% of pre-vaccination specimens were high-risk 
HPV positive (10% of which were HPV31 positive and 10% HPV33 positive), and 
30% of post-vaccination specimens were high-risk HPV positive (15% HPV31 
positive and 15% HPV33 positive), then there would be a 50% absolute increase for 
both HPV types. However, there would be no change in the relative frequency of 
either HPV type among those who were high-risk HPV positive.  
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Analyses restricted to laboratories participating in both the pre-vaccination and post-
vaccination period: The laboratories collecting samples in the pre-vaccination period 
were also included in the post-vaccination specimen collection to obtain as stable 
population as possible over time. However, as previously explained in Section 4.3.1, 
it was necessary to increase the number of collecting laboratories in the post-
vaccination period. Therefore, I performed a sub-analysis including only the six 
laboratories included in both the pre- and post-vaccination periods.  
Analyses excluding Lewisham and Leeds laboratories: The chlamydia positivity from 
the Lewisham and Leeds laboratories was higher than that seen at other 
laboratories (and higher than expected in these areas compared to the overall 
chlamydia positivity from these laboratories). The reason for this was explored with 
the two laboratories but could not be determined. Therefore, there was some 
concern that samples were selected according to their chlamydia result contrary to 
instructions from PHE. As a result, I conducted a sub-analysis excluding data from 
these two laboratories (both laboratories only provided samples for the post-
vaccination period). 
The results of these sensitivity analyses are shown in Chapter 6. 
4.3.14. Comparison of HPV prevalence within the post-vaccination period 
These analyses were conducted on post-vaccination samples collected between 
2010 and 2016. 
I calculated HPV prevalence and 95% confidence intervals for each time period 
separately. Changes in prevalence over time were compared using a log-binomial 
regression model with year of data collection as a continuous variable. P-values for 
trend across years were calculated using the Wald test. As with the pre- and post-
vaccination period analysis, multivariable regression models were adjusted for age, 
testing venue and chlamydia positivity.  
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To explore the association between changes in the prevalence of HPV infection and 
estimated HPV vaccination coverage, I included a continuous variable in the 
regression model with the estimated HPV vaccination coverage (as a proportion) for 
each combination of year and age-group. This allowed calculation of an adjusted 
HPV prevalence ratio comparing a female population with no vaccination (i.e. 
coverage=0) with a fully vaccinated female population (i.e. coverage=1). These 
analyses were stratified by age-group. 
4.3.15. Calculation of vaccine effectiveness 
These analyses were conducted on post-vaccination samples with a known 
vaccination status collected between 2010 and 2016. 
For the subgroup of women for whom HPV vaccination status was available 
(Section 4.3.6), direct comparison of HPV prevalence in vaccinated compared to 
unvaccinated women was calculated as follows:  
vaccine effectiveness =  HPV prevalenceunvaccinated – HPV prevalencevaccinated  
           HPV prevalenceunvaccinated 
 
Results were stratified by age-group (16-18 years old, 19-21 years old and 22-24 
years old). Vaccine effectiveness against HPV prevalence was assessed using a 
log binomial regression model in Stata. A multivariable regression model was used 
to adjust the vaccine effectiveness estimates for testing venue type, age and 
chlamydia positivity which was used as a proxy for high-risk sexual behaviour (as in 
Section 4.3.12). The vaccine effectiveness was calculated as 1-aRR. As a 
sensitivity analysis, I also adjusted for patients’ IMD, available in the post-
vaccination period only in a complete case analysis; the results of this are presented 
in Section 6.4.3. 
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4.3.16. Sensitivity analyses for comparison of HPV prevalence in the post-
vaccination period and for calculation of vaccine effectiveness  
In the post-vaccination period only, data on index of multiple deprivation (IMD) were 
available for some patients. The initial intention was to adjust for IMD as an 
additional potential confounder, but due to varying proportions of missing data over 
time, this was not carried out for the main analyses. However, as a sensitivity 
analysis, I conducted a complete case analysis comparing the unadjusted 
prevalence ratio for HPV associated with estimated HPV vaccination coverage and 
the adjusted prevalence ratio (with and without further adjustment for patients’ 
quintile of IMD). I also adjusted the vaccine effectiveness for patients’ IMD in a 
complete case analysis. The results of both of these sensitivity analyses are 
provided in Section 6.4.3. 
Furthermore, prior to 2014, the recommended dose schedule for the bivalent 
vaccine was three doses, with the second dose given between 1 and 2.5 months 
after the first dose and the third dose between 5 and 12 months after the first dose. 
However, if the second or third dose was not administered within the recommended 
timeframe, the advice is that the course should still be continued without repeating 
previous doses[121]. In sensitivity analyses, I recalculated the vaccine effectiveness 
including only women who were known to have received the full vaccine course 
within the recommended time interval (i.e. excluding those receiving less than three 
doses, those receiving an unknown number of doses or those who received three 
doses but outside of the recommended time interval). 
4.3.17. Estimation of the herd protection effect of vaccination 
To estimate the herd protection effect, I compared the HPV prevalence in the pre-
vaccination period to the HPV prevalence in unvaccinated women in the post-
vaccination period. As above, results were stratified by age-group (16-18 years old, 
19-21 years old and 22-24 years old). Similar to methods described in Section 
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4.3.12, differences in the prevalence between the unvaccinated and vaccinated 
women were compared using PRs, calculated using a log binomial model 
regression model in Stata. A multivariable regression model was used to compare 
estimates, adjusted (as with other analyses) for testing venue type, age and 
chlamydia test result to adjust for known changes over time. Odds ratios were 
adjusted for the change in assay between the pre- and post-vaccination periods as 
described in the next section. 
4.4. Adjustment to assess and correct for differences in 
HPV detection between pre- and post-vaccination 
periods 
4.4.1.  Comparison of pre- and post-vaccination HPV test detection rate 
As previously described, in this national surveillance, the assay used to test residual 
samples for HPV DNA infection in the pre-vaccination period was different to the 
assay used in the post-vaccination period. The decision to change assay was 
largely due to the reduced cost of performing relatively high-throughput HPV testing 
with an in-house assay rather than a commercial assay.  
Therefore, whilst the HPV assay used to test specimens has been constant 
throughout the post-vaccination period, this is different from the assay used in the 
pre-vaccination period. Given this change in HPV assay between the two periods, 
changes in the prevalence of specific HPV types may not be due to HPV 
vaccination alone but could be affected by the different detection rates of these two 
HPV assays.  
4.4.2.  Validation study comparing pre- and post-vaccination HPV assays 
This validation study was conducted by the VRD at PHE and does not constitute 
part of this PhD.  
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Prior to the introduction of the Luminex HPV Genotyping Assay in national 
surveillance studies, an in-house evaluation of the assay performance in various 
residual clinical samples was conducted by PHE. As part of this evaluation, a total 
of 428 specimens collected as part of the pre-vaccination surveillance were retested 
using the post-vaccination Luminex-based test to investigate the potential for bias 
resulting from this assay change. The results of this validation study were published 
internally within PHE in August 2011. 
Importantly, both assays detected a similar positivity rate for the high-risk HPV 
vaccine types (22.2% for the pre-vaccination assay and 23.8% for the post-
vaccination assay) with a high agreement (kappa = 0.81). However, when the other 
non-vaccine types were assessed, there were some differences in the detection 
rate. Overall, the post-vaccination assay identified more non-vaccine high-risk HPV 
positives than the pre-vaccination HC2/Linear array assay (51.6% vs. 45.8%, kappa 
0.78). This difference was likely due to the reduced sensitivity of the HC2 assay 
compared to a direct PCR amplification-based assay. The positivity for all HPV 
types using the two assays is given in Table C1 in the Appendix. 
4.4.3. Adjustment of pre-vaccination prevalence estimates  
I have previously described how I proposed to compare the HPV prevalence in the 
pre-vaccination period to the post-vaccination period using prevalence ratios 
(Sections 4.3.12 and 4.3.13). In this section, I describe techniques I developed and 
applied to estimate the prevalence of HPV infection in the pre-vaccination period 
that we would have expected to observe if we had used the post-vaccination assay. 
In Section 4.4.4, I describe techniques used to compare the HPV prevalence in the 
pre- and post-vaccination periods, adjusted for this assay change.  
As described in the previous section, the assays used in the pre-vaccination and 
post-vaccination periods had different diagnostic accuracy for detection of certain 
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HPV types. Therefore, unadjusted HPV prevalence estimates would not have been 
comparable between the pre- and post-vaccination period. To account for this, I 
adjusted pre-vaccination prevalence to estimate the prevalence that would have 
been observed if the post-vaccination assay had been used. To do this, I  use the 
following formula proposed by Rogan and Gladen[122] to adjust for an imperfect 
test;                           
 =
(!"#$%&)
('"#$%&)
       (1) 
where; 
p is the pre-vaccination prevalence if testing using the post-vaccination assay 
t is the proportion of specimens testing positive using the pre-vaccination assay 
α is the sensitivity of the pre-vaccination assay compared to the post-vaccination assay 
β is the specificity of the pre-vaccination assay compared to the post-vaccination assay 
This estimate requires a known sensitivity and specificity for the test. In the HPV 
infection surveillance, the sensitivity and specificity comparing the pre-vaccination 
and post-vaccination assay were not known but were estimated from a validation 
study (as described in Section 4.4.2), resulting in the following formula; 
 !" = (#$%!&!' )*+(,"%!&!' )*+       (2) 
Rogan and Gladen demonstrated that (2) above would be considerably less biased 
than just using proportion of specimens testing positive using the pre-vaccination 
assay.  
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The simplest approach to calculate confidence intervals for this estimate would be 
to use the asymptomatic variance of p̂ obtained by Taylor series expansion; 
!!!!!!!!!!!!-./( !"+ = #$(*)#$+012!!%!!3!" 4,"!(*)!,"+015!%!6*%3!" +4&!' (*)&!' 7018(,"%!&!')*+4    (3) 
       
!!!!9:;/;!<# > <,!.<?!<&!./;!@:;!A.B C;!ADE;A!FA;?!@G!;A@DB.@;!@H> IJ!.<?!K$!/;A ;L@D-;CM 
However, Lang and Reiczigel have since demonstrated that the coverage 
probability of confidence intervals derived from (3) could fall below the nominal level 
in some situations (importantly here, the coverage of these confidence intervals 
could be incorrect if the samples sizes nα or nβ are not large)[123]. Consequently, 
Lang and Reiczigel proposed an approach to estimate confidence intervals with 
improved coverage when sensitivity and specificity estimates are unknown[123]. I 
used this approach to calculate the lower and upper confidence limits for prevalence 
estimated in the HPV infection surveillance. Specifically, if; 
<3N =!<3 O!PQRS#T        (4) 
@N = ! (1U#$+%!VWXY24 0T1U%!VWXY24        (5) 
Then the confidence interval for t’ is; 
@N ± PQRS#Z [@\ (*)#]+1U]        (6) 
Where the sensitivity and specificity are estimated, let; 
<,N = <, O ^        (7) 
<&N = <& O ^        (8) 
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IN =! 15(,%*+15%T         (9) 
KN =! 18(&%*+18%T         (10) 
 N =! #]%&])*,]%&])*        (11) 
Substituting the equations (7) to (11) above to the corresponding terms (i.e. its 
primed equivalent) in (3), gives the variance of p’. The adjusted confidence intervals 
for the prevalence will then be;  
 N O ? ! ± PQRS# Z _-./( N+      (12) 
where; 
? = ^Z PQRS#T Z ` NZ ,](*),]+15] a (b a  N+Z
&](*)&]+
18] c    (13) 
In this same paper, Lang and Reiczigel show that the mid-point of the confidence 
interval in (13) is more biased than the estimate suggested by Rogan and Gladen 
above, hence I used (2) for prevalence estimates and the approach by Lang and 
Reiczigel for the confidence intervals. The adjusted prevalence estimates and 
confidence intervals described above were not included in the papers presented in 
Section 6.2 or 6.3. However, adjusted prevalence estimates are presented in Table 
6.1, alongside the unadjusted prevalence estimates for comparison. Section 4.4.4 
below describes further analyses I conducted to adjust for this assay change when 
comparing HPV infection between the pre- and post-vaccination periods; the 
resulting odds ratios are included in the paper presented in Section 6.2 and in Table 
6.2.  
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4.4.4.  Adjustment of comparison between pre- and post-vaccination 
prevalence 
The techniques described above allowed calculation of prevalence estimates for the 
pre-vaccination period adjusted for the change in assay. In order to compare HPV 
infection between the pre- and post-vaccination periods with adjustment for the 
change in HPV assay, I calculated an odds ratio adjusted for age, collection venue 
type and chlamydia positivity, using the logitem command in Stata. This command 
performs logistic regression when the binary outcome is measured with uncertainty 
by using an expectation-maximisation algorithm to estimate a maximum-likelihood 
regression model with a known sensitivity and specificity (the sensitivity and 
specificity for the post-vaccination period were assumed to be 100% with an 
imperfect sensitivity and specificity for the pre-vaccination period). A similar 
statistical model to adjust for assay change was not available for use with 
prevalence ratios (PR), and thus equivalent PR analyses were not carried out.  
The estimated ORs provided using the logitem command would not account for the 
uncertainty surrounding the sensitivity and specificity estimates (estimated from the 
validation study described in Section 4.4.2). In order to incorporate this additional 
uncertainty to the standard errors (SEs) of the ORs for each HPV types, I devised a 
technique using bootstrapping methods, as follows.  
(i) I created a validation dataset mimicking the type-specific agreement data 
from the validation study that compared the two assays 
(ii) I selected a bootstrap sample from this validation dataset to calculate a 
sensitivity and specificity estimate for the pre-vaccination assay compared 
to the post-vaccination assay [to incorporate the uncertainty of the 
sensitivity and specificity estimates] 
(iii) From my main dataset (i.e. the data including the pre- and post-vaccination 
test results and individual demographics), I selected a separate bootstrap 
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sample [to incorporate the uncertainty of the odds ratio due to the sample 
size of the HPV infection surveillance population] 
(iv) I calculated an odds ratio using the logitem command with the sensitivity 
and specificity estimates from (ii)  
(v) I repeated steps (i) to (iv) 1,000 times and extracted the resultant odds ratio 
from each run 
Once the bootstrap was completed, the dataset containing the 1,000 odds ratios 
was used to calculate confidence intervals (taken as the 2.5th and 97.5th percentile 
of the ORs). The Stata programme which I wrote to perform this bootstrapping is 
available in Appendix C2.  
In this chapter, I have outlined the HPV infection surveillance methods used to 
evaluate the National HPV Immunisation Programme in England, which inform 
research questions 1, 2 and 3 of this thesis. In Chapter 5, I describe work conducted 
for this PhD to compare HPV vaccination records collected from different sources. 
The results of this comparison informed interpretation of the vaccine effectiveness 
analyses and estimation of herd protection effects. 
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Chapter 5: Validation of HPV vaccination records  
In this chapter, I present the methods used to collect individual’s HPV vaccination 
records from Child Health Information Systems (CHIS). I also describe the rationale, 
methods and results of a study I designed and conducted in order to validate a 
sample of these vaccination records against records held at general practices. The 
implications of the results of this study are discussed briefly here and explored in 
more detail in Chapter 6. 
5.1. Background 
5.1.1. National collection of HPV vaccination status 
As previously mentioned in Section 2.7.2, all vaccinations administered to children 
(defined as those aged 0-18 years) in England should be recorded on a Child 
Health Information Service (CHIS) System. These systems are held and operated at 
a local level (within a local authority (LA) or, previously, a primary care trust (PCT)) 
within Child Health Records Departments (CHRD). The systems do not use 
standard software and hence there is not a single national CHIS dataset. The 
vaccination data held on these systems are collated from school nursing services 
and GP systems. HPV vaccination doses given at schools should also be held on 
GP records although not all areas will inform GPs of vaccinations performed in 
school settings. 
In addition to ensuring that HPV vaccination status is recorded on CHIS for all 
vaccinated children, it is the responsibility of CHIS/CHRD to report HPV 
vaccinations undertaken in schools and other venues to the Cervical Screening 
System (held on National Health Applications and Infrastructure System, NHAIS, 
otherwise known as the Exeter system or Open Exeter) so that a woman’s 
vaccination status is available to those conducting cervical screening. As such, 
complete HPV vaccination records should be held for all vaccinated females on at 
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least two data systems (i.e. CHIS and Open Exeter), and ideally on GP records as 
well (Figure 5.1).  
 
 
 
In practice, the degree of data transfer between systems varies across different 
areas. In almost all local areas, vaccination was offered in schools for routinely 
vaccinated girls (i.e. 12-13 year olds) and the younger catch-up cohorts (i.e. ≤16 
year olds) and in primary care settings for the older catch-up cohorts (i.e. >16 year 
olds). I previously contributed towards an unpublished analysis (conducted outside 
of this PhD) which compared HPV vaccination uptake data from CHIS from eight 
PCTs with uptake from the Clinical Practice Research Datalink (CPRD) for practices
within the same PCTs. The results demonstrated that HPV vaccination uptake using 
the CPRD data was similar to that in the CHIS data for women in the older catch-up 
cohorts (i.e. largely vaccinated at general practices) but the uptake in women in the 
younger cohorts was (i.e. largely vaccinated at schools) was much lower in the 
CPRD data compared to CHIS data (Table 5.1).  
Figure 5.1: Process to report and exchange data on individual HPV vaccination 
status 
107 
 
Table 5.1: HPV vaccination uptake among the routine, younger catch-up and 
older catch-up cohorts for Child Health Information System (CHIS) and 
Clinical Practice Research Datalink (CPRD) 
HPV vaccination cohort 
CHIS CPRD 
% (95%CI) % (95%CI) 
Routine (12-13 years)  88.4 (88.1-88.7) 60.6 (60.1, 61.2) 
Younger catch-up (14-16 years) 88.4 (88.0-88.8) 50.4 (49.8, 51.0) 
Older catch-up (≥16 years) 55.8 (55.1-56.4) 52.0 (51.5-52.5) 
 
Importantly, the results of this unpublished analysis also demonstrated that 
recorded uptake of HPV vaccination in some general practices appeared to be very 
low. Table 5.2 shows categories of HPV vaccination uptake (<20%; 20-40%; 40-
60%; 60-80% and 80-100%) for practices in the eight PCTs included in the CPRD 
analysis.  
Table 5.2: Categories of HPV vaccination uptake at general practices in eight 
PCTs using Clinical Practice Research Datalink (CPRD) data, by vaccination 
cohort 
HPV vaccination 
uptake (%) 
Routine  
(12-13 yrs) 
Younger catch-up  
(14-16 yrs) 
Older catch-up 
(≥16 yrs) 
Number of 
practices (%) 
Number of 
practices (%) 
Number of 
practices (%) 
<20%  77 (18.5%) 125 (30.0%) 66 (15.5%) 
20-40% 37 (8.9%) 33 (7.9%) 54 (12.7%) 
40-60% 35 (8.4%) 41 (9.8%) 115 (27.1%) 
60-80% 135 (32.5%) 135 (32.4%) 148 (34.8%) 
80-100% 132 (31.7%) 83 (19.9%) 42 (9.9%) 
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Whilst it was expected that some areas/practices would have lower uptake than 
others, there was an unexpectedly high proportion of practices with <20% uptake 
(18.5% of practices for routine cohorts, 30.0% for younger catch-up cohorts, and 
15.5% for older catch-up cohorts). This suggests that the level of data transfer 
between CHIS and GP records was inadequate at some practices; particularly for 
younger vaccination cohorts (<16 years old) for which vaccination uptake was 
expected to be higher. This could be that data were not sent from CHIS to GPs or 
that data were sent in paper format and not transferred to electronic GP records. 
Further to data in Table 5.1 and Table 5.2, conversations with GPs, CHRDs and 
other local providers, have also provided some insight into the process of recording 
and transferring HPV vaccination records. These conversations suggested that 
vaccination records for routine cohorts and younger catch-up cohorts (i.e. those 
largely vaccinated at schools) are more complete on CHIS but may not always be 
available on GP systems (this supports results in Table 5.1 and Table 5.2). 
Furthermore, these conversations suggested that vaccination records for older 
catch-up cohorts (i.e. those vaccinated at general practices) are usually available on 
GP systems but in some local areas these data are not always uploaded to CHIS. 
This is in contrast to the results from the eight PCTs presented in Table 5.1 and 
suggests that these results may not be generalisable to all practices. In addition to 
this, the data which are uploaded from CHIS to Open Exeter appears incomplete in 
almost all local areas, particularly for the catch-up cohorts[78]. This varies by local 
area and birth cohort but the data from the 2013/14 vaccination cohort showed that 
HPV vaccination coverage on Open Exeter was between 4.2% and 86.5% lower by 
area team than the aggregated coverage data reported via ImmForm (Section 
2.7.2)[78]. 
For the HPV infection surveillance described in Chapter 4, I made use of HPV 
vaccination data held in CHIS. I described this process briefly in Section 4.3.6, and 
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in more detail below in Section 5.2.2. I also performed a validation study to compare 
HPV vaccination records in CHIS with GP records for samples collected from one of 
the laboratories included in this surveillance (this validation study is described in 
Section 5.3). 
5.1.2. Why is accurate recording of HPV vaccination records required?  
As women reach the age at which they are invited for cervical screening, access to 
an individual’s vaccination records becomes important for two reasons. Firstly, PHE 
are conducting enhanced surveillance to perform HPV testing on all cervical 
cancers diagnosed in women who would have been eligible to have received the 
HPV vaccine. This surveillance does not fall within the scope of this PhD but 
accurate individual vaccination records are essential to identify potential vaccine 
failures (i.e. routinely vaccinated women who are diagnosed with an HPV16/18 
positive cervical cancer). Secondly, although currently cervical screening protocols 
are identical for vaccinated and unvaccinated women, there is a possibility that 
screening procedures may differ depending on vaccination status in the future 
(particularly if the nonavalent vaccine were introduced in the UK)[124]. For this to be 
possible, accurate HPV vaccination records would need to be linked to a woman’s 
cervical screening records (i.e. Open Exeter).  
Furthermore, I have previously described in Section 4.2.1 the benefits of collecting 
HPV vaccination status for national HPV infection surveillance. Inaccurate recording 
of HPV vaccination status could affect the calculation of vaccine effectiveness, 
particularly if there was a bias in reporting (e.g. if those at higher risk of HPV 
infection were more likely to have inaccurate HPV vaccination status). This latter 
point is explored further in Section 6.4.4.   
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5.2. (Methods 1) Collection of HPV vaccination records 
from Child Health Information Systems for HPV 
infection surveillance 
5.2.1.  Eligible population 
I previously described methods for the HPV infection surveillance conducted at 10 
laboratories across England and, briefly, the linkage with individual HPV vaccination 
records in CHIS (Section 4.3.6). In this section I provide more detail on the methods 
to collect HPV vaccination records for individuals included in this surveillance who 
met the following criteria:  
· Valid NHS number 
NHS number was the only patient identifier which could uniquely identify 
records in the CHIS and the HPV surveillance study and hence was required for 
linkage. I assessed that available NHS numbers were 10 digit numbers with an 
eligible 10th check digit[125]. 
· Known local authority of residence (formerly Primary Care Trust) 
As described, the majority of local areas held records in separate CHIS 
databases; therefore in these areas, a known LA/PCT of residence was required to 
be able to contact the holder of the relevant CHIS data. 
· Eligible to receive the HPV vaccine as part of the National HPV Immunisation 
Programme 
This included all women born on or after the 1st September 1990. 
Of all eligible residual VVS specimens collected for the HPV infection surveillance 
(see Section 4.3) that were taken from women who would have been offered the 
HPV vaccination as part of the national programme, 39% (4,457/11,541) were from 
women from whom vaccination records could potentially be obtained (i.e. had a 
valid NHS number). The remaining 61% (7,084/11,541) of specimens were released 
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for HPV testing with an unknown vaccination status (Section 4.3.7). Of those with a 
valid NHS number, vaccination records were only requested for 77% (3,432/4,457) 
of women as for remaining women, because either the local authority of residence 
was unknown or the local CHRD did not agree (or were unable) to link with the local 
CHIS system. The full details of linkage to vaccination records, stratified by 
laboratory are provided in Table 5.3. 
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Table 5.3: Collection of HPV vaccination records by testing laboratory and local authority (including data to end 2016) 
Laboratory Name Local authority (LA) or 
Primary Care Trust (PCT) 
Number of 
eligible 
samples 
received  
Number (%) born 
on or after  
1st September 
1990 
Number (%) 
eligible and with 
valid NHS 
number 
CHIS contact 
approached 
(N/Y)? 
CHIS contact 
agreed to 
participate 
(N/Y)? 
Number (%) 
returned 
Addenbrookes Cambridge 313 164 (52%) 5 (3%) 
Y
3
 Y
3
 130 (49%)
3
 
 
Huntingdonshire 292 169 (58%) masked
4
 
 
Fenland 171 98 (57%) 0 (0%) 
 
South Cambridgeshire 126 64 (51%) 0 (0%) 
 
East Cambridgeshire 84 43 (51%) masked
4
 
 
Other
1
 23 15 (65%) 0 (0%) 
 
Unknown† 353 329 (93%) 259 (79%) 
        
Aintree Liverpool 409 268 (66%) 44 (16%) Y N 
 
 
Cheshire West and Chester 315 203 (64%) 40 (20%) Y N 
 
 
Wirral 203 127 (63%) 12 (9%) Y Y 10 (83%) 
 
Cheshire East 149 96 (64%) 18 (19%) Y N 
 
 
Sefton 124 80 (65%) 0 (0%) N 
  
 
St. Helens 40 27 (68%) masked
4
 N 
  
 
Halton 31 18 (58%) 0 (0%) N 
  
 
Knowsley 36 18 (50%) 0 (0%) N 
  
 
Warrington 22 17 (77%) 0 (0%) N 
  
 
Other
1
 61 43 (70%) masked
4
 N 
  
 
Unknown 57 32 (56%) 16 (50%) - 
          
Cornwall Cornwall 3,454 2501 (72%) 2267 (91%) Y Y 1932 (85%) 
 
Other
1
 54 36 (67%) 32 (89%) N 
  
 
Unknown 31 27 (87%) 16 (59%) - 
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East Kent Canterbury 1144 929 (81%) 289 (31%) Y N 
 
 
Thanet 616 521 (85%) 41 (8%) Y N 
 
 
Ashford 485 382 (79%) 19 (5%) Y N 
 
 
Dover 438 346 (79%) 18 (5%) Y N 
 
 
Shepway 396 299 (76%) 28 (9%) Y N 
 
 
Swale 279 253 (91%) 49 (19%) Y N 
 
 
Other
1
 71 65 (92%) 6 (9%) N 
  
 
Unknown 461 400 (87%) 96 (24%) - 
          
Leeds Leeds 2345 1783 (76%) 184 (10%) Y N 
 
 
Bradford 260 179 (69%) 8 (4%) N 
  
 
Other
1
 120 86 (72%) 0 (0%) N 
  
 
Unknown 271 225 (83%) masked
4
 - 
          
Lewisham Lewisham 382 146 (38%) NA
2
 NA
2
 NA
2
 82 (56%) 
 
Greenwich 39 18 (46%) NA
2
 NA
2
 NA
2
 10 (56%) 
 
Bromley 36 16 (44%) NA
2
 NA
2
 NA
2
 8 (50%) 
 
Southwark 29 13 (45%) NA
2
 NA
2
 NA
2
 5 (38%) 
 
Other
1
 31 10 (32%) NA
2
 NA
2
 NA
2
 6 (60%) 
 
Unknown 201 124 (62%) NA
2
 NA
2
 NA
2
 66 (53%) 
        
Norfolk and 
Norwich 
Waveney 124 87 (70%) 0 (0%) N 
  Great Yarmouth 92 65 (71%) 0 (0%) N 
  
 
Norwich 46 33 (72%) 0 (0%) N 
  
 
South Norfolk 23 12 (52%) 0 (0%) N 
  
 
Broadland 20 16 (80%) 0 (0%) N 
  
 
Other
1
 43 30 (70%) 0 (0%) N 
  
 
Unknown masked
4
 masked
4
 0 (0%) N 
          Portsmouth Portsmouth 107 61 (57%) 59 (97%) Y Y 17 (29%) 
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Havant 54 32 (59%) 31 (97%) Y N 
 
 
Gosport 52 33 (63%) 31 (94%) Y N 
 
 
Fareham 36 18 (50%) 17 (94%) Y N 
 
 
Other
1
 17 11 (65%) 11 (100%) N 
  
 
Unknown 0 NA NA - 
          
Stoke Stoke-on-trent 496 319 (64%) 214 (67%) Y Y 54 (25%) 
 
Newcastle-under-Lyme 236 172 (73%) 135 (78%) Y Y 21 (16%) 
 
Staffordshire Moorlands 119 101 (85%) 85 (84%) Y Y 7 (8%) 
 
Stafford 86 78 (91%) 65 (83%) Y Y 0 (0%) 
 
Other
1
 68 50 (74%) 24 (48%) N 
  
 
Unknown 8 masked
4
 masked
4
 - 
          
UCL Islington 137 96 (70%) 0 (0%) N 
  
 
Camden 135 44 (33%) 0 (0%) N 
  
 
Hackney 45 27 (60%) 0 (0%) N 
  
 
Haringey 42 24 (57%) 0 (0%) N 
  
 
Other
1
 115 52 (45%) 0 (0%) N 
    Unknown 10 5 (50%) 0 (0%) N     
NA = Not applicable 
1: Includes LAs/PCTs with <10 women with potential vaccination records 
2: Lewisham laboratory had access to patient's HPV vaccination records. Therefore, vaccination records were sent directly on data collection forms and NHS 
number was not required for linkage 
3: CHIS data from Addenbrookes were searched across all local areas 
4: In accordance with PHE data sharing policy, cells with values between 1 and 4 inclusive were masked. If masked cells could be deduced from values of 
other cells then the next smallest cell was also masked 
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5.2.2. Methods for HPV vaccination data collection from CHIS and linkage 
with the HPV infection surveillance database 
For each area (either LA or PCT) with eligible specimens to link to HPV vaccination 
records, it was necessary to contact the person responsible for the relevant Child 
Health Information System. If it was not clear who the relevant contact was, I 
contacted the Screening and Immunisation Teams (SITs). SITs are employed by 
PHE and provide local leadership for screening and immunisation services within an 
Area Team (AT). Therefore, SITs have close relationships with screening and 
immunisation colleagues within their area and often had the ability to put me in 
touch with the relevant CHIS contact.  
Once the relevant contact at CHIS was identified, I contacted them (either by 
telephone or initially by email and then following up on the telephone if necessary) 
to describe the rationale, methods and legal/ethical basis of the HPV infection 
surveillance. If the CHIS department was able to assist with the data linkage then 
initially I liaised with PHE Business Development colleagues to produce data 
sharing agreements for that area. Only when this was in place did I request any 
data linkage or transfer. As data extraction from CHIS required a significant amount 
of work for NHS and/or PHE SIT colleagues, I did not contact local authorities where 
there were only a small number of eligible patients (i.e. less than 10). 
Once the above was in place, I sent a list of valid NHS numbers for the eligible 
women included in the surveillance to the relevant CHIS contact by secure 
encrypted email, requesting the following information: 
· Vaccination status (unvaccinated, partially vaccinated, fully vaccinated) 
· Date received (dose 1) 
· Batch number (dose 1) (if known) 
· Date received (dose 2) 
· Batch number (dose 2) (if known) 
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· Date received (dose 3) 
· Batch number (dose 3) (if known) 
· Vaccine type (bivalent or quadrivalent) 
· GP name (for Cornwall local authority only – see Section 5.3) 
· GP practice name (for Cornwall local authority only – see Section 5.3) 
On receipt of data from CHIS, I linked the returned data with the HPV surveillance 
dataset using the NHS number. Once the vaccination data were linked, patient 
identifiable information (including date of birth, NCSP/CTAD test identifier and NHS 
number) were irreversibly deleted (with the exception of those included in the 
validation study; Section 5.3). Only once the patient identifiable data were deleted 
were these specimens released for testing by the VRD laboratory (Section 4.3.8).  
5.2.3. Results of HPV vaccination coverage from CHIS for the national 
HPV infection surveillance 
Across all laboratories, 68% (2,348/3,432) of HPV vaccination records which were 
requested were returned and linked. I discuss the representativeness of these 
records in Section 6.3 and Section 6.4.4. Full details of the number of records 
requested and returned, stratified by laboratory, are shown in Table 5.3. Of those 
returned, the proportion of women who had received at least one dose of the 
vaccine was 82% (1,924/2,348) although this varied by the age at which vaccination 
was offered (93% in routine cohorts, 89% in younger catch-up cohorts and 69% in 
older catch-up cohorts). Vaccination coverage stratified by age-group and laboratory 
is shown in Table 5.4. 
Further details of the characteristics of vaccinated and unvaccinated women, and of 
women with and without recorded vaccination status are given in Section 6.3 and 
Section 6.4.4. I also present the results of HPV prevalence in vaccinated women 
compared to unvaccinated women in Section 6.3. 
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Table 5.4: HPV vaccination coverage in CHIS for individuals included in HPV 
infection surveillance, stratified by age at vaccination and testing laboratory1  
 
Unvaccinated 
Vaccinated  
(at least one dose) 
Lewisham2 
       12 year-olds masked3 masked3 
     14-15 year olds masked3 masked3 
     16-17 year olds 81 (67.5%) 39 (32.5%) 
     All ages 96 (60.4%) 63 (39.6%) 
Cambridge   
     12 year-olds 6 (4.6%) 124 (95.4%) 
     14-15 year olds 0 0 
     16-17 year olds 0 0 
     All ages 6 (4.6%) 124 (95.4%) 
Aintree   
     12 year-olds 0 0 
     14-15 year olds 0 masked3 
     16-17 year olds 5 masked3 
     All ages 5 (50.0%) 5 (50.0%) 
Cornwall 
       12 year-olds 51 (7.8%) 603 (92.2%) 
     14-15 year olds 45 (9.1%) 448 (90.9%) 
     16-17 year olds 184 (23.4%) 601 (76.6%) 
     All ages 280 (14.5%) 1,652 (85.5%) 
Portsmouth 
       12 year-olds 0 0 
     14-15 year olds masked3 16 
     16-17 year olds 0 0 
     All ages masked3 16 
Stoke   
     12 year-olds 0 masked3 
     14-15 year olds masked3 masked3 
     16-17 year olds masked3 37 
     All ages 22 (26.8%) 60 (73.2%) 
1: Restricted to laboratories for which vaccination status was available 
2: In Lewisham, data were collected directly from laboratory using data on 
chlamydia-test request form 
3: In accordance with PHE data sharing policy, cells with values between 1 and 4 
inclusive were masked. If masked cells could be deduced from values of other cells 
then the next smallest cell was also masked  
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5.3.  (Methods 2) Validation of HPV vaccination records 
using GP records 
5.3.1.  Rationale  
As previously described, there was some concern that vaccination records in CHIS 
may not be accurate in some areas, particularly for women vaccinated outside of 
schools (see Section 5.1.1). Given the importance of accurate HPV vaccination data 
for HPV infection surveillance, I designed and conducted a validation study to 
ascertain the accuracy of HPV vaccination records on CHIS compared to data 
collected at general practices in Cornwall. 
5.3.2.  Setting for the validation study 
As there is no national general practice database, it was not possible to check all 
CHIS records against GP records. Therefore I decided to select a sample of women 
for whom vaccination status in the different systems could be compared. This 
sample of women had to be from a local authority with available CHIS data for 
linkage with the HPV infection surveillance data (Section 5.2.1). Cornwall local 
authority had the highest proportion of CHIS records linked to the HPV infection 
surveillance data. In addition, the administration of HPV vaccination in the Cornwall 
local authority (formerly Cornwall PCT) was unique in that it was a GP-based 
programme for all ages (i.e. HPV vaccination was not performed in schools as it 
was in other local authorities). Therefore, I decided to conduct a validation study to 
ascertain whether HPV vaccination records held at general practices were 
accurately recorded on CHIS in Cornwall.   
I contacted the SIT who had facilitated collection of CHIS data for the Cornwall local 
authority to discuss validation of the CHIS data using GP records in this area. The 
validation was supported by the Screening and Immunisation Lead (SIL) of the SIT 
and, on the advice of the SIL, the SIL and I jointly approached the Cornwall Local 
Medical Committee (LMC) and the South West Regional Medical Director for NHS 
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England. There were some concerns expressed about the burden for GPs if they 
were asked to provide detailed HPV vaccination records for each patient (including 
dates for each dose received). Therefore, in response I proposed (i) to limit the 
number of GPs included and the number of records searched at each practice and, 
(ii) to ask GPs to provide only vaccination status (unvaccinated, 1-dose received, 2-
doses received, 3-doses received) rather than full details of the dates and batch 
numbers for each dose given. With this change, the Cornwall LMC and NHS 
England South (SW) Medical Director both supported this study. The original 
permissions for this HPV infection surveillance (Section 4.3.2) included collection of 
GP details to enable collection of HPV vaccination records. Therefore, once it was 
agreed that this study could proceed, I requested data (in addition to the data 
collected in Section 5.2.2) on patients’ GPs (including the GP name and practice 
name) from the Cornwall CHIS.  
5.3.3. Sample size for the validation study 
Table 5.5 gives the number of CHIS records held for Cornwall local authority in April 
2016 (in the column “Total Population”). Patients were from 67 general practices 
across Cornwall local authority (with between 1 and 133 eligible patients from each 
practice). As described in the previous section, to perform a validation of all CHIS 
records at all general practices was considered impractical given the additional work 
required by GPs.  Selecting approximately 40% of specimens allowed sufficient 
precision around estimates of the expected agreement (Table 5.5). However, to 
achieve this sample size would have either involved collection of 40% of records 
from all 231 practices, or, all records from 40% of practices (which would be up to 
133 records from the largest practice). Both of these options were considered 
impractical, hence ~40% of partially vaccinated females (n=37) and unvaccinated 
females (n=95) were selected but only ~10% of fully vaccinated females (n=127) 
which provided sufficient power for the required precision in all groups. 
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Table 5.5: Estimated precision comparing HPV vaccination status on CHIS vs. GP, for given sample sizes 
  Total population  Validation population 
      Precision for given sample size 
Status CHIS (%) 
Number of 
specimens 
 
Estimated 
Agreement (%) Sample size 95% CI 
95% CI with finite 
population 
correction 
Fully vaccinated 79.8% 1249  90 127 84.8-95.2 85.1-95.0 
Fully vaccinated 79.8% 1249  80 127 73.1-87.0 73.4-86.6 
Fully vaccinated 79.8% 1249  70 127 62.0-78.0 62.4-77.6 
Fully vaccinated 79.8% 1249  60 127 51.5-68.5 51.9-68.1 
Partially vaccinated 5.9% 92  90 37 80.3-99.7 81.1-98.9 
Partially vaccinated 5.9% 92  80 37 67.1-92.9 68.2-91.8 
Partially vaccinated 5.9% 92  70 37 55.2-84.8 56.5-83.5 
Partially vaccinated 5.9% 92  60 37 44.2-75.8 45.5-74.5 
Unvaccinated 14.4% 225  90 95 84.0-96.0 85.4-94.6 
Unvaccinated 14.4% 225  80 95 72.0-88.0 73.9-86.1 
Unvaccinated 14.4% 225  70 95 60.8-79.2 63.0-77.0 
Unvaccinated 14.4% 225  60 95 50.2-69.9 52.5-67.5 
    Total 259   
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5.3.4.  Methods for HPV vaccination data collection from GPs 
For ease of data collection, practices were sampled rather than individual patients. 
The patient records to include in the validation study were selected as follows: 
(i) Practices were categorised according to the number of registered patients with 
HPV vaccination records in CHIS (≤7 patients; 8-17 patients; 18-30 patients; 
>30 patients) 
(ii) I randomly selected 6 practices within each group defined in (i) (i.e. 24 
practices in total). This included 18% of practices (i.e. 24 of 133 practices) but 
by selecting proportionately more of the larger clinics, this included around 
40% of women. 
(iii) From each selected practice, I selected all unvaccinated patients, all partially 
vaccinated patients and a random selection of approximately 25% of fully 
vaccinated patients (i.e. representing 40% of partially and unvaccinated women 
and about 10% of fully vaccinated women from all practices).  
I drafted a letter for GPs, describing the remit of PHE to monitor the HPV 
Immunisation Programme and the importance of this HPV infection surveillance. 
The content of this letter was approved by the Screening and Immunisation Lead 
(SIL) and was signed by me as well as the SIL (Appendix D1). I also drafted a data 
collection form which included patients’ NHS number and a choice of boxes to tick 
to indicate patients’ vaccination status (no record of patient; unvaccinated; one-dose 
received; two-doses received; three-doses received) (Appendix D1). I then sent this 
letter and the data collection form to each practice. The letter and form were 
addressed to a named person within the practice and double enveloped (both the 
internal and external envelope were addressed to the same named person but only 
the internal envelope was marked “Private and Confidential”).
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I sent letters to the 24 selected practices to request HPV vaccination status for 259 
women. Full details are given in Table 5.6. GPs were sent two return envelopes 
which were addressed to me at PHE (so the form could be returned double 
enveloped as above). Data were entered by colleagues at PHE onto a specifically 
designed spreadsheet. If forms were not returned within two weeks, I contacted the 
GP by telephone or secure email (nhs.net to nhs.net) to check the status of the 
response. I continued to follow up directly with the GP until data collection forms 
were returned.  
Table 5.6: Requests sent to GPs in Cornwall for selected patients’ HPV 
vaccination status 
General Practice Number of patients requested 
  Total Fully vaccinated Partially vaccinated Unvaccinated 
Practice 1 51 25 11 15 
Practice 2 33 22 3 8 
Practice 3 28 10 3 15 
Practice 4 17 8 3 6 
Practice 5 16 5 5 6 
Practice 6 14 3 4 7 
Practice 7 14 8 1 5 
Practice 8 14 10 1 3 
Practice 9 12 6 2 4 
Practice 10 10 2 2 6 
Practice 11 9 6 0 3 
Practice 12 7 3 0 4 
Practice 13 7 4 0 3 
Practice 14 6 1 1 4 
Practice 15 5 3 0 2 
Practice 16 4 1 0 3 
Practice 17 4 4 0 0 
Practice 18 2 1 1 0 
Practice 19 1 0 0 1 
Practice 20 1 1 0 0 
Practice 21 1 1 0 0 
Practice 22 1 1 0 0 
Practice 23 1 1 0 0 
Practice 24 1 1 0 0 
Total 259 127 37 95 
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5.4. Results 
5.4.1. Response rate 
Either in direct response to the initial letter or after follow-up communication, I 
received data from all 24 practices with HPV vaccination status for 223/259 (85%) of 
patients (35 patients were no longer registered at the practice and vaccination 
records were not available, 1 patient’s vaccination status was unknown).  
5.4.2. Results of validation study comparing CHIS and GP records of HPV 
vaccination status 
The vaccination status on CHIS compared to GP systems is provided in Table 5.7. 
Women who were recorded as unvaccinated on CHIS were slightly more likely to 
have a missing record on their corresponding GP system (i.e. were no longer 
registered at the practice or vaccination records were not available; 18.9% of 
unvaccinated women had a missing record compared to 11.8% for fully vaccinated 
women and 8.1% for partially vaccinated women). I discuss the potential bias of 
these missing records in Section 5.4.3 below. Among those with GP records 
available, there was generally very good agreement for women recorded as fully 
vaccinated in CHIS (107/112 (95.5%) were also recorded as fully vaccinated on GP 
records) and those recorded as unvaccinated (66/77 (85.7%)). However, of 34 
women recorded as partially vaccinated in CHIS who had a GP record, 9 (26.5%) 
were recorded as fully vaccinated and 4 (11.8%) were recorded as unvaccinated, 
with only 61.8% agreement for partial vaccination status.
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Table 5.7: HPV vaccination status on CHIS compared to GP systems (n=259) 
  CHIS vaccination 
  Status 
No record 
at practice 
(n=36)1 
 Vaccination status at general practice 
n (%) Unvaccinated 
(n=74) 
Partially vaccinated 
(n=27) 
Fully vaccinated 
(n=122) 
  Unvaccinated 
  (n=95) 
18 (50.0%) 77 (34.5%) 
n=66 
85.7% (75.9-92.6) 
n=5 
6.5% (2.1-14.5) 
n=6 
7.8% (2.9-16.2) 
  Partially vaccinated 
  (n=37) 
3 (8.3%) 34 (15.2%) 
n=4 
11.8% (3.3-27.5) 
n=21 
61.8% (43.6-77.8) 
n=9 
26.5% (12.9-44.4) 
  Fully vaccinated 
  (n=127) 
15 (41.7%) 112 (50.2%) 
n=4 
3.6% (1.0-8.9) 
n=1 
0.9% (0.0-4.9) 
n=107 
95.5% (89.9-98.5) 
1: 35 patients were no longer registered at the practice and vaccination records were not available, 1 patient’s vaccination                            
status was unknown 
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5.4.3. Discussion 
As stated in the background of this Chapter, collection of accurate HPV vaccination 
records is important for national HPV infection surveillance to enable accurate 
monitoring of the population-level effects of HPV vaccination and calculation of the 
vaccine effectiveness against HPV infection. Nationally, it is not clear whether CHIS 
or GPs are the “gold standard” data source for HPV vaccination records; as 
described in Section 5.1.1, this is likely to vary according to area and HPV 
vaccination cohort (due to the venue of vaccine delivery). CHIS seems to be, on 
average, more accurate for school-based vaccination but in some areas, GP 
records are likely to be more accurate for older catch-up cohorts. CHIS has the 
advantage of having a single database for all individuals within a local authority. 
However, given the known inadequate reporting of vaccination receipt between 
different systems, it is difficult to assume that an absence of an HPV vaccination 
record in a system implies that a woman is unvaccinated without checking other 
data sources.  
The validation study described in this chapter aimed to assess the robustness of 
calculating effectiveness of HPV vaccination against HPV infection using 
vaccination status data from CHIS (as described in Section 4.3.15), specifically in 
Cornwall where vaccinations were offered in general practice. There was strong 
agreement between the CHIS and GP records for those recorded as fully 
vaccinated and those recorded as unvaccinated. Given that vaccination was offered 
via general practice, it is surprising that there were any women recorded as 
unvaccinated at the practice but partially or fully vaccinated on CHIS, although there 
were relatively few of these (n=8/74). Furthermore, although the numbers of women 
recorded as partially vaccinated were also relatively small, those recorded as 
partially vaccinated on CHIS were often recorded as fully vaccinated on GP 
systems, likely suggesting some missed doses on CHIS. I discuss below some 
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limitations of this validation study. I discuss the potential implications of 
misclassification of HPV vaccination status, based on results from this validation 
study, in Section 6.4.4. 
This validation study had some limitations. Firstly, this study was conducted in one 
local authority only; the only local authority in the country that offered routine HPV 
vaccination via general practice for women of all ages (rather than in school settings 
for younger women). Therefore, these results may not be generalisable to younger 
women from other local authorities included in the national HPV infection 
surveillance where vaccinations for younger cohorts would have been offered in 
schools. The results may be more likely to inform data collection for older catch-up 
cohorts vaccinated outside of schools although, as described in Section 5.1.1, the 
transfer of data is variable across different areas. Secondly, although there was 
100% response from GPs, there were still some missing data for individuals (36 out 
of 259 women (13.9%)), mostly due to women no longer being registered at the 
same GP as when they were vaccinated, a particular issue when collecting 
vaccination status retrospectively. The proportion of women recorded as 
unvaccinated on CHIS was somewhat higher among those with missing GP data 
compared to those with non-missing GP data (50.0% vs. 34.5% respectively; p-
value 0.074). The vast majority of missing GP data was because women were no 
longer registered at the general practice. If moving practice was unrelated to 
whether GP and CHIS records were discrepant (i.e. non-differential 
misclassification) then the missing data would not affect the agreement estimates in 
Table 5.7, other than to widen the confidence interval. However, if women with 
missing GP records were more likely to be unvaccinated (for example, if they were 
not offered HPV vaccination because they moved practice; i.e. differential 
misclassification) then this could have underestimated the agreement for 
unvaccinated women and overestimated the agreement for vaccinated women (both 
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partially and fully vaccinated, given that 18 of the 36 women with no GP records 
were recorded as vaccinated on CHIS). Thirdly, despite sampling a higher 
proportion of unvaccinated women and partially vaccinated women compared to 
fully vaccinated women, the numbers in these groups were still relatively small. 
Therefore, there is more uncertainty around the agreement for these women, as 
expected from precision estimates conducted prior to conducting this study (Table 
5.5). Finally, in order to limit the additional work for GPs, we only collected 
vaccination status rather than full details so it was not possible to validate details of 
age at vaccination and time between doses (which would have also required an 
even larger sample size).  
CHIS data have clear advantages when collecting vaccination data for large 
populations of women. In this study, I only had to approach one CHIS to obtain HPV 
vaccination status for all women living in the Cornwall local authority but I would 
have had to contact 67 GPs to obtain all the corresponding data from GP records. 
However, the difficulty in obtaining CHIS records described in Section 5.1.1, 
particularly collecting data retrospectively, highlights the importance of ensuring 
these data are transferred to Open Exeter and available when women attend for 
cervical screening (this is discussed further in Section 9.4).  
In this chapter, I have provided further description of the methods I adopted to 
collect HPV vaccination status, an important aspect of the HPV infection 
surveillance to allow estimation of the direct effect of HPV vaccination and indirect 
effect of herd protection. I have also presented the results of a study which 
compared HPV vaccination status from different sources. In the following chapter 
(Chapter 6), I present these results which address research questions 1, 2 and 3 of 
this thesis. In the discussion of this next chapter (Section 6.4.4), I explore how the 
results of the validation study presented above could have affected the 
interpretation of the results of the HPV infection surveillance.
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Chapter 6: Results of HPV infection surveillance 
to evaluate the National HPV Immunisation 
Programme 
6.1. Introduction 
In this chapter, I present the results of the ongoing repeat cross-sectional 
surveillance of type-specific HPV infections among young sexually active women in 
England. This chapter includes two papers.  
In the first paper, published in BMJ Open in 2016, I extended analyses I had 
originally conducted prior to the start of this PhD. The original analyses were based 
on the first 4,178 post-vaccination specimens from sexually active young females in 
England (2010-2011), and focussed largely on changes in HPV16/18 prevalence 
(with limited power to consider changes in other HPV types)[126]. In the new 
analysis conducted for the first paper in this Chapter, I included additional post-
vaccination samples (a total of 7,321 post-vaccination specimens collected up to 
April 2013) and explored changes in non-vaccine types. I also performed an 
adjusted analysis to account for the changes in the HPV assay between the pre- 
and post-vaccination periods (using the methods outlined in Section 4.4). This paper 
focussed on changes in prevalence between the pre-vaccination period and the 
post-vaccination period for twenty HPV types.  The supplementary Table for this 
publication, which outlines changes in non-vaccine HPV types among women with 
at least one HPV type detected, is included in Appendix E. 
In the second paper in this chapter (submitted for publication), I further updated this 
analysis, including 15,549 post-vaccination specimens taken up to December 2016, 
and also included direct calculation of vaccine effectiveness. There were three main 
elements of this analysis. Firstly, for all women, I focussed on the changes in type-
specific HPV prevalence within the post-vaccination period and the association 
between these changes and population vaccination coverage. The HPV testing 
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assay has remained constant within the post-vaccination period so unlike the first 
paper, there was no need to adjust for the change in HPV assay between time 
periods. Secondly, for a subset of women with known vaccination status, I 
calculated vaccine effectiveness. Finally, I also assessed the herd protection effect 
in unvaccinated women.  
At the end of the chapter, I include some further analyses and discussion around 
three areas; (i) Changes over time which could affect the results in the above two 
papers (including the change in the HPV assay between the pre- and the post-
vaccination period, changes in chlamydia positivity over time, and potential 
confounding due to changes in other unrecorded patient demographics and 
behaviour); (ii) the potential misclassification of HPV vaccination status from CHIS 
was described in detail in Chapter 5; and (iii) further interpretation of the changes in 
non-vaccine types, including exploration of possible methods that could be used to 
quantify the potential effect of type-replacement and/or unmasking in the post-
vaccination period.
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Abstract 
Background: The National HPV Immunisation Programme was introduced in 
England in September 2008 using the bivalent vaccine.  
Methods: We collected residual vulva-vaginal swab (VVS) specimens from 16-24 
year old women attending for chlamydia screening between 2010 and 2016 and 
tested them for HPV DNA. We compared changes in type-specific (vaccine and non-
vaccine) HPV prevalence over time and the association with vaccination coverage. 
For women with known vaccination status, vaccine-effectiveness was estimated.  
Results: HPV DNA testing was completed for 15,459 specimens. The prevalence of 
HPV16/18 decreased between 2010/11 and 2016 from 8.2% to 1.6% in 16-18 year 
olds and from 14.0% to 1.6% in 19-21 year olds. Declines were also seen for 
HPV31/33/45 (6.5% to 0.6% for 16-18 year olds and 8.6% to 2.6% for 19-21 year 
olds). Vaccine-effectiveness for HPV16/18 was 82.0% (95% CI: 60.6-91.8) and for 
HPV31/33/45 was 48.7% (95% CI: 20.8-66.8). Prevalence of HPV16/18 was 
compared to findings in 2007-8 (pre-vaccination) and to predictions from Public 
Health England’s mathematical model. 
Discussion: Eight years after the introduction of a national HPV vaccination 
programme, substantial declines have occurred in HPV16/18 and in HPV31/33/45. 
The prevalence of other high-risk HPV types has not changed.  
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Introduction 
Cervical cancer is caused by persistent human papillomavirus (HPV) infection[127]. 
In the UK, a national programme was introduced in 2008 to offer HPV vaccination 
routinely to 12-13 year olds, and offer catch-up vaccination to girls up to the age of 
18 years old. The UK national programme initially used the bivalent HPV vaccine 
(Cervarix®). This vaccine has demonstrated high efficacy against two high-risk (HR) 
HPV types, HPV16 and HPV18[128, 129], which have been shown to be 
responsible for around 70% of cervical cancers worldwide[130] and around 80% of 
cancers in the UK[131]. In 2012, the UK programme changed to use the 
quadrivalent vaccine (Gardasil®) which additionally offers high efficacy against two 
low-risk (LR) types, HPV6 and HPV11[132, 133], which cause the majority of genital 
warts[134]. HPV vaccination coverage in England has been high with over 80% of 
12-13 year olds receiving the full course (3-doses prior to September 2014, 2-doses 
since). Coverage within the catch-up cohorts has been lower and more variable 
(ranging from 39% to 76%)[78]. A reduction in cervical cancer incidence is not 
expected for some years given the time interval between vaccination and the age of 
most cervical cancer diagnoses; thus, a reduction in the prevalence of HPV infection 
can provide an early indication of the effectiveness of the vaccination programme. 
Data from several countries have already demonstrated reductions in vaccine types 
and HPV31, 33 and 45 since the introduction of national HPV vaccination 
programmes[135, 136].  
In England, we utilise residual genital specimens, collected for chlamydia screening, 
for national HPV surveillance. We previously reported results showing lower 
prevalence of HPV16/18 in the period after vaccination compared to before 
vaccination was introduced, as well as some evidence of a reduction in HPV31, 
likely due to cross-protection[19, 90, 126]. The latest of these reports[90] compared 
type-specific prevalence for 2,354 specimens collected in 2008 to 7,321 specimens 
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collected from 2010 to 2013. These findings largely related to females eligible for 
catch-up vaccination.  We now report an extension of these results with specimens 
collected to December 2016, including females eligible for routine vaccination. We 
also include results stratified by HPV vaccination status.  
We report trends in HPV16/18 prevalence since HPV vaccination began in England 
and vaccine-effectiveness estimates for the bivalent HPV vaccine. We compare 
findings to predictions from transmission dynamic model that informed the 
vaccination policy[137]. Evidence for herd protection effects and for cross-protection 
against non-vaccine HPV types is also explored.   
Methods 
Specimen and data collection 
The methods for collection and testing of specimens and linkage with data have 
been described elsewhere[90, 126]. In brief, residual vulva-vaginal swab (VVS) 
specimens were collected from 16-24 year old women attending for chlamydia 
screening at general practices (GP), community and sexual health services (CaSH) 
or youth clinics. Residual specimens were collected from ten laboratories where 
chlamydia testing was performed (University Hospital Aintree [Aintree]; Leeds 
Teaching Hospitals [Leeds]; University Hospital of North Staffordshire [Stoke]; 
Norfolk and Norwich University Hospital [Norfolk and Norwich]; Addenbrooke’s 
Hospital [Cambridge]; East Kent Hospitals University [East Kent]; Queen Alexandra 
Hospital [Portsmouth]; Royal Cornwall Hospital [Cornwall]; University College 
London Hospital [UCL]; and University Hospital Lewisham [Lewisham]). Specimens 
were sent to the Virus Reference Department (VRD) at Public Health England (PHE) 
for HPV testing. Demographic data were reported to PHE separately, either by the 
clinic (prior to 2012) or laboratory performing the chlamydia testing (from 2012 
onwards). Demographic data were linked to specimens using a unique study 
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number and, once linked, all other identifiable data were removed prior to HPV 
testing. Laboratories were asked to submit a specified number of specimens for 
each year/age-group to meet target sample sizes. Since 2015, samples were only 
requested from 16-20 year olds who would have largely been in routine vaccination 
cohorts. As these samples were collected for routine public health surveillance 
conducted to monitor the HPV vaccination programme, individual patient consent 
was not required. PHE has permission to handle these data under section 251 of the 
UK National Health Service Act of 2006 (previously section 60 of the Health and 
Social Care Act of 2001), which was renewed annually by the ethics and 
confidentiality committee of the National Information Governance Board until 2013. 
Since then, the power of approval of public health surveillance activity has been 
granted directly to PHE.  
The present analysis included women who were eligible for bivalent HPV 
vaccination as part of the national programme (i.e. born on or after 1st September 
1990) as well as some too old to have been eligible. The latter were included to 
provide a comparison to vaccine-eligible women, and allow observation of changes 
in HPV prevalence due to herd protection. The number of women eligible for the 
quadrivalent vaccine in the national programme (i.e. born on or after 1st September 
1999) was very small; these women were excluded. Since 2014, HPV vaccination 
status has been retrospectively sought for specimens collected from women eligible 
for vaccination. Two different methods have been used to obtain these data: data 
obtained from laboratories from the chlamydia-test request form, and data obtained 
by linkage with local Child Health Information Service (CHIS) Systems. The latter 
method could only be used if (i) chlamydia testing laboratories provided NHS 
number, and (ii) local CHIS system was able to conduct the linkage. One laboratory 
used the former method (Lewisham) and for four we used the latter method 
(Cambridge, Cornwall, Portsmouth and Stoke). The completion of linkage to vaccine 
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status varied greatly across these laboratories. For the remaining five laboratories 
(Aintree, East Kent, Leeds, Norfolk and Norwich and UCL) HPV vaccination status 
data were unavailable. Data collected from CHIS included the number of doses 
given and dates of each dose. Data collected from the chlamydia-test request form 
was self-reported vaccination status and did not include information on the dates of 
doses. We assumed that vaccinated women with an unknown number of doses 
(126/1952; 6.5%) were fully vaccinated; this was explored further in sensitivity 
analyses.  
Vaccination coverage for all women, stratified by year and age group, was estimated 
by combining individual-level vaccination coverage (for those whom vaccination 
status could be obtained) with the published national vaccination coverage (for 
those whom vaccination status could not be obtained).  
HPV testing 
Eligible specimens were tested using an in-house multiplex PCR and Luminex-
based genotyping test for 13 HR HPV types 
(HPV16/18/31/33/35/39/45/51/52/56/58/59/68), five possible HR types 
(HPV26/53/70/73/82) and two LR types (HPV6/11)[116]. An inadequate result was 
given if the samples were negative for both HPV and the housekeeping gene, 
pyruvate dehydrogenase (PDH)[116]. 
Statistical analysis 
We calculated the HPV prevalence and 95% confidence intervals for three age-
groups (16-18, 19-21 and 22-24 year olds) and four time periods post-vaccination 
(2010-2011, 2012-2013, 2014-2015 and 2016). This was calculated for; (i) individual 
HPV types, (ii) any HR HPV type (HPV16/18/31/33/35/39/45/51/52/56/58/59/68); (iii) 
HPV vaccine types (HPV16/18);  (iv) HPV31/33/45 with cross-protective efficacy 
established by clinical trials[73, 76]; (v) any other HR HPV type 
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(HPV35/39/51/52/56/58/59/68)[2], and (vi) additional HR HPV types included in the 
nonavalent HPV vaccine (HPV31/33/45/52/58). Changes in prevalence over time 
were compared using a log-binomial regression model, adjusted for age, testing 
venue and chlamydia (as a marker for sexual behaviour). For HPV16/18, previously 
published prevalence estimates for 2007/2008 (i.e. prior to HPV vaccination) were 
included in trend analyses[19]. For all other HPV types, trend analysis considered 
changes within the post-vaccination period only, due to differences in detection rates 
for certain types with the different assay used in the pre- vaccination period.  This 
trend analysis approximated the effect of increasing vaccination coverage on HPV 
prevalence (i.e. what are the changes in HPV prevalence as vaccination coverage 
increases over time). However, to further quantify the association between HPV 
vaccination coverage and changes in post-vaccination HPV prevalence for all 
women across all years (2010-2016), we included a continuous variable in the 
regression model with the estimated HPV vaccination coverage (as a proportion). 
This allowed us to estimate an adjusted prevalence ratio for HPV infection 
comparing a population with no female vaccination (coverage=0) with a fully 
vaccinated population (coverage=1).  Percentage declines in HPV16 and HPV18 
within the post-vaccination period were also plotted against predictions from a 
previously published model[137] . To do this, we input the published vaccination 
coverage[78] into this transmission dynamic model and calculated the percentage 
reductions for HPV16 and HPV18 from 100 best fitting scenarios to the pre-
vaccination prevalence[137]. The median of these 100 outputs were then calculated 
along with minimum and maximum values to give a range.  
Risk ratios (RRs) comparing HPV prevalence in vaccinated vs. unvaccinated women 
(for all years combined, 2010-2016) were calculated using a log-binomial regression 
model (adjusted (aRR) for age, testing venue type and chlamydia positivity). 
Vaccine-effectiveness was calculated as 1-aRR. These analyses were stratified by 
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age at vaccination (females offered vaccination at 12-15 years old vs. females 
offered vaccination at 16-17 years old).  
Sensitivity analysis 
In sensitivity analyses, we calculated vaccine-effectiveness for women known to 
have had all vaccine doses in the recommended time interval. Specifically, we 
excluded women with (i) unknown number of doses (n=126), and (ii) vaccinated 
outside of the recommended dose schedule for the bivalent vaccine (n=307). 
Results 
Participant characteristics 
A total of 15,459 specimens were included in this analysis : 4,044 samples collected 
in 2010-2011, 7,253 in 2012-2013 2,737 in 2014-15 and 1,425 in 2016 (Table 1).  
The distribution of specimens by ethnicity has remained relatively stable with a 
slightly higher proportion of black women in 2010-2011 and an increasing proportion 
with missing ethnicity in more recent years as data have been sourced from 
laboratories rather than clinics. Over time, the proportion of samples from women 
attending GPs has increased, and the proportion from CaSH and youth clinics has 
decreased. Chlamydia positivity has decreased over time from just over 8% in 2010-
11 to around 6% in the later periods, likely reflecting changes in the population 
undergoing chlamydia screening. Changes in distributions of samples by ethnicity, 
recruitment venue and chlamydia positivity were similar within each age-group (data 
not shown).  
As expected, the proportion of women who had been eligible for vaccination 
increased over time (Table 1). This was partly due to a higher proportion of women 
in later years having been offered the vaccine at younger ages with higher national 
coverage but also due to a change in our sampling as we only requested samples 
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from 16-20 year olds from 2015 onwards. Of 11,199 women eligible to receive the 
HPV vaccine as part of the national programme, 2,318 (20.7%) had a known 
vaccination status (1,924 (84%) from Cornwall laboratory). Of these, 2,159 (93.1%) 
were obtained from CHIS records and 159 (6.9%) were self-reported. Among these 
women, full-course coverage was 58.2%, 75.7%, 85.4% and 86.7% in 2010-2011, 
2012-2013, 2014-2015 and 2016 respectively.  
Characteristics of women who would have been eligible for vaccination in the 
national programme are given in Table 2, stratified by vaccination status 
(unvaccinated, vaccinated or unknown status). Among unvaccinated women, there 
was a slightly higher chlamydia positivity, a higher proportion of black women and 
higher proportion of samples from family planning clinics compared to vaccinated 
women.   
HPV16 and/or 18 infection 
In the younger age-groups,  HPV16/18  prevalence decreased within the post-
vaccination period between 2010/11 to 2016 from 8.2% to 1.6% in 16-18 year olds 
and 14.0% to 1.6% in 19-21 year olds (compared to 17.6% and 16.9% in the pre-
vaccination period[19] respectively; p-trend for both age-groups <0.001; Table 3, 
Figure 1). These decreases were strongly associated with the increasing estimated 
vaccination coverage (aPR (95% CI), 0.2 (0.1-0.3) and 0.3 (0.2-0.4) for 16-18 and 
19-21 year olds respectively). In the oldest age-group, the prevalence in 2014-2015 
was 7.5% compared to 16.4% 2010-2011 (15.3% in the pre-vaccination period[19]; 
p-trend 0.417) although when we considered changes relative to vaccination 
coverage, there was evidence of an association (aPR=0.3 (0.1-0.6)) (Table 3). 
Observed percentage reductions were similar to model predictions for both HPV 
types (Figure 3).  
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The prevalence of HPV16/18 in cohorts offered routine vaccination was 2.0% (1.5-
2.4%) and 1.3% (0.7%-2.0%) in those aged 16-18 years and 19-21 years at sample 
collection respectively.  
Among the subset of women with known vaccination status, full-course vaccine-
effectiveness against HPV16/18 was 82.0 (60.6-91.8) for women vaccinated <15 
years and 48.7 (20.8-66.8) for women vaccinated at 15-17 years (Table 4, Figure 2). 
HPV31, 33 and/or 45 infection 
In the younger age-groups, there was evidence of a decrease in the prevalence of 
HPV31/33/45 within the post vaccination period (6.5% to 0.6% for 16-18 year olds 
and 8.6% to 2.6% for 19-21 year olds; Table 3, Figure 1). These reductions were 
associated with estimated vaccination coverage (aPRs for HPV31/33/45 were 0.3 
(0.2-0.5) and 0.5 (0.3-0.7) for 16-18 and 19-21 year olds respectively).  
Restricting to women with a known vaccination status, there was also evidence of a 
protective effect of receiving the vaccine (vaccine-effectiveness against types 
HPV31/33/45 of 54.3 (8.6-77.2) for the women vaccinated <15 years and 36.7 (-3.4-
61.2) for women vaccinated at age 15-17) (Table 4, Figure 2). 
Non-vaccine HR HPV types 
In 16-18 year olds, the prevalence of non-16/18/31/33/45 HPV types remained 
relatively stable at 31.0% in 2010-2011 to 26.7% in 2016 (p-trend 0.211). The 
prevalence also remained relatively stable for 19-21 year olds (34.0% in 2010-2011 
to 32.9% in 2016; p=0.877) but there was a slight increase among 22-24 year olds 
(27.0% in 2010-2011 to 31.7% in 2014; p<0.001). 
The prevalence of HPV6/11 remained relatively constant over time (Table 3). 
Among those with HPV vaccination status, there was no protective effect of the 
bivalent vaccine against these HPV types (vaccine-effectiveness 26.5 (-26.8-57.4) 
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for women vaccinated <15 years and 18.8 (-24.6-47.1) for women vaccinated at 15-
17 years). 
Sensitivity analysis 
Restricting vaccine-effectiveness estimates to women who were known to have 
three HPV vaccine doses within the recommended schedule gave very similar 
results to the main analysis for HPV16/18 (vaccine-effectiveness (95% CI) of 81.7% 
(58.8-91.8%) for vaccination <15 years and 47.9% (17.7-67.1%) for vaccination at 
age 15-17).  
Herd protection  
In 16-21 year old women, the prevalence of HPV16 /18 in those unvaccinated 
(either with known vaccination status or not eligible to receive the HPV vaccine) 
reduced from 15.9% in 2010-2011 (n=141/885) to 12.5% in 2012-2013 (n=56/449) 
to 6.9% in 2014-2016 (n=5/72) (p-trend=0.013). For HPV31/33/45, the prevalence 
estimates were 9.4% (2010-2011), 10.7% (2012-2013) and 6.9% (2014-2016); p-
trend=0.577. 
Discussion 
We have previously reported changes in the prevalence of HPV types between the 
pre- and the post-vaccination period[90, 126]. Interpretation of these findings was 
complicated by a change in the HPV assay used between the pre- and post-
vaccination periods which affected the detection of some non-vaccine HPV types. In 
this report, we consider changes over time within the post-vaccination period during 
which testing was conducted consistently with our in-house assay. If HPV 
vaccination is causing a decrease or increase in certain HPV types we expect to see 
these decreases or increases strengthening over time since vaccination, as later 
periods include women vaccinated at a younger age and with higher vaccination 
coverage. Additionally, for a subset of women with vaccination status, we have 
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calculated vaccine-effectiveness, directly comparing HPV prevalence in vaccinated 
and unvaccinated women.  
Among ages offered HPV vaccination, we have demonstrated clear reductions in 
infections with the HPV vaccine types since the introduction of the HPV vaccination 
programme in England, with greater reductions in younger women (with higher 
vaccination coverage and vaccinated at a younger age).Vaccine-effectiveness in 
those vaccinated <15 years was high, as expected given the high vaccine efficacy 
from per-protocol analyses of clinical trials[128, 129, 132, 133]. The lower 
effectiveness in the older catch-up females is also to be expected, given risk of prior 
exposure to HPV. We have also demonstrated that these declines are associated 
with increasing vaccination coverage within the post-vaccination period. We have 
compared percentage declines in HPV vaccine types in this surveillance with 
predicted outputs from a dynamic transmission model conducted prior to the 
introduction of HPV vaccination in England[137]. These results provide reassurance 
that observed declines in HPV16/18 prevalence are similar to what was expected.   
Encouragingly, there is also evidence of a substantial herd protection effect with 
HPV16/18 prevalence also reducing over time in unvaccinated women which is 
consistent with data from other countries[95, 96, 135]. We have also seen clear 
evidence of cross-protection following introduction of a bivalent vaccine with 
declines in HPV31/33/45 within the post-vaccination period overall. In the younger 
age groups, percentage reductions over time have been similar for vaccine types 
and HPV31/33/45 (Figure 1) despite lower vaccine-effectiveness for HPV31/33/45 
(54.3% vs 82.0% in those vaccinated age 15 or younger). This is consistent with 
predictions from mathematical modelling; that the lower basic reproductive number 
for some HPV types means herd protective effects could be greater [138] (i.e. it may 
be easier to reduce prevalence of types with a lower basic reproductive number 
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(such as HPV18, HPV31, HPV33 and HPV45) as herd protection effects are 
stronger).  
We have previously reported increases in non-vaccine types between the pre- and 
post-vaccination periods and potential reasons for this were discussed[90]. In this 
analysis we have seen stable prevalence of non-16/18/31/33/45 HR types within the 
post-vaccination period.  This is not consistent with what we would expect to see if 
vaccination against HPV16/18 was driving increases of other non-vaccine types, or 
type-replacement. This supports our caution in prior discussion of the changes 
between the pre-vaccination and the post-vaccination period to end 2014, and 
suggests these were likely unrelated to HPV vaccination.  
Our results for reductions in the HPV vaccine types are consistent with elsewhere in 
the UK and worldwide. A systematic review and meta-analysis including data from 
Scotland, England, US and Australia demonstrated decreases in HPV16/18 
prevalence among 13-19 year old women (risk ratio 0.32 (95% CI 0.19-0.52))[135]. 
A large study of over 12,000 samples from 13-22 year old women attending for 
chlamydia screening in Sweden showed a reduction in HPV16 (from 14.9% pre-
vaccination to 8.7% post-vaccination) and HPV18 (7.9% to 4.3%)[91]. Another study 
of 1,087 16-22 year old women which was conducted in The Netherlands compared 
HPV prevalence in vaccinated vs. unvaccinated women and demonstrated a slightly 
higher vaccine-effectiveness against HPV16/18 of 89.9% (81.7-94.4%)[139]. 
Updated data from Scotland has reported similar results with a vaccine-
effectiveness against HPV16/18 of 89% (85-92%) among those vaccinated at age 
12-13 years old[95]. However, evidence for changes in the non-vaccine types is less 
consistent across different studies. The meta-analysis conducted by Drolet et al 
demonstrated a reduction in HPV31/33/45 combined (RR 0.72 (0.54-0.96)) for both 
vaccines combined. However, a related systematic review and meta-analysis which 
considered changes in individual non-vaccine types only demonstrated reductions in 
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HPV31 in women ≤19 years old but not HPV33 or HPV45[136]. In a study in 
Sweden, where the quadrivalent vaccine has been used, there was also some 
suggestion of a reduction in HPV31 but not in the other closely related HPV 
types[91]. However, a more recent study of 8,584 20-21 year old women attending 
for cervical screening in Scotland, where the bivalent vaccine was used, 
demonstrated a lower prevalence among vaccinated women compared to 
unvaccinated women for types HPV31/33/45 individually and a very high combined 
vaccine-effectiveness of 85.1% and 83.6% in women vaccinated at 12-13 years and 
14 years respectively[95]. Similarly, data from The Netherlands who adopted the 
bivalent vaccine has also shown lower prevalence of HPV31/33/45 among 
vaccinated compared to unvaccinated women[139].   
There are certain limitations of our surveillance which should be taken into account 
when interpreting these results. Firstly, analyses comparing changes in HPV 
prevalence over time may reflect changes due to HPV vaccination; however, other 
changes at a population level, or individual differences not adjusted for in our 
analysis, should not be ruled out. We have adjusted for the testing venue, age and 
chlamydia positivity, but the extent to which changes in sexual behaviour (in addition 
to the adjustment for chlamydia positivity) or other unrecorded changes have 
affected HPV prevalence estimates is unclear. Secondly, there may be inequalities 
in HPV vaccination uptake which affect our analyses of vaccine-effectiveness and 
estimation of herd protection effects. We have compared characteristics by 
vaccination status (Table 2) and, similarly to the above, we have attempted to 
address these inequalities by adjusting vaccine-effectiveness for venue type, age 
and chlamydia positivity. However, there may be other factors associated with 
vaccine uptake and HPV prevalence which have not been accounted for. For 
example, for both analyses we have missing data on ethnicity which is a potential 
confounder as it is known to be associated with HPV vaccination uptake and HPV 
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prevalence. Due to the large proportion of missing data, particularly in more recent 
years, we were not able to adjust our estimates for ethnicity which may have biased 
our results. Calculation of vaccine-effectiveness was only possible for women with 
known vaccination status (21% of women eligible to receive the vaccine). The 
women with vaccination data available may not be representative of all women 
included in this study as missing vaccination status occurred largely at an area-level 
(either laboratories not providing NHS number or local CHIS systems not being able 
to conduct linkage). Over 80% of these specimens came from one testing laboratory 
in Cornwall. Vaccination in Cornwall differed from the vast majority of other areas in 
England as the vaccine was largely delivered during these years in primary care 
(rather than schools). As such, if there is any reason that this method of vaccine 
delivery could affect vaccine-effectiveness then these results may not be 
representative of the rest of England. For example, vaccination at primary care is 
likely to lead to vaccine doses given outside of the optimum schedule as individuals 
will need to be followed up individually for 2nd and 3rd doses rather than having mop-
up sessions at schools which is likely to underestimate vaccine-effectiveness. 
However, excluding women who received 3-doses of the vaccine outside of the 
recommended schedule had little effect on the HPV16/18 vaccine-effectiveness 
(from 82.0% to 81.7% for 16-18 year olds). A further limitation of our analysis of 
vaccine-effectiveness is the relatively small number of unvaccinated women, 
particularly at younger ages. Consequently, some confidence intervals for vaccine-
effectiveness are wide. 
This large surveillance includes HPV results from over 15,000 samples which have 
allowed us to consider a breadth of analyses to monitor changes in the prevalence 
of HPV infection in young women since the introduction of national HPV vaccination. 
A key strength of this analysis is the ability to monitor the population effects of 
vaccination among vaccinated and unvaccinated women prior to these women 
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entering cervical screening, therefore offering information to inform screening 
services. We clearly demonstrate dramatic declines in the prevalence of vaccine 
HPV types in this population, similar to predictions from effectiveness models. We 
also demonstrate clear evidence of declining prevalence of HPV31/33/45, most 
likely attributable to cross-protection. As cervical screening is changing to HPV 
testing as a primary screen our data can inform decisions regarding HPV testing 
strategies. These data should also be used to inform assessments of the additional 
benefit of introducing the nonavalent vaccine to the national vaccination programme.  
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Table 1: Patient characteristics by year of surveillance 
 
Post-vaccination 
 
2010-2011 2012-2013 2014-2015 2016 
  n=4,044 n=7,253 n=2,737 n=1,425 
Number of samples by laboratory 
      North West (Aintree) 203 (5.0%) 1198 (16.5%) 0 (0.0%) 0 (0.0%) 
  Yorkshire and The Humber (Leeds) 683 (16.9%) 1478 (20.4%) 790 (28.9%) 0 (0.0%) 
  West Midlands (Stoke) 344 (8.5%) 224 (3.1%) 199 (7.3%) 233 (16.4%) 
  East of England (Norfolk and Norwich) 222 (5.5%) 123 (1.7%) 0 (0.0%) 0 (0.0%) 
  East of England (Cambridge) 345 (8.5%) 697 (9.6%) 27 (1%) 272 (19.1%) 
  South East (East Kent) 563 (13.9%) 1326 (18.3%) 1048 (38.3%) 673 (47.2%) 
  South East (Portsmouth) 215 (5.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
  South West (Cornwall) 566 (14.0%) 2028 (28.0%) 673 (24.6%) 247 (17.3%) 
  London (UCL) 476 (11.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
  London (Lewisham) 427 (10.6%) 179 (2.5%) 0 (0.0%) 0 (0.0%) 
     
Age - years (data completeness) (100%) (100%) (100%) (100%) 
  16-18 years 1128 (27.9%) 2094 (28.9%) 1953 (71.4%) 629 (44.1%) 
  19-21 years 1704 (42.1%) 2892 (39.9%) 664 (24.3%) 796 (55.9%) 
  22-24 years 1212 (30.0%) 2267 (31.3%) 120 (4.4%) 0 (0.0%) 
     
Ethnicity (data completeness) (75%) (36%) (37%) (44%) 
  White 2393 (78.8%) 2292 (89.0%) 917 (91.6%) 566 (89.6%) 
  Black 399 (13.1%) 168 (6.5%) 51 (5.1%) 34 (5.4%) 
  Asian 80 (2.6%) 47 (1.8%) 16 (1.6%) 16 (2.5%) 
  Other 164 (6.9%) 68 (3.0%) 17 (1.9%) 16 (2.8%) 
     
Sample collection venue (data completeness) (100%) (100%) (100%) (100%) 
  General practice (GP) 1212 (30.0%) 3018 (41.6%) 1321 (48.3%) 1230 (86.3%) 
  Family planning (Community Sexual Health Services; CaSH) 2714 (67.1%) 4029 (55.5%) 1416 (51.7%) 195 (13.7%) 
  Youth clinic 118 (2.9%) 206 (2.8%) 0 (0%) 0 (0%) 
     chlamydia positivity (data completeness) 8.3% (100%) 6.2% (100%) 6.3% (100%) 6% (100%) 
     
HPV vaccination cohort (data completeness) (100%) (100%) (100%) (100%) 
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  Routine cohorts (offered vaccination 12-13 years old) 13 (0.3%) 659 (9.1%) 2261 (82.6%) 1365 (95.8%) 
  Younger catch-up cohorts (offered vaccination 14-16 years old) 604 (14.9%) 1598 (22.0%) 279 (10.2%) 60 (4.2%) 
  Older catch-up cohorts (offered vaccination 17-18 years old) 1425 (35.2%) 2807 (38.7%) 127 (4.6%) 0 (0%) 
  Not eligible for HPV vaccination 2002 (49.5%) 2189 (30.2%) 70 (2.6%) 0 (0%) 
     
HPV vaccination status in eligible cohorts (data completeness) (13%) (25%) (19%) (21%) 
  Fully vaccinated 119 (44.4%) 913 (73.6%) 440 (85.4%) 255 (86.7%) 
  Partially vaccinated 17 (6.3%) 69 (5.6%) 25 (4.9%) 11 (3.7%) 
  Vaccinated (unknown number of doses)
a
 37 (13.8%) 26 (2.1%) 0 (0%) 0 (0%) 
  Unvaccinated 95 (35.4%) 233 (18.8%) 50 (9.7%) 28 (9.5%) 
     
Estimated 3-dose coverage in those with unknown vaccination status
b
 53.6% 58.6% 81.9% 83.3% 
a
 Vaccination status data from Lewisham did not include the number of doses given was unavailable 
   
b
 Estimated using national HPV vaccination coverage for relevant birth cohorts; these women were assumed to be fully vaccinated in our main 
analysis 
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Table 2: Patient characteristics comparing vaccinated and unvaccinated women in the post-vaccination period 
 
Vaccinated 
(n=1,912) 
Unvaccinated 
(n=406) 
Total with known 
vaccination 
status 
(n=2,318) 
 
Unknown status 
(n=8,880) 
Age - years (data completeness) (100%) (100%) (100%) 
 
(100%) 
  16-18 years 990 (51.8%) 123 (30.3%) 1,113 (48.0%) 
 
4,691 (52.8%) 
  19-21 years 845 (44.2%) 263 (64.8%) 1,108 (47.8%) 
 
3,928 (44.2%) 
  22-24 years 77 (4.0%) 20 (4.9%) 97 (4.2%) 
 
261 (2.9%) 
      Ethnicity (data completeness) (12%) (32%) (15%) 
 
(52%) 
  White 191 (86.8%) 72 (56.3%) 263 (75.6%) 
 
4,051 (88.4%) 
  Black 25 (11.4%) 49 (38.3%) 74 (21.3%) 
 
321 (7.0%) 
  Asian <5
a
 <5
a
 <5
a
 
 
82 (1.8%) 
  Other <5
a
 <10
a
 <10
a
 
 
126 (2.8%) 
      Sample collection venue (data completeness) (100%) (100%) (100%) 
 
(100%) 
  General practice 1,554 (81.3%) 255 (62.8%) 1,809 (78.0%) 
 
3,165 (35.6%) 
  Family planning (Community Sexual Health Services; CaSH) 326 (17.1%) 138 (34.0%) 464 (20.0%) 
 
5,525 (62.2%) 
  Youth clinic 32 (1.7%) 13 (3.2%) 45 (1.9%) 
 
190 (2.1%) 
      chlamydia positivity (data completeness) 6.4% (100%) 8.4% (100%) 6.7% (100%) 
 
7.7% (100%) 
a
 small numbers masked in line with Public Health England data sharing policy
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Table 3: Post-vaccination type-specific HPV prevalence by age-group among all women 
  
Post-vaccination prevalence (95% CI) 
p-value 
for 
trend
c
 
Prevalence ratio associated with 
estimated vaccination coverage
d
 
HPV type 2010-2011 2012-2013 2014-2015
a
 2016 
Unadjusted 
(95% CI) 
Adjusted
b
 
(95%CI) 
16-18 years old n=1,128 n=2,094 n=1,953 n=629       
[Estimated HPV vaccination coverage] [60%] [77%] [84%] [84%] 
   Any High-risk HPV 37.7 (34.8, 40.5) 35.9 (33.9,  38.0) 33.8 (31.7,  35.9) 28.1 (24.6,  31.7) <0.001 0.7 (0.6,  0.8) - 
Other high-risk HPV (not 16/18/31/33/45) 31.0 (28.3, 33.7) 31.1 (29.1, 33.1) 31.4 (29.3, 33.4) 26.9 (23.4, 30.3) 0.211 0.8 (0.7, 1.0) - 
Vaccine HPV types 
       HPV16 and/or HPV18 8.2 (6.6,  9.9) 3.2 (2.5,  4.0) 1.8 (1.2,  2.4) 1.6 (0.6,  2.6) <0.001 0.1 (0.1,  0.2) 0.2 (0.1,  0.3) 
HPV16 6.4 (5.0,   7.8) 2.4 (1.7,  3.0) 1.5 (0.9, 2.0) 1.4 (0.5,  2.4) <0.001 0.1 (0.1, 0.2) 0.2 (0.1, 0.3) 
HPV18 2.8 (1.9, 3.8) 1.0 (0.5, 1.4) 0.4 (0.1, 0.7) 0.3 (-0.1, 0.8) <0.001 0.1 (0.1, 0.3) 0.1 (0.1, 0.3) 
Nonavalent HPV types 
       HPV31/HPV33/HPV45/HPV52/HPV58 16.9 (14.7, 19.1) 14.7 (13.1, 16.2) 10.2 (8.8, 11.5) 7.2 (5.1, 9.2) <0.001 0.4 (0.3, 0.6) 0.6 (0.4, 0.8) 
HPV31/HPV33/HPV45 6.5 (5.0, 7.9) 5.8 (4.8, 6.8) 2.8 (2.1, 3.6) 0.6 (0.0, 1.3) <0.001 0.2 (0.2, 0.4) 0.3 (0.2, 0.5) 
HPV31 0.9 (0.3, 1.4) 1.7 (1.1, 2.2) 0.3 (0.0, 0.5) 0.2 (-0.2, 0.5) 0.001 0.1 (0.1, 0.3) 0.2 (0.1, 0.4) 
HPV33 3.1 (2.1, 4.1) 2.6 (1.9, 3.3) 1.8 (1.2, 2.4) 0.3 (-0.1, 0.8) <0.001 0.3 (0.1, 0.5) 0.3 (0.1, 0.6) 
HPV45 2.7 (1.8, 3.7) 1.7 (1.2, 2.3) 0.8 (0.4, 1.2) 0.2 (-0.2, 0.5) <0.001 0.3 (0.1, 0.7) 0.3 (0.1, 0.9) 
HPV52 8.2 (6.6, 9.9) 6.5 (5.5, 7.6) 6.6 (5.5, 7.7) 4.9 (3.2, 6.6) 0.015 0.7 (0.5, 1.2) 1.1 (0.7, 1.9) 
HPV58 3.8 (2.7, 4.9) 3.8 (3.0, 4.6) 1.7 (1.1, 2.3) 2.1 (1.0, 3.2) <0.001 0.4 (0.2, 0.7) 0.6 (0.3, 1.2) 
HPV6/11 7.8 (6.2, 9.4) 9.5 (8.2, 10.8) 10.7 (9.3, 12.1) 8.3 (6.1, 10.4) 0.181 0.7 (0.5, 1.0) 0.8 (0.5, 1.2) 
HPV6 4.7 (3.5, 5.9) 5.5 (4.5, 6.5) 6.2 (5.2, 7.3) 4.0 (2.4, 5.5) 0.650 0.9 (0.5, 1.5) 1.1 (0.6, 1.9) 
HPV11 4.4 (3.2, 5.6) 5.4 (4.5, 6.4) 6.3 (5.2, 7.4) 5.4 (3.6, 7.2) 0.136 0.6 (0.3, 0.9) 0.6 (0.4, 1.0) 
        
19-21 years old n=1,704 n=2,892 n=664 n=796 
   [Estimated HPV vaccination coverage] [25%] [49%] [79%] [84%] 
   Any High-risk HPV 45.8 (43.5, 48.2) 46.4 (44.6, 48.3) 39.5 (35.7, 43.2) 35.3 (32.0, 38.6) <0.001 0.8 (0.8, 0.9) 0.9 (0.8, 1) 
Other high-risk HPV (not 16/18/31/33/45) 34.0 (31.8, 36.3) 38.9 (37.2, 40.7) 35.8 (32.2, 39.5) 32.9 (29.6, 36.2) 0.877 1.0 (0.9, 1.1) 1.1 (1.0, 1.2) 
Vaccine HPV types 
       HPV16 and/or HPV18 14.0 (12.4, 15.7) 8.1 (7.1, 9.0) 2.7 (1.5, 3.9) 1.6 (0.8, 2.5) <0.001 0.2 (0.2, 0.3) 0.3 (0.2, 0.4) 
HPV16 11.0 (9.5, 12.5) 6.7 (5.8, 7.6) 1.8 (0.8, 2.8) 1.5 (0.7, 2.4) <0.001 0.3 (0.2, 0.4) 0.3 (0.2, 0.5) 
HPV18 3.6 (2.7, 4.5) 1.8 (1.3, 2.2) 0.9 (0.2, 1.6) 0.1 (-0.1, 0.4) <0.001 0.1 (0.1, 0.2) 0.1 (0.1, 0.3) 
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Nonavalent HPV types 
       HPV31/HPV33/HPV45/HPV52/HPV58 21.6 (19.6, 23.6) 21.0 (19.5, 22.5) 16.1 (13.3, 18.9) 12.7 (10.4, 15) <0.001 0.7 (0.6, 0.8) 0.7 (0.6, 0.9) 
HPV31/HPV33/HPV45 8.6 (7.3, 10.0) 8.2 (7.2, 9.2) 4.2 (2.7, 5.7) 2.6 (1.5, 3.8) <0.001 0.4 (0.3, 0.5) 0.5 (0.3, 0.7) 
HPV31 2.3 (1.6, 3.1) 2.7 (2.1, 3.2) 0.8 (0.1, 1.4) 0.6 (0.1, 1.2) <0.001 0.3 (0.2, 0.6) 0.5 (0.3, 0.9) 
HPV33 2.9 (2.1, 3.7) 3.3 (2.6, 3.9) 2.3 (1.1, 3.4) 1.3 (0.5, 2.0) 0.003 0.5 (0.3, 0.8) 0.6 (0.3, 1.0) 
HPV45 3.6 (2.7, 4.5) 2.6 (2.0, 3.2) 1.4 (0.5, 2.2) 0.9 (0.2, 1.5) <0.001 0.3 (0.2, 0.5) 0.4 (0.2, 0.6) 
HPV52 10.3 (8.8, 11.7) 10.9 (9.7, 12.0) 9.2 (7.0, 11.4) 7.4 (5.6, 9.2) 0.020 0.8 (0.7, 1.0) 0.9 (0.7, 1.1) 
HPV58 4.9 (3.8, 5.9) 4.9 (4.1, 5.7) 5.1 (3.4, 6.8) 3.8 (2.4, 5.1) 0.352 0.9 (0.6, 1.2) 0.8 (0.5, 1.2) 
HPV6/11 8 (6.7, 9.3) 9.0 (7.9, 10.0) 9.2 (7.0, 11.4) 7.0 (5.3, 8.8) 0.752 1.1 (0.8, 1.4) 1.1 (0.8, 1.4) 
HPV6 5.2 (4.1, 6.2) 4.9 (4.2, 5.7) 5.9 (4.1, 7.7) 3.1 (1.9, 4.4) 0.451 0.9 (0.7, 1.3) 0.9 (0.6, 1.4) 
HPV11 3.9 (3.0, 4.9) 5.4 (4.6, 6.3) 5.4 (3.7, 7.1) 4.8 (3.3, 6.3) 0.135 1.3 (0.9, 1.7) 1.2 (0.8, 1.8) 
        
22-24 years old n=1,212 n=2,267 n=120 n=0 
   [Estimated HPV vaccination coverage] [0%] [7%] [25%] 
    Any High-risk HPV 40.3 (37.5, 43.0) 46.8 (44.8, 48.9) 40.0 (31.1, 48.9) 
 
<0.001 1.0 (0.8, 1.2) 1.0 (0.8, 1.3) 
Other high-risk HPV (not 16/18/31/33/45) 27.0 (30.8, 34.6) 32.7 (30.8, 34.6) 31.7 (23.2, 40.1) 
 
<0.001 1.4 (1.1, 1.7) 1.4 (1.1, 1.8) 
Vaccine HPV types 
       HPV16 and/or HPV18 16.4 (14.3, 18.5) 15.9 (14.4, 17.4) 7.5 (2.7, 12.3) 
 
0.417 0.3 (0.2, 0.6) 0.3 (0.1, 0.6) 
HPV16 14.6 (12.6, 16.6) 13.4 (12, 14.8) 5.8 (1.6, 10.1) 
 
0.956 0.3 (0.2, 0.6) 0.3 (0.1, 0.6) 
HPV18 2.6 (1.7, 3.5) 3.1 (2.4, 3.8) 1.7 (-0.7, 4.0) 
 
0.008 0.3 (0.1, 1.5) 0.3 (0.1, 1.3) 
Nonavalent HPV types 
       HPV31/HPV33/HPV45/HPV52/HPV58 18.4 (16.2, 20.6) 23.3 (21.6, 25.1) 18.3 (11.3, 25.4) 
 
0.001 1.1 (0.8, 1.5) 1.2 (0.8, 1.7) 
HPV31/HPV33/HPV45 7.8 (6.3, 9.4) 10.9 (9.7, 12.2) 8.3 (3.3, 13.4) 
 
0.016 0.6 (0.3, 1.2) 0.6 (0.3, 1.3) 
HPV31 2.5 (1.6, 3.4) 3.1 (2.4, 3.8) 2.5 (-0.3, 5.3) 
 
0.501 0.7 (0.2, 2.2) 0.5 (0.2, 2.0) 
HPV33 2.1 (1.3, 2.9) 3.3 (2.6, 4.0) 3.3 (0.1, 6.6) 
 
0.155 0.9 (0.3, 2.6) 0.8 (0.2, 2.4) 
HPV45 3.6 (2.6, 4.7) 4.8 (3.9, 5.7) 2.5 (-0.3, 5.3) 
 
0.096 0.5 (0.2, 1.4) 0.6 (0.2, 1.9) 
HPV52 8.6 (7.0, 10.2) 11.0 (9.7, 12.3) 7.5 (2.7, 12.3) 
 
0.010 1.5 (1.0, 2.4) 1.6 (1.0, 2.7) 
HPV58 3.2 (2.2, 4.2) 3.7 (2.9, 4.5) 5.0 (1.0, 9.0) 
 
0.261 1.9 (0.9, 4.1) 2.0 (0.9, 4.6) 
HPV6/11 3.5 (2.4, 4.5) 6.0 (5.0, 6.9) 1.7 (-0.7, 4.0) 
 
0.008 1.9 (1.0, 3.5) 1.5 (0.8, 3.1) 
HPV6 1.3 (0.7, 2.0) 3 (2.3, 3.7) 0.8 (-0.8, 2.5) 
 
<0.001 1.7 (0.6, 4.5) 1.1 (0.4, 3.2) 
HPV11 2.1 (1.3, 3.0) 3.6 (2.8, 4.4) 0.8 (-0.8, 2.5)   0.288 2.0 (0.9, 4.4) 1.9 (0.8, 4.5) 
a
 No samples were collected for 22-24 year olds in 2015 or 2016; 
b
 Adjusted for age, venue type and chlamydia positivity; 
c
 p-values for trend compare changes in prevalence  
over time using a log-binomial regression model, adjusted for age, testing venue and chlamydia positivity; 
d
 Prevalence ratios for the association between estimated HPV 
vaccination coverage and changes in post-vaccination HPV prevalence
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Table 4: Vaccine-effectiveness for the bivalent vaccine comparing HPV infection in the post-vaccination period, by age group (2010-2016)  
 
Unvaccinated Fully vaccinated
a
 Fully vaccinated
b
 
 
    (95% CI) 
Younger HPV vaccination cohorts
c
 combined n=117 n=1,176 
 HPV 16/18 with or without other HR types 10 (8.5%) 16 (1.4%) 82.0 (60.6, 91.8) 
    Non-vaccine type(s) with or without HPV 16/18 
        HPV 31/33/45 9 (7.7%) 42 (3.6%) 54.3 (8.6, 77.2) 
     HPV 31/33/45/52/58 18 (15.4%) 138 (11.7%) 16.4 (-30.9, 46.5) 
     HPV6/11 13 (11.1%) 98 (8.3%) 26.5 (-26.8, 57.4) 
    Older catch-up HPV vaccination cohorts n=289 n=614 
 HPV 16/18 with or without other HR types 39 (13.5%) 38 (6.2%) 48.7 (20.8, 66.8) 
    Non-vaccine type(s) with or without HPV 16/18 
        HPV 31/33/45 28 (9.7%) 35 (5.7%) 36.7 (-3.4, 61.2) 
     HPV 31/33/45/52/58 70 (24.2%) 116 (18.9%) 20.6 (-3.5, 39.1) 
     HPV6/11 31 (10.7%) 52 (8.5%) 18.8 (-24.6, 47.1) 
a
 Excludes 122 women who were partially vaccinated  
b
 Adjusted for age, venue type and chlamydia positivity 
  c Including routine cohorts and younger vaccination cohorts (i.e. all women offered vaccination at age 15 or younger) 
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Figure 1: Prevalence of HPV infection by year of sample collection  
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Figure 2: Prevalence of HPV infection by year of sample collection  
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Figure 3: Observed percentage reductions in HPV16 and HPV18 prevalence compared to previous model predictions 
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6.4. Further discussion of potential bias in the results of 
HPV infection surveillance 
6.4.1. The effect of the assay change between the pre-vaccination and 
post-vaccination period 
The paper in Section 6.2 compared the prevalence of HPV between the pre-
vaccination and post-vaccination period. As described in Section 6.3, the 
interpretation of these results was inhibited by the change in assay between the two 
time periods. Therefore, in the updated analyses presented in Section 6.3, I 
investigated changes within the post-vaccination period (during which time the 
assay did not change), and the association of these changes with increased 
vaccination coverage over time. However, for completeness, I include in this Section 
the updated results comparing the HPV prevalence in the pre-vaccination period 
with the post-vaccination period after applying the methods that I developed in this 
thesis to adjust for the effect of the different assay between the two time periods.  
In Section 4.4.3, I describe methods which I used to adjust the pre-vaccination 
prevalence for the assay change in the post-vaccination period. This adjusted 
prevalence represents the prevalence that would be expected if these samples were 
tested using the post-vaccination assay. This adjustment made use of results from a 
validation study which compared the two assays and was conducted outside of this 
PhD (the results are shown in Appendix C1). Table 6.1 shows the unadjusted and 
adjusted pre-vaccination prevalence for the HPV infection surveillance alongside the 
post-vaccination HPV prevalence for comparison. For all age-groups, the pre-
vaccination prevalence was similar with and without adjustment for HPV16/18 
combined and HPV31/33/45/52/58 combined although the adjusted prevalence was 
slightly lower for type-specific results for HPV18, HPV31 and HPV58. Conversely, 
the adjusted pre-vaccination prevalence for the non-vaccine high-risk HPV types 
combined was higher than the unadjusted pre-vaccination prevalence.  
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In Section 4.4.4, I described the methods I developed to adjust estimates of the 
odds ratio for type-specific HPV in the pre-vaccination period compared with the 
post-vaccination period. Table 6.2 shows the unadjusted odds ratio and prevalence 
ratio, the odds ratio and prevalence ratio adjusted for known demographic and 
behaviour characteristics and the odds ratio additionally adjusted for the change in 
the assay between the two periods. Similar to the previous results (presented in the 
first paper in this Chapter; Section 6.2), the unadjusted and adjusted prevalence 
ratios and odds ratios were similar for HPV16/18 combined and demonstrated a 
clear reduction in these types following the introduction of HPV vaccination. There 
was also some evidence of a protective effect of HPV vaccination against 
HPV31/33/45 infection although, after adjustment for the assay change, this was 
less clear due to the additional uncertainty which widened the confidence intervals 
for the odds ratios. For all age-groups, the odds ratios and prevalence ratios for 
other high-risk HPV types combined were greater than 1.0, suggesting that the 
prevalence of these HPV types increased following vaccine introduction. In line with 
the results in Table 6.1, the odds ratio reduced (towards the null) after adjustment 
for the assay change although there was still some evidence of increases, 
particularly in the older age-groups. I explore possible reasons for this increase in 
detail in the discussion of the first paper in this Chapter (Section 6.2) and further in 
Section 6.5.1 below.  
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Table 6.1: Pre- and post-vaccination HPV prevalence in the HPV infection surveillance; with adjustment of pre-vaccination prevalence 
for the assay change between the two periods (including specimens collected to the end-December 2016) 
 
Pre-vaccination 
prevalence 
(95% CI) 
Adjusted pre-vaccination 
prevalence 
(95% CI)
1
 
Post-vaccination prevalence (95% CI) 
 
HPV type 2010-2011 2012-2013 2014-2015 2016 
16-18 years old n=1,047 n=1,047 n=1,128 n=2,094 n=1,953 n=629 
[Estimated HPV vaccination coverage] [0%] [0%] [60%] [77%] [84%] [84%] 
Any High-risk HPV 32.6 (29.7, 35.4) 34.8 (27.7, 41.6) 37.7 (34.8, 40.5) 35.9 (33.9,  38.0) 33.8 (31.7,  35.9) 28.1 (24.6,  31.7) 
Any other high-risk HPV  24.9 (22.3, 27.6) 29.6 (23.9, 35.9) 31.0 (28.3, 33.7) 31.1 (29.1, 33.1) 31.4 (29.3, 33.4) 26.9 (23.4, 30.3) 
Vaccine HPV types 
 
 
    
HPV16 and/or HPV18 17.6 (15.3, 19.9) 18.0 (13.5, 22.7) 8.2 (6.6,  9.9) 3.2 (2.5,  4.0) 1.8 (1.2,  2.4) 1.6 (0.6,  2.6) 
HPV16 11.9 (10.0, 13.9) 12.8 (9.2, 16.8) 6.4 (5.0,   7.8) 2.4 (1.7,  3.0) 1.5 (0.9, 2.0) 1.4 (0.5,  2.4) 
HPV18 7.8 (6.2, 9.5) 6.1 (3.1, 9.5) 2.8 (1.9, 3.8) 1.0 (0.5, 1.4) 0.4 (0.1, 0.7) 0.3 (-0.1, 0.8) 
Nonavalent HPV types 
 
 
    
HPV31/HPV33/HPV45/HPV52/HPV58 14.5 (12.4, 16.7) 14.6 (10.4, 18.9) 16.9 (14.7, 19.1) 14.7 (13.1, 16.2) 10.2 (8.8, 11.5) 7.2 (5.1, 9.2) 
HPV31/HPV33/HPV45 8.4 (6.7, 10.1) 7.2 (3.8, 10.9) 6.5 (5.0, 7.9) 5.8 (4.8, 6.8) 2.8 (2.1, 3.6) 0.6 (0.0, 1.3) 
HPV31 3.7 (2.6, 4.9) 2.3 (0.2, 4.6) 0.9 (0.3, 1.4) 1.7 (1.1, 2.2) 0.3 (0.0, 0.5) 0.2 (-0.2, 0.5) 
HPV33 2.4 (1.5, 3.3) 2.3 (0.4, 4.6) 3.1 (2.1, 4.1) 2.6 (1.9, 3.3) 1.8 (1.2, 2.4) 0.3 (-0.1, 0.8) 
HPV45 2.9 (1.9, 3.9) 3.3 (1.0, 6.1) 2.7 (1.8, 3.7) 1.7 (1.2, 2.3) 0.8 (0.4, 1.2) 0.2 (-0.2, 0.5) 
HPV52 4.0 (2.8, 5.2) 4.7 (2.2, 7.3) 8.2 (6.6, 9.9) 6.5 (5.5, 7.6) 6.6 (5.5, 7.7) 4.9 (3.2, 6.6) 
HPV58 3.7 (2.6, 4.9) 2.8 (1.2, 4.7) 3.8 (2.7, 4.9) 3.8 (3.0, 4.6) 1.7 (1.1, 2.3) 2.1 (1.0, 3.2) 
HPV6/11 5.8 (4.4, 7.2) 5.8 (3.1, 9.1) 7.8 (6.2, 9.4) 9.5 (8.2, 10.8) 10.7 (9.3, 12.1) 8.3 (6.1, 10.4) 
HPV6 4.8 (3.5, 6.1) 3.6 (1.3, 6.2) 4.7 (3.5, 5.9) 5.5 (4.5, 6.5) 6.2 (5.2, 7.3) 4.0 (2.4, 5.5) 
HPV11 1.4 (0.7, 2.2) 6.7 (0.0, 12.0) 4.4 (3.2, 5.6) 5.4 (4.5, 6.4) 6.3 (5.2, 7.4) 5.4 (3.6, 7.2) 
       
19-21 years old n=804 n=804 n=1,704 n=2,892 n=664 n=796 
[Estimated HPV vaccination coverage] [0%] [0%] [25%] [49%] [79%] [84%] 
Any High-risk HPV 34.3 (31.0, 37.6) 37.0 (29.6, 44.3) 45.8 (43.5, 48.2) 46.4 (44.6, 48.3) 39.5 (35.7, 43.2) 35.3 (32.0, 38.6) 
Any other high-risk HPV  26.9 (23.8, 29.9) 32.3 (26.1, 39.2) 34.0 (31.8, 36.3) 38.9 (37.2, 40.7) 35.8 (32.2, 39.5) 32.9 (29.6, 36.2) 
Vaccine HPV types 
 
 
    
HPV16 and/or HPV18 16.9 (14.3, 19.5) 17.1 (12.5, 22.1) 14.0 (12.4, 15.7) 8.1 (7.1, 9.0) 2.7 (1.5, 3.9) 1.6 (0.8, 2.5) 
HPV16 12.6 (10.3, 14.9) 13.6 (9.7, 18.0) 11.0 (9.5, 12.5) 6.7 (5.8, 7.6) 1.8 (0.8, 2.8) 1.5 (0.7, 2.4) 
HPV18 6.5 (4.8, 8.2) 4.5 (1.5, 7.8) 3.6 (2.7, 4.5) 1.8 (1.3, 2.2) 0.9 (0.2, 1.6) 0.1 (-0.1, 0.4) 
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Nonavalent HPV types 
 
 
    
HPV31/HPV33/HPV45/HPV52/HPV58 15.2 (12.7, 17.7) 15.4 (11.0, 20.1) 21.6 (19.6, 23.6) 21.0 (19.5, 22.5) 16.1 (13.3, 18.9) 12.7 (10.4, 15) 
HPV31/HPV33/HPV45 8.3 (6.4, 10.2) 7.1 (3.6, 11.1) 8.6 (7.3, 10.0) 8.2 (7.2, 9.2) 4.2 (2.7, 5.7) 2.6 (1.5, 3.8) 
HPV31 4.7 (3.3, 6.2) 3.5 (1.2, 6.3) 2.3 (1.6, 3.1) 2.7 (2.1, 3.2) 0.8 (0.1, 1.4) 0.6 (0.1, 1.2) 
HPV33 2.0 (1.0, 3.0) 1.7 (-0.1, 4) 2.9 (2.1, 3.7) 3.3 (2.6, 3.9) 2.3 (1.1, 3.4) 1.3 (0.5, 2.0) 
HPV45 2.6 (1.5, 3.7) 2.9 (0.6, 5.8) 3.6 (2.7, 4.5) 2.6 (2.0, 3.2) 1.4 (0.5, 2.2) 0.9 (0.2, 1.5) 
HPV52 4.1 (2.7, 5.5) 4.8 (2.2, 7.8) 10.3 (8.8, 11.7) 10.9 (9.7, 12.0) 9.2 (7.0, 11.4) 7.4 (5.6, 9.2) 
HPV58 5.0 (3.5, 6.5) 4 (2.3, 6.5) 4.9 (3.8, 5.9) 4.9 (4.1, 5.7) 5.1 (3.4, 6.8) 3.8 (2.4, 5.1) 
HPV6/11 5.8 (4.2, 7.5) 5.9 (2.9, 9.4) 8 (6.7, 9.3) 9.0 (7.9, 10.0) 9.2 (7.0, 11.4) 7.0 (5.3, 8.8) 
HPV6 5.3 (3.8, 6.9) 4.3 (1.8, 7.3) 5.2 (4.1, 6.2) 4.9 (4.2, 5.7) 5.9 (4.1, 7.7) 3.1 (1.9, 4.4) 
HPV11 0.5 (0.0, 1.0) 2.3 (-1.3, 5.7) 3.9 (3.0, 4.9) 5.4 (4.6, 6.3) 5.4 (3.7, 7.1) 4.8 (3.3, 6.3) 
  
 
    
22-24 years old n=503 n=503 n=1,212 n=2,267 n=120 n=0 
[Estimated HPV vaccination coverage] [0%] [0%] [0%] [7%] [25%] 
 
Any High-risk HPV 32.8 (28.7, 36.9) 35.1 (27.1, 43.0) 40.3 (37.5, 43.0) 46.8 (44.8, 48.9) 40.0 (31.1, 48.9) 
 
Any other high-risk HPV  26.4 (22.6, 30.3) 31.7 (24.8, 39.5) 27.0 (30.8, 34.6) 32.7 (30.8, 34.6) 31.7 (23.2, 40.1) 
 
Vaccine HPV types 
 
 
    
HPV16 and/or HPV18 15.3 (12.2, 18.5) 15.1 (10.1, 20.6) 16.4 (14.3, 18.5) 15.9 (14.4, 17.4) 7.5 (2.7, 12.3) 
 
HPV16 10.9 (8.2, 13.7) 11.5 (7.4, 16.3) 14.6 (12.6, 16.6) 13.4 (12, 14.8) 5.8 (1.6, 10.1) 
 
HPV18 5.8 (3.7, 7.8) 3.6 (0.4, 7.3) 2.6 (1.7, 3.5) 3.1 (2.4, 3.8) 1.7 (-0.7, 4.0) 
 
Nonavalent HPV types 
 
 
    
HPV31/HPV33/HPV45/HPV52/HPV58 16.7 (13.4, 20.0) 17.3 (12.2, 23.0) 18.4 (16.2, 20.6) 23.3 (21.6, 25.1) 18.3 (11.3, 25.4) 
 
HPV31/HPV33/HPV45 8.9 (6.4, 11.4) 7.9 (3.9, 12.7) 7.8 (6.3, 9.4) 10.9 (9.7, 12.2) 8.3 (3.3, 13.4) 
 
HPV31 3.2 (1.6, 4.7) 1.7 (-0.6, 4.5) 2.5 (1.6, 3.4) 3.1 (2.4, 3.8) 2.5 (-0.3, 5.3) 
 
HPV33 2.6 (1.2, 4.0) 2.6 (0.4, 5.8) 2.1 (1.3, 2.9) 3.3 (2.6, 4.0) 3.3 (0.1, 6.6) 
 
HPV45 4.2 (2.4, 5.9) 5.4 (2.3, 9.9) 3.6 (2.6, 4.7) 4.8 (3.9, 5.7) 2.5 (-0.3, 5.3) 
 
HPV52 5.2 (3.2, 7.1) 6.4 (3.2, 10.4) 8.6 (7.0, 10.2) 11.0 (9.7, 12.3) 7.5 (2.7, 12.3) 
 
HPV58 3.0 (1.5, 4.5) 2.0 (0.3, 4.4) 3.2 (2.2, 4.2) 3.7 (2.9, 4.5) 5.0 (1.0, 9.0) 
 
HPV6/11 4.4 (2.6, 6.2) 3.9 (0.9, 7.5) 3.5 (2.4, 4.5) 6.0 (5.0, 6.9) 1.7 (-0.7, 4.0) 
 
HPV6 3.8 (2.1, 5.4) 2.4 (-0.1, 5.5) 1.3 (0.7, 2.0) 3 (2.3, 3.7) 0.8 (-0.8, 2.5) 
 
HPV11 0.8 (0.0, 1.6) 3.7 (-1.3, 9.4) 2.1 (1.3, 3.0) 3.6 (2.8, 4.4) 0.8 (-0.8, 2.5) 
 
1: The pre-vaccination prevalence was adjusted to provide an estimate of the prevalence if the specimens had been tested using the same assay as the post-vaccination specimens (see 
description in Section 4.4.3) 
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Table 6.2: Unadjusted and adjusted prevalence ratio and odds ratio of HPV infection in the post-vaccination period compared to the 
pre-vaccination period, by age-group (including specimens collected to end-December 2016) 
 
Unadjusted 
 
Adjusted for patient characteristics
1
 
 
Adjusted for patient 
characteristics and assay 
change
2
 
HPV type Odds ratio (95% CI) Prevalence ratio (95% CI) 
 
Odds ratio (95% CI) Prevalence ratio (95% CI) 
 
Odds ratio (95% CI) 
16-18 years old        
Any High-risk HPV 1.1 (1.0, 1.3) 1.1 (1.0, 1.2) 
 
1.3 (1.1, 1.5) - 
3
 
 
1.2 (0.9, 1.5) 
Any other high-risk HPV  1.5 (1.3, 1.7) 1.3 (1.2, 1.5) 
 
1.7 (1.5, 2.0) - 
3
 
 
1.4 (1.0, 1.8) 
Vaccine HPV types 
       HPV16 and/or HPV18  0.2 (0.1, 0.2)  0.2 (0.2, 0.2) 
 
 0.2 (0.2, 0.2)  0.2 (0.2, 0.3) 
 
0.2 (0.1, 0.3) 
HPV16  0.2 (0.2, 0.3)  0.2 (0.2, 0.3) 
 
 0.2 (0.2, 0.3)  0.3 (0.2, 0.3) 
 
0.2 (0.1, 0.3) 
HPV18  0.1 (0.1, 0.2)  0.1 (0.1, 0.2) 
 
 0.2 (0.1, 0.2)  0.2 (0.1, 0.2) 
 
0.2 (0.1, 0.5) 
Nonavalent HPV types 
       HPV31/HPV33/HPV45/HPV52/HPV58  0.9 (0.7, 1.0)  0.9 (0.7, 1.0) 
 
 1.0 (0.8, 1.2)  1.0 (0.9, 1.2) 
 
1.0 (0.8, 1.5) 
HPV31/HPV33/HPV45  0.5 (0.4, 0.6)  0.5 (0.4, 0.7) 
 
 0.6 (0.4, 0.7)  0.6 (0.5, 0.8) 
 
0.7 (0.4, 1.3) 
HPV31  0.2 (0.2, 0.3)  0.2 (0.2, 0.4) 
 
 0.3 (0.2, 0.4)  0.3 (0.2, 0.4) 
 
0.5 (0.2, 3.2) 
HPV33  0.9 (0.6, 1.4)  0.9 (0.6, 1.4) 
 
 1.0 (0.6, 1.6)  1.0 (0.6, 1.6) 
 
1.1 (0.5, 3.7) 
HPV45  0.5 (0.3, 0.8)  0.5 (0.3, 0.8) 
 
 0.6 (0.4, 0.9)  0.6 (0.4, 0.9) 
 
0.5 (0.2, 1.3) 
HPV52  1.7 (1.2, 2.4)  1.7 (1.2, 2.3) 
 
 2.0 (1.4, 2.8)  1.9 (1.4, 2.6) 
 
1.7 (1.0, 3.2) 
HPV58  0.8 (0.5, 1.1)  0.8 (0.6, 1.1) 
 
 0.9 (0.6, 1.4)  0.9 (0.6, 1.3) 
 
1.3 (0.8, 3.1) 
HPV6 and/or HPV11  1.7 (1.3, 2.2)  1.6 (1.3, 2.1) 
 
 1.9 (1.4, 2.5)  1.8 (1.4, 2.4) 
 
 1.9 (1.2, 3.4) 
HPV6  1.1 (0.8, 1.6)  1.1 (0.8, 1.5) 
 
 1.3 (1.0, 1.9)  1.3 (1.0, 1.8) 
 
 1.6 (1.0, 4.0) 
HPV11  4.0 (2.4, 6.8)  3.9 (2.3, 6.5) 
 
 4.2 (2.4, 7.1)  4.0 (2.3, 6.7) 
 
 0.9 (0.2, 4.0) 
        
19-21 years old 
       Any High-risk HPV 1.5 (1.3, 1.8) 1.3 (1.2, 1.4) 
 
1.8 (1.5, 2.1) - 
3
 
 
1.6 (1.3, 2.1) 
Any other high-risk HPV  1.8 (1.6, 2.2) 1.5 (1.3, 1.7) 
 
2.1 (1.8, 2.5) 1.6 (1.4, 1.8) 
 
1.6 (1.2, 2.1) 
Vaccine HPV types 
       HPV16 and/or HPV18  0.4 (0.4, 0.5)  0.5 (0.4, 0.6) 
 
 0.5 (0.4, 0.7)  0.6 (0.5, 0.7) 
 
0.5 (0.4, 0.8) 
HPV16  0.5 (0.4, 0.6)  0.5 (0.4, 0.7) 
 
 0.6 (0.5, 0.8)  0.7 (0.5, 0.8) 
 
0.6 (0.4, 0.9) 
HPV18  0.3 (0.2, 0.4)  0.3 (0.2, 0.4) 
 
 0.3 (0.2, 0.5)  0.3 (0.2, 0.5) 
 
0.5 (0.3, 2.1) 
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Nonavalent HPV types 
       HPV31/HPV33/HPV45/HPV52/HPV58  1.4 (1.1, 1.7)  1.3 (1.1, 1.5) 
 
 1.6 (1.3, 1.9)  1.4 (1.2, 1.7) 
 
1.6 (1.2, 2.3) 
HPV31/HPV33/HPV45  0.8 (0.6, 1.1)  0.9 (0.7, 1.1) 
 
 1.0 (0.8, 1.3)  1.0 (0.8, 1.3) 
 
1.3 (0.7, 2.8) 
HPV31  0.4 (0.3, 0.6)  0.4 (0.3, 0.6) 
 
 0.5 (0.3, 0.7)  0.5 (0.3, 0.7) 
 
0.7 (0.4, 2.9) 
HPV33  1.4 (0.8, 2.4)  1.4 (0.8, 2.3) 
 
 1.7 (1.0, 2.8)  1.6 (1.0, 2.7) 
 
2.1 (0.9, 6248.7) 
HPV45  1.0 (0.6, 1.5)  1.0 (0.6, 1.5) 
 
 1.2 (0.7, 1.9)  1.1 (0.7, 1.8) 
 
1.0 (0.5, 4.3) 
HPV52  2.6 (1.8, 3.7)  2.5 (1.7, 3.5) 
 
 2.9 (2.0, 4.2)  2.7 (1.9, 3.8) 
 
2.5 (1.5, 5.0) 
HPV58  1.0 (0.7, 1.3)  1.0 (0.7, 1.3) 
 
 1.0 (0.7, 1.4)  1.0 (0.7, 1.3) 
 
1.2 (0.8, 2.1) 
HPV6 and/or HPV11  1.5 (1.1, 2.0)  1.4 (1.1, 1.9) 
 
 1.5 (1.1, 2.1)  1.5 (1.1, 2.0) 
 
 1.5 (0.9, 2.9) 
HPV6  0.9 (0.7, 1.3)  0.9 (0.7, 1.2) 
 
 1.0 (0.7, 1.4)  1.0 (0.7, 1.3) 
 
 1.2 (0.7, 2.6) 
HPV11 10.4 (3.8, 27.8)  9.9 (3.7, 26.5) 
 
10.4 (3.9, 28.1)  9.9 (3.7, 26.6) 
 
 2.4 (0.5, 21.6) 
        
22-24 years old 
       Any High-risk HPV 1.6 (1.3, 2.0) 1.4 (1.2, 1.5) 
 
1.8 (1.5, 2.2) 1.4 (1.2, 1.6) 
 
1.6 (1.2, 2.2) 
Any other high-risk HPV  1.6 (1.3, 2.0) 1.4 (1.2, 1.6) 
 
1.8 (1.4, 2.2) 1.5 (1.3, 1.7) 
 
1.4 (1.0, 1.9) 
Vaccine HPV types 
       HPV16 and/or HPV18  1.0 (0.8, 1.3)  1.0 (0.8, 1.3) 
 
 1.1 (0.8, 1.4)  1.1 (0.9, 1.3) 
 
1.1 (0.8, 1.7) 
HPV16  1.3 (1.0, 1.7)  1.2 (1.0, 1.6) 
 
 1.3 (1.0, 1.8)  1.3 (1.0, 1.7) 
 
1.3 (0.8, 2.0) 
HPV18  0.5 (0.3, 0.7)  0.5 (0.3, 0.7) 
 
 0.5 (0.3, 0.8)  0.5 (0.3, 0.8) 
 
0.8 (0.4, 5.6) 
Nonavalent HPV types 
       HPV31/HPV33/HPV45/HPV52/HPV58  1.4 (1.1, 1.8)  1.3 (1.0, 1.6) 
 
 1.5 (1.2, 2.0)  1.4 (1.1, 1.7) 
 
1.5 (1.0, 2.2) 
HPV31/HPV33/HPV45  1.1 (0.8, 1.5)  1.1 (0.8, 1.5) 
 
 1.1 (0.8, 1.6)  1.1 (0.8, 1.5) 
 
1.3 (0.8, 2.8) 
HPV31  0.9 (0.5, 1.5)  0.9 (0.5, 1.5) 
 
 1.0 (0.6, 1.7)  1.0 (0.6, 1.6) 
 
1.7 (0.7, -) 
HPV33  1.1 (0.6, 2.0)  1.1 (0.6, 2.0) 
 
 1.2 (0.7, 2.2)  1.2 (0.7, 2.2) 
 
1.2 (0.5, 15.4) 
HPV45  1.0 (0.7, 1.7)  1.0 (0.7, 1.6) 
 
 1.1 (0.7, 1.7)  1.0 (0.7, 1.6) 
 
0.8 (0.4, 1.8) 
HPV52  2.1 (1.4, 3.1)  2.0 (1.3, 2.9) 
 
 2.2 (1.5, 3.4)  2.1 (1.4, 3.1) 
 
1.8 (1.1, 3.7) 
HPV58  1.2 (0.7, 2.1)  1.2 (0.7, 2.0) 
 
 1.6 (0.9, 2.8)  1.5 (0.9, 2.7) 
 
2.4 (1.2, 20.6) 
HPV6 and/or HPV11  1.1 (0.7, 1.8)  1.1 (0.7, 1.8) 
 
 1.2 (0.7, 1.9)  1.2 (0.7, 1.8) 
 
 1.3 (0.7, 5.0) 
HPV6  0.6 (0.4, 1.0)  0.6 (0.4, 1.0) 
 
 0.6 (0.4, 1.0)  0.6 (0.4, 1.0) 
 
 0.9 (0.4, 558.4) 
HPV11  3.9 (1.4, 10.6)  3.8 (1.4, 10.3) 
 
 4.0 (1.4, 10.9)  3.9 (1.4, 10.5) 
 
 0.9 (0.2, 6.8) 
1: Adjusted for age, venue type and chlamydia positivity 
2: Adjusted for age, venue type, chlamydia positivity and the assay change between the pre-vaccination and post-vaccination period 
3: regression model did not converge 
       
172 
 
6.4.2. The effect of potential changes in chlamydia screening over time 
This HPV surveillance made use of residual specimens taken originally from young 
women attending for chlamydia screening as part of the National Chlamydia 
Screening Programme. This is ongoing surveillance started in 2008 and I presented 
post-vaccination data collected between October 2010 and December 2016 in the 
second paper in this Chapter (Section 6.3). Over the same time period that this HPV 
infection surveillance was conducted, there were changes within the Chlamydia 
Screening Programme. There are two notable changes which could have affected 
the risk of HPV infection in the HPV infection surveillance population; the number of 
chlamydia tests performed annually, and the change in recording of chlamydia 
testing from the NCSP dataset to CTAD (as described in Section 4.2.5). I explore 
these two changes in more detail and then assess the potential effect that these 
changes could have on the results presented in the two papers in this section. 
Firstly, I considered changes in the total number of chlamydia screening tests 
performed in England between 2010 and 2016. Assuming one test per person, an 
estimated 44% of young females were tested for chlamydia in 2010. This compared 
to an estimated 41% of females tested in 2011[140]. These proportions are not 
directly comparable to data from 2012 onwards, given the change from NCSP data 
collection to CTAD data collection. However, a report of CTAD data (published by 
Public Health England) indicated that between 2012 and 2016, the total number of 
chlamydia screening tests continued to steadily decline from an estimated 37% of 
females being screened in 2012 to around 30% in 2016[118]. Data from this report 
suggested that if a higher number of women were attending for chlamydia screening 
nationally, it’s likely that, on average, the chlamydia positivity among those tested 
would be lower (as this would include higher and lower risk women). Conversely, if 
a lower number of women were attending for chlamydia screening nationally, then 
it’s likely these would be higher risk women with a higher proportion positive for 
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chlamydia infection[118]. Therefore, if the proportion of women attending for 
chlamydia screening changed over time then this could potentially have affected the 
results reported in the above papers if there was a change in the risk profile of 
women included in the surveillance. Specifically, if women attending for chlamydia 
screening had a varying risk of chlamydia infection over time, they also could have 
had a varying risk of HPV infection, as the two infections have many shared risk 
factors. I explore the potential effect of this change at the end of this section. 
Secondly, the surveillance population was intended to be restricted to women 
attending for an opportunistic chlamydia screening test (see Section 4.3.1). Other 
reasons for attending for a chlamydia test could have been because a woman had 
symptoms or because she had been notified of a potential risk of chlamydia 
infection from a partner (i.e. partner notification). Women attending for either of 
these reasons would have been more likely to have had a chlamydia infection 
compared to women attending for opportunistic screening, and thus potentially 
would have been at higher risk of HPV infection. When data were collected using 
the NCSP dataset (before April 2012), the reason for chlamydia testing was 
recorded so I was able to confirm that laboratories had correctly sent specimens 
only from women attending for an opportunistic test and exclude samples from 
women attending for other reasons; a relatively small proportion of all linked residual 
specimens (2.1%) were excluded because they were recorded as being taken from 
a women not attending for opportunistic screening. However, since the introduction 
of CTAD in April 2012, this information (i.e. the reason for chlamydia testing) was no 
longer collected (see Section 4.2.5) hence I was not able to confirm that laboratories 
had exclusively sent samples collected for opportunistic sampling. Therefore, 
although there was no change in how laboratories were asked to select residual 
specimens, and although women attending for chlamydia screening would have 
been unaware of this change in data collection, it is plausible that following April 
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2012, there were some women included in the surveillance who had not attended 
for opportunistic chlamydia screening.  
Both of the above changes (the decrease in the numbers of women attending for 
chlamydia screening nationally after 2010 and the potential inclusion of some 
higher-risk women due to the move from NCSP database to CTAD) could have 
affected the risk of chlamydia infection in the HPV infection surveillance; most likely 
leading to a higher chlamydia positivity in later years of the surveillance, as 
described above. This could in turn have resulted in the inclusion of a higher 
proportion of HPV positive women in the later years of the post-vaccination period. If 
this were the case, this would have underestimated the effect of HPV vaccination on 
HPV prevalence. The effect of these two changes was mitigated in the analysis by 
adjusting for chlamydia positivity which I used as a proxy for sexual behaviour (the 
effect of residual confounding by unmeasured sexual behaviour is discussed further 
in Section 6.4.3). However, to further investigate to what extent these two changes 
could have affected the results of the HPV infection surveillance, I compared 
chlamydia positivity over time, as reported in Figure 6.1. 
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Figure 6.1: Change in chlamydia positivity over time among the HPV infection 
surveillance population, by age-group 
 
This Figure shows that there were clear changes in the prevalence of chlamydia in 
the surveillance population over time, with markedly higher chlamydia positivity in 
the first quarter of 2012 compared to 2010/2011 and compared to the second 
quarter of 2012 onwards for all age-groups. However, the observed variations over 
time weren’t consistent with the expected effect of either a decline in the number of 
women attending for chlamydia screening or of the change from the NCSP 
database to CTAD. There were two laboratories who not only provided specimens 
with notably higher chlamydia positivity than the other laboratories included in this 
analysis (14.8% at Leeds and 8.4% at Lewisham compared to 4.7% at all other 
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laboratories combined) but importantly also had a greater variation in chlamydia 
positivity over time. Figure 6.2 shows the chlamydia positivity among specimens 
included in the HPV infection surveillance after excluding specimens from Leeds 
and Lewisham laboratories. After these exclusions, there was far less variation in 
the prevalence of chlamydia positivity over time, although there was a small 
increase among the younger two age-groups after 2014. 
As a sensitivity analysis, I calculated changes in HPV prevalence after excluding 
specimens from the Leeds and Lewisham laboratories. The results excluding these 
two laboratories were very similar to those from the main analysis; declines in the 
prevalence of HPV16 and/or 18 were seen for all age-groups and there was 
evidence of a reduction in HPV31/33/45 prevalence in the younger two age-groups. 
The prevalence of other high-risk HPV types remained relatively stable within the 
post-vaccination period (Figure 6.3). The similarity of these results to the main 
analysis presented in the second paper of this Chapter (Section 6.3) reassures that 
changes in chlamydia positivity due to variations over time in two geographical 
areas (served by two laboratories) did not substantially affect the results presented 
in this Chapter. I also include in Appendix F, the same Figure restricted to women 
testing negative for chlamydia. As expected, the HPV prevalence is slightly lower 
but the pattern of declines over time is again similar to the main analysis; numbers 
were too small to repeat this analysis restricted to women testing positive for 
chlamydia. In the next section (Section 6.4.3), are the results of further exploration 
of the possibility that other changes in sexual behaviour over time (not accounted 
for by adjustment in chlamydia positivity) could potentially bias the results of the 
HPV infection surveillance. 
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Figure 6.2: Change in chlamydia positivity over time among the HPV infection 
surveillance population, by age-group (excluding specimens from Leeds 
laboratory and Lewisham laboratory) 
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Figure 6.3: Prevalence of HPV infection by year of sample collection 
(excluding specimens from Leeds laboratory and Lewisham laboratory) 
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6.4.3. Potential bias due to missing data and unmeasured confounding 
variables 
The NCSP and CTAD datasets had a considerable amount of missing data for 
some variables of interest to HPV surveillance. I described this in Section 4.2.5 
(Table 4.1) for the general datasets and I explore this specifically for the specimens 
included in the HPV surveillance in Table 6.3, below.  
There was no (or very little) missing data for the venue where the sample was 
collected, for age or for chlamydia positivity and hence these could be adjusted for 
in the analysis. Data on the number of sexual partners has not been available since 
2012 with the introduction of CTAD. Therefore, this variable could not be considered 
in analyses within the post-vaccination period. Unfortunately, data on quintile of 
deprivation was not available for pre-vaccination specimens. Within the post-
vaccination period the percentage of specimens with missing IMD varied from 2% to 
26% across different years. Due to the variation in IMD data completeness over 
time, I did not adjust for IMD in the calculation of the prevalence ratio associated 
with estimated vaccination coverage (Table 3 in the second paper of this Chapter; 
Section 6.3) or the calculation of the vaccine effectiveness (Table 4 in the second 
paper of this Chapter; Section 6.3) Here, I have included a complete case analysis 
adjusted for quintile of IMD below (Table 6.4 for the prevalence ratio associated with 
vaccination coverage and Table 6.5 for the vaccine effectiveness). The results for 
both these analyses were very similar to those without adjustment for IMD. There 
was a much higher proportion of missing data for ethnicity and this also varied 
considerably over time (between 12% and 95%). Therefore it was not appropriate to 
conduct an analysis incorporating only specimens with non-missing ethnicity and 
this variable was not included in multivariable analyses. I discuss the implications of 
this below.
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Table 6.3: Percentage of specimens included in the HPV surveillance with missing data in the NCSP dataset (2008-March 2012) or in 
CTAD (April 2012-2016), stratified by year of specimen collection 
 
Year of specimen collection 
 
2008 2010/2011 2012 2013 2014 2015 2016 
Socio-demographic data 
       Age 0% 0% 0% 0% 0% 0% 0% 
Ethnicity 12% 25% 38% 95% 83% 50% 55% 
Quintile of IMD1 100% 2% 6% 16% 7% 5% 26% 
>1 sexual partner in previous 12 months2 19% 55% 63% 100% 100% 100% 100% 
Any new sexual partner in previous 3 months2 12% 13% 22% 100% 100% 100% 100% 
        
Details of chlamydia test 
       Sample collection venue 0% 0% 0% 0% 0% 0% 0% 
Result of chlamydia test 1% <1% 0% 0% 0% 0% 0% 
1: Index of multiple deprivation (IMD) was derived from the postcode of residence. This was not linked prior to anonymisation 
for pre-vaccination specimens in 2008 hence these data are not available for this year 
2: Sexual behaviour data were collected in the NCSP dataset but not in CTAD 
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Table 6.4: Complete case analysis for prevalence ratio for HPV associated with estimated HPV vaccination coverage including 
additional adjustment for IMD, by age-group and HPV type (specimens collected 2010-2016) 
  Prevalence ratio associated with estimated vaccination coverage 
HPV type Unadjusted (95% CI) Adjusted1 (95%CI) IMD adjusted2 (95%CI) 
16-18 years old n=5,260 n=5,260 n=5,260 
 
   
Any High-risk HPV 0.7 (0.6, 0.8) - - 
Any other high-risk HPV  0.7 (0.6, 0.9) - - 
Vaccine HPV types 
   HPV16 and/or HPV18 0.1 (0.1, 0.2) 0.2 (0.1, 0.3) 0.2 (0.1, 0.3) 
HPV16 0.1 (0.1, 0.2) 0.2 (0.1, 0.3) 0.2 (0.1, 0.3) 
HPV18 0.1 (0.0, 0.3) 0.1 (0.0, 0.3) 0.1 (0.1, 0.4) 
Nonavalent HPV types 
   HPV31/HPV33/HPV45/HPV52/HPV58 0.4 (0.3, 0.6) 0.5 (0.4, 0.8) 0.6 (0.4, 0.8) 
HPV31/HPV33/HPV45 0.2 (0.2, 0.4) 0.3 (0.2, 0.5) 0.3 (0.2, 0.5) 
HPV31 0.1 (0.1, 0.4) 0.2 (0.1, 0.5) 0.2 (0.1, 0.6) 
HPV33 0.3 (0.1, 0.5) 0.3 (0.1, 0.6) 0.3 (0.1, 0.6) 
HPV45 0.2 (0.1, 0.6) 0.3 (0.1, 0.7) 0.3 (0.1, 0.7) 
HPV52 0.7 (0.4, 1.1) 1.0 (0.6, 1.8) 1.1 (0.6, 1.8) 
HPV58 0.5 (0.2, 0.9) 0.7 (0.3, 1.5) 0.7 (0.3, 1.5) 
HPV6/11 0.8 (0.5, 1.2) 0.9 (0.6, 1.4) 0.9 (0.6, 1.4) 
HPV6 1.1 (0.6, 1.9) 1.4 (0.7, 2.6) 1.4 (0.7, 2.6) 
HPV11 0.6 (0.3, 0.9) 0.6 (0.4, 1.0) 0.6 (0.4, 1.1) 
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19-21 years old n=5,460 n=5,460 n=5,460 
    
Any High-risk HPV 0.9 (0.8, 0.9) 1.0 (0.9, 1.2) - 
Any other high-risk HPV  1.0 (0.9, 1.1) 1.0 (0.9, 1.2) 1.0 (0.9, 1.2) 
Vaccine HPV types 
   HPV16 and/or HPV18 0.2 (0.2, 0.3) 0.3 (0.2, 0.4) 0.3 (0.2, 0.4) 
HPV16 0.3 (0.2, 0.4) 0.3 (0.2, 0.5) 0.3 (0.2, 0.5) 
HPV18 0.1 (0.1, 0.3) 0.1 (0.1, 0.3) 0.1 (0.1, 0.3) 
Nonavalent HPV types 
   HPV31/HPV33/HPV45/HPV52/HPV58 0.7 (0.6, 0.8) 0.8 (0.6, 0.9) 0.8 (0.6, 0.9) 
HPV31/HPV33/HPV45 0.4 (0.3, 0.6) 0.5 (0.4, 0.7) 0.5 (0.4, 0.7) 
HPV31 0.4 (0.2, 0.6) 0.5 (0.3, 0.9) 0.5 (0.3, 0.9) 
HPV33 0.5 (0.3, 0.9) 0.6 (0.3, 1.0) 0.6 (0.3, 1.0) 
HPV45 0.4 (0.2, 0.6) 0.4 (0.2, 0.7) 0.4 (0.2, 0.7) 
HPV52 0.9 (0.7, 1.1) 0.9 (0.7, 1.2) 0.9 (0.7, 1.2) 
HPV58 0.9 (0.6, 1.3) 0.9 (0.6, 1.3) 0.9 (0.6, 1.3) 
HPV6/11 1.2 (0.9, 1.5) 1.1 (0.8, 1.5) 1.1 (0.8, 1.5) 
HPV6 1.0 (0.7, 1.5) 0.9 (0.6, 1.4) 0.9 (0.6, 1.4) 
HPV11 1.4 (1.0, 2.0) 1.3 (0.9, 2.0) 1.3 (0.9, 2.0) 
    22-24 years old n=3,348 n=3,348 n=3,348 
 
   
Any High-risk HPV 1.0 (0.8, 1.2) 1.0 (0.8, 1.3) 1.0 (0.8, 1.3) 
Any other high-risk HPV  1.3 (1.0, 1.6) 1.3 (1.0, 1.7) 1.3 (1.0, 1.7) 
Vaccine HPV types 
   HPV16 and/or HPV18 0.3 (0.2, 0.6) 0.3 (0.1, 0.6) 0.3 (0.2, 0.6) 
HPV16 0.3 (0.2, 0.6) 0.3 (0.1, 0.6) 0.3 (0.1, 0.6) 
HPV18 0.4 (0.1, 1.7) 0.3 (0.1, 1.6) 0.3 (0.1, 1.5) 
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Nonavalent HPV types 
   HPV31/HPV33/HPV45/HPV52/HPV58 1.1 (0.8, 1.6) 1.2 (0.8, 1.7) 1.2 (0.8, 1.7) 
HPV31/HPV33/HPV45 0.6 (0.3, 1.2) 0.6 (0.3, 1.3) 0.6 (0.3, 1.3) 
HPV31 0.6 (0.2, 2.2) 0.5 (0.1, 2.0) 0.5 (0.1, 2.0) 
HPV33 1.0 (0.3, 2.9) 0.9 (0.3, 2.6) 0.9 (0.3, 2.7) 
HPV45 0.4 (0.1, 1.4) 0.5 (0.2, 1.8) 0.5 (0.2, 1.9) 
HPV52 1.6 (1.0, 2.5) 1.7 (1.0, 2.9) 1.7 (1.0, 2.8) 
HPV58 2.1 (1.0, 4.5) 2.2 (0.9, 5.1) 2.2 (0.9, 5.1) 
HPV6/11 2.1 (1.1, 3.9) 1.8 (0.9, 3.4) 1.8 (0.9, 3.4) 
HPV6 2.0 (0.8, 5.3) 1.3 (0.5, 3.7) 1.3 (0.5, 3.6) 
HPV11 2.1 (1.0, 4.8) 2.1 (0.9, 5.0) 2.1 (0.9, 5.0) 
1: Adjusted for age, venue type and chlamydia positivity 
2: Adjusted for age, venue type, chlamydia positivity and quintile of IMD 
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Table 6.5: Complete case analysis for vaccine effectiveness comparing HPV infection in the post-vaccination period               
including additional adjustment for IMD, by age-group 
 
VE
1
 (full vaccination)  VE
2
 (full vaccination)  
 
(95% CI) (95% CI) 
Younger HPV vaccination cohorts
3
 combined n=1,124 n=1,124 
HPV 16/18 with or without other HR types 79.9 (50.0, 91.9) 80.7 (51.8, 92.2) 
   Non-vaccine type(s) with or without HPV 16/18 
       HPV 31/33/45 60.3 (20.1, 80.3) 60.1 (19.7, 80.2) 
     HPV 31/33/45/52/58 21.1 (-26.5, 50.8) 20.2 (-28.0, 50.2) 
     HPV6/11 12.0 (-63.6, 52.6) 11.8 (-63.8, 52.5) 
   Older catch-up HPV vaccination cohorts n=860 n=860 
HPV 16/18 with or without other HR types 51.5 (24.8, 68.8) 53.7 (27.6, 70.3) 
   Non-vaccine type(s) with or without HPV 16/18 
       HPV 31/33/45 38.9 (-0.8, 63.0) 37.3 (-3.8, 62.1) 
     HPV 31/33/45/52/58 20.8 (-3.7, 39.6) 19.4 (-5.9, 38.6) 
     HPV6/11 10.9 (-40.0, 43.3) 9.8 (-42.2, 42.8) 
1: Adjusted for age, venue type and chlamydia positivity 
2: Adjusted for age, venue type, quintile of IMD and chlamydia positivity 
   3: Including routine cohorts and younger vaccination cohorts (i.e. all women offered vaccination at age 15 or younger) 
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Estimates of changes in HPV prevalence over time among women attending for 
chlamydia screening could be subject to confounding if there are changes in related 
demographics or sexual behaviour of the screened population over the same time 
period. As described in the previous section, I attempted to account for these 
changes by including relevant available variables in multivariable regression models 
(age, chlamydia positivity and testing venue). However, other unrecorded population 
changes over time which were related to HPV prevalence may have confounded the 
estimated association between HPV vaccination coverage and  trends in HPV 
prevalence. I discuss below some of the known confounding variables which could 
not be included in our analyses. 
Sexual behaviour: In the earlier years of this HPV surveillance, some data were 
available on the proportion of women with multiple sexual partners in the previous 
12 months and the proportion of women with at least one new sexual partner within 
the last 3 months. These data variables were collected from clinics at the time of the 
chlamydia test. Unfortunately, with the change to data collection from laboratories in 
April 2012, these data could no longer be collected so these variables could not be 
included in this analysis. I compared changes in sexual behaviour over time (up to 
April 2012) in the analysis I conducted prior to the start of this PhD[126] but the 
interpretation was limited by the high proportion of missing data. As discussed 
above, in the updated analyses included in this Chapter I was also able to adjust for 
chlamydia positivity as a proxy for sexual behaviour. However, other changes in 
sexual behaviour may not have been addressed by adjustment by chlamydia 
positivity alone. The expectation, and concern, when interpreting these results, is 
that those with higher risk sexual behaviour would have a lower HPV vaccination 
uptake but a higher risk of HPV infection (i.e. a positive confounder) Therefore, by 
not including sexual behaviour in the analysis, the association between vaccination 
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coverage and HPV prevalence may be overestimated. I explore variations in HPV 
vaccination uptake in different population subgroups in Chapter 8.  
Ethnicity: As previously discussed, the proportion of specimens with missing 
ethnicity was considerable hence this variable was not included in the analysis. I 
explore later in this thesis whether women of non-white ethnicity have lower HPV 
vaccination uptake (Section 8.4). There was some evidence of lower vaccination 
coverage in black women and women of mixed ethnicity although this was not clear 
after adjustment for other variables. Others have shown that the prevalence of HPV 
is higher in black women but lower in Asian women (Section 2.3). As with sexual 
behaviour, if black women were likely have lower vaccination uptake and higher 
HPV prevalence, lack of adjustment would overestimate the association between 
vaccination coverage and HPV prevalence. For Asian women, the reverse is true if 
these women had lower vaccination uptake but also lower HPV prevalence. This 
could have potentially underestimated the association between vaccination and 
HPV prevalence although the number of specimens from Asian women was small 
so this is likely to have less impact. 
Smoking status: Smoking has been shown to be associated with increased HPV 
infection (Section 2.3). The work to explore variations in HPV vaccination coverage 
in Chapter 7 and Chapter 8 did not consider smoking status. However, others have 
shown lower vaccination uptake among women who smoked[141]. As with previous 
factors, smoking could be a positive confounder and hence not collecting and 
adjusting for this could have overestimated the effect of vaccination on HPV 
prevalence.  
6.4.4. Misclassification of HPV vaccination status 
Calculation of vaccine effectiveness and estimation of herd protection effects in the 
second paper of this chapter (Section 6.3) were only possible for women for whom 
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HPV vaccination status was collected in the HPV infection surveillance. In this 
section, I discuss three limitations of this HPV vaccination data collection, 
specifically; (i) vaccination status was only available for a minority of women in this 
surveillance; (ii) the vast majority of vaccination status data were for samples from 
one laboratory (Cornwall); (iii) the vast majority of vaccination status data were 
collected from CHIS. 
Firstly, vaccination status was only available for 21% of eligible women included in 
this analysis. Vaccination status data were often missing for an entire geographical 
area (either because local laboratories sending residual specimens did not have 
access to NHS number or because it was not possible to link with local CHIS data; 
Table 5.3). The concern, when considering the results of the HPV vaccine 
effectiveness analysis, is that the women without vaccination records differed in 
their risk of HPV infection compared to women with vaccination records. In Table 2 
of the second paper in this Chapter (Section 6.3), I compared patient characteristics 
of women with and without vaccination status and of vaccinated and unvaccinated 
women. There was a higher proportion of black women with a known vaccination 
status compared to those with unknown vaccination status. There were also marked 
differences in the proportion of women attending general practices and family 
planning venues between those with and without known vaccination status; 
although this was  most likely due to the greater availability of NHS numbers at 
some venues compared to others. As described in the paper, the chlamydia 
positivity was slightly higher among unvaccinated women. There was also a higher 
proportion of black women and women attending family planning clinics for 
unvaccinated women compared to vaccinated women. As the majority of 
vaccination records (>80%) were for specimens from one testing laboratory in 
Cornwall (discussed in more detail in the next paragraph), I repeated this analysis 
restricted to results from the Cornwall laboratory to see if this mitigated some of 
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these differences (Table 6.6, below). It is encouraging that within Cornwall, the 
differences in chlamydia positivity were less marked. As above, the differences in 
the proportions from each sample collection venue in those with and without 
vaccination status was largely due to certain venues having access to NHS 
numbers, enabling linkage to vaccination records. However, within Cornwall, the 
proportion from each recruitment venue was similar for vaccinated and 
unvaccinated women. There was very little complete data on ethnicity from samples 
collected from the Cornwall laboratory, and differences by ethnicity could not be 
considered. 
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Table 6.6: Patient characteristics of vaccinated and unvaccinated women, and of women with and without recorded vaccination 
status, in the post-vaccination period (restricted to specimens collected from the Cornwall laboratory) 
 
Known vaccination status   
 
 
Unknown 
vaccination 
status (n=628) 
 
Vaccinated 
(n=1,647) 
Unvaccinated 
(n=277) 
Total with 
known 
vaccination 
status 
(n=1,924) 
  
Age - years [data completeness] [100%] [100%] [100%] 
 
[100%] 
  16-18 years 853 (51.8%) 78 (28.2%) 931 (48.4%) 
 
270 (27.1%) 
  19-21 years 718 (43.6%) 179 (64.6%) 897 (46.6%) 
 
413 (65.8%) 
  22-24 years 76 (4.6%) 20 (7.2%) 96 (5.0%) 
 
45 (7.2%) 
      Ethnicity1 [data completeness] [2%] [2%] [2%] 
 
[0%] 
      Sample collection venue [data completeness] [100%] [100%] [100%] 
 
[100%] 
  General practice 1,416 (86.0%) 232 (83.8%) 1,648 (85.7%) 
 
407 (64.8%) 
  Family planning (Community Sexual Health Services; CaSH) 207 (12.6%) 36 (13.0%) 243 (12.6%) 
 
198 (31.5%) 
  Youth clinic 24 (1.5%) 9 (3.2%) 33 (1.7%) 
 
23 (3.7%) 
      Chlamydia positivity [data completeness] 6.9% [100%] 7.9% [100%] 7.0% [100%]   6.4% [100%] 
1: Numbers too small to include      
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Secondly, more than 80% of vaccination records were for specimens from one 
testing laboratory in Cornwall. Vaccination in Cornwall differed from elsewhere in 
England as the vaccination was offered and delivered in general practice rather than 
in schools. This could potentially affect the estimation of vaccine effectiveness if this 
method of delivery was suboptimal (Section 6.3); I briefly discussed whether 
vaccination at primary care may mean that women were less likely to receive the 
vaccine doses within the recommended schedule as they would need to be followed 
up individually rather than having mop-up sessions at schools. Women included in 
the HPV infection surveillance would have been vaccinated using the three dose 
schedule for Cervarix; the second dose given between one and two and a half 
months after the first dose; the third dose given between five and 12 months after 
the first dose[121]. If second or third doses were given outside of the recommended 
schedule, this could have resulted in a lower estimate of vaccine effectiveness. 
There was no evidence that the proportion of fully vaccinated women in the HPV 
infection surveillance vaccinated within the recommended schedule was different at 
the Cornwall laboratory compared to other laboratories (Table 6.7). However, the 
numbers of women with vaccination status from the other laboratories were small; 
therefore, to explore this further, I recalculated the vaccine effectiveness after 
excluding women who received 3-doses of the vaccine outside of the recommended 
schedule. There was a small difference in the HPV16/18 vaccine effectiveness in all 
fully vaccinated women versus women vaccinated within the recommended 
schedule (from 82.0% to 85.1% for women vaccinated at a younger age; Table 6.8). 
This suggests that collection of vaccination status largely from women vaccinated at 
general practice may have led to slightly lower vaccine effectiveness estimates. 
191 
 
Table 6.7: Proportion of women recorded as fully vaccinated who were vaccinated within the recommended schedule2 
 
Cornwall laboratory 
 
All other laboratories 
 
Younger vaccination 
cohorts  
(vaccinated <16 yrs old) 
(n=992) 
Older vaccination 
cohorts  
(vaccinated ≥16 yrs old) 
(n=546) 
 
Younger vaccination 
cohort  
(vaccinated <16 yrs old) 
(n=184) 
Older vaccination 
cohorts  
(vaccinated ≥16 yrs old) 
(n=68) 
      Unknown
1
 0 0 
 
24 39 
      Vaccinated within recommended schedule
2
 84.4% (82.1, 86.7) 83.2% (79.7, 86.2) 
 
79.4% (72.3, 85.4) 82.8% (64.2, 94.2) 
Vaccinated outside recommended schedule
2
 15.5% (13.3, 17.9) 16.8% (13.8, 20.3) 
 
20.6% (14.6, 27.7) 17.2% (5.8, 35.8) 
      
1: Vaccination data from Lewisham laboratory did not include dates of HPV vaccination 
   2: the second dose given between one and two and a half months after the first dose; the third dose given between five and 12 months after the first dose 
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Table 6.8: Vaccine effectiveness1 comparing HPV infection in the post-vaccination period, for women with and without vaccination 
delivered within the recommended schedule 
 
VE (full vaccination)  
VE
2
 (full vaccination within 
recommended schedule)  
 
(95% CI) (95% CI) 
Younger HPV vaccination cohorts
3
 combined n=1,293 n=1,093 
HPV 16/18 with or without other HR types 82.0 (60.6, 91.8) 85.1 (62.5, 94.1) 
   Non-vaccine type(s) with or without HPV 16/18 
       HPV 31/33/45 54.3 (8.6, 77.2) 61.0 (26.7, 79.2) 
     HPV 31/33/45/52/58 16.4 (-30.9, 46.5) 23.6 (-17.1, 50.1) 
     HPV6/11 26.5 (-26.8, 57.4) 30.3 (-17.2, 58.5) 
   Older catch-up HPV vaccination cohorts n=903 n=779 
HPV 16/18 with or without other HR types 48.7 (20.8, 66.8) 54.4 (26.4, 71.8) 
   Non-vaccine type(s) with or without HPV 16/18 
       HPV 31/33/45 36.7 (-3.4, 61.2) 44.8 (8.8, 66.6) 
     HPV 31/33/45/52/58 20.6 (-3.5, 39.1) 21.7 (-2.9, 40.5) 
     HPV6/11 18.8 (-24.6, 47.1) 8.0 (-42.2, 40.4) 
1: Adjusted for age, venue type and chlamydia positivity 
2: the second dose given between one and two and a half months after the first dose; the third dose given between five and 12 
months after the first dose 
 3: Including routine cohorts and younger vaccination cohorts (i.e. all women offered vaccination at age 15 or younger) 
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Finally, vaccine effectiveness in the second paper in this Chapter (Section 6.3) was 
calculated using HPV vaccination records largely collected from CHIS data. This 
could be a concern if vaccination records in CHIS were incomplete or inaccurate; as 
suggested in Section 5.1.1, this is particularly plausible for vaccinations 
administered outside of school settings. In the results of the HPV infection 
surveillance in the second paper in this chapter (Section 6.3), 83% of women with 
vaccination data were from the laboratory in Cornwall (where women were 
vaccinated in general practice and the results reported to CHIS) and a further 8% 
were from women who were over 16 years old when the National HPV 
Immunisation Programme was introduced (also likely offered vaccination in general 
practices).  
I described in Section 5.3 a validation study which compared CHIS data with GP 
data in Cornwall (the results are shown in Table 5.7). Here, I explore the 
implications of misclassification of vaccination status using CHIS data. If this 
misclassification was non-differential (i.e. incorrect recoding of a women’s 
vaccination status was unrelated to HPV positivity) then the bias would likely have 
underestimated vaccine effectiveness. However, it is possible that there was 
differential misclassification (for example, if those with inaccurate recording were 
from higher-risk populations). If women recorded as fully vaccinated on CHIS were 
truly vaccinated but there was some misclassification of unvaccinated women as 
vaccinated, then this would underestimate the vaccine effectiveness if misclassified 
women were at higher risk for HPV infection compared to women correctly classified 
as unvaccinated. Conversely, if women classified as unvaccinated on CHIS were 
truly unvaccinated but there was some misclassification of vaccinated women as 
unvaccinated, then this would overestimate the vaccine effectiveness if 
misclassified women were higher-risk for HPV infection. Reassuringly, results from 
the validation study (as presented in Section 5.4.2) show relatively high agreement 
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for fully vaccinated and unvaccinated women. There was less agreement for 
partially vaccinated women (Table 5.7) but as these represented a relatively small 
proportion of women in the HPV infection surveillance (~5% of those with a known 
vaccination status) this had less potential to bias the vaccine effectiveness 
estimates.  
In this section, I have added to the discussion of the second paper of this chapter 
(Section 6.3) about the limitations of HPV vaccination status data used in the HPV 
infection surveillance. I have discussed the potential misclassification bias of 
inaccurate vaccination status data in Cornwall, acknowledging that there may well 
be different misclassification bias for vaccination data from other areas (for 
example, among the small number of records with self-reported vaccination status 
collected on the chlamydia test request form). The fact that HPV vaccination status 
data were only available from a relatively small proportion of women, largely from 
one particular area, is not overly concerning unless there is reason to believe that 
the vaccine effectiveness results are not generalisable to the rest of England. 
Despite this, in an ideal scenario, the HPV infection surveillance presented in the 
second paper in this chapter (Section 6.3) would have included HPV vaccination 
status data for all women. The difficulty I have experienced in obtaining accurate 
vaccination status data for this surveillance highlights the need for a single 
standardised dataset of HPV vaccination records regardless of where vaccination is 
offered and delivered. I discuss this further in the main discussion of this thesis 
(Sections 9.2.2 and 9.4).   
6.5. Potential increases in non-vaccines HPV types 
In the next section, I discuss the interpretation of changes in non-vaccine HPV types 
in the post-vaccination period and describe methods for a study which could 
theoretically be conducted if there was any suggestion of potential type-replacement 
in the future. 
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6.5.1. Background 
As described in Chapter 3, there have been concerns that reductions in the HPV 
vaccine types will lead to other non-vaccine HPV types filling this ecological niche 
and becoming more common, known as type-replacement. Surveillance to monitor 
the likely impact of the HPV vaccination programme should remain vigilant for such 
increases. If there was type-replacement then we would expect there to be 
increases in the prevalence of non-vaccine HPV types between the pre-vaccination 
and post-vaccination period. Importantly, we would also expect increases within the 
post-vaccination period, associated with decreases in vaccine types.  
The interpretation of changes in non-vaccine types in this surveillance are not 
straight forward and should be interpreted with care. In the analysis presented in the 
first paper in this analysis (Section 6.2), there was no evidence of a decrease in the 
closely-related HPV types (HPV31, 33 and 45) between the pre- and post-
vaccination period. For the other non-vaccine high-risk HPV types there was an 
observed increase between the pre- and post-vaccination periods. However, when 
considering these changes in non-vaccine types, it is important to take into account 
the change in the HPV assay between the pre- and post-vaccination period. As 
reported in Section 4.4.2, a validation study comparing the two assays 
demonstrated that positivity was similar for the vaccine types but there were some 
differences in sensitivity and specificity for some non-vaccine types. I adjusted in 
this analysis for the change in sensitivity and specificity after the new assay was 
introduced, but the uncertainty surrounding some sensitivity estimates, particularly 
for the rarer types, led to wide confidence intervals for these odds ratios. To mitigate 
the limitation of the change in the assay between the pre- and post-vaccination 
periods, the more recent analyses in Section 6.3 (the second paper in this Chapter) 
focussed on changes within the post-vaccination period and their association with 
vaccination coverage. This analysis showed a decrease in the prevalence of HP31, 
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33 and 45 over time within the post-vaccination period and vaccine effectiveness in 
younger vaccinated cohorts against these HPV types of 54% (95% CI; 9% to 77%). 
The prevalence of the other high-risk risk types has remained relatively stable within 
the post-vaccination period, if not slightly declining in more recent years.  
In summary, if increases in non-vaccine types were associated with higher 
vaccination coverage and/or decreasing HPV16/18 prevalence then this would be of 
concern. However, the results from Chapter 3 and Section 6.3 are reassuring that 
there does not appear to be any evidence of increases in non-vaccine HPV types 
due to type-replacement. 
6.5.2. What is the unmasking effect? 
Broad-spectrum assays, such as those used in both the pre- and post-vaccination 
periods of this national surveillance, can have lower accuracy to detect type-specific 
HPV infections in the presence of multiple infections (Section 2.7.3). As explained 
previously, HPV types at low concentration (i.e. low copy number) are particular 
vulnerable if present alongside an HPV type at high concentration (i.e. high copy 
number) as the types with lower copy numbers may well be “masked” by the other 
HPV type.  
This is of concern for our HPV surveillance due to the reductions in vaccine types 
(HPV16 and HPV18) following the introduction of the HPV vaccination programme. 
In the absence of these vaccine types, the broad spectrum assays may have 
identified other HPV types which would have otherwise been masked (i.e. in the 
pre-vaccination period). Therefore, this unmasking effect may have made it appear 
that there was an increase in non-vaccine high-risk HPV types which was entirely 
artificial.  
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6.5.3. Future approaches to quantify the unmasking effect  
Rationale 
In the analyses conducted as part of this thesis, there was no clear evidence of 
type-replacement or unmasking. Despite this lack of evidence it is still important to 
remain vigilant for potential increases in non-vaccine types. Any increases due to 
type-replacement or unmasking are likely to present with similar results as both 
would be associated with decreases in HPV16/18 infection. However, the 
implications of type-replacement (i.e. true increases in non-vaccine types) vs. 
unmasking (i.e. the false impression of increasing non-vaccine types) are clearly 
very different for public health policy. Therefore, if there were increases in non-
vaccine high-risk types, it would be important to quantify the potential unmasking 
effect so that these increases can be accurately interpreted. Others have estimated 
an unmasking effect in different settings[18, 142]. However, this effect will be 
dependent on the sample type and the HPV assay used for testing. I briefly describe 
below a proposed approach to quantify the potential proportion of non-vaccine HPV 
infections which could be masked by HPV16/18 infection when using the broad-
spectrum HPV assays used for surveillance in England. To quantify the level of 
unmasking, samples which tested positive for HPV16 and/or 18 but negative for 
other high-risk HPV-types using the broad spectrum assay could be retested for the 
other high-risk types using a type-specific PCR. Type-specific PCR tests are not 
subject to the same issue of unmasking as the primers used are single target and 
hence provide a more sensitive test in the presence of multiple infections[17, 143].  
In practice, I have not proposed that such a study should be conducted since there 
is little evidence to date of increases in non-vaccine types since the introduction of 
the HPV vaccine in England (hence costs for additional testing cannot be justified to 
explore a theoretical problem which has not yet materialised). The below is a brief 
description of an approach which could be considered if there were ever evidence of 
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increases in the prevalence of non-vaccine HPV types which were associated with 
decreasing HPV16/18 infection. 
Theoretical choice of non-vaccine type 
If there was evidence of type-replacement then ideally, any future study to 
investigate this would involve testing for all non-vaccine high-risk HPV types. 
However, in practice, it is unlikely that there would be sufficient residual specimen to 
conduct this testing and, even if there was sufficient material, the cost of doing this 
would be prohibitive. Therefore, a more reasonable approach would be to select a 
single non-vaccine type which can be used to investigate unmasking and the results 
then broadly applied to other types. A suitable non-vaccine type should meet the 
following criteria: 
(i) Be a type of the same species as one of the two HPV vaccine types as 
these types are more likely to fill the ecological niche of HPV16 or HPV18 
(i.e. either α7 species related to HPV16, or α9 species related to HPV18; 
Table 2.1). 
(ii) Have high concordance between the pre-vaccination and post-vaccination 
assay so that this does not complicate the quantification with the need for 
further adjustment for the change in assay between the two periods. 
The non-vaccine type would also, ideally (but not essentially): 
(iii) Have a higher prevalence in the post-vaccination period vs. the pre-
vaccination period; as stated in the rationale above, there is little evidence 
of increases in non-vaccine types to date. However, this would be an ideal 
criterion when considering such a study. 
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(iv) Have no evidence from clinical trials of cross-protection (which would lead 
to a reduction of the HPV type in vaccinated women) 
A summary of these criteria for non-vaccine high-risk types included in the HPV 
infection surveillance are shown in Table 6.9 below. None of the HPV types meet all 
of the above criteria but four high-risk types meet all except for one non-essential 
criteria (HPV33, HPV39, HPV52 and HPV58). I therefore considered HPV58 as a 
theoretical example for the below methodology. 
Methods 
Residual samples, previously testing negative for HPV58 by a broad spectrum 
assay, could be selected for re-testing with type-specific PCR. Samples which were 
positive and negative for HPV16 and/or HPV18 by the same broad spectrum assay 
should be re-tested.  
Which residual specimens to include for type-specific testing would depend on how 
increases in non-vaccine types manifest. If there were an increase in non-vaccine 
types between the pre- and post-vaccination periods then the approach would be to 
re-test pre-vaccination specimens which were negative for the candidate non-
vaccine type using the broad-spectrum assay. Estimates of pre-vaccination 
prevalence of the candidate type could then be adjusted upwards to account for any 
effect of masking. If there were increases in non-vaccine types within the post-
vaccination period then the approach would be to re-test earlier post-vaccination 
specimens which were negative for the candidate non-vaccine type using the broad-
spectrum assay.  
The laboratory methods for the two broad spectrum assays have been described 
previously (prior to this PhD[19] for the pre-vaccination specimens, and in Section 
4.3.9 for post-vaccination specimens). As this is a theoretical approach to explore 
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changes in non-vaccine types, I am not able to describe the laboratory methods of a 
suitable type-specific test. However, generally, the approach would be to re-test 
residual specimens (blind to the original HPV16/18 status) using a type-specific 
PCR for HPV58.  
Power to detect a difference in HPV prevalence 
The prevalence of HPV58 in samples originally HPV16/18 positive vs. those 
HPV16/18 negative would be compared using logistic regression to calculate odds 
ratios and associated 95% confidence intervals.  
Table 6.10 below gives the minimum detectable difference of HPV prevalence which 
could be identified for 80%, 85% and 90% power, a type-specific prevalence of 
HPV58 of 2.5% and 5% in HPV16/18 negative specimens and two fixed samples 
sizes based on data collected to the end of 2016; the first if testing pre-vaccination 
specimens (n=369 in each group) and the second if testing post-vaccination 
specimens (n=1,193 in each group). These odds ratios are all relatively large and 
may exceed expectations of any potential effect of masking. This suggests that if 
this study were to be conducted then additional sources of residual specimens may 
need to be added to increase the sample size. This is ongoing surveillance so, over 
time, the number of post-vaccination specimens will increase. 
This concludes the first part of this PhD (Chapters 3 to 6) which considered changes 
in the prevalence of HPV infection. I will discuss the implications of the results 
presented in this chapter in the final chapter of this thesis (Chapter 9). In the next 
Chapter (Chapter 7), I describe the data sources and methods of surveillance to 
monitor the serological response to the vaccine HPV types (as a biological marker 
to estimate vaccination coverage). I also describe the methods of a nested case-
control study designed to estimate the potential effect of the bivalent HPV vaccine 
on the incidence of genital warts. 
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Table 6.9: Selection of non-vaccine types for type-specific HPV testing to quantify unmasking effect  
(entries in red do not meet essential criteria; entries in orange do not meet desirable criteria) 
 
HPV type Species Evidence for 
cross protection 
Concordance in 
validation study 
(kappa) 
OR (pre- vs. post-
vaccination) in 16-18 
year olds1 
Number of specimens 
pre-vaccination 16/18 
positive, candidate 
type negative 
Number of specimens 
post-vaccination 16/18 
positive, candidate type 
negative 
31 α9 Yes 0.77 0.5 (0.2-3.2) 358  1,231 
33 α9 Yes 0.75 1.1 (0.5-3.7) 374  1,220 
35 α9 No 0.496 11.3 (0.3-418.5) 389  1,248 
39 α7 No 0.77 1.2 (0.8-3.6) 346 1,169 
45 α7 Yes 0.71 0.5 (0.2-1.3) 373 1,189 
51 α5 No 0.746 1.9 (1.1-4.0) 327 1,158 
52 α9 Yes 0.769 1.7 (1.0-3.2) 356 1,077 
56 α6 No 0.771 2.3 (1.1-4.2) 373 1,151 
58 α9 No 0.878 1.3 (0.8-3.1) 369 1,193 
59 α7 No 0.476 -2 348 1,224 
68 α7 No 0.284 2.9 (0.5-16.8) 384 1,232 
1: Odds ratio comparing odds of HPV infection in the pre-vaccination periods vs. the post-vaccination period, adjusted for chlamydia 
positivity, testing venue, age and the assay change between the two periods. Includes data up to end-December 2016  
2: does not converge 
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Table 6.10: Minimum detectable odds ratio for given sample sizes and power 
Power (%) Sample size HPV58 type-specific 
prevalence among HPV16/18 
negative specimens 
Minimum detectable odds 
ratio 
80 
Pre-vaccination; n=369 
0.025 2.87 
0.05 2.23 
Post-vaccination; n=1,193 
0.025 1.89 
0.05 1.61 
85 
Pre-vaccination; n=369 
0.025 3.04 
0.05 2.34 
Post-vaccination; n=1,193 
0.025 1.97 
0.05 1.66 
90 
Pre-vaccination; n=369 
0.025 3.28 
0.05 2.48 
Post-vaccination; n=1,193 
0.025 2.06 
0.05 1.72 
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Chapter 7: Estimation of HPV vaccination 
coverage using serosurveillance (Methods) 
7.1. Introduction 
I describe the immune response to HPV vaccination in the Background (Section 
2.6.1). In summary, results from clinical trials have shown that almost all vaccinated 
women seroconvert for the HPV types included in the vaccine with, on average, far 
higher antibody concentrations than those attained following a natural HPV 
infection. Therefore, serological surveillance of HPV type-specific antibody 
concentrations in vaccine-eligible populations allows estimation of the proportion of 
women with a vaccine-induced antibody response. This is useful to confirm HPV 
vaccination coverage in England but also has the potential to provide additional 
information not available from the nationally reported data. In particular, research 
question 4 of this thesis was to compare HPV vaccination coverage among different 
subgroups of the population and to investigate evidence for potential declines in 
antibody levels over time since vaccination (i.e. antibody waning). In this chapter I 
further describe the data sources and methods used to determine vaccine-induced 
seropositivity for this serosurveillance. 
7.2. Rationale of serological surveillance 
7.2.1. Why is it important to confirm national HPV vaccination coverage? 
Maintaining high HPV vaccination coverage in the population is essential for the 
success of the national programme. As a consequence, HPV vaccination coverage 
is one of the Public Health Outcome Framework (PHOF) indicators; these are a 
series of key public health indicators that allows comparison between counties, 
districts and regions. Accurate monitoring of this uptake is also important when 
measuring the impact of the National HPV Immunisation Programme as this will be 
a predictor for the likely declines in HPV infection and related disease in the longer 
term.  Independent validation of this uptake is of particular interest for the older 
 204 
 
vaccination cohorts who were largely vaccinated outside of school as the recording 
of vaccinations given as ‘mop-up’ doses (i.e. doses given after the initial year that 
the vaccine was offered) was expected to be less reliable. Full details of how 
national HPV vaccination coverage is collated by PHE using data collected at the 
local area level are provided in Section 2.7.2. As discussed, the collection of these 
data is reliant on manual data recording, often from multiple data sources for each 
local area.  
7.2.2. Why is it important to monitor inequalities in HPV vaccination 
coverage? 
PHE’s key role is “to protect and improve the nation's health and wellbeing, and 
reduce health inequalities”. There may be inequalities in HPV vaccination coverage; 
for example, there may be lower vaccination uptake in certain population subgroups 
leading to a higher subsequent risk of cervical cancer in these women. This is of 
particular importance if there is a ‘double inequality’, i.e. that women who do not 
receive HPV vaccination are (i) those at higher risk of HPV infection and/or (ii) those 
less likely to attend for cervical screening. It is important to be aware of any such 
inequalities to inform interventions to improve uptake in subgroups with lower 
coverage.  
Furthermore, variations in vaccination coverage in different population subgroups 
could affect the predicted reductions in cervical cancer due to vaccination, which are 
based on modelling estimates which do not take inequalities in vaccine uptake or 
inequalities in attendance at cervical screening into account. If the impact of HPV 
vaccination on the incidence of cervical cancer is lower than expected, it will be 
necessary to interpret the reasons for this correctly (i.e. inequalities in vaccination 
uptake vs. reduced effectiveness of the vaccine) to inform any changes to improve 
the vaccination programme.  
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Details of other studies that have examined HPV vaccination uptake in population 
subgroups in areas of England are provided in Table 7.1[82, 141, 144-146]. In 
summary, these papers fairly consistently demonstrated lower vaccination 
coverage among ethnic minorities and also some evidence of lower coverage in 
those from a lower socio-economic status. However, there were limitations with 
study design for these studies. One study provided data from an ecological 
analysis[82] and whilst there was little evidence of associations at the area-level, 
there may have been associations at the individual level which were not seen 
using this analysis. Three of the studies[144-146] were limited to certain 
geographical areas so the results were not necessarily generalisable to the whole 
population. Furthermore, all five studies included in Table 7.1 relied on either self-
collected vaccination status or CHIS records. I have already described potential 
inaccuracies with CHIS data (Section 5.1.1). Self-collected vaccination using 
patient questionnaires could have been subject to recall bias (particularly in older 
women who were offered vaccination at a younger age). Serological surveillance, 
as conducted in this PhD, offers a robust method to estimate individual HPV 
vaccination status which is not subject to measurement error due to recall bias or 
inaccurate recording of vaccination status.  
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Table 7.1: Studies considering inequalities in HPV vaccination coverage in the UK 
Publication Year 
Geographic 
area Participants 
Sample 
size 
Study design/ 
Selection of 
participants Data sources Main findings Critical evaluation  
Fisher et 
al[146] 
2008-
2011 
3 PCTs in 
South West 
England 
Young females 
eligible for 
vaccination 
who attended 
school or were 
resident in the 
local authority 
14,282 Retrospective 
cohort study.  
 
Females were 
identified through 
PCT records. 
Demographics 
Date of birth, postcode, 
ethnicity, MMR 
vaccination details and 
name of school were 
obtained from CHIS. 
Postcode was used to 
ascertain LSOA 
deprivation quintile. 
Vaccination status 
Dates and location of 
HPV vaccination were 
obtained from CHIS 
Deprivation 
Little evidence of 
differences in vaccine 
uptake by quintile of 
deprivation 
Ethnicity 
Strong evidence of lower 
3-dose uptake among 
women identifying as 
black (70%), Asian (75%) 
or Chinese (71%) 
compared to White 
British women (85%) 
◦ Missing ethnicity data for 
17% women 
◦ Potential data coding errors 
and missing data for 
vaccination status  in CHIS  
◦ Limited to one geographical 
area hence not necessarily 
representative of general 
population 
Sacks et 
al[141] 
2011 19 hospital-
based and 
13 
community-
based SHS 
across 
England 
13-19 year old 
females 
attending 
sexual health 
services (SHS) 
across 
England 
2,247 Cross-sectional 
study. 
 
Eligible females 
attending SHS 
were asked by 
receptionist to 
complete and 
return a 
questionnaire. 
Demographics 
Self-completed paper 
questionnaire on patient 
demographics and HPV-
related risk factors 
Vaccination status 
Self-completed 
questionnaire 
Lower completion in 
those offered vaccination 
(65%) compared to 
national data. 
 
Among those offered the 
vaccine, there was lower 
3-dose completion 
among black women 
(55%); women not in 
education, employment 
or training (48%); women 
within London (58%); 
smokers (59%); and 
those with an STI 
diagnosis (53%). 
◦ 2247/2861 (79%) 
completed questionnaires 
returned  
◦ Self-reported HPV 
vaccination status via 
questionnaire hence subject 
to recall bias. 
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Hughes et 
al[82] 
2008-
2011 
Data from 
151 Primary 
Care Trusts 
(PCTs) in 
England 
National 
vaccination 
coverage for 
females 
offered the 
HPV vaccine 
between 2008 
and 2011 
Area-
level 
data for 
151 
PCTs 
Ecological study. Demographics 
Area-level deprivation 
from rank of IMD score 
for each PCT 
Vaccination status 
Area-level data from 
published national HPV 
vaccination coverage 
Some evidence of lower 
vaccination coverage in 
more deprived areas for 
the catch-up cohorts only 
(Spearman’s rank 
correlation coefficient = 
0.10 (p=0.09) for 14-15 
yrs and <0.0001 
(p<0.0001) for 16-17 yrs. 
◦ Vaccination uptake and 
deprivation are recorded at 
PCT area-level only.  
◦ Other potential risk factors 
not considered (e.g. 
ethnicity, religion, sexual 
behaviour) 
 
Bowyer et 
al[144] 
2012 12 state-
funded 
schools 
across 
London 
Females in UK 
school year 11 
1,912 Cross-sectional 
study. 
 
All eligible 
females at 
schools were 
given an 
information sheet 
and questionnaire 
(parents of girls 
could opt the girls 
out prior to study). 
Demographics 
Self-reported data 
collected on age, 
ethnicity, religion, 
household wealth 
(measured using the 
Family Affluence Scale), 
smoking status, sexual 
behaviour and intention 
to attend for cervical 
screening.  
Vaccination status 
Self-reported  
3-dose uptake was lower 
among girls from black, 
Asian and “other” ethnic 
background compared to 
white girls (85% for white 
girls; 78% for Asian girls; 
69% for black girls; 74% 
for “other” ethnicity). 
◦ 2165/2183 (99%) 
questionnaires completed. 
253 removed due to 
anomalous results (n=3) or 
missing vaccination status 
(n=250). 
◦ Self-reported HPV 
vaccination status via 
questionnaire hence subject 
to recall bias.  
◦ Limited to a geographical 
area hence not necessarily 
representative of general 
population 
Roberts et 
al[145] 
2007-
2008 
Secondary 
school 
attenders at 
2 PCTs in 
Manchester 
12-13 year old 
females 
2,817 Prospective 
cohort study. 
 
All females invited 
for vaccination at 
relevant PCTs 
were included in 
this analysis.  
Demographics 
Postcode (obtained from 
PCT) was used to 
ascertain LSOA 
deprivation quintile. 
Ethnicity was obtained 
from ethnic monitoring 
forms sent to 
participants.  
Vaccination status 
HPV vaccination data 
were obtained from CHIS 
for the relevant PCTs 
Uptake was lower in 
more deprived areas (OR 
for a 10-point increase in 
IMD = 0.89; 95% CI 0.85-
0.94) and in ethnic 
minority girls (OR 
comparing which with 
non-white ethnicity = 
0.67; 95% CI 0.49-0.92). 
◦ Ethnicity was not available 
from CHIS at relevant PCTs 
hence was requested using 
forms sent to parents. Only 
62% of forms were returned.  
◦ These data were from a 
feasibility study conducted in 
a specific area prior to the 
roll out of the National HPV 
Immunisation Programme. 
Therefore, these results may 
not be generalisable. 
Abbreviations: CHIS = Child Health Information System; IMD = index of multiple deprivation; LSOA = Lower Layer Super Output Area; OR = Odds ratio; PCT = Primary Care 
Trust; SHS = Sexual Health Services 
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7.2.3. Waning of HPV antibodies in vaccinated populations 
Data from clinical trials have shown the vast majority of vaccinated women remain 
seropositive for up to 10 years after vaccination with the bivalent vaccine, and that 
geometric mean titres remained far higher than those elicited following natural 
infection[61]. There is no established correlate of protection for the HPV vaccines. It 
has been suggested that the level of antibodies elicited by  these vaccines will likely 
provide long-term protection[147]. However, the actual duration of protection 
provided by the current HPV vaccines can be better determined with post-
vaccination follow-up of vaccinated women.  
7.2.4. Data sources 
To investigate the above, I made use of two data sources which I describe in more 
detail in Sections 7.3 and 7.4: 
(i) Sera samples from young women attending for routine microbiological 
and/or biochemical tests (PHE Sero-epidemiology Unit (SEU)). This 
serological surveillance of HPV seropositivity was established prior to 
this PhD (although no analyses to monitor HPV vaccination uptake had 
been conducted using these data prior to the PhD). The methods of this 
surveillance are described in Section 7.3. This SEU serosurveillance was 
designed to confirm national HPV vaccination coverage among young 
women and to determine if there was any evidence of waning antibody 
levels among vaccinated women. There was relatively limited patient 
information collected with these specimens, hence this surveillance did 
not allow comparison of HPV vaccination coverage in different 
subgroups of the population. 
(ii) Sera samples from young women attending sexual health clinics and 
having an HIV and/or syphilis test. I established this surveillance as part 
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of this PhD, as described in Section 7.4. The data from this 
serosurveillance provides an estimate of the vaccination coverage 
among women attending sexual health clinics (i.e. those likely to be at 
higher risk of STIs including HPV infection). Patient data collected as 
part of this serosurveillance enabled stratification of coverage by 
demographics to help identify subgroups of the population with lower 
vaccination coverage. Finally, I designed and conducted a case-control 
study nested within this surveillance to investigate whether the bivalent 
vaccine offers protection against genital warts; this is explored further in 
Section 7.5. 
7.3. Methods for SEU serosurveillance  
7.3.1.  Background 
The PHE Sero-Epidemiology Unit (SEU) is part of the Serum Archive Unit and 
collects residual serum for use in several serological surveillance studies[148]. 
Participating laboratories are asked to send aliquots of residual serum from routine 
microbiological and/or biochemical tests. These aliquots are sent to the Vaccine 
Evaluation Unit (VEU) at PHE along with patient data on age at collection, gender, 
year of collection and whether the specimen was collected at a sexual health clinic. 
Specimens from immunocompromised patients and repeat specimens from the 
same individuals are excluded. 
In 2010 (prior to the start of this PhD), it was proposed that HPV serological 
surveillance could be conducted using these residual SEU specimens to monitor the 
HPV vaccine-type antibody levels following the introduction of the National HPV 
Immunisation Programme. For the purposes of this HPV surveillance, the numbers 
of residual serum specimens requested from women aged 15-19 years old in 2010 
to 2013 (i.e. those that would have been eligible to have received the HPV 
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vaccination as part of the national programme) were increased to approximately 
1,000 specimens per year.  
7.3.2. HPV antibody testing 
Sera specimens were analysed for Immunoglobulin G (IgG) antibodies to HPV16 
and HPV18 using a type-specific virus like particle (VLP)-based enzyme linked 
immunosorbent assay (ELISA). All reagents for the assay, including VLPs, were 
provided by GSK. Testing was performed at the PHE VEU in Manchester according 
to the manufacturer’s protocols. Briefly, microtiter plates coated with either purified 
VLP16 or VLP18 antigens were incubated with serial dilutions of sera. The bound 
antibody was reacted using horseradish peroxidase conjugated goat anti-human 
IgG and optical density was determined. Quantitative results, expressed as ELISA 
units per millilitre (EU/mL), were calculated from the standard. Seropositivity was 
determined using the cut-offs of 19 and 18 EU/mL for HPV16 and HPV18, 
respectively[149]. Further details of the testing methods are provided in the Methods 
of the published paper provided in Section 8.2. 
7.3.3. Determination of HPV vaccination status 
To determine HPV vaccination status of women using the results of anti-HPV16 and 
18 antibody testing, I made use of three pieces of prior knowledge, as follows: 
(i) Data from clinical trials show that 100% (or close to 100%) of vaccinated 
women seroconvert for both HPV16 and HPV18 and this remains high for 
up to 10 years[61]. 
(ii) Data from clinical trials also demonstrate that, on average, antibody 
responses in vaccinated women are far higher than antibody responses 
following a natural HPV infection[61]. 
(iii) Prior to the introduction of HPV vaccination in England, although 11.7% of 
15-20 year old women were seropositive for either HPV16 or HPV18, only 
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1.8% (95% confidence internal: 0.9%-3.4%) were seropositive for both 
types (unpublished additional analysis from a previous surveillance study 
conducted by PHE among 500 females obtained from the PHE SEU prior to 
the introduction of the National HPV Immunisation Programme[23]). 
 
Using (i) above, I categorised all women who were seronegative for either one or 
both HPV types as unvaccinated. In those who were seropositive for both HPV 
types, I wanted to distinguish between vaccinated and unvaccinated women. The 
above data suggest that women with high antibody concentrations to both HPV16 
and HPV18 are likely to have been vaccinated. However, up to 3.4% of women 
could have a serological response following natural infection (point (iii) above) and 
whilst average antibody levels following vaccination are higher than those following 
natural infection, the range of antibody concentrations in these two groups overlap. 
Therefore, it is not always clear whether those with low antibody concentrations are 
unvaccinated (having seroconverted after natural infection to HPV16 and HPV18) or 
vaccinated with a lower than average immune response following vaccination. 
Similarly, those with higher antibody concentrations are likely to have been 
vaccinated but could include a small proportion who are unvaccinated but had a 
higher than average immune response following natural infection. 
To determine which women were likely to have been vaccinated, I first used the 
above knowledge to categorise antibody concentrations for HPV16 and HPV18 as 
low, medium or high (Table 7.2). As I knew that the majority of women seropositive 
for both HPV types would have been vaccinated (see point (iii) above), I considered 
low antibody concentrations as those which were below the 5% range of 
concentrations among those who were seropositive for both HPV16 and HPV18 (i.e. 
an unusually low concentration for dual seropositivity, hence presumed largely 
unvaccinated). Similarly, as I knew that the vast majority (if not all) women 
seropositive for only one HPV type were unvaccinated, I considered high antibody 
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concentrations to be above the 95% range of concentrations among those who 
were seropositive for only one type (i.e. an unusually high concentration for those 
presumed to have a natural infection). Medium concentrations fell between these 
two values (Table 7.2).  
I then categorised specimens as either: 
(i) ”Seronegative for both types”: below the assay cut-off for both HPV types. 
(ii) “Probable natural infection”: Seropositive for only one HPV type. 
(iii) “Possible natural infection or vaccine-induced seropositivity”: Seropositive for 
both HPV types but with either low antibody concentrations for both HPV types 
or low concentrations for one type and moderate concentrations for the other. 
(iv) “Probable vaccine-induced seropositivity”: Seropositive for both HPV types with 
moderate antibody concentrations for both HPV types or high antibody 
concentrations for one or both types. 
This is shown graphically in Figure 7.1. 
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Table 7.2: Classification of HPV16 or HPV18 seropositives 
 Classification  Description 
Seronegative Antibody concentration below assay cut-off for seropositivity 
Seropositive           
Low antibody concentrations Antibody concentration above assay cut-off but below the 5% range of concentrations 
among those seropositive for both HPV types  
Moderate antibody concentrations 
Antibody concentration above the 5% range of concentrations among those seropositive 
for both HPV types but below the 95% range of concentrations among those with a single 
antibody  
High antibody concentrations 
Antibody concentration above the 95% range of concentrations among those seropositive 
for only one HPV type  
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Figure 7.1: Estimation of HPV vaccination status using HPV16 and HPV18 antibody titres 
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7.3.4. Data analysis 
The first HPV vaccine dose is usually given in September (i.e. the start of the 
academic year). Females included in this SEU surveillance would have been offered 
3-doses of the HPV vaccine with the 3rd dose given up to 6 months after the first 
dose[121]. Therefore, a woman may not be fully vaccinated until March of the 
following year at the earliest. Consequently, sera which were collected before March 
of the year following the expected date of a woman’s first vaccine dose were 
excluded in order to monitor seroprevalence following the receipt of the full vaccine 
course. 
As described in the Background (Section 2.7.2), reported HPV vaccination coverage 
data are published annually for each academic birth year (September to 
August)[78]. I compared the serological coverage estimates with this published 
national HPV vaccination coverage. Serological coverage estimates were calculated 
using two definitions; (i) women with probable vaccine-induced seropositivity, and 
(ii) women with probable or possible vaccine-induced seropositivity (Figure 7.1).  
Age (in years) at the time the serum specimen was taken was known for all women. 
However, only a proportion of women (~62%) had a known date of birth which 
meant that the birth cohort (i.e. year that the HPV vaccine would have been offered) 
was not known. For women with a date of birth, I generated the age and year that 
the HPV vaccine would have been offered as part of the National HPV Immunisation 
Programme. For women with no known date of birth, I adapted a previous approach 
to estimate national vaccination coverage for a calendar year (rather than academic 
year) for each age-group[84]. For example, a woman aged 17 in 2011 could have a 
date of birth which falls somewhere over a 24 month period, with the oldest possible 
woman attending on 1st January 2011 and turning 18 on 2nd January 2011 (i.e. born 
2nd January 1993), and the youngest possible woman turning 17 on the 30th 
December 2011 and attending on 31st December 2011 (i.e. born 30th December 
 216 
 
1994). Therefore, a 17 year old in 2011 could fall within one of three different 
academic birth cohorts (depending on her exact age and the date the sample was 
taken). Each of these birth cohorts had different national vaccination coverage 
(based on data reported from the local area) hence I assumed stable attendance 
patterns through the year to calculate a weighted average for national coverage by 
age and year, as follows:  
Coverage = (m1/24)*c1 + (m2/24)*c2 + (m3/24)*c3 
Where; 
mi is the number of months in birth cohort i 
 ci is the national reported HPV vaccination coverage (as reported by local 
areas) 
In the example above, those born between 2nd January 1993 and 31st August 1993 
fall in one birth cohort (with reported national coverage of 48.1%). Those born 
between 1st September 1993 and 31st August 1994 fall in second birth cohort (with 
reported national coverage of 70.8%). Those born between 1st September 1994 and 
31st December 1994 fall in a third birth cohort (with reported national coverage of 
75.7%). Therefore, the estimated national coverage for a 17 year old in 2011 is: 
(8/24)*48.1% + (12/24)*70.8% + (4/24)*75.7% = 64.1%. This is represented 
graphically in Figure 7.2. 
Antibody concentrations for HPV16 and HPV18 were presented as geometric mean 
concentrations (GMCs) of EU/mL among seropositive specimens. To explore 
waning of antibodies since vaccination, I calculated GMCs (with 95% confidence 
intervals) by time since vaccination was offered (0-1 years, 1-2 years, 2-3 years, 3-4 
years and 4-5 years). In this waning analysis, I restricted to women with a known 
date of birth. Data were plotted, stratified by the age at which the vaccine was 
offered.
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Figure 7.2: Estimation of HPV vaccination coverage by calendar year and age, based on published national coverage 
 
Published 3-dose national coverage is calculated using reported data from local areas 
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7.4. Methods for serosurveillance among sexual health 
clinic attenders 
7.4.1.  Background  
The GUMCAD STI surveillance system is a dataset which collects pseudo-
anonymised patient-level data on all attendances and diagnoses at sexual health 
clinics in England. Data collection for GUMCAD commenced on 1st January 2008. 
An anonymous unique patient ID allows attendances from the same patient to be 
linked to previous attendances since 2008. In contrast to the SEU data, patient 
demographics are collected at each attendance, including age at attendance, 
gender, country of birth, ethnicity and index of multiple deprivation (based on lower 
layer super output area (LSOA)). Further details are provided in Section 7.4.3. 
Surveillance to monitor HPV serology in a high-risk population of young women 
attending sexual health clinics was established and conducted by me as part of this 
PhD. The objectives for the serosurveillance among sexual health clinic attenders 
were to: 
(i) Estimate vaccine-induced seroprevalence. 
(ii) Compare vaccine-induced seroprevalence to the published national 
vaccination coverage. 
(iii) Compare differences in vaccine-induced seroprevalence between 
subgroups of the population (ethnicity [categorised as white, black, 
Asian, other]; quintile of deprivation; whether a patient has a current or 
previous STI). 
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Residual sera from females attending a sexual health clinic were requested 
retrospectively from five laboratories in England which I recruited using the following 
criteria: 
(i) To provide a geographical spread across the country 
(ii) To include specimens from women tested in urban and rural areas 
(iii) To include laboratories with sufficient numbers of HIV/syphilis blood 
samples taken (see Section 7.4.2) 
(iv) To be a laboratory that held residual sera samples for at least 1 year 
(preferably 2 years) to allow for samples to be requested retrospectively 
(v) Optional: Ideally, to be a laboratory that had been involved with previous 
PHE surveillance activities 
These five laboratories tested specimens collected from six sexual health clinics; 
Nottingham University Hospital Department of Microbiology (specimens from 
Nottingham City Hospital GUM clinic); Sheffield Teaching Hospital Microbiology 
Department (specimens from Royal Hallamshire Hospital sexual health clinic); 
Homerton University Hospital Department of Microbiology (specimens from 
Homerton Hospital sexual health clinic); The Countess of Chester Hospital 
(specimens from Countess of Chester Hospital sexual health clinic); and, 
Gloucestershire Royal Hospital Microbiology Department (specimens from 
Cheltenham General Hospital sexual health clinic and Gloucester Royal Hospital 
GUM clinic).  
I selected residual serum specimens from women aged 16-20 years who attended 
one of these six sexual health clinics between 1st January 2011 and 31st December 
2015 and who had a blood sample taken for an HIV and/or syphilis test (identified 
using GUMCAD data). The process of specimen and data collection are shown in 
Figure 7.3 (and described in further detail in the next sections). 
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PHE Manchester assigned a unique 
HPV study number. Residual specimens 
were labelled with a barcode with this 
HPV study number and a duplicate 
barcodes were added to the paper list. 
Paper lists were returned to me for 
double data entry (by the data entry 
team) in to an Access database 
Participating laboratories returned 
residual specimens and completed 
data lists (which indicated whether a 
sample was identified or not) to PHE 
Manchester 
I identified attendances where a 
blood sample was taken for 
HIV/syphilis test and sent to a 
participating laboratory 
All patient identifiers were removed 
from sample tubes except for the 
barcode and HPV study number 
I irreversibly unlinked all patient 
identifiable data from HPV surveillance 
dataset for eligible patients (keeping 
only HPV study ID) 
I linked sample result with HPV 
surveillance dataset for analysis 
I randomly selected the required 
number of specimens. For these 
specimens, I sent a list of GUMCAD 
identifiers and attendance dates to 
laboratories 
Pseudo-anonymised samples were 
tested for anti-HPV16 and anti-HPV18 
antibodies  
Only for eligible specimens returned to 
PHE Manchester  
Additional GUMCAD demographic data 
were linked to the Access database 
Figure 7.3: Methods to request and collect residual sera specimens from sexual 
health clinics attenders and link with corresponding GUMCAD data 
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7.4.2. Sample size  
I calculated the sample size for objective (iii) (Section 7.4.1) which required the 
largest sample size; specifically, to detect at least a 7.5% difference in coverage by 
ethnicity (using white women as the reference group), by whether women had a 
current or previous STI and by quintile of deprivation (using the least deprived 
quintile as the reference group). I calculated the required number of women in each 
subgroup (to compare proportions in the subgroup vs. the reference group) using 
the below formula for comparing a difference in proportions: 
 = !
(" + !")#$(%&(1 ' %&) +$%#(1 ' %#))
(%# '$%&)
#
$ 
Where; 
  n = Number of women in each group 
  p1 = proportion of vaccinated women in subgroup 1 
  p2 = proportion of vaccinated women in subgroup 2 
Smaller population subgroups were not oversampled for this surveillance, and so 
the final sample size is likely to have had a similar demographic distribution as the 
total population of female sexual health clinic attenders. For example, if 402 women 
were of Asian/mixed/other ethnicity, representing 9% of the population, then the 
total required sample size would be 4,467 women (3,440 (77%) white ethnicity, 625 
(14%) black ethnicity and 402 (9%) Asian/mixed/other ethnicity). Therefore, to allow 
for unequal group sizes, I calculated the total required sample size (Table 7.3), as:
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Where,  
  N’ = total sample size adjusted for unequal group size 
  N = total sample size 
  r = ratio of uneven groups 
Table 7.3: Sample size calculations for each population subgroup with α=0.05 
and 80% power 
Population subgroup Proportion of 
population
1
 
HPV vaccine 
coverage
2
 
Sample size Total sample 
size 
Ethnicity     
  White 77% 55% Reference  
  Black 14% 47.5% 411 2,936 
  Asian/mixed/other 9% 47.5% 388 4,311 
     
Current/previous STI     
  No 79% 55% Reference  
  Yes 21% 47.5% 440 2,095 
     
Quintile of IMD      
  Q1 (most deprived) 38% 47.5% Reference  
  Q2 18% 55% 514 2,856 
  Q3 14% 55% 477 3,407 
  Q4 14% 55% 477 3,407 
  Q5 (Least deprived) 16% 55% 495 3,094 
1: Proportion of 16-20 year old females attending a sexual health clinic and having an 
HIV/syphilis test recorded in the GUMCAD STI surveillance system (unpublished analyses, 
conducted by me) 
2: Estimates of HPV vaccination coverage were based on (i) published national HPV 
vaccination coverage (for ages/years included in this surveillance), and (ii) informed by 
differences between different subgroups from the published literature (Table 7.1) 
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The final sample size of 4,311 was taken as the highest value in the final column in 
Table 7.3. To allow for samples which could not be retrieved at local laboratories 
and for inadequate test results, I increased this number by 10% to give the total 
number of samples to be requested of 4,742. 
7.4.3. Specimen collection 
I used GUMCAD to retrospectively identify eligible patient sexual health 
attendances that included HIV/syphilis tests at relevant clinics to meet the sample 
size calculations in the previous section. Limited GUMCAD data for each specimen 
(restricted to fields which were required to identify eligible specimens for this 
surveillance and to determine case/control status, as outlined in Section 7.5) were 
saved in a secure Microsoft Access database which I developed specifically for this 
serosurveillance study. These data fields are summarised in Table 7.4. I generated 
lists of the clinic ID, clinic patient ID and date of attendance to send to participating 
laboratories to request residual specimens. In addition, I designed a laboratory 
protocol including detailed instructions for laboratories on how to select, label and 
submit samples to PHE (Appendix G1) which was sent along with these lists. These 
protocol instructions requested laboratories to send aliquots of between 250µl to 
2mL for all residual serum specimens on the list that I provided. If a specimen on 
this list had an identical clinic ID and clinic patient ID to a specimen at the laboratory 
but the date of attendance on the list was within 7 days of the date recorded at the 
laboratory (i.e. not an exact match), then I asked the specimen to be sent with a 
note of the laboratory’s recorded date of attendance on the list. If the specimen was 
not available then laboratories were asked to record this on the list along with a 
reason (e.g. no specimen within 7 days of the given date, or the specimen had been 
discarded). 
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Table 7.4: GUMCAD data extracted for specimens included in the serosurveillance among sexual health clinic attenders 
Field Name Description Coding 
 
Data fields directly taken from GUMCAD 
clinic_code Clinic code Derived by GUMCAD team 
patient_id ID of patient Derived by sexual health clinic 
age Age at attendance date in years Numeric (999 Not known) 
gender Gender / sex 1 Male; 2 Female; 9 Not specified/indeterminate 
attendance_date Date of clinic attendance dd/mm/yyyy 
raw_sti_code SHHAPT code entered by sexual health clinic See Appendix G2 
clean_sti_code SHHAPT code amended for data coding errors by GUMCAD See Appendix G2 
 
Derived data fields (using other data from GUMCAD) 
 
first_date Earliest date of attendance in GUMCAD dd/mm/yyyy 
last_date Last date of attendance in GUMCAD dd/mm/yyyy 
p1a HIV antibody test at attendance Binary 
s2 HIV antibody test and sexual health screen at attendance Binary 
t3 Chlamydia, gonorrhoea and syphilis test at attendance Binary 
t4 Chlamydia, gonorrhoea, syphilis and HIV test at attendance Binary 
c11a_ever Ever had a first case of genital warts Binary 
c11b_ever Ever had recurrent genital warts Binary 
c11c_ever Ever had re-registered case of genital warts Binary 
case Case definition for nested case-control study (see Section 7.6) Binary 
control Control definition for nested case-control study (see Section 7.6) Binary 
select Sample selected for surveillance study Binary 
requested Sample requested from local laboratory Binary 
match Identifier to link matched cases and controls Numeric  
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Laboratories were asked to send the residual specimens and lists to PHE VEU at 
Manchester. On receipt, PHE VEU verified that the number of specimens returned 
matched the number expected according to the data lists. They also generated a 
unique HPV study number and attached a barcode for each returned sample to the 
specimen tube with a duplicate barcode attached to the data list (Figure 7.3). PHE 
VEU retained only this HPV study number to identify residual specimens. The 
completed lists were then sent to me at PHE Colindale. For each requested 
specimen on the list, the Access database was updated with information of whether 
a specimen had been returned (or a reason for not sending). For returned 
specimens, the HPV study number and the laboratory date of attendance (if 
different to GUMCAD) were also entered. 
7.4.4. GUMCAD data linkage 
As described in the previous section, only limited data were held for specimens 
requested from the laboratories. This was because the GUMCAD team, who review 
and approve all projects using GUMCAD data, determined that additional patient 
demographic data should only be linked for those with a residual serum specimen 
identified by the participating laboratories. Therefore, for returned specimens only, I 
oversaw, along with a member of the GUMCAD team, the linkage back to GUMCAD 
data (using clinic ID and clinic patient ID) to obtain the following data: Age (complete 
for 99% of patients); country of birth (complete for ~90% of patients); ethnicity 
(complete for ~95% of patients) and LSOA which was used to determine socio-
economic status (complete for ~90% of patients). Additionally, a concurrent or 
previous diagnosis of syphilis, gonorrhoea or chlamydia was also included as a 
proxy for sexual behaviour. This is shown in more detail in Table 7.5. Following data 
linkage with GUMCAD, I irreversibly deleted all patient identifiable data (except for 
the HPV study number) from the Access database and securely discarded any 
paper records. I released samples for testing after data were pseudonymised. 
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Table 7.5: Demographic and sexual behaviour from GUMCAD recorded for each specimen requested and returned for the 
serosurveillance among sexual health clinic attenders 
Field Name Description Coding 
Data fields directly taken from GUMCAD 
country_birth Patient's country of birth ISO country codes  
sex_orientation Sexual orientation/risk 1 heterosexual; 2 homosexual; 3 bisexual; 9 not stated/not known 
ethnicity Ethnicity White 
A British 
B Irish 
C Any other White background 
Mixed 
D White and Black Caribbean 
E White and Black African 
F White and Asian 
G Any other mixed background 
Asian or Asian British 
H Indian 
J Pakistani 
K Bangladeshi 
L Any other Asian background 
Black or Black British 
M Caribbean 
N African 
P Any other Black background 
Other Ethnic Groups 
R Chinese 
S Any other ethnic group 
 
Z not stated 
99 Not known 
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la Local authority (formerly PCT) of 
residence 
National LA codes 
lsoa Lower layer super output authority of 
residence 
National LSOA codes 
pct Primary Care Trust of residence National PCT codes 
Derived data fields (using other data from GUMCAD) 
a1_ever Ever had a primary Syphilis diagnosis Binary 
a2_ever Ever had a secondary Syphilis 
diagnosis 
Binary 
a3_ever Ever had an early latent Syphilis 
diagnosis 
Binary 
gonn_ever Ever had a Herpes diagnosis Binary 
chl_date* Date(s) of chlamydia diagnoses 
(SHHAPT codes C4A, C4B, C4C or 
C4D - see Appendix G2) 
dd/mm/yyyy (missing if no chlamydia diagnosis) 
c10_ever Ever had a Herpes diagnosis Binary 
imd_rank IMD rank from LSOA code Derived from the English indices of deprivation for 2010 
imd_score IMD score from LSOA code Derived from the English indices of deprivation for 2010 
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7.4.5. HPV antibody testing 
At the start of this surveillance, it was planned that testing for HPV antibodies would 
be conducted by VEU using the same approach as that used for the SEU 
serological surveillance. However, there was a problem with availability of the 
reagents being provided by GSK for testing. Unfortunately, this could not be 
resolved hence residual sera specimens were transferred from VEU to the German 
Cancer Research Center (Deutsches Krebsforschungszentrum; DKFZ) in 
Heidelberg Germany for testing. The 2mL Eppendorf specimen tubes were sent to 
DKFZ labelled only with the unique HPV study number and no other patient 
identifiers. Specimens were sent on dry ice in packaging which conformed to UN 
3373 regulations for shipment of risk group B samples.  
Sera specimens were tested for antibodies to L1 proteins for HPV6, 11, 16 and 18 
using a multiplex serology assay which allowed analysis of antibody responses to 
several antigens in one reaction[150]. Antigens were expressed as Glutathione S-
transferase (GST) fusion proteins and affinity-purified on glutathione-derivatized 
polystyrene beads (Luminex Corp, Austin, TX, USA). Different antigens were 
purified on different bead sets as defined by the beads’ internal fluorescence. The 
antigen-loaded bead sets were then mixed and incubated with serum. A Luminex 
flow cytometer distinguished between the bead sets (and hence the loaded antigen) 
and quantified the amount of bound serum antibody by a human IgG secondary 
antibody and Streptavidin-R-phycoerythrin fluorescent reporter conjugate. The 
output was the median reporter fluorescence intensity (MFI) of at least 100 beads 
per set per sample. Net MFI were generated by subtracting two background values 
resulting from a blank (a well containing no serum but antigen-loaded beads and all 
secondary reagents) as well as from a bead set loaded with GST only. Antigen-
specific cut-offs were defined by visual inspection of frequency distribution curves 
(percentile plots) at the approximate inflection point of the curve to dichotomize 
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antibody responses as seropositive and seronegative (this approach has been used 
previously in other settings[151-155]). For the surveillance among sexual health 
clinic attenders described in this chapter, a cut-off of 100 MFI was used to classify 
seropositivity for HPV16 L1 antibodies and HPV18 L1 antibodies. As a sensitivity 
analysis, different cut-offs were considered for seropositivity of 80 MFI and 120 MFI.  
7.4.6. Determination of HPV vaccination status 
Seropositivity for each HPV type could be ascertained using the methods described 
in the previous section (Section 7.4.5). However, due to unexpected degradation of 
the glutathione-derivatized polystyrene beads (which was not apparent until after 
testing had been completed), the MFI results could not be used to quantify antibody 
concentrations for the serosurveillance among females attending sexual health 
clinics. This issue meant that, for sexual health clinic attenders, I was unable to 
apply the same techniques that I developed for the SEU surveillance to determine 
vaccine-induced seropositivity (described in Section 7.3.3). Consequently, I 
classified patients as having vaccine-induced seropositivity if they were seropositive 
to L1 proteins for both HPV16 and HPV18 at the cut-off of 100 MFI. This approach 
is likely to have misclassified some patients as having a vaccine-induced response 
whereas, in fact, they had an immune response to both types following natural 
infection. I discuss the implications of this in Section 8.5.1.  
7.4.7. Data analysis 
I calculated the proportion of specimens with a valid serological result who were 
assumed to have vaccine-induced seropositivity in this analysis (i.e. had an 
antibody response to HPV16-L1 and HPV18-L1). Although oversampling of specific 
socio-demographic subgroups was not undertaken, women with a diagnosis of 
genital warts were oversampled (Section 7.5.2). Thus results were weighted to take 
account of this over-sampling, in order for these to be representative of the 
population of women attending sexual health clinics and having an HIV and/or 
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syphilis test taken; samples from women with a diagnosis of genital warts were 
given less weight and samples from women with no diagnosis of genital warts were 
given more weight. Specifically, weights were calculated for each year and age as: 
weight ! = " proportion"of"all"women
#"with"a"diagnosis"of"genital"warts"for"age/year
Proportion"of"women"in"HPV"surveillance"with"a"diagnosis"of"genital"warts"for"age/year
 
weight$%" ! = "
proportion"of"all"women#"with"no"diagnosis"of"genital"warts"for"age/year
Proportion"of"women"in"HPV"surveillance"with"no"diagnosis"of"genital"warts"for"age/year
 
* women attending a sexual health clinic included in this surveillance who had an HIV and/or syphilis 
test recorded in GUMCAD 
The prevalence of vaccine-induced seropositivity, with 95% confidence intervals, 
was presented alongside the published national HPV vaccination coverage. To 
compare whether vaccination coverage in this high-risk population was different to 
the national vaccination coverage, I estimated 1-dose and 3-dose coverage for each 
age and year using national data and the methods previously described (Section 
7.3.4).  
Comparison of vaccine-induced seropositivity in different subgroups was conducted 
using a logistic regression model to calculate odds ratios and associated 95% 
confidence intervals. The prevalence of vaccine-induced seropositivity was 
compared for the following subgroups; ethnicity (categorised as white, black, Asian, 
mixed or other); Quintile of deprivation; whether the patient had a concurrent or 
previous diagnosis of syphilis, gonorrhoea or chlamydia; country of birth (UK vs. 
outside of the UK); and age at attendance. Adjusted odds ratios were calculated 
using a multivariable regression model including all these variables. Year of 
specimen collection was included a prior to adjust for potential confounding as more 
women from younger birth cohorts, with higher vaccination coverage, would have 
been eligible for this surveillance in later years. As above, odds ratios were 
weighted for oversampling of women with a diagnosis of genital warts. 
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7.5. Methods for the case-control study to assess the 
effectiveness of the bivalent vaccine against genital 
warts  
7.5.1.  Background 
Genital warts are the most commonly diagnosed viral sexually transmitted condition 
in high-income country settings. In England, in 2016 there were 27,342 first 
episodes of genital warts diagnosed in females at sexual health clinics [50]. 
Recurrence of genital warts was also relatively common with 20,232 recurrent 
episodes of genital warts in females in the same year[50]. Whilst not associated with 
severe morbidity or mortality, genital warts have a major impact on patients’ quality 
of life and cause substantial costs to diagnose and treat[51, 156]. 
National programmes that vaccinate women with the quadrivalent HPV vaccine 
have been introduced in many countries worldwide. Early data suggest an early and 
substantial effect on the incidence of genital warts in these countries. In Australia 
the quadrivalent vaccine has been offered to all girls aged 12 years old since 2007 
with a catch-up programme offering the vaccine free-of-charge to all females up to 
26 years of age. Ali et al report analyses of national surveillance data which showed 
declines in the rate of genital warts between 2007 and 2011 of 92.6% in Australian-
born females aged under 21 years old and 72.6% in females aged 21-30 years 
old[157]. These data also suggest declines in Australian-born heterosexual men, 
with an 82% reduction in the proportion with genital warts (likely due to herd 
immunity as vaccination of men in Australia was not introduced until 2012). In 
Denmark the quadrivalent vaccine has been offered free of charge to all 12 year old 
girls since January 2009 with catch-up vaccination offered to all girls up to age 15 
since October 2008. Baandruup et al published data which demonstrated an 
average annual decline in the incidence of genital warts of 45.3% in Denmark 
among young women aged 16-17 years[158].  
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Vaccination with the bivalent vaccine was not initially expected to have any 
protective effect against the low-risk HPV types that cause genital warts since the 
low-risk types are not closely related to two vaccine HPV types. However, ecological 
data from sexual health clinics in England have shown a reduction in genital warts 
diagnoses amongst 16–19 year old females between 2008 and 2011[84]. Declines 
were positively associated with estimated vaccination coverage. The same pattern 
was not seen among older women, or for other STIs. Since the start of this PhD, we 
have updated these ecological analyses (which are not included as part of this 
PhD). This updated analysis included data collected up to 2014 and demonstrated a 
30.6% decline in the diagnosis of genitals warts among women [159]. There was 
also evidence of a 25.4% decline in heterosexual men of the same age, but no such 
declines were seen in MSM, potentially suggesting herd protection from female 
vaccination with the bivalent vaccine. These analyses were supported by a post-hoc 
analysis of the PATRICIA trial which demonstrated moderate efficacy for the 
bivalent vaccine against persistent infection with a number of low-risk HPV 
types[74]. The authors of this study suggested that a plausible mechanism for the 
cross-protection against these low-risk HPV types could be due to cross-reactivity at 
the T-helper cell (CD4 receptor) level.  
Only a few countries in the world introduced a national vaccination programme 
using solely the bivalent vaccine (including the Netherlands, England, Scotland, 
Wales, and Northern Ireland). Of these, England has the most comprehensive 
surveillance of genital warts diagnoses with the use of GUMCAD data (Section 
7.4.1). In England and in the rest of the UK, the HPV vaccine changed from the 
bivalent to the quadrivalent vaccine in September 2012. Therefore, early data from 
women vaccinated in the first years of the National HPV Immunisation Programme 
in England offer a unique opportunity to assess if there is any effect of the bivalent 
vaccine against genital warts. Such data are important for two reasons. Firstly, this 
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could inform potential introduction of HPV vaccination and the choice of vaccine in 
countries who have not yet introduced a vaccination programme. Secondly, these 
results could affect cost-effectiveness analyses performed to inform changes to the 
vaccine used in the national programme in England (i.e. bivalent, quadrivalent or 
nonavalent). 
Whilst the ecological data described above provide a suggestion of a moderate 
protective effect of the bivalent vaccine against genital warts, these data could be 
affected by other population changes such as changing sexual behaviour or 
changes in service provision. These are explored in more detail in the above 
publications but conclude that the declines seen and the specific age- and sex- 
patterns are suggestive of a direct protective effect of the bivalent vaccine. I 
therefore established a matched case-control study to further investigate (using 
individual-level data) whether bivalent HPV vaccination has an effect on genital 
warts incidence. The matched case-control study was nested opportunistically 
within residual specimens collected from sexual health clinics as described 
previously (Section 7.4). The full methods of this case-control study are described 
below (the results of the study and discussion of the findings are provided in 
Chapter 8). 
7.5.2. Case definition  
I defined cases as females aged 16-20 years attending a sexual health clinic 
between 2011 and 2015, with a diagnosis of a first attack of genital warts (i.e. 
assumed to be an incident case), and who also had a syphilis or HIV blood test. I 
had carefully considered the appropriateness of this case definition, taking into 
account several issues. Firstly, it has been previously estimated that, of all 
individuals with genital warts who present to either their GP or at a sexual health 
clinic, around 2.2% would present to their GP only[156]. Therefore, almost all young 
women with a first diagnosis of genital warts would be expected to attend a sexual 
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health clinic. Secondly, cases in this study only included those women who had an 
HIV/syphilis test at the same attendance as their genital warts diagnosis, which 
limited the number of cases who were eligible and could have affected the sample 
size for this study. The British Association for Sexual Health and HIV (BASHH) 
guidelines recommend screening for other STIs in all women diagnosed with genital 
warts. Therefore, although this restriction does limit the number of available cases 
of women aged 16-20 years attending a sexual health clinic with a diagnosis of a 
first attack of genital warts, a relatively high proportion (approximately 60%) were 
known to have had an HIV or syphilis test at the same visit (unpublished analysis of 
GUMCAD dataset which I conducted).  
7.5.3. Control definition  
I defined controls as females aged 16-20 years attending a sexual health clinic for a 
syphilis or HIV test between 2011 and 2015, with no current or previous diagnoses 
of genital warts from 2008 to the date of the syphilis or HIV test. Thus, controls were 
sampled from the population which gave rise to the cases (i.e. sexual health clinics). 
I describe the matching of cases and controls in the next section (Section 7.5.4) and 
the number of controls matched to each case in Section 7.5.5). 
7.5.4. Selection of cases and controls (concurrent vs. exclusive sampling) 
Cases and controls were matched on laboratory and age (years). Prior to July 2012, 
controls were selected from those without current or previous genital warts 
diagnosis attending sexual health clinics in the same year of diagnosis as the 
relevant case (i.e. also matched on year of sample collection). Once selected, cases 
and controls were ineligible to be reselected. With this exclusive sampling method 
(due to the restriction of not allowing controls to be reselected), the analyses were 
limited to estimating an odds ratio which, given the fact that HPV is relatively 
common, may not be numerically similar to a rate ratio[160]. After I identified this 
potential problem, I reviewed the selection of controls in this study. As a 
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consequence of this review, specimens requested from July 2012 onwards were 
selected using concurrent sampling (otherwise known as density sampling) as, 
using this method, the case-control odds ratio would estimate a rate ratio[161]. 
Specifically for this study, I selected controls attending in the same quarter/year of 
diagnosis of the relevant case (i.e. controls were matched on laboratory, age (in 
years) and quarter and year of sample collection). Cases could be selected as 
controls prior to their first genital warts diagnosis[162] which can lead to inconsistent 
estimators if previously selected controls are excluded from further sampling[163]. 
Therefore, controls could also be reselected in subsequent quarters as a control (as 
well as a case) to avoid this potential bias. As only those with a first attack of genital 
warts were eligible to be cases, a case could not be reselected on subsequent 
attendances. The potential implications of the selection of controls are further 
discussed in Sections 8.4 and 8.5.3. 
Due to the change in case and control selection to concurrent sampling, I extended 
the duration of specimen collection from three years to five years (specimens taken 
between 2011 and 2015) to meet the target sample size (see next Section).  
7.5.5. Sample size  
The proportion of controls who were vaccinated was assumed to be 50% in this 
age-group (largely comprising catch-up vaccination cohorts). Power to detect a 
vaccine effectiveness of the bivalent vaccine against genital warts of 30% and 35% 
were considered, hence the proportion of cases vaccinated for these two scenarios 
would be 45.6% and 41.2% respectively (assuming VE=1-OR).  
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To calculate the sample size in the case of one matched control per case, I used the 
following formula[164]: 
& =
[
' 
2
+ !"#$%(1 & $)]'
($ & 1/2)'
(*,-. +%*.-,)
 
Where; 
  n = Number of cases 
  P = OR/(1+OR) 
  p0 = proportion of vaccinated controls 
  p1 = proportion of unvaccinated controls 
  q0 = proportion of vaccinated cases 
  q1 = proportion of unvaccinated cases 
 
To calculate the sample size with multiple matched controls per case, I used the 
following formula to adjust the above sample size calculation (where c is the number 
of matched controls per case)[164]: 
03 =
(4 + 1)0
24
 
Using the above formulae, sample size calculations for the number of cases are 
shown in Table 7.6 with 5% significance level, with power ranging from 80% to 90% 
and between 1 and 6 matched controls for each case. 
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Table 7.6: Sample size calculations for matched case-control study (target numbers represent required number of cases) 
Proportion 
of controls 
vaccinated 
Proportion of 
controls 
unvaccinated 
Vaccine 
effectiveness 
(1-OR) 
Proportion 
of cases 
vaccinated1 
Proportion of 
cases 
unvaccinated1 
α2 β2 
Sample size (number of cases) for case:control ratio 
1:1 1:2 1:3 1:4 1:5 1:6 
0.5 0.5 0.3 0.412 0.588 0.05 0.1 666 500 445 416 400 389 
0.5 0.5 0.3 0.412 0.588 0.05 0.15 570 428 380 356 342 333 
0.5 0.5 0.3 0.412 0.588 0.05 0.2 499 374 333 312 299 291 
0.5 0.5 0.35 0.394 0.606 0.05 0.1 459 344 307 287 275 268 
0.5 0.5 0.35 0.394 0.606 0.05 0.15 393 295 263 246 236 229 
0.5 0.5 0.35 0.394 0.606 0.05 0.2 344 258 230 215 206 201 
1: calculated using assumed proportion of controls vaccinated and vaccine effectiveness  
2: zα=1.96 (two-sided) for α=0.05; zβ=1.28, 1.04, 0.84 (one-sided) for β=0.1, 0.15 and 0.2 respectively 
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Further to the above, I first added 15% to allow for multivariable regression analysis 
and then added a further 10% to the above sample size calculations to account for 
specimens which (i) could not be retrieved at local laboratories, or (ii) had an 
inadequate serology result (Table 7.7).  
I requested a sample size of 420 cases with 3 matched controls for each case. 
Requesting additional controls for each case would have provided limited additional 
power. With this number of cases and controls (allowing for those not retrieved or 
with an inadequate test result), this gives over 90% power to identify a vaccine 
effectiveness of 35% and around 80% power for a vaccine effectiveness of 30% 
(Table 7.7). 
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Table 7.7: Sample size calculations for matched case-control study (target numbers represent required number of cases) allowing for 
an additional 10% for specimens which could not be retrieved or had an inadequate serology test and 15% for multivariable 
regression 
Proportion 
of controls 
vaccinated 
Proportion of 
controls 
unvaccinated 
Vaccine 
effectiveness 
(1-OR) 
Proportion 
of cases 
vaccinated1 
Proportion of 
cases 
unvaccinated1 
α2 β2 
Sample size (number of cases) for case:control ratio 
1:1 1:2 1:3 1:4 1:5 1:6 
0.5 0.5 0.3 0.412 0.588 0.05 0.1 842 633 563 526 506 492 
0.5 0.5 0.3 0.412 0.588 0.05 0.15 721 541 481 450 433 421 
0.5 0.5 0.3 0.412 0.588 0.05 0.2 631 473 421 395 378 368 
0.5 0.5 0.35 0.394 0.606 0.05 0.1 581 435 388 363 348 339 
0.5 0.5 0.35 0.394 0.606 0.05 0.15 497 373 333 311 299 290 
0.5 0.5 0.35 0.394 0.606 0.05 0.2 435 326 291 272 261 254 
1: calculated using assumed proportion of controls vaccinated and vaccine effectiveness  
2: zα=1.96 for α=0.05; zβ=1.28, 1.04, 0.84 for β=0.1, 0.15 and 0.2 respectively 
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7.5.6. Data analysis 
I conducted all statistical analyses in Stata v13.  
HPV vaccination status was determined as previously described (Section 7.4.6). For 
the case-control analysis, I performed two separate analyses, as follows:  
The first analysis included all cases and controls regardless of how they were 
selected (i.e. exclusive sampling or concurrent sampling). I included the variables 
used for the matching (quarter of specimen collection, age and laboratory) in an 
unconditional logistic regression model[165]. To adjust for other potential 
confounding between case/control status and vaccination status, I further adjusted 
for adjusted for ethnicity (white, black and Asian, mixed ethnicity or other ethnicity), 
country of birth (UK or outside of the UK), quintile of deprivation (calculated using 
LSOA of residence if available or LSOA of clinic otherwise) and whether the patient 
had been diagnosed with syphilis, gonorrhoea or chlamydia (either at the time the 
serum specimen was taken or previously). 
The second analysis included only cases and controls selected by concurrent 
sampling (selected from July 2012 onwards as described in detail in Section 7.5.4). I 
performed a conditional logistic regression for a matched analysis. Cases and 
controls that could not be retrieved from local laboratories or that had an inadequate 
serology result were excluded from the analysis. If a case was excluded then any 
matched controls were also excluded. If a control was excluded then the case was 
retained along with remaining controls and the analysis was conducted with a 
variable number of matched controls per case. If all matched controls for a case 
were excluded then the case was also excluded. As above, conditional multivariable 
regression model was adjusted for ethnic group, country of birth, quintile of IMD and 
presence of an STI in a multivariable regression model.  
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For both analyses, unadjusted and adjusted odds ratios (which estimated rate ratios 
for the second analysis) and 95% confidence intervals were presented. There were 
some missing data for ethnicity, country of birth and quintile of deprivation. For both 
analyses, I conducted a complete-case analysis including only individuals with no 
missing information for adjustment variables.  
In summary, in this Chapter I have outlined the methods I developed to estimate 
HPV vaccination status, based on the results of HPV immune responses in residual 
serum specimens. I applied these methods to two distinct populations. I also 
outlined methods for a case-control study which I designed to estimate the effect of 
the bivalent HPV vaccine on the incidence of genital warts. The results of the two 
surveillance studies and of the case-control study are presented in the next chapter 
(Chapter 8).
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Chapter 8: Results of serological surveillance to 
estimate HPV vaccination coverage and vaccine 
effectiveness against genital warts  
8.1. Introduction 
In this chapter, I give the results of the two separate surveillance activities to 
monitor HPV vaccination coverage using results from immunological testing of 
serology specimens. This chapter includes two manuscripts and a report with 
updated analyses from the first manuscript.  
The aim of the analysis included in the first manuscript, published in PLOS One in 
2016, was to confirm the reportedly high proportion of women in the population who 
have received the HPV vaccine (based on aggregate data compiled and published 
by PHE) by considering the immune response in a sample of women broadly 
representative of the general population (the SEU serosurveillance). The results 
reported in the paper were updated with an analysis I carried out with an additional 
two years of data. These updated results were made available in 2016 as a PHE 
Health Protection Report; this report is also included in this Chapter.  
The second manuscript (about to be submitted) explores two quite distinct research 
questions. Firstly, I present estimated vaccination coverage in a population of young 
women attending a sexual health clinic for an HIV and/or syphilis test between 2011 
and 2015 (the serosurveillance among sexual health clinic attenders). I also 
compare vaccination coverage in different population subgroups. Secondly, I report 
the results of the nested case-control study designed to investigate the potential 
effectiveness of the bivalent vaccine against genital warts. After these papers, I 
have included some additional discussion about the limitations of the 
serosurveillance among sexual health clinic attenders and potential biases in the 
results.
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Background 
Seroconversion occurs following an estimated 50-70% of incident natural human papillomavirus 
(HPV) infections in women [1-4] and natural infection often elicits only a weak antibody 
response. Conversely, vaccination induces seroconversion in ~100% of HPV-naïve recipients 
and generally results in far higher antibody concentrations than those following natural 
infection [5,6]. As such, serological assays which provide a quantitative measure of the level of 
HPV type-specific antibodies can be used to estimate HPV vaccination coverage. 
 (as part of work to monitor 
and evaluate the National HPV Immunisation Programme) has begun with a study of young 
women in the first birth cohorts to be offered HPV immunisation, primarily to compare vaccine-
induced seroprevalence to nationally reported coverage data. The first results from this 
surveillance have been published previously with data from 2,146 specimens collected between 
2010 and 2011 [7]. We report here updated findings with results from 3,772 specimens 
collected up to 2013.  
Methods  
Residual serum specimens were collected for 15-19 year old females from the PHE 
Seroepidemiology Unit (SEU). SEU specimens are collected from individuals attending for 
microbiological and/or biochemical tests. Serum samples were submitted with data on gender, 
age at collection and year of collection from fourteen laboratories in England. Laboratories were 
asked to identify, if possible, any specimens collected via Genitourinary (GU) Medicine clinics 
(defined as No, Yes or Not known). Specimens collected from 2010 to 2013 are included in this 
analysis.   
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Where date of birth was available, this was used to generate the age and calendar year that 
HPV vaccination would have been offered: this was available for 2355/3772 (62.4%) of women. 
For the remainder, with age in years available, likely year of eligibility for HPV vaccination was 
estimated. Specimens collected in January-March following the due date of first vaccine dose 
were excluded in order to study seroprevalence after, not during, the scheduled full course of 
vaccination. 
Specimens were tested for antibodies to HPV types 16 and 18 using a type-specific ELISA. 
Testing was performed at the PHE Vaccine Evaluation Unit (VEU), Manchester. Specimens 
were considered to be seropositive above cut-offs determined previously with this assay: 19 and 
18 ELISA units per millilitre (EU/mL) for HPV 16 and 18, respectively. 
Methods to determine vaccine-induced seropositivity were as previously described [7]. In brief, 
-
induced seropositivity if seropositive for both types with high concentration for at least one type 
or moderate concentrations for both types
for both types or low seropositivity for one type and moderate for the other. Antibody 
concentrations are presented as geometric mean concentrations (GMCs) among seropositive 
specimens. 
Routinely published data on HPV vaccine coverage in England has been reported by academic 
year. To compare these data with seroprevalence we estimated coverage by year of age and 
calendar year.  
Results 
A total of 4,045 specimens had a valid result for type-specific HPV antibodies for both HPV 
types 16 and 18. Excluding 323 samples which were collected in the January to March of the 
year following the due date of first vaccine dose; 3,722 specimens were included in this analysis 
(1205, 941, 952 and 674 collected in 2010, 2011, 2012 and 2013, respectively). The mean age 
of women providing a specimen was 17.8 years (SD 1.42 years). Overall, just under one-third 
(32.4%) of all specimens were identified as coming from a GU setting although this was not 
known for the majority of other specimens (64.1%): specimens from a known non-GU setting 
had higher seroprevalence (p=0.01 for vaccine-induced seropositivity). Table 1 shows the 
demographics of all eligible women alongside the proportion seropositive for at least one HPV 
type. 
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Table 1. Seropositivity by clinical setting, age and laboratory sending specimen 
Number with 
valid result 
Proportion 
seropositive for 
HPV 16 and/or 18 
Proportion 
seropositive for 
HPV 16 and 18 
Vaccine-induced 
seropositivity 
  n n (%) n (%) n (%) 
Total 3,772 2,861 (75.8) 2,638 (69.9) 2,472 (65.5) 
  
Genito-urinary Medicine (GUM) 
clinic setting 
  
Yes 1,206 928 (76.9) 852 (70.6) 798 (66.2) 
No 149 126 (84.6) 119 (79.9) 114 (76.5) 
Unknown 2,417 1,807 (74.8) 1,667 (69.0) 1,560 (64.5) 
  
Age specimen taken   
15 years 643 527 (82.0) 512 (79.6) 492 (76.5) 
16 years 729 600 (82.3) 573 (78.6) 547 (75.0) 
17 years 590 464 (78.6) 433 (73.4) 401 (68.0) 
18 years 957 713 (74.5) 645 (67.4) 600 (62.7) 
19 years 853 557 (65.3) 475 (55.7) 432 (50.6) 
  
Laboratory1   
North East   
     Newcastle 361 305 (84.5) 280 (77.6) 258 (71.5) 
North West   
     Manchester 577 443 (76.8) 413 (71.6) 395 (68.5) 
Yorkshire and The Humber   
     Leeds 946 729 (77.1) 671 (70.9) 624 (66.0) 
East Midlands   
     Cambridge 166 116 (69.9) 107 (64.5) 100 (60.2) 
     Leicester 347 285 (82.1) 277 (79.8) 264 (76.1) 
West Midlands   
     Birmingham 81 51 (63.0) 43 (53.1) 41 (50.6) 
London   
     Barts and The London 230 134 (58.3) 121 (52.6) 108 (47.0) 
      167 99 (59.3) 83 (49.7) 77 (46.1) 
     PHL London2 139 96 (69.1) 82 (59.0) 76 (54.7) 
South Central   
     Southampton 103 85 (82.5) 79 (76.7) 74 (71.8) 
South East   
     Brighton3 49 30 (61.2) 25 (51.0) 24 (49.0) 
South West   
     Bristol 69 58 (84.1) 55 (79.7) 51 (73.9) 
     Exeter 510 412 (80.8) 384 (75.3) 363 (71.2) 
     Gloucester 27 18 (66.7) 18 (66.7) 17 (63.0) 
        
   1: Proportion seropositive for each laboratory are age and year-standardised  
   2: PHL = Public Health Laboratory; specimens collected in 2012 and 2013 only  
   3: Specimens collection in 2010 only   
 
 
Health Protection Report   Vol. 10  No. 34  7 October 2016 
A total of 69.9% (2,638/3,772) of specimens were seropositive for both types HPV16 and 
HPV18. Seropositivity for HPV16 only and for HPV18 only was found in 4.4% (165) and 1.5% 
(58) of specimens respectively (table 2; figure 1). Antibody concentrations were generally far 
higher for specimens seropositive for both HPV types than amongst those seropositive for only 
one type (median 2017.5 EU/ml vs 70 EU/ml for HPV16 and 804.5 EU/ml vs 59 EU/ml for 
HPV18) (table 2).  
 Table 2. Antibody concentrations for types HPV16 and HPV18  
HPV type 16  HPV type 18 
HPV type n (%)   
Median 
EU/mL (IQR) 
95% range 
  
Median 
EU/mL (IQR) 95% Range 
Both types negative 911 (24.2%)       
16 negative, 18 positive 58 (1.5%)   59 (30-172) 18  590 
16 positive, 18 negative 165 (4.4%) 70 (37-156) 23-571   
Both types positive 2,638 (69.9%)  
2,017.5 
(929-4200) 177  11,675  
804.5  
(343-1,756) 64  5,460 
Total 3,772 (100%)            
Figure 1. Classification of vaccine-induced seropositivity (n=3,772)  
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Vaccine-induced seropositivity was highest in the younger ages with higher expected vaccine 
coverage (table 3). This finding was consistent in sub-analyses by region (data not shown). The 
overall proportion of females with probable vaccine-induced seropositivity was 66% 
(2,472/3,772) and 4.4% (166/3,772) with possible natural infection or possible vaccine-induced 
seropositivity. The proportion of females with vaccine-induced seropositivity was slightly lower 
than the reported three-dose coverage for 15 and 16 year olds but higher at older ages (table 3 
and figure 2). 
 
Table 3. Seropositivity for HPV 16 and 18 amongst all specimens tested for both HPV types, by age 
Age in years 
HPV type 15 16 17 18 19 Total 
Both types negative 18.0% (116) 17.7% (129) 21.4% (126) 25.5% (244) 34.7% (296) 24.2% (911) 
Natural infection seropositivity:     
- Probable 18 only 1.1% (7) 1.2% (9) 1.0% (6) 2.0% (19) 2.0% (17) 1.5% (58) 
- Probable 16 only 1.2% (8) 2.5% (18) 4.2% (25) 5.1% (49) 7.6% (65) 4.4% (165) 
- Probable 18 or 16  2.3% (15) 3.7% (27) 5.3% (31) 7.1% (68) 9.6% (82) 5.9% (223) 
- Probable and possible 5.4% (35) 7.3% (53) 10.7% (63) 11.8% (113) 14.7% (125) 10.3% (389) 
Vaccine-induced seropositivity:     
- Probable  76.5% (492) 75.0% (547) 68.0% (401)  62.7% (600)  50.6% (432)  65.5% (2,472)  
- Probable and possible  79.6% (512) 78.6% (573) 73.4% (433) 67.4% (645) 55.7% (475) 69.9% (2,638) 
Expected 1-dose (national) 86.0% 82.3% 74.2% 66.7% 52.1% - 
Expected-3-dose (national) 80.6% 76.0% 65.6% 54.5% 38.4% - 
 
The GMCs amongst all women and those with probable vaccine-induced seropositivity group 
declined slightly with age (table 4). Furthermore, in women with a known date of birth, the 
GMCs declined after the first year but then seemed to remain stable at a level far higher, on 
average, than the GMCs for those seropositive for only one HPV type (figure 3). 
 
Table 4: Geometric mean concentrations (GMCs; 95% CI) of EU/mL for HPV16 and HPV18, by age 
Age in years 
15 16 17 18 19 
Type 16      
 Seropositive 2,207 
(1,979-2,461) 
1,840 
(1,661-2,037) 
1,424 
(1,246-1,628) 
1,357 
(1,213-1,517) 
1,042 
(911-1,193) 
 Vaccine-induced 
seropositive 
2,632 
(2,402-2,883) 
2315 
(2,134-2,513) 
2,078 
(1,871-2,309) 
2,087 
(1,920-2,269) 
1,929 
(1,750-2,125) 
Type 18      
 Seropositive 857 
(766-959) 
792 
(714-878) 
664 
(585-753) 
631 
(569-699) 
589 
(520-668) 
Vaccine-induced 
seropositive 
993 
(896-1,100) 
925 
(841-1,017) 
819 
(730-919) 
814 
(744-891) 
799 
(715-894) 
 
 
Figure 2. Published HPV vaccine coverage and vaccine-induced seropositivity, by age (n=3,772) 
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Figure 3. Geometric mean concentrations (GMCs; EU/mL) and 95% CI for HPV16 and HPV18 among those 
with probable vaccine-induced seropositivity (restricted to women with a known date of birth who would 
have been eligible for vaccination as part of the national immunisation programme  (n=1,569)  
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Discussion  
We have previously reported that serological surveillance confirms high vaccine coverage of 
the HPV vaccination programme in young females in England, particularly in those offered 
the vaccine at younger ages, but that there was a slightly higher proportion with vaccine-
induced seropositivity compared to reported three-dose coverage in females offered HPV 
vaccination at an older age suggesting that three-dose coverage in the catch-up cohorts 
could be higher than reported and/or that two-dose coverage at these ages is associated 
with high antibody responses. These updated analyses strengthen these conclusions. In 
addition, we demonstrate that whilst geometric mean antibody concentrations declined 
immediately after vaccination, levels then remained fairly stable up to five years post-
vaccination. Furthermore, the average antibody concentrations were still far greater than 
antibody concentrations following a natural HPV infection.  
Vaccine status of women in this study is unknown which leads to two important limitations. 
Firstly, vaccine-induced seropositivity 
hence we must assume that these women are representative of the general population with 
similar HPV vaccination coverage to national reported data. Residual serum specimens for 
this surveillance are taken from females attending for diagnostic and screening tests. No 
additional demographic data are collected on social deprivation, education, ethnicity or other 
factors which may be associated with vaccine uptake. However, everyone in England has 
free access to health care which reduces the potential bias associated with health-seeking 
behaviour and previous studies have suggested that results are comparable for other 
vaccines [8]. Secondly, measuring changes in natural infection among unvaccinated women 
compared to similar surveys conducted prior to the introduction of vaccination would allow us 
to consider if there is evidence of a herd protection effect. However, a limitation of this 
analysis was that it wa
infection and women who have been vaccinated. 
Among those vaccinated between 14 to 17 years of age, these results show initial waning of 
antibody concentrations immediately following vaccination and then stabilisation, which is 
fairly consistent with results from clinical trials [5]. 
vaccination in the routinely vaccinated cohorts as sera from 12-14 years olds were not 
included in this analysis. Whilst the level of protection required to prevent HPV infection and 
related disease is not known, the plateau of antibody concentrations is still far higher than 
those seen with a natural infection for all ages. As such, annual monitoring may not be 
essential but periodic surveillance to monitor that antibody concentrations are remaining high 
in the general population could be valuable, and to check antibody concentrations in 
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recipients of the two dose schedule in due course. Future studies should also consider 
variations in the proportion of women with vaccine-induced seropositivity from different 
subgroups which will be required to accurately monitor of the impact of HPV vaccination.   
Conclusion 
These data add to previous data confirming high coverage of HPV vaccination in England 
but with some potential under-reporting of vaccination of older females and/or a potential 
protective effect of receiving fewer than three doses. This updated analysis provides data on 
antibody responses up to five years post-vaccination. Whilst there is some evidence of slight 
declines in antibody concentrations over time since vaccination, these still remain far higher 
than antibody concentrations following a natural infection. 
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Abstract  
Background: The National HPV Immunisation Programme was introduced in 
England in September 2008 using the bivalent vaccine. We used serological 
surveillance to consider variations in HPV vaccination uptake by patient 
characteristics. We also conducted a case-control study to consider the effect of the 
bivalent vaccine against genital warts. 
Methods: We collected residual serum specimens from 16-20 year old women 
attending a sexual health clinic in England for an HIV and/or syphilis test. Sera were 
tested for antibodies against HPV16 and HPV18 using a GST L1-based multiplex 
serology assay. Patients were classified as having vaccine-induced seropositivity if 
they were seropositive for both HPV16 and HPV18. 
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We compared differences in vaccine-induced seropositivity by patient 
characteristics using a weighted logistic regression model. For the case-control 
study, cases and controls were selected using two approaches; exclusive sampling 
and concurrent sampling. We conducted an unconditional logistic regression 
adjusted for matching variables for all women and a separate matched analysis 
which included only cases and controls selected using concurrent sampling.  
Results: A total of 3,959 (99.6%) serum specimens had a valid result for both HPV 
types. The proportion of women with vaccine-induced seropositivity decreased with 
age (from 72.4% in 16 year olds to 44.8% in 20 year olds). We also demonstrated 
lower vaccine-induced seropositivity among women born outside the UK, women 
from more deprived areas and women with a history of chlamydia diagnosis. A 
difference in uptake by ethnic group was also seen but this was largely explained by 
differences in deprivation and country of birth. There was no evidence of a 
protective effect of the HPV vaccine against genital warts (adjusted odds ratio of 
1.05; 95% CI 0.84 to 1.29 for all women. adjusted odds ratio of 1.02; 95% CI 0.72 to 
1.45 restricted to cases and controls selected using concurrent sampling). 
Discussion: Our results do not support a cross-protective effect of the bivalent 
vaccine against genital warts. Vaccine-induced seropositivity in this high-risk 
population did demonstrate lower HPV vaccination uptake in some sub-groups.
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Introduction 
The National HPV Immunisation Programme was introduced in the UK in 
September 2008. Initially the bivalent vaccine was used with routine vaccination of 
12-13 year olds and a catch-up programme in the first two years of vaccination for 
all females up to the age of 18 years. All vaccinations as part of the national 
programme were offered free of charge. Vaccination of routine cohorts and younger 
catch-up cohorts was almost exclusively offered in schools whereas vaccination of 
older catch-up cohorts was offered in different primary care and education settings 
and varied by local area. 
Monitoring of national HPV vaccination coverage in England relies on aggregated 
numerator and denominator data reported to Public Health England (PHE) from 
local areas. These national data have shown high vaccine coverage of over 80% for 
all routine cohorts[78]. Coverage among the catch-up cohorts was more variable 
depending on the age the vaccine was offered (3-dose coverage ranging between 
39% and 76%)[78]. There are two main limitations of this method of monitoring 
vaccine coverage. Firstly, these data rely on accurate recording of vaccine doses 
given at local areas which, particularly in the older catch-up cohorts, are often 
derived by collating data from different data systems and different settings. 
Secondly, the national data are stratified by academic year (i.e. birth cohort) but not 
by ethnicity, sexual risk or any other factors. We have previously investigated the 
first of these two limitations by developing a robust technique to monitor HPV 
vaccine-induced seropositivity using serological testing of residual specimens from 
a broadly population based survey conducted in England. These results confirmed 
the high vaccine coverage among young women although there was some evidence 
of slightly higher vaccine-induced seropositivity in the older cohorts compared to the 
nationally published vaccine coverage[166]. In this paper, we aim to address the 
second limitation of the national published HPV vaccine coverage by considering 
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the equity of HPV vaccination uptake among women at higher risk of STIs including 
HPV. This is important to ascertain whether there has been lower vaccination 
uptake in those who may be at higher risk for HPV (and therefore cervical cancer) 
and to allow more accurate predictions of the impact of HPV vaccination on disease 
incidence in the future. We have investigated HPV seroepidemiology in young 
women attending sexual health clinics in England (i.e. at higher risk of STIs) and 
stratified vaccine-induced seropositivity by age, ethnicity, country of birth, index of 
multiple deprivation (IMD) and current or previous history of other STIs.  
Additionally, we have conducted a nested case-control study to investigate the 
effect of vaccination with the bivalent vaccine on the incidence of genital warts. 
Whilst a cross-protective effect of the bivalent vaccine against low-risk HPV types 
which cause genital warts was not initially expected, ecological observations in 
England have shown moderate declines in diagnoses of genital warts since the 
introduction of the bivalent vaccine that were associated with vaccination coverage 
by age[84, 159]. Also, a post-hoc analysis of the PATRICIA trial reported efficacy 
against HPV6/11[74]. Together, these findings raised a hypothesis that the bivalent 
vaccine confers some moderate cross-protective effect against genital warts. To test 
this hypothesis, and so inform vaccine choice in the future, we designed a nested 
case-control study within our serosurveillance. This was done by sampling cases 
and controls before the quadrivalent vaccine was introduced into the National HPV 
Immunisation Programme in 2012.  
Methods 
Eligible population and specimen collection 
The GUMCAD STI Surveillance System is held and managed at PHE and collects 
information on all attendances, STI tests and diagnoses at sexual health services in 
England. We made use of this data collection system to identify eligible attendances 
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for the purposes of our HPV surveillance. Specifically, eligible women were aged 
16-20 years old and had attended for an HIV and/or syphilis test at one of six sexual 
health clinics across England between 2011 and 2015; Cheltenham General 
Hospital, Gloucester Royal Hospital, Nottingham City Hospital, Royal Hallamshire 
Hospital, Homerton Hospital and Countess of Chester. These women would have 
been eligible for their first HPV vaccination dose between 2008 and 2012, when 
aged between 12 and 18 years old (Table 1): the bivalent vaccine was offered 
through the National HPV Immunisation Programme for all of this time period.  
We randomly selected eligible attendances to meet a pre-defined target number of 
specimens (see sample size below) for each age-group and clinic. HIV and syphilis 
testing for these women was performed at five local laboratories (testing for 
Cheltenham General Hospital and Gloucester Royal Hospital was performed at the 
same local laboratory) and residual specimens were frozen and held for at least two 
years following this test at each laboratory. Therefore, we were able to 
retrospectively request residual sera specimens directly from each testing 
laboratory. We sent local laboratories a list of patient IDs and the attendance dates 
of the eligible HIV or syphilis test. Laboratories were asked to identify the residual 
serum specimen associated with these attendances. If no specimen was taken on 
the exact attendance date but there was a specimen within 7 days (either direction) 
then the laboratories were asked to provide this specimen. 
The five laboratories were requested to provide rigid polypropylene serum vials with 
a screw-cap with O-ring seal, with a capacity of no more than 2mL. A minimum 
volume of 250µl was requested for each specimen. Serum samples were labelled 
only with the patient ID and attendance date. Residual specimens were sent to the 
PHE Vaccine Evaluation Unit (VEU) for processing. On receipt at VRD, samples 
were relabelled with a unique HPV study number which was electronically linked 
with the patient ID and attendance date. 
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Data collection 
Prior to HPV testing, additional GUMCAD data were linked to the HPV study 
number; ethnicity (categorised as white, black, Asian, mixed and other (including 
Chinese and any other ethnicity)), country of birth, index of multiple deprivation 
(based on lower layer super output area (LSOA) of patient where available (93% of 
patients) or otherwise LSOA of clinic (7% of patients)), and whether a patient had a 
concurrent or previous diagnoses of gonorrhoea, herpes or chlamydia. 
Following linkage, samples were pseudonymised prior to release for HPV testing by 
discarding patient ID and attendance date, keeping only the unique HPV study 
number.  
Case-control study 
Prior to requesting specimens, we determined the case and control status using 
data from GUMCAD. Cases were defined as women with a diagnosis of a first 
episode of genital warts (i.e. assumed to be an incident case). Controls were 
defined as women with no current or previous diagnoses of genital warts since 2008 
(i.e. the date that GUMCAD data were first collected).  
Cases and controls selected from specimens taken between January 2011 and 
June 2012 were selected using exclusive sampling, meaning that once selected, 
cases and controls could not be reselected. Three controls from the same 
laboratory and age were selected for each case. Cases and controls selected from 
specimens taken between July 2012 and December 2015 were selected slightly 
differently. Three controls were matched to each case (on testing laboratory, quarter 
and year of sample collection and age) using a concurrent sampling method. 
Specifically, controls were selected from all women who had no warts diagnosis (or 
previous diagnoses) in the same quarter/year that the case was diagnosed. Cases 
could have been selected as controls prior to their first warts diagnosis. Similarly, 
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controls could be selected more than once on different attendances. This change in 
sampling was to allow estimation of a rate ratio (rather than odds ratio).  
Patient consent 
This surveillance made use of residual specimens taken originally for other 
purposes. Specimens were unlinked from any patient identifiable information prior to 
being tested for the purposes of Public Health Monitoring. As such, patient consent 
was not required.  
HPV serology testing and determining vaccine-induced seropositivity 
The 2mL Eppendorf specimen tubes were sent in dry ice to DKFZ, labelled only with 
the unique HPV study number and no other patient identifiers. Multiplex serology 
was performed as described previously[150]. Briefly, multiplex serology is a 
fluorescent bead-based assay allowing for analysis of antibody responses to several 
antigens in one reaction. Antigens were expressed as Glutathione S-transferase 
(GST) fusion proteins and affinity-purified on glutathione-derivatized polystyrene 
beads (Luminex Corp, Austin, TX, USA). Different antigens were purified on 
different bead sets as defined by the beads’ internal fluorescence. The antigen-
loaded bead sets were mixed and incubated with serum. A Luminex flow cytometer 
then distinguished between the bead sets, and therefore the loaded antigen, as well 
as quantified the amount of bound serum antibody by a human IgG secondary 
antibody and Streptavidin-R-phycoerythrin fluorescent reporter conjugate. The 
output was the median reporter fluorescence intensity (MFI) of at least 100 beads 
per set per sample. Net MFI were generated by subtracting two background values 
resulting from a blank (a well containing no serum but antigen-loaded beads and all 
secondary reagents) as well as from a bead set loaded with GST only. Antigen-
specific cut-offs were defined by visual inspection of frequency distribution curves 
(percentile plots) at the approximate inflection point of the curve to dichotomize 
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antibody responses as seropositive and seronegative as previously described[151-
155]. A cut-off of 100 MFI was used to determine seropositivity for the L1 proteins of 
both HPV16 and HPV18. As a sensitivity analysis, we considered different cut-offs 
for seropositivity of 80 MFI and 120 MFI.  
Patients were classified as having vaccine-induced seropositivity if they were 
seropositive to L1 proteins for both HPV16 and HPV18. 
Data analysis 
The proportion of women who had vaccine-induced seropositivity was weighted to 
account for the over-sampling of women who had a history of genital warts for the 
nested case-control study. Weights were calculated for each year and age 
according to the probability of selection from the total number of attendances with 
and without a diagnosis of genital warts (using the full GUMCAD dataset for the 
clinics and years included in this surveillance). The proportion with vaccine-induced 
seropositivity was presented alongside the expected HPV vaccination coverage. 
Expected coverage was estimated for this population by applying national age and 
year-specific 3-dose HPV vaccination coverage estimates from published data[78] 
and calculating an average by dividing by the total number of eligible women 
included in this surveillance. The expected uptake of the first HPV vaccine dose, 
based on national published data, was also estimated for this survey population in a 
similar way. 
Weighted logistic regression was used to explore the differences in vaccine-induced 
seropositivity by age, ethnicity, country of birth, IMD quintile and presence of an STI. 
All variables were included in the multivariable logistic regression analysis. Year of 
specimen collection was also included in the multivariable regression model to 
adjust for potential confounding by calendar period. Results were presented as 
unadjusted and adjusted odds ratios (ORs) and confidence intervals (95% CI). 
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Exact date of birth and HPV vaccination cohort was unknown for women included in 
this surveillance and hence we were unable to determine the exact year and age 
that each woman would have been offered the HPV vaccine as part of the National 
HPV Immunisation Programme. However, based on the age and year of sample 
collection, it was possible to ascertain a range of ages which a woman could have 
been offered the HPV vaccine (Table 1). The above analyses were stratified for 
women for whom it could be determined (with certainty) that they fell within either 
the routine cohorts or the catch-up cohorts. 
For the case-control study, we conducted two analyses. The first analysis included 
all cases and controls (i.e. those selected by exclusive sampling and concurrent 
sampling). We performed an unconditional logistic regression adjusted for matching 
variables: quarter and year of specimen collection, age and laboratory[165]. To 
control for potential confounding between case/control status and vaccination 
status, we also adjusted for ethnic group, country of birth, quintile of IMD and 
presence of an STI. Unadjusted and adjusted odds ratios and 95% confidence 
intervals were presented. The second, matched, analysis included only cases and 
controls selected by concurrent sampling (from July 2012 onwards). Controls were 
excluded from this analysis if the specimen from their matched case was not 
available, and similarly cases were excluded if none of the specimens from their 
three matched controls were returned. If at least one matched control was returned 
for a case, then these cases and controls were included in the analysis (see Figure 
1). We performed a conditional logistic regression for a matched analysis. As above, 
the conditional multivariable regression model was adjusted for ethnic group, 
country of birth, quintile of IMD and presence of an STI. Unadjusted and adjusted 
odds ratios (which, given the concurrent sampling, estimated rate ratios) and 95% 
confidence intervals were presented.  
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For both sets of analyses, individuals with missing data for variables included in the 
multivariable model were excluded from the analysis (i.e. a complete-case analysis). 
Sample size 
We powered our surveillance to compare HPV vaccine-induced seropositivity 
between population subgroups (ethnicity [categorised as white, black and 
Asian/mixed/other combined]; quintile of deprivation and whether a patient had a 
current or previous STI). The largest required sample size was to compare 
coverage in white women (~77% of attenders) with Asian/mixed/other women (~9% 
of attenders). To detect a 7.5% absolute difference in vaccine-induced seropositivity 
among Asian/mixed/other women (compared to an estimated 55% coverage among 
the reference group, white women), with alpha=0.05 and beta=0.2, required a 
sample size of 4,311 women (~3,319 white women, ~604 black women, ~388 
Asian/mixed/other women).  
The nested case-control study was powered to identify a vaccine effectiveness of 
the bivalent vaccine against genital warts of 30%. This gave a required sample size 
of 333 cases (assuming approximately 50% of controls were vaccinated, with 
alpha=0.05 and beta=0.2). We increased the number of samples to allow for 
multivariable regression analysis (15%) which gave a final sample size of 383 cases 
(and 1,149 matched controls). We requested 420 cases (and 1,260 controls by 
concurrent sampling) to allow for approximately 10% of residual samples that 
couldn’t be retrieved or had an inadequate serology result.  
Results 
Data and sample collection 
A total of 3,973/4,888 (81.3%) requested serum specimens were retrieved and 
returned for serology testing (Figure 1). Of these, 3,959 (99.6%) had a valid result 
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for both HPV 16 L1 antibodies and HPV 18 L1 antibodies and were included in the 
analysis. There were 191 women with missing data (for either ethnicity (n=64), 
quintile of IMD (n=1) or country of birth (n=149)) and hence these women were 
excluded from regression analyses. 
Estimation of HPV vaccine-induced seropositivity 
The age at which HPV vaccination would have been offered by age and year of 
sample collection is shown in Table 1. The overall proportion of women with 
vaccine-induced seropositivity was 65.2% compared to expected 1-dose and 3-dose 
vaccination coverage of 74.3% and 65.8% respectively (based on national 
published data). As expected, the proportion of women with vaccine-induced 
seropositivity was higher in younger women who would have been vaccinated at 
younger ages (72.4% in 16 year olds, 73.1% in 17 year olds, 68.3% in 18 year olds, 
61.3% in 19 year olds and 44.8% in 20 year olds; Table 2). This surveillance was 
originally powered to consider differences in vaccine-induced seropositivity between 
women of white ethnicity vs. the combined group of Asian women, women of mixed 
ethnicity and women of other ethnicity. However, we found that the vaccine-induced 
seropositivity varied widely between Asian women and women of mixed and other 
ethnicity (with lower vaccine-induced seropositivity in women of mixed ethnicity and 
of other ethnicity but similar in Asian women compared to white women, Table 2); 
therefore, we did not consider it appropriate to combine their results. Vaccine-
induced seropositivity was also lower in black women compared to white women. 
However, after adjustment for quintile of deprivation and country of birth, these 
differences in vaccine-induced seropositivity by ethnic group were diminished 
(Figure 2 and Supplementary Table 1). In contrast, the lower vaccine-induced 
seropositivity among women born outside of the UK persisted (adjusted OR; 0.58 
(0.44-0.75)), and clear evidence remained of lower vaccine-induced seropositivity in 
more deprived quintiles (p-value for trend<0.0001). Vaccine-induced seropositivity 
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was also lower in women who had a current or previous diagnosis of gonorrhoea or 
chlamydia, but again this was attenuated after adjustment for other factors (Figure 
2).  
The analysis of this surveillance was not powered to consider differences in 
vaccine-induced seropositivity by patient characteristics when stratified by age at 
vaccination. For completeness, these data are included in Figure 2. For women 
offered the vaccine as part of the catch-up (at 14-18 years old), similar to all women, 
there was noticeable lower vaccine-induced seropositivity in older ages, women 
born outside of the UK and in women from more deprived areas. This was less clear 
for women offered the vaccine routinely (at 12-13 years old) although numbers were 
small. 
Case-control study to consider the effect of the bivalent vaccine against genital 
warts 
Analysis of all returned cases and controls (553 cases and 1,548 controls) gave an 
unadjusted odds ratio for vaccination against genital warts diagnoses of 1.08 (95% 
CI 0.88 to 1.34) (Table 3). After adjustment for potential confounding, there 
remained little evidence for a protective effect of the vaccine against genital warts 
(adjusted OR 1.05; 95% CI 0.84 to 1.29). The odds ratios from the matched analysis 
of cases and controls selected using concurrent sampling (thus estimating rate 
ratios; including 281 cases and 644 controls) similarly, showed little evidence of any 
association between vaccine-induced seropositivity and the rate of genital warts 
diagnoses (unadjusted OR 1.05; 95% CI 0.75 to 1.46, and adjusted OR 1.02; 95% 
CI 0.72 to 1.45). 
Sensitivity analyses 
Sensitivity analyses using different cut-offs for seropositivity for HPV16 and HPV18 
(80 MFI and 120 MFI) changed the overall proportion of vaccine-induced 
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seropositivity only slightly (from 65.2% to 68.4% and 62.4% respectively). The 
results of variations by patient characteristics and the odds ratio for vaccination 
against genital warts were similar to the main analysis using these cut-offs (results 
not shown).  
Discussion  
We present two analyses in this paper. Firstly, we have considered HPV vaccine-
induced seropositivity among young women attending sexual health services and 
variations in uptake by certain characteristics. Secondly, with a nested case-control 
study, we have explored the hypothesis, born from earlier ecological observations 
and a post-hoc analysis of clinical trial data, that vaccination with the bivalent 
vaccine confers a protective effect against genital warts. 
The overall vaccine-induced seropositivity in this survey was 65.2% but, as 
expected, this varied by year of collection and age of the woman. Applying age and 
year-specific vaccination coverage estimates from published data[78] the results for 
the women included in our surveillance gave an expected 3-dose vaccination 
coverage of 65.8%. This suggests that vaccine-induced seropositivity in higher-risk 
women attending for HIV and syphilis testing at sexual health clinics is similar to the 
3-dose coverage in the general population. However, the expected proportion of 
women who would have received one or more doses according to national 
published data was 74.3%. Unfortunately, in our surveillance we were not able to 
distinguish between women who were partially vaccinated vs. fully vaccinated. 
Considering the likelihood that partial vaccination would elicit an immune response 
in some women (i.e. some of the women with vaccine-induced seropositivity in this 
surveillance could be a result of receiving fewer than 3 vaccine doses) it seems 
likely that the true vaccination coverage among women attending sexual health 
clinics is lower than in the general population. This could be lower still if some 
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natural infections with both HPV16/18 in this population were wrongly assigned as 
having vaccine-induced seropositivity (discussed further below in the limitations of 
this surveillance). Our surveillance also demonstrates lower vaccine-induced 
seropositivity among women born outside the UK, women from more deprived areas 
and women with a history of chlamydia diagnosis. A difference in uptake by ethnic 
group was especially clear although this seemed to be largely explained by 
differences in deprivation and country of birth. The suggestion that HPV vaccination 
uptake may be lower for women attending sexual health clinics could call for 
consideration of mop-up vaccination in this setting, albeit largely based at this point 
in time on evidence from the catch-up cohorts (i.e. offering the vaccine to women 
aged up to 17 years old attending sexual health clinics, particularly women born 
outside of the UK, women from more deprived areas, or possibly of black women or 
women from other ethnic groups where vaccine-induced seropositivity appeared to 
be lower). Similarly, this raises the importance of ensuring that these women 
participate in cervical screening in the future as unvaccinated women will be at 
higher risk for cervical cancer than vaccinated women. 
Others have considered inequality of HPV vaccination coverage in the UK. Sacks et 
al compared self-reported HPV vaccination status for 2,247 females ages 13-19 
attending sexual health services across England in 2011[141]. This study showed 
lower HPV vaccination coverage compared to the general population. Among those 
offered the vaccine, there was lower completion among black women, women not in 
education, employment or training, women living in London, smokers and those with 
an STI diagnosis. Bowyer et al compared self-collected HPV-vaccination status 
among 1,912 girls in school year 11 (aged 15-16 years old at the time of 
participation) who would have been offered routine HPV vaccine at 12-13 years old. 
The authors demonstrated 3-dose uptake to be lower among black girls, Asian girls 
and girls from other ethnic groups compared to white girls[144]. Two studies 
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compared HPV vaccination among women eligible for routine HPV vaccination 
using data obtained from Child Health Information Systems [145, 146]. Both studies 
showed higher vaccination uptake among white girls compared to other ethnic 
groups. One of these studies (n=2,817) showed lower uptake in more deprived 
areas[145] whereas the other study (n=14,282) showed little evidence of differences 
in vaccine uptake by deprivation[146]. Finally, an ecological study conducted at 
PHE, which compared published estimates of area-level HPV vaccination coverage, 
demonstrated lower coverage in more deprived areas for the older catch-up cohorts 
(women offered the vaccine at 16-18 years old)[82].  
We conducted two analyses for the case-control study to consider the association 
between the bivalent vaccine and diagnoses of genital warts. The odds ratio 
calculated using cases and controls sampled using both exclusive and concurrent 
sampling (including 553 cases and 1,548 controls) could have over-estimated the 
vaccine-effectiveness. We therefore conducted a second, matched analysis 
including only cases and controls selected using concurrent sampling (281 cases 
and 644 controls). In the end, this distinction was less important as we found no 
evidence of an association between HPV vaccine-induced seropositivity and the 
odds (or rate) of genital warts diagnoses using either analysis. These results do not 
support the hypothesis, born from ecological analyses, which showed declines in 
diagnoses of genital warts among women in vaccinated age-groups [84, 159], and 
post-hoc analyses from a clinical trial which also suggested a moderately protective 
effect of the bivalent vaccine against HPV types 6 and 11 combined [74]. However, 
this is consistent with some other findings since the introduction of the HPV 
vaccination programme in England and other countries. A population-based study in 
the Czech Republic compared genital warts acquisition by self-reported vaccination 
status. This study showed no evidence of protection against genital warts from the 
bivalent vaccine[167]. In another study among 1,198 young STI clinic attenders in 
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the Netherlands, the prevalence ratio (PR) for anogenital warts comparing 
unvaccinated women with women vaccinated with at least one dose was 0.67 (95% 
CI; 0.22 to 2.07). In the same population, there was no evidence of any protection 
against HPV types 6 and 11 (adjusted PR 1.03; 95% CI 0.74 to 1.43)[98]. In post-
vaccination surveillance of HPV DNA infection among 15,459 young sexually active 
women in England, there has been no evidence of a change in the prevalence of 
HPV 6/11 infection within the post-vaccination period (paper submitted for 
publication). We have previously discussed alternative explanations for the 
ecological reductions in genital warts but concluded that a moderate protective 
effect of the bivalent vaccine was the most plausible justification as the magnitude 
of other potential explanations were not sufficient to explain the observed 
declines[84, 159]. In light of our results presented in this paper, it seems more likely 
that there is either another unexplored change which caused this decline in genital 
warts at the population level, or that this is a result of more than one change (i.e. a 
combination of more than one of the previously explored explanations).  
These data and analyses have some limitations. Firstly, a limitation of this study 
was the arbitrarily defined cut-offs for seropositivity for the L1 proteins of HPV16 
and HPV18. The numerical MFI value used for cut-off definition was lower than what 
has been used in other studies using the same technology; this was based on a set 
of polystyrene beads with slightly diminished loading capacity. However, sensitivity 
analyses exploring different cut-offs (80 MFI and 120 MFI) made little change to the 
overall conclusions of this manuscript. Furthermore, A comparisons of GST-L1 
multiplex serology with other serological methods has shown excellent correlation 
for both HPV16 and HPV18 with the gold-standard pseudovirion-based 
neutralization assay (PBNA; correlation coefficients of 0.95 and 0.93, 
respectively)[168, 169] and the assay has been utilized in large-scale HPV vaccine 
trials[170]. Secondly, our measure of vaccine-induced seropositivity is likely to have 
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been overestimated as we assumed all women with dual seropositivity had vaccine-
induced seropositivity. Among a sample of lower risk women aged 15-20 years who 
were attending for routine microbiological and biochemical investigations prior to the 
introduction of HPV vaccination around 1.8% were seropositive for both HPV16 and 
HPV18[23]. In this population of women attending a sexual health clinic, this 
proportion can be expected to be higher which would have incorrectly inflated our 
estimates of vaccine-induced seropositivity. Another limitation is that the number of 
residual samples that were requested but not obtained was higher than expected 
(19% compared to 10% expected). As a consequence, our sample size was slightly 
lower than originally planned and our power to consider differences in vaccine-
induced seropositivity between different ethnic groups was therefore lower. Finally, 
we adjusted the case-control analysis for the presence of certain STIs as a proxy for 
sexual behaviour but there may have been other differences in sexual behaviour 
which this adjustment did not address. In addition, past history of STIs in GUMCAD 
is limited as data collection started in 2008 and pseudo-anonymised patient records 
can only be linked within a particular clinic. Therefore, STI diagnoses prior to 2008 
or recorded at different clinics were not identified. 
We should also consider the appropriateness of our control selection. Eligible cases 
and controls in this surveillance all attended one of six sexual health clinics and had 
a blood sample taken for an HIV/syphilis test. However, it is plausible that there are 
some important differences between cases and controls. Firstly, cases were all 
diagnosed with genital warts and were likely to have experienced symptoms. Some 
controls may well have been attending for routine sexual health examinations and if 
this health seeking behaviour also meant that controls were more likely to be 
vaccinated then this could have introduced a potential bias and potential 
overestimation of vaccine effectiveness. Secondly, it’s possible that sexual risk 
could differ between cases and controls, a potential bias if women with genital warts 
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diagnoses are higher risk women who have lower vaccination uptake, as we have 
demonstrated here in our first analysis. Both of these biases would work towards 
showing an apparent protective effect against genital warts (i.e. OR<1 for the 
association of vaccination with genital warts). As we did not see a protective effect, 
these potential biases do not throw doubt on our finding of no protective effect. For 
this finding to be incorrect, we need to suppose a bias that erroneously increased 
the odds ratio towards the null. It is possible that residual negative confounding 
masked a protective effect of the vaccine, but we can think of no plausible 
alternative reason why cases would have higher uptake of vaccination than controls.  
In conclusion, our surveillance does not support a moderate cross-protective effect 
of the bivalent vaccine against genital warts. Vaccine-induced seropositivity in this 
high-risk population is similar to the aggregate national data on 3-dose population 
coverage but lower than the 1-dose uptake. Together with the likelihood of 
overestimation of vaccine-induced seropositivity by our testing method, women 
attending sexual health clinics probably have a slightly lower HPV vaccination 
coverage overall, and in some sub-groups in particular.  
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Table 1: Age at which the bivalent HPV vaccination would have been first offered in the National 
HPV Immunisation Programme, by age and year of sample collection 
Year of sample  
collection 
Age 
16 years old 17 years old 18 years old 19 years old 20 years old 
2011 
12-16 yrs 
n=218 
14-17 yrs 
n=139 
15-18 yrs 
n=209 
16-18 yrs 
n=362 
17-18 yrs 
n=332 
2012 
12-15 yrs 
n=147 
12-16 yrs 
n=93 
14-17 yrs 
n=188 
15-18 yrs 
n=320 
n=0
1
 
2013 
12-13 yrs 
n=101 
12-15 yrs 
n=103 
12-16 yrs 
n=207 
14-17 yrs 
n=279 
n=0
1
 
2014 
12-13 yrs 
n=83 
12-13 yrs 
n=128 
12-15 yrs 
n=203 
12-16 yrs 
n=215 
n=0
1
 
2015 
12-13 yrs 
n=89 
12-13 yrs 
n=137 
12-13 yrs 
n=168 
12-15 yrs 
n=238 
n=0
1
 
Cells shaded red identify women who would have been offered vaccination routinely (at age 12-13 years 
old); cells shaded green identify women who would have been offered vaccination as part of the catch-up 
(at age 14-18 years old); cells shaded grey identify women who may have been offered the vaccine as part 
of the routine or catch-up programme 
1: No residual serum specimens were requested from 20 year old women in 2012 to 2015 
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Table 2: Patient characteristics and estimated HPV vaccine-induced seropositivity 
  
 
All women 
 
Routine vaccination cohorts
1
 Catch-up vaccination cohorts
1
 
  
n (%) 
Vaccine-induced 
seropositivity
2
;  
% (95% CI) 
  n (%) 
Vaccine-induced 
seropositivity;  
% (95% CI) 
n (%) 
Vaccine-induced 
seropositivity;  
% (95% CI) 
Age 
       
  16 years old 638 (16.1%) 72.4% (68.6%, 75.9%) 
 
273 (38.7%) 81.6% (76.2%, 85.9%) 0 (0%) - 
  17 years old 600 (15.2%) 73.1% (69.1%, 76.8%) 
 
265 (37.5%) 81.6% (76.2%, 86.0%) 139 (7.6%) 62.4% (52.8%, 71.2%) 
  18 years old 975 (24.6%) 68.3% (69.5%, 71.5%) 
 
168 (23.8%) 74.5% (66.7%, 81.0%) 397 (21.7%) 56.7% (51.1%, 62.1%) 
  19 years old 1,414 (35.7%) 61.3% (58.5%, 64.2%) 
 
0 (0%) - 961 (52.5%) 54.4% (50.9%, 57.9%) 
  20 years old 332 (8.4%) 44.8% (38.8%, 50.9%) 
 
0 (0%) - 332 (18.2%) 44.8% (38.8%, 50.9%) 
        
Ethnic group 
       
  White 3,217 (82.6%) 68.0% (66.2%, 69.8%) 
 
618 (90.5%) 80.0% (76.4%, 83.1%) 1416 (78.2%) 57.0% (54.0%, 59.9%) 
  Black 357 (9.2%) 49.5% (43.9%, 55.1%) 
 
14 (2%) 85.2% (55.9%, 96.3%) 243 (13.4%) 43.6% (36.9%, 50.5%) 
  Asian 49 (1.3%) 65.9% (50.4%, 78.6%) 
 
9 (1.3%) 88.4% (48.7%, 98.4%) 24 (1.3%) 46.5% (26.1%, 68.2%) 
  Mixed 239 (6.1%) 57.1% (50.2%, 63.9%) 
 
30 (4.4%) 90.7% (69.8%, 97.6%) 116 (6.4%) 41.6% (32.2%, 51.6%) 
  Other
3
 33 (0.8%) 41.2% (25.1%, 59.5%) 
 
12 (1.8%) 60.3% (30.0%, 84.3%) 11 (0.6%) 30.8% (10.3%, 63.2%) 
  Unknown 64 
  
23 
 
19 
         
Country of birth 
       
  UK 3,504 (92%) 66.5% (64.8%, 68.2%) 
 
590 (92.3%) 81.7% (78.1%, 84.7%) 1652 (91.4%) 55.6% (52.9%, 58.3%) 
  Outside of UK 306 (8%) 47.5% (41.4%, 53.6%) 
 
49 (7.7%) 64.0% (49.0%, 76.7%) 156 (8.6%) 37.3% (29.3%, 45.9%) 
  Unknown 149 
  
67 
 
21 
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Quintile of deprivation        
  Q5 (least deprived) 854 (21.6%) 71.0% (67.6%, 74.2%)  168 (23.8%) 84.5% (78.8%, 89.5%) 361 (19.7%) 62.8% (57.2%, 68.0%) 
  Q4 698 (17.6%) 73.5% (69.6%, 77.0%)  136 (19.3%) 83.3% (75.5%, 89.0%) 306 (16.7%) 62.5% (56.0%, 68.7%) 
  Q3 648 (16.4%) 69.2% (65.0%, 73.1%) 
 
137 (19.4%) 80.7% (72.7%, 86.8%) 283 (15.5%) 59.6% (52.9%, 66.1%) 
  Q2 586 (14.8%) 62.6% (58.2%, 66.9%)  96 (13.6%) 77.4% (67.6%, 84.9%) 265 (14.5%) 49.4% (42.7%, 56.1%) 
  Q1 (most deprived) 1,172 (29.6%) 55.5% (52.3%, 58.6%)  169 (23.9%) 73.3% (65.6%, 79.8%) 613 (33.5%) 43.8% (39.5%, 48.2%) 
  Unknown 1 
    
1 
       
Herpes (current or previous attendance) 
       
  No 3,769 (95.2%) 65.2% (63.5%, 66.8%) 
 
676 (95.8%) 79.5% (76.0%, 82.5%) 1729 (94.5%) 53.2% (50.5%, 55.9%) 
  Yes 190 (4.8%) 66.5% (58.9%, 73.4%) 
 
30 (4.2%) 89.0% (70.9%, 96.4%) 100 (5.5%) 62.7% (52.1%, 72.3%) 
        Gonorrhoea (current or previous 
attendance) 
       
  No 3,807 (96.2%) 65.8% (64.1%, 67.4%) 
 
689 (97.6%) 80.1% (76.7%, 83.0%) 1749 (95.6%) 54.2% (51.6%, 56.8%) 
  Yes 152 (3.8%) 53.4% (45.0%, 61.7%) 
 
17 (2.4%) 73.1% (46.4%, 89.5%) 80 (4.4%) 45.3% (34.1%, 57.0%) 
       Chlamydia (current or previous 
attendance) 
       
  No 3,286 (83%) 66.5% (64.7%, 68.3%) 
 
608 (86.1%) 78.9% (75.2%, 82.1%) 1475 (80.6%) 56.0% (53.1%, 58.8%) 
  Yes 673 (17%) 59.5% (55.4%, 63.5%) 
 
98 (13.9%) 86.1% (77.2%, 91.9%) 354 (19.4%) 45.2% (39.6%, 50.9%) 
       Genital warts
4
 (current or previous 
attendance) 
       
  No 3,235 (81.7%) 65.2% (63.6%, 66.9%) 
 
632 (89.5%) 79.9% (76.6%, 82.9%) 1436 (78.5%) 53.8% (51.2%, 56.3%) 
  Yes 724 (18.3%) 67.5% (63.2%, 71.5%) 
 
74 (10.5%) 71.5% (58.0%, 82.1%) 393 (21.5%) 56.3% (51.0%, 61.5%) 
1: Vaccination cohorts determined from age and year at sample collection (see Table 1); routine vaccination cohorts include women offered the HPV vaccine at age 12-13 
years; catch-up vaccination cohorts include women offered the HPV vaccine at age 14-18 years 
2: estimates are weighted to account for the oversampling of specimens from women with genital warts 
3: includes women categorised as "Chinese" or "any other ethnic group" 
4: Women with a diagnosis of genital warts were oversampled for the nested case-control study 
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 Table 3: Odds ratios for the association between bivalent vaccination status and diagnosis of genital warts 
All cases (n=576) and controls (n=1,638) 
 
Analysis restricted to concurrent sampling: 
cases (n=303) and matched controls (n=753) 
OR (95% CI) adjusted for 
matching variables1 
OR (95% CI) adjusted for 
all variables2  
Unadjusted OR                  
(95% CI) 
Adjusted3 OR 
(95% CI)  
n=2,101 n=2,101  n=925 n=925 
1.08 (0.88, 1.34) 1.05 (0.84, 1.29) 
 
1.05 (0.75, 1.46) 1.02 (0.72, 1.45) 
1: adjusted for quarter, age and testing laboratory to account for matching 
2: adjusted for quarter, age, testing laboratory, ethnic group, country of birth, quintile of IMD and diagnosis (past 
or present) with gonorrhoea, chlamydia or herpes 
3: conditional logistic regression adjusted for ethnic group, country of birth, quintile of IMD and diagnosis (past or 
present) with gonorrhoea, chlamydia or herpes 
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Figure 1: Specimen collection and eligibility for different analyses  
 
293 
Figure 2: Adjusted and unadjusted odds ratio for vaccine-induced seropositivity, by patient characteristics 
 
1: Adjusted for ethnicity; quintile of IMD; whether the patient had a concurrent or previous diagnosis of syphilis, gonorrhoea or chlamydia; country of birth (UK 
vs. outside of the UK); age at attendance and year of specimen collection
 294 
 
Supplementary Table 1: Adjusted and unadjusted odds ratio for vaccine-induced seropositivity, by patient characteristics  
 
All women Routine vaccination cohorts
1
 Catch-up vaccination cohorts
1
 
  
Unadjusted OR 
(95% CI) 
Adjusted OR
2
 
 (95% CI) 
Unadjusted OR 
(95% CI) 
Adjusted OR
2
 
 (95% CI) 
Unadjusted OR 
(95% CI) 
Adjusted OR
2
 
 (95% CI) 
Age 
      
  16 years old 1.0 1.0 1.0 1.0 - - 
  17 years old 1.0 (0.8, 1.3) 0.8 (0.6, 1.1) 1.0 (0.6, 1.6) 0.8 (0.5, 1.4) 1.0 1.0 
  18 years old 0.8 (0.6, 1.0) 0.6 (0.5, 0.8) 0.5 (0.3, 0.9) 0.4 (0.2, 0.7) 0.8 (0.5, 1.2) 0.7 (0.4, 1) 
  19 years old 0.6 (0.5, 0.7) 0.5 (0.4, 0.6) - - 0.7 (0.5, 1.1) 0.5 (0.4, 0.8) 
  20 years old 0.3 (0.2, 0.4) 0.4 (0.3, 0.6) - - 0.5 (0.3, 0.8) 0.5 (0.3, 0.7) 
       
Ethnic group 
      
  White 1.0 1.0 1.0 1.0 1.0 1.0 
  Black 0.5 (0.4, 0.6) 0.9 (0.7, 1.2) 1.1 (0.3, 5.0) 1.6 (0.3, 7.5) 0.6 (0.4, 0.8) 1.0 (0.7, 1.4) 
  Asian 0.9 (0.5, 1.8) 1.3 (0.7, 2.4) 1.6 (0.2, 11.2) 2.6 (0.3, 20.7) 0.6 (0.3, 1.5) 0.9 (0.4, 2.2) 
  Mixed 0.6 (0.5, 0.8) 0.9 (0.7, 1.3) 2.0 (0.5, 8.0) 2.3 (0.6, 9.4) 0.5 (0.4, 0.8) 0.8 (0.5, 1.2) 
  Other
3
 0.4 (0.2, 0.7) 0.5 (0.2, 1.0) 0.4 (0.1, 1.2) 0.9 (0.2, 3.7) 0.4 (0.1, 1.3) 0.6 (0.2, 2.4) 
       
Country of birth 
      
  UK 1.0 1.0 1.0 1.0 1.0 1.0 
  Outside of UK 0.5 (0.4, 0.6) 0.6 (0.4, 0.8) 0.5 (0.3, 1.0) 0.6 (0.3, 1.5) 0.5 (0.3, 0.6) 0.6 (0.4, 0.8) 
       
Quintile of deprivation       
  Q5 (least deprived) 1.0 1.0 1.0 1.0 1.0 1.0 
  Q4 1.1 (0.9, 1.4) 1.1 (0.9, 1.4) 0.9 (0.4, 1.7) 0.8 (0.4, 1.6) 1.0 (0.7, 1.3) 1.0 (0.7, 1.4) 
  Q3 0.9 (0.7, 1.1) 0.9 (0.7, 1.2) 0.6 (0.3, 1.1) 0.6 (0.3, 1.1) 0.9 (0.6, 1.2) 0.9 (0.7, 1.3) 
  Q2 0.7 (0.5, 0.8) 0.8 (0.6, 1.0) 0.6 (0.3, 1.2) 0.6 (0.3, 1.2) 0.5 (0.4, 0.8) 0.6 (0.5, 0.9) 
  Q1 (most deprived) 0.5 (0.4, 0.6) 0.6 (0.5, 0.8) 0.5 (0.3, 0.9) 0.4 (0.2, 0.8) 0.5 (0.4, 0.6) 0.6 (0.4, 0.8) 
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Herpes (current or previous 
attendance) 
      
  No 1.0 1.0 1.0 1.0 1.0 1.0 
  Yes 1.1 (0.8, 1.4) 1.2 (0.9, 1.6) 2.1 (0.7, 6.4) 1.7 (0.5, 5.4) 1.5 (1.0, 2.2) 1.6 (1.0, 2.4) 
       Gonorrhoea (current or previous 
attendance) 
      
  No 1.0 1.0 1.0 1.0 1.0 1.0 
  Yes 0.6 (0.4, 0.8) 1.2 (0.9, 1.6) 0.7 (0.2, 2.0) 0.8 (0.3, 2.5) 0.7 (0.5, 1.1) 0.9 (0.6, 1.4) 
       Chlamydia (current or previous 
attendance) 
      
  No 1.0 1.0 1.0 1.0 1.0 1.0 
  Yes 0.7 (0.6, 0.9) 0.9 (0.7, 1.0) 1.7 (0.9, 3.0) 1.5 (0.8, 2.8) 0.6 (0.5, 0.8) 0.7 (0.6, 0.9) 
       
1: Vaccination cohorts determined from age and year at sample collection (see Table 1); routine vaccination cohorts include women offered the HPV vaccine at age 12-13 
years; catch-up vaccination cohorts include women offered the HPV vaccine at age 14-18 years 
2: Adjusted for ethnicity; quintile of IMD; whether the patient had a concurrent or previous diagnosis of syphilis, gonorrhoea or chlamydia; country of birth (UK vs. outside of the  
UK); age at attendance and year of specimen collection 
3: includes women categorised as "Chinese" or "any other ethnic group" 
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8.5. Additional discussion of the serological surveillance  
The above sections include the results from two serological surveillance studies (the 
SEU serosurveillance in Sections 8.2 and 8.3, and the serosurveillance among 
sexual health clinic attenders in Section 8.4). There were some limitations of the 
SEU serosurveillance, notably the assumption that the women included in this 
surveillance were representative of the general population. I discuss this along with 
other limitations in the paper and report presented in Sections 8.2 and 8.3. What 
follows below, are more specific issues relating to the serosurveillance among 
sexual health clinic attenders.  
There were three key elements of the serosurveillance among sexual health clinic 
attenders which were not conducted as originally planned. The first was the change 
from exclusive sampling to concurrent sampling of cases and controls. The rationale 
and implications for this change was described in the Section 7.5.4. I presented 
results using each sampling technique in Section 8.4 and, as highlighted in the 
paper, the results using both approaches were very similar. I also discuss this in the 
paper (Section 8.4) so I do not discuss further here. The second and third changes 
relate to the HPV assay and were outside of my control. The change from using the 
VLP-based ELISA assay to the Luminex-based GST-T1 multiplex serology assay 
(described in Section 7.4.5) was unfortunate as this delayed testing. However, the 
more serious issue was that, due to a problem encountered by the laboratory with 
the testing, the results from this assay were not able to provide a quantifiable 
measure of antibody concentration. This was described in detail in Section 7.4.6 
and meant that the only approach available for this analysis was to assume all 
women with dual seropositivity for HPV16 and HPV18 had vaccine-induced 
seropositivity, rather than to delineate women with possible or probable vaccine-
induced seropositivity based on their antibody concentrations, as described in 
Section 7.3.3. The implications of the potential misclassification of vaccination 
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status are described below. I also provide a more detailed discussion of other 
limitations of this surveillance and potential biases for the nested case-control study.  
8.5.1. Potential misclassification of vaccination status in the 
serosurveillance among sexual health clinic attenders 
As described above, I assumed all women with dual seropositivity for HPV16 and 
HPV18 had vaccine-induced seropositivity for the serosurveillance among sexual 
health clinic attenders in Section 8.4. However, serological data from the PHE SEU 
which were tested prior to the introduction of HPV vaccination demonstrated that 
1.8% (95% confidence internal: 0.9%-3.4%) of 15-19 year old women were 
seropositive for both HPV16 and HPV18 due to natural infection. The women 
included in the serosurveillance among sexual health clinic attenders in this thesis 
are likely to have an even higher risk of dual seropositivity following natural 
infection. Therefore, by assuming that all women seropositive for HPV16 and 
HPV18 had vaccine-induced seropositivity, I will have likely overestimated the true 
HPV vaccination coverage in this population.  
In Table 8.1, the estimated extent of potential overestimation of vaccine-induced 
seropositivity is presented. I considered varying levels of natural infection of 0% (i.e. 
no overestimation), 1.8% (the pre-vaccination prevalence of natural infection in the 
SEU data), 3.0%, 4.5% and 6.0%. I also considered, as suggested in Section 8.4, 
that women at higher risk of HPV infection could be less likely to be vaccinated, with 
relative risks of natural infection compared to unvaccinated women of 1.0 (i.e. 
assuming natural infection is not associated with vaccination), 0.9, 0.8 and 0.7. 
Estimated true vaccination coverage was calculated as follows: 
 !""#$%&"'(%)!*% !" =
#$%&'(&)*(+,,-.&*,/(&'+0& 1*2345
6 1*2345
 
7+,,-.&*,/(&'+0&345 = 88 9*
#$%&'(&)*(+,,-.+:-/.*,/(&'+0& 1*2345
6 1*2345
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hence; 
;'<&*(+,,-.&*,/(&'+0&
= 7+,,-.&*,/(&'+0& !" 9 >6 1 2345? @*7+,,-.&*,/(&'+0&345 9 A2345B 
Where; 
#$%&'(&)*(+,,-.&*,/(&'+0& is 65.2% in the surveillance included in this thesis 
(i.e. the proportion with vaccine-induced seropositivity) 
 2345 is the proportion of women who would have natural seropositivity for HPV16 
and HPV18 in an unvaccinated population 
7+,,-.+:-/.*,/(&'+0& !" is the vaccination coverage in women without natural 
seropositivity for HPV16 and HPV18 
7+,,-.+:-/.*,/(&'+0&345 is the vaccination coverage in women with natural 
seropositivity for HPV16 and HPV18 
88 is the relative risk of HPV vaccination in women with natural seropositivity 
compared to women without natural seropositivity 
In the most extreme scenario, with 6% of the population having dual seropositivity 
from natural infection and a 30% lower risk of being vaccinated in women with 
natural infection, the estimated true vaccination coverage was 61.8% compared to 
the observed coverage of 65.2%. This suggests that even in a worst-case scenario, 
the overestimation of true vaccination coverage in Section 8.4 is less than 5%. 
As well as considering overestimation of vaccination coverage, I also considered the 
impact of misclassification of vaccination status on the results of the nested case-
control study. If this was non-differential misclassification of vaccination status (i.e. 
inaccurately assigning a woman as vaccinated was unrelated to having genital 
warts) then this bias would likely have resulted in an underestimate of the vaccine 
effectiveness. However, it is likely that those with inaccurate recording were from 
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higher-risk populations with a higher risk of dual seropositivity from natural infection. 
If these women were also more likely to be diagnosed with genital warts, then this 
differential misclassification bias would tend to overestimate any protective effect of 
the bivalent vaccine against genital warts and thus would not explain the lack of 
protective effectiveness which was seen.  
The results of the above section suggest that this misclassification is unlikely to 
have had a large impact on the results of the serosurveillance among sexual health 
clinic attenders presented in Section 8.4. However, it is a limitation of this analysis 
that I was not able to use a similar approach as the one I developed for the SEU 
serosurveillance to ascertain probable vaccine-induced seropositivity based on 
antibody concentrations (see Section 7.3.3). As described in Section 7.4.6, the 
reason that antibody concentrations could not be assessed for the serosurveillance 
among sexual health clinic attenders was due to an unexpected degradation of the 
polystyrene beads used in the assay. Therefore, my colleagues at PHE and I are 
currently considering options to have these residual specimens re-tested to address 
this limitation. Future re-testing of specimens would enable updating of the analysis 
presented in Section 8.4.
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Table 8.1: Potential misclassification of vaccination status for serosurveillance among sexual health clinic attenders. Numbers are 
estimated vaccination coverage in different scenarios 
Relative risk of being 
vaccinated in women with 
natural dual seropositivity1 
Proportion of women with natural seropositivity for HPV16 and HPV18 in an unvaccinated 
population 
0.0% 1.8% 3.0% 4.5% 6.0% 
1.0 65.2% 64.6% 64.1% 63.6% 63.0% 
0.9 65.2% 64.4% 63.9% 63.3% 62.6% 
0.8 65.2% 64.3% 63.7% 63.0% 62.2% 
0.7 65.2% 64.2% 63.5% 62.7% 61.8% 
1: The relative risk of HPV vaccination in women with natural seropositivity compared to women without natural seropositivity 
 301 
 
8.5.2. Potential bias due to missing data and unmeasured confounding in 
the serosurveillance among sexual health clinic attenders 
There were missing data for ethnicity, IMD and/or country of birth for around 5% of 
women included in the serosurveillance among sexual health clinic attenders. In 
Table 8.2, I compared the patient characteristics for all women with the patient 
characteristics for women with and without missing data. IMD was only missing for 
one woman (who also had missing data on both ethnicity and country of birth). 
Women with missing data for ethnicity were far more likely to have missing data for 
country of birth compared to women with non-missing ethnicity data (34.4% vs. 
3.3% respectively) and vice versa. However, reassuringly patient characteristics 
were similar for all women and for women with no missing data (the latter group 
being those used for regression analyses).  
Table 8.2: Patient characteristics among all women, women with no missing 
data and women with missing data for at least one variable 
 
All women 
(n=3,959) 
Women with no 
missing data 
(n=3,768) 
Women with 
some missing 
data (n=191)
1
 
 
n (%) n (%) n (%) 
Age 
     16 years old 638 (16.1%) 614 (16.3%) 24 (12.6%) 
  17 years old 600 (15.2%) 549 (14.6%) 51 (26.7%) 
  18 years old 975 (24.6%) 930 (24.7%) 45 (23.6%) 
  19 years old 1414 (35.7%) 1348 (35.8%) 66 (34.6%) 
  20 years old 332 (8.4%) 327 (8.7%) 5 (2.6%) 
    Ethnic group 
     White 3217 (82.6%) 3112 (82.6%) 105 (82.7%) 
  Black 357 (9.2%) 347 (9.2%) 10 (7.9%) 
  Asian 49 (1.3%) 44 (1.2%) masked
5
 
  Mixed 239 (6.1%) 233 (6.2%) 6 (4.7%) 
  Other
3
 33 (0.8%) 32 (0.8%) masked
5
 
    Country of birth 
     UK 3504 (92%) 3476 (92.3%) 28 (66.7%) 
  Outside of UK 306 (8%) 292 (7.7%) 14 (33.3%) 
    Quintile of deprivation 
     Q1 (most deprived) 1172 (29.6%) 1112 (29.5%) 60 (31.6%) 
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  Q2 586 (14.8%) 555 (14.7%) 31 (16.3%) 
  Q3 648 (16.4%) 623 (16.5%) 25 (13.2%) 
  Q4 698 (17.6%) 651 (17.3%) 47 (24.7%) 
  Q5 (least deprived) 854 (21.6%) 827 (21.9%) 27 (14.2%) 
    Herpes (diagnosed at current or 
previous attendance) 
     No 3769 (95.2%) 3587 (95.2%) 182 (95.3%) 
  Yes 190 (4.8%) 181 (4.8%) 9 (4.7%) 
    Gonorrhoea (diagnosed at current 
or previous attendance) 
     No 3807 (96.2%) 3623 (96.2%) 184 (96.3%) 
  Yes 152 (3.8%) 145 (3.8%) 7 (3.7%) 
    Chlamydia (diagnosed at current or 
previous attendance) 
     No 3286 (83%) 3116 (82.7%) 170 (89%) 
  Yes 673 (17%) 652 (17.3%) 21 (11%) 
    Genital warts
4
 (diagnosed at 
current or previous attendance) 
     No 3235 (81.7%) 3070 (81.5%) 165 (86.4%) 
  Yes 724 (18.3%) 698 (18.5%) 26 (13.6%) 
1: Women missing data for ethnicity (n=64), IMD (n=1) or country of birth (n=149) 
2: estimates are weighted to account for the oversampling of specimens from women with genital warts 
3: includes women categorised as "Chinese" or "any other ethnic group" 
4: Women with a diagnosis of genital warts were oversampled for the nested case-control study 
5: In accordance with PHE data sharing policy, cells with values between 1 and 4 inclusive were masked.  
If masked cells could be deduced from values of other cells then the next smallest cell was also masked 
 
An additional consideration is the potential effect of unmeasured sexual risk 
behaviour on the results of the serosurveillance among sexual health clinic 
attenders. I partially controlled for differences in sexual behaviour by adjusting for 
the presence of sexually transmitted infections (either at the current or at previous 
attendances) as a proxy. However, similarly to the analyses in Chapter 6, there are 
likely to have been other differences in sexual behaviour which were not addressed 
by adjusting for these STIs. A further complication in this surveillance is the potential 
underestimation of previous history of STIs using GUMCAD. GUMCAD data contain 
a pseudo-anonymised patient identifier to allow patient records within the same 
clinic to be linked to previous visits and STI diagnoses. However, no information on 
previous diagnoses or attendances made at other clinics is available. Furthermore, 
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GUMCAD data recording only started in 2008, so attendances and diagnoses 
before this date are not recorded. If the previous history of STIs were 
underestimated then this would mean there was further potential for residual 
confounding due to unmeasured differences in sexual behaviour. In this analysis, 
misclassification of the previous history of STIs could have resulted in residual 
confounding of both the analysis of variations in vaccine-induced seropositivity by 
patient characteristics and the estimation of vaccine effectiveness against genital 
warts. The effect of misclassification of a confounder varies according to whether 
the misclassification is non-differential or differential. In general, non-differential 
misclassification attenuates the adjustment of the confounder and the direction of 
the bias would depend on the direction of this confounding. The direction and 
magnitude of potential bias due to non-differential misclassification is harder to 
predict. For these analyses, it is difficult to know the extent to which unmeasured or 
underestimated sexual risk behaviour could have biased the reported results as 
there are limited data on the extent to which patients move between different sexual 
health clinics and whether this varies by patient characteristic.  
8.5.3. Selection of controls for nested case-control study 
There are further considerations about the appropriateness of the controls selected 
for the nested case-control study to investigate the potential protective effect of the 
bivalent vaccine against genital warts. Firstly, there is the possibility that controls 
may have been previously diagnosed with genital warts but that this was 
unrecorded. As described in the previous section, GUMCAD data are only able to 
identify previous STIs diagnosed at the same sexual health clinic since 2008. 
Controls could therefore have been previously diagnosed with genital warts and 
hence, according to the sampling described in Section 7.5.4, would not have been 
an eligible control for this case-control study. If controls who had an unrecorded 
previous diagnosis of genital warts were less likely to be vaccinated than correctly 
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classified controls (in line with the hypothesis that vaccination protects against 
warts) then this could have underestimated the vaccine effectiveness estimates. 
Conversely, if controls with a previous diagnosis of genital warts were more likely to 
be vaccinated than other controls (for example, if a previous diagnosis of warts 
prompted these women to get vaccinated) then their inclusion would have 
overestimated the vaccine effectiveness. As in the previous section, it is difficult to 
quantify this potential effect as there are limited data on the proportion of women 
who attend multiple sexual health clinics (and who therefore could have been 
diagnosed elsewhere prior to their attendance). Given that the results presented in 
the paper in Section 8.4, provided no evidence that the vaccine protected against 
genital warts, the former scenario (underestimation of vaccine effectiveness) is 
more pertinent. However, it seems unlikely that this could have entirely explained 
the lack of vaccine effectiveness found, as it would necessitate a large proportion of 
controls to have a previous history of genital warts and for these women to have 
similar odds of vaccination as the cases.  
Secondly, as previously described in Section 7.5.2, the vast majority of women who 
present to health services with genital warts will attend a sexual health clinic[156] 
although there is limited information on the proportion of women with genital warts 
who do not attend any health services. A suitable control should be sampled from 
the population that gave rise to the cases (i.e. sexual health clinic attenders) and 
sampled independently of their exposure status (i.e. HPV vaccination). If these two 
principles are not met, this can lead to selection bias. Eligible women in this 
surveillance attended a sexual health clinic and had a blood sample taken for an 
HIV/syphilis test. Therefore, the first of these principles seems appropriate as 
controls attended the same sexual health clinic as the cases. The second of the 
above principles is less clear; cases with genital warts will almost certainly have 
been aware of their infection and may well have been attending the sexual health 
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clinic specifically for this purpose. Conversely, controls may have attended for other 
reasons; some controls may have attended for a symptomatic STI (other than 
genital warts); others may have been asymptomatic (regardless of whether they had 
another STI) and therefore may have attended due to a potential exposure to an STI 
or simply for a general sexual health check. If the latter women’s health seeking 
behaviour extended to vaccination then the selected controls could have had a 
higher uptake of HPV vaccine than the background population, and this could have 
resulted in an overestimate of vaccine effectiveness. Again, given that the results in 
Section 8.4 did not demonstrate a protective effect of the bivalent vaccine against 
genital warts, overestimation of vaccine effectiveness is less of a concern here.  
This concludes the findings of this thesis, including both the surveillance of HPV 
DNA infection and the serological surveillance. In the following chapter (Chapter 9), 
I summarise the overall findings from these studies and what these add to prior 
knowledge. I also discuss the overall strengths and limitations of the data sources 
used and how the studies were conducted. Finally, I consider the implications of the 
findings for prevention of HPV and for future research.
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Chapter 9: Discussion 
9.1. What this PhD adds to prior knowledge 
I review below what was known prior to the start of this PhD and what the results of 
this PhD add to current understanding (either within England specifically or within 
the wider context). 
9.1.1. Post-vaccination HPV infection surveillance (Chapters 3 to 6, 
Research questions 1 to 3) 
What was already known? 
The clinical trials for the bivalent vaccine demonstrated a very high prophylactic 
efficacy against HPV infection with vaccine types as well as some evidence of 
vaccine efficacy against some closely related high-risk HPV types, although the 
latter was less consistent across studies. However, the results from these 
randomised controlled trials told us little about the potential impact of national 
vaccination in a population setting which will differ for many reasons; (i) vaccinated 
women may not receive the vaccine according to the recommended timing, (ii) in a 
non-randomised setting there may be some inequalities in vaccination uptake which 
could affect the population-level impact, (iii) in population settings, particularly in 
countries with high vaccine coverage, there may be a herd protection effect in 
addition to the direct effect from vaccination, and (iv) there is potential for type 
replacement (i.e. non-vaccine types becoming more common in vaccinated 
populations). This latter effect was not seen in clinical trials although many trials 
were limited in population size and/or duration of follow-up which would limit the 
ability to detect changes in the prevalence of less common HPV types over time. It 
is important for population level surveillance to monitor infection with non-vaccine 
types to either quantify type-replacement if it does exist, or, to reinforce confidence 
in the vaccine and national programme if there is no evidence of type-replacement. 
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The UK introduced a national HPV vaccination programme for females from 
September 2008. Other countries introduced HPV vaccination with a similar 
timeframe to the UK and some of these countries vaccinated in similar settings and 
achieved similar vaccination coverage to the UK. As such, relevant information on 
the evaluation of HPV vaccination has not necessarily been restricted to data from 
the UK but also elsewhere in the world. Some early results of post-vaccination 
surveillance had been published at the start of this PhD. In the USA, there was 
some early evidence demonstrating declines in the vaccine-type HPV 
prevalence[87, 88, 171]. However, the vaccination coverage in the USA was much 
lower than in England hence these results were less relevant for our population. 
Australia had a more similar setting to the UK with vaccination coverage closer to 
coverage in England for routinely vaccinated women. The first data considering the 
impact of HPV vaccination on vaccine HPV types in Australia were published in 
October 2012[172]. This interim analysis of samples from 404 women demonstrated 
a substantial decrease in vaccine-targeted genotypes. Both the USA and Australia 
introduced the quadrivalent vaccine to their national programmes. In England, we 
published the first results of national HPV surveillance conducted by PHE in July 
2013, the same month that this PhD started. This was the first evidence of 
reductions in the prevalence of HPV16/18 infection following introduction of a 
national bivalent vaccination programme.  
What this thesis adds? 
The national surveillance of type-specific HPV prevalence in England has added to 
the evidence of substantial reductions in HPV vaccine-type prevalence following 
introduction of a national vaccination programme (Chapter 6). The analyses 
comparing HPV vaccine-type prevalence among women with a known vaccination 
status in Section 6.3 suggest that these declines were due to direct protection of the 
vaccine (i.e. high vaccine effectiveness) and indirect herd protection. Because many 
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countries are conducting similar surveillance in their own countries this PhD has 
been well timed to add to international data as well as providing necessarily specific 
results to evaluate the programme in England. One notable difference of the UK 
national vaccination programme compared to other countries is that it was the first 
country to exclusively use the bivalent HPV vaccine in its national programme. 
Although the vaccine used was changed to the quadrivalent vaccine in 2012, there 
are nine birth cohorts of vaccinated women who were vaccinated with the bivalent 
vaccine and this offers an opportunity to monitor the impact of this vaccine on HPV 
infection and early disease outcomes. This is of particular interest when considering 
cross-protection as results from clinical trials suggested some differences in vaccine 
efficacy against non-vaccine types between the two vaccines[76]. The most recent 
analysis of national surveillance in England presented in the paper in Section 6.3 
demonstrate greater declines in HPV31, 33 and 45 infection than those seen in 
countries introducing the quadrivalent vaccine. This is consistent with recent 
evidence from Scotland which has also shown substantial cross-protection[95].  
This thesis also includes results from an international systematic review that 
examined the evidence for changes in non-vaccine types following HPV vaccine 
introduction. Combining the data using meta-analysis allowed exploration of 
changes in rarer non-vaccine types which could not be done in individual 
surveillance studies with limited sample sizes. This was the first meta-analysis to 
investigate changes in individual non-vaccine types and it did not provide any clear 
evidence for type replacement; an important finding to give reassurance that the 
vaccine is not only reducing vaccine-types but that vaccination is not leading to 
large increases in HPV infections with other high-risk types. This was also 
supported by updated results from the post-vaccination HPV infection surveillance 
in England which showed a relatively stable prevalence of non-vaccine and non-
cross-protective high-risk types in the post-vaccination period (Chapter 6). 
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9.1.2. Immune response to the vaccine (Chapter 7 and 8, Research 
question 4) 
What was already known?  
Vaccination coverage in England was (and still is) reported nationally using local 
data. At the start of this PhD, 3-dose vaccine coverage for the routine cohorts was 
consistently reported to be above 80% but coverage for the catch-up cohorts was 
more variable (70.8% and 75.7% for younger catch-up cohorts largely vaccinated at 
schools; 38.9%, 47.4% and 48.1% for older catch-up cohorts vaccinated in different 
education and primary care settings). These national coverage data were stratified 
by birth cohort and local area but not by any other factors (e.g. ethnicity). If there 
were inequalities in delivering the vaccine then this could potentially affect the level 
of herd protection, leaving some population subgroups at a higher risk of 
subsequent HPV-related disease. Other studies have considered inequities of 
vaccination uptake but most were restricted to one local area and all relied on either 
self-collected vaccination status or CHIS data[82, 141, 144-146]. Therefore, there 
were no nationally representative and technically robust data to address whether 
there was different vaccine coverage in different sup-populations in England.  
What this thesis adds? 
The two serosurveillance studies included in this thesis are the first to estimate 
vaccine coverage in England using serological data. The data for the first of these 
two analyses were from a population which can be considered to approximate the 
general population (Sections 8.2 and 8.3) which is an additional strength of this 
analysis. These data confirm high coverage and immune response in younger 
women but an important finding that the proportion of women with an immune 
response in the older vaccination cohorts was slightly higher than national data 
suggests. This could be due to higher vaccine coverage which was not reported by 
local areas or a higher immune response in the partially vaccinated at older ages. A 
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more likely explanation is that this is due to a combination of both of these factors. 
Whilst it was anticipated that there may be some under-reporting in older catch-up 
cohorts, largely vaccinated outside of schools, the results from this surveillance are 
the first evidence of this. The analyses of these data also demonstrated that 
although there was some waning of antibody concentrations over time since 
vaccination, these remained far higher than the immune response following natural 
infection up to five years post-vaccination. 
I also looked at immune response in a higher-risk population attending sexual health 
clinics to estimate vaccine uptake in this group and I compared uptake within 
subgroups of this high-risk population to identify if there were any inequalities in 
vaccine uptake (Section 8.4). This is not unique in itself, as one questionnaire-
based study previously had considered HPV vaccination uptake in sexual health 
settings in England[141]. However, the analyses in this thesis do represent the only 
UK study to use serological data to monitor HPV immune response following 
vaccination. A relatively high proportion of women in this surveillance had an 
immune response to the vaccine types which was comparable to the proportion 
receiving 3-doses in the nationally published data. This surveillance also 
demonstrated lower vaccination uptake among women born outside of the UK, 
women from more deprived areas and women with a history of chlamydia diagnosis. 
There was lower uptake in some ethnic groups (black, mixed and other ethnicity) 
although this was less clear after adjustment for quintile of deprivation (IMD) and 
country of birth. 
9.1.3. Does the bivalent vaccine protect against genital warts? (Chapter 7 
and 8, Research question 5) 
What was already known? 
A post-hoc analysis of the PATRICIA clinical trial examined vaccine efficacy against 
low-risk HPV types[74]. These analyses showed a vaccine efficacy against low risk 
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types HPV6/11 of 34.5% (95% CI; 11.3-51.8). The evaluation of whether the 
bivalent vaccine had any impact on diagnoses of genital warts in a population 
setting could be uniquely investigated in England for two reasons; (i) the UK was 
one of very few countries who adopted exclusively the bivalent vaccine, and (ii) 
England have data on all attendances and diagnoses of all individuals attending 
sexual health clinics in England (where an estimated 95% of GW diagnoses are 
seen[156]). Ecological analysis of trends in genital warts diagnoses in England over 
time had suggested an association between increasing HPV vaccination coverage 
and modest declines in the diagnoses of genital warts in females[84], supporting the 
results from the post-hoc analysis of the PATRICIA trials.  
What this thesis adds? 
The analyses of the case-control study demonstrated no evidence of a protective 
effect of the bivalent HPV vaccine against acquisition of genital warts. Previous 
investigation of this research question at PHE had relied on ecological data. The 
results of this case-control study are less affected by other potential changes over 
time in sexual behaviour and service delivery at sexual health clinics and provide 
more reliable evidence. Whilst these results are inconsistent with the ecological 
findings in the UK (Sections 7.5.1) they are consistent with our findings of no 
changes in HPV6/11 prevalence within the post-vaccination period (Section 6.3). 
9.2. Overall strengths and limitations of this PhD  
In this thesis, I have presented results from different surveillance and 
epidemiological studies to consider several research questions. I have addressed 
specific limitations for each separate study and surveillance activity in Chapters 3, 6 
and 8. One common factor throughout all the research conducted is the use of (i) 
routinely collected data, and (ii) residual specimens collected originally for other 
purposes. Such approaches come with their own unique strengths and limitations 
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which I explore below, along with some of the other overall strengths and limitations 
of this thesis. 
9.2.1. Opportunistic use residual specimens and routinely collected data 
Strengths: Many of the surveillance activities included in this thesis made use of 
routinely collected data which were linked prior to anonymisation and testing of 
residual specimens taken for other purposes. Data sources used in this thesis 
included the NCSP dataset, CTAD dataset, SEU dataset, GUMCAD and some 
additional linkage to Child Health Information Systems, general practices and the 
Office for National Statistics population data. The use of routinely collected data is 
relatively quick and cheap compared to primary data collection and allowed us to 
make use of the strengths of each different data source. Patient data could be used 
to determine surveillance eligibility. In addition, data on patient characteristics could 
be incorporated into multivariable models to control for potential confounding. 
Similarly, the use of residual samples allows collection of a large number of samples 
within a fairly short time frame and is relatively quick and cheap to establish. 
Furthermore, as the use of residual samples for surveillance to monitor the impact 
of national vaccination programmes falls under PHE’s remit of public health 
monitoring, individual patient consent is not required. This provides the additional 
strength that, although the populations sampled may not be fully representative of 
the entire target population, there is less potential for the selection bias introduced 
by patient refusals.  
Limitations: In using residual samples for HPV DNA and serology testing, there are 
some limitations. Firstly, it is necessary to identify a suitable sample type. For 
example, HPV DNA testing of urine is known to have a lower sensitivity for HPV 
detection in females than cervical specimens or vulva-vaginal swabs specimens. 
We also require a residual sample which has been stored correctly and has 
sufficient volume for the relevant testing platform. Using residual samples, we may 
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expect a higher proportion of inadequate samples due to insufficient volume or 
degradation of the sample collected outside of optimal conditions. Secondly, it is 
important to identify a suitable population. To determine changes in the prevalence 
HPV infection due to vaccination as soon as possible, it is necessary to identify a 
population of young women having suitable samples taken for other purposes. 
Collection of genital samples in young women restricted the choice to higher-risk 
populations of women attending sexual health services to be screened for sexually 
transmitted infection. I discuss below the strengths and limitations of conducting 
surveillance in high-risk populations (Section 9.2.3). Another limitation is that, within 
these populations, these are women with health seeking behaviour and those with 
even higher risk may not attend such settings. 
There are also limitations using routinely collected data. Patient data are restricted 
to what is collected in the routine datasets so data could not be tailored to answer 
particular questions. For all surveillance activities included in this surveillance there 
are potential confounders which could not be adjusted for as the data were not 
available. This availability often changes as routine data collection is adapted over 
time so is sometimes not consistent within the surveillance. This was a limitation 
with the analysis of data from women attending for chlamydia screening with the 
change from the NCSP dataset (which collected data on sexual behaviour) to CTAD 
(which had no data on sexual behaviour). Another limitation is the often high 
proportion of missing data for data fields which are not mandatory. For example, 
ethnicity was missing for a considerable proportion of specimens and therefore 
could not be included in the analysis of the HPV infection surveillance (Chapter 6). 
Finally, as described in Section 5.1.1, there was no single source of routinely 
collected data which held individual-level HPV vaccination status data. This was a 
limitation for all of the surveillance activities included in this thesis. Firstly, for the 
HPV DNA surveillance (Chapter 6), this restricted the main analysis to considering 
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individual level outcomes (i.e. HPV prevalence) but ecological level exposure. 
Linkage to CHIS records was only possible for a relatively small proportion of 
women included in this surveillance which limited the ability to directly compare HPV 
prevalence in vaccinated and unvaccinated women (this is discussed further in the 
following section). Secondly, for the serological surveillance (Chapter 8), I 
determined probable vaccine status based on antibody concentrations for HPV16 
and HPV18. Whilst this appeared to provide a robust proxy, I was unable to formally 
compare immune responses in known vaccinated vs. known unvaccinated women 
to validate this approach. 
9.2.2. Collection of HPV vaccination status data 
Strengths: Comparing HPV prevalence between the pre-vaccination and post-
vaccination period or over time within the post-vaccination period provides important 
evidence of the population-level impact of HPV vaccination. However, this does not 
provide an estimate of the direct effect in vaccinated women compared to 
unvaccinated women (i.e. vaccine effectiveness). Collection of HPV vaccination 
status had been proposed prior to the start of this PhD but, due to the complications 
of data collection, the first data were not collected until 2014, as described in this 
thesis. Analyses of this data have not only allowed estimation of vaccine 
effectiveness in England but also allow estimation of the effect of herd protection 
among unvaccinated women. 
Limitations: Other countries have national registers which collect and store HPV 
vaccination records for all women (for example, Scotland have a national 
vaccination register which can be linked using individuals’ Community Health Index 
(CHI) number). In England, there is no national vaccination register; data are 
collected on different systems depending on where vaccination took place and 
these are collated only at a local level. I have described these limitations in detail in 
Chapter 5. The lack of a national database for vaccination records has meant that in 
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the final analysis of the HPV DNA surveillance, vaccination status data were only 
available for 21% of women eligible to receive the vaccine. As touched upon in the 
previous section, this affected my ability to estimate accurately the direct effect of 
the HPV vaccine.  
9.2.3. Monitoring the impact of HPV vaccination in high-risk populations  
Strengths: Serological surveillance in this thesis was conducted in both a high-risk 
population of women attending sexual health clinics and a more representative 
population; the appropriateness of the latter assumption for women having blood 
taken was discussed in Section 8.2. This allowed direct comparison of HPV immune 
response in the two populations. For the HPV DNA surveillance, women attending 
for chlamydia screening have a higher risk of chlamydia infection and hence likely 
also have a higher risk of HPV infection. This increases the power to look at 
changes in vaccine and related HPV types sooner than would be possible in lower 
risk populations. It is also encouraging that an impact on HPV infection is being 
seen among women at higher risk for HPV infection (and therefore subsequent HPV 
related disease). This reassures that there is not an inequality in vaccination of 
higher risk women. 
Limitations: It is likely that if reductions in the prevalence of HPV infection are seen 
in high-risk populations then there will be reductions in the lower-risk populations. 
However, restricting analyses to higher risk women could potentially limit the 
representativeness of results of impact on infection and HPV vaccination uptake for 
the general population. 
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9.3. Implications for primary prevention of HPV and related 
diseases  
9.3.1. Continuation of HPV vaccination of females  
The main aim of the HPV vaccination programme is to reduce the incidence of 
cervical cancer. When the vaccine was introduced in 2008 for 12-18 year olds, 
dramatic declines in cervical cancers were not expected for several years given the 
peak age of cancers in England at around 25-29 years old[37]. Therefore, to wait for 
cancer registration data to demonstrate whether the vaccine is having an impact on 
HPV infection or disease would take at least 10 years since introduction to see the 
early impact of the programme, and even longer to see substantial declines. To wait 
10 years whilst offering vaccination to all eligible females (approximately 250,000 
routinely vaccinated women per year in England) before any data on the population 
level impact of the vaccine would clearly be unacceptable given the costs of 
vaccination. HPV vaccines are expensive compared to many other vaccines; 
although in England the price paid for the vaccine is kept confidential, in other high-
income countries the HPV vaccines is one of the most expensive vaccines included 
in their national programmes[173]. By examining changes in HPV infection in 
younger women, this thesis provides earlier reassurance that there will very likely be 
a substantial reduction in the incidence of cervical disease and cervical cancer in 
England as vaccinated women reach the screening age and peak age of cervical 
cancer incidence. One concern of course is that the reductions in vaccine types and 
other closely-related HPV types may lead to other types becoming more common. 
This was seen following vaccination for pneumococcal infection[174]. Type 
replacement is considered less plausible for HPV due to the lower genetic mutation 
rate, but it is still important to remain vigilant for potential increases in non-vaccine 
types. Data from both the systematic review (Chapter 3) and considering changes 
within the post-vaccination period (Section 6.3) are consistent with there being no 
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clear evidence of type-replacement to date although ongoing monitoring of this is 
needed.  
In light of all the positive evidence in this PhD, and from similar work conducted 
elsewhere in the world, the evidence is clear that an HPV vaccination programme 
should continue in England. I cover below how the results from this thesis may 
inform potential changes to how HPV vaccination is delivered. 
9.3.2. Targeting groups with lower vaccination coverage 
As described above, this thesis has shown some inequities in HPV vaccination 
uptake in some subgroups. This is of particular concern if women with lower HPV 
vaccination uptake are also women with lower cervical screening uptake as this will 
only widen this health inequality. If the HPV vaccine only provided a direct 
protection against HPV then these inequities would mean that an 80% reduction in 
HPV16/18 infections in the screened population may not necessarily transfer to an 
80% reduction in HPV16/18 related cervical cancer. However, with the indirect 
effects of herd protection there is likely to be an impact on infection and disease 
among unvaccinated women, as has been demonstrated in this thesis. It is also 
very reassuring that we are seeing substantial declines in HPV vaccine types and 
closely related types in a higher risk population of women attending for chlamydia 
screening (Section 6.3). However, herd protection will be affected by the level of 
sexual mixing between these population subgroups. For example, if women from 
more deprived areas with lower vaccination uptake and lower screening coverage 
are more likely to have sex with people within a similar area, this will theoretically 
limit the potential herd protection. Therefore, the results of the serological 
surveillance among sexual health clinic attenders could inform consideration for 
mop-up vaccination in certain subgroups with apparently lower HPV vaccination 
coverage and/or targeting subgroups to improve cervical screening uptake.  
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9.3.3. Informing the decision on whether to introduce the nonavalent 
vaccine to the National HPV Immunisation Programme 
Post-vaccination monitoring of the impact of HPV vaccination on HPV prevalence 
has consistently shown clear evidence of reductions in the prevalence of vaccine 
types. With the licencing of the nonavalent vaccine by the European Medicines 
Agency (EMA), the additional benefit of this vaccine against high-grade disease and 
cervical cancer should be considered. In the UK, we have previously shown that the 
high-risk types HPV16 and 18 are associated with around 82.6% of cervical cancers 
and the other high-risk types included in the nonavalent vaccine are associated with 
an additional 13.7% of cervical cancers[131]. However, an important factor to 
consider when comparing the likely impact of the three vaccines (bivalent, 
quadrivalent and nonavalent) against cervical cancer is the potential cross-
protection and/or type-replacement seen with the lower valency vaccines. High 
cross-protection of vaccination against closely related HPV types would mean that 
the relative additional benefit of the nonavalent vaccine would diminish. Conversely, 
if there was evidence of an increase in non-vaccine types due to type replacement, 
then the potential impact of the nonavalent vaccine would increase and therefore its 
introduction would be more cost-effective. The Papillomavirus Rapid Interface for 
Modelling and Economics (PRIME) tool is a WHO resource developed to give users 
estimates of impact and cost-effectiveness of HPV vaccination. This tool has 
demonstrated that the effects of cross-protection and herd protection could 
substantially affect the cost-effectiveness estimates for introduction of the 
nonavalent vaccine[175]. Others have suggested that if there is a moderate cross-
protective effect on non-HPV16/18 infections (such as HPV31, 33 and 45), that it 
may be easier to further reduce the prevalence of these HPV types in the population 
via herd protection, due to their lower prevalence and lower basic reproduction 
number[138]. The evidence in Section 6.3 of this thesis that there were substantial 
declines in HPV31, 33 and 45 within the post-vaccination period support this 
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modelling work. Whereas the bivalent vaccine will not offer the same protection 
against high-risk infection as the nonavalent vaccine, substantial cross-protection 
will certainly make the bivalent vaccine a serious competitor when countries decide 
which vaccine is more cost-effective for their national programme.   
9.3.4. Informing the decision on whether to introduce vaccination of males 
Gender neutral vaccination: In this thesis, I have not directly investigated the herd 
protection effect among men. I discuss this omission below in Section 9.5. However, 
this thesis has demonstrated a herd protection affect among unvaccinated females 
and, in most recent years, very low prevalence of HPV16, 18, 31, 33 and 45 
(Section 6.3).  These declines were even greater than vaccine coverage. These 
results strongly suggest that herd protection from a female vaccination programme 
has already reduced HPV infection in heterosexual men. These results will inform 
the potential additional benefit of male vaccination for the incidence of cervical 
cancer but also for male HPV-related cancers. 
Targeted vaccination of men who have sex with men (MSM): Although there is 
evidence to suggest that there is some sexual mixing between some MSM and 
women [176, 177], the potential herd protection effect of female vaccination among 
MSM will be lower than the herd protection effect for heterosexual men. The results 
of declining HPV16 and 18 prevalence in women from this surveillance (Section 6.2) 
were incorporated into the cost effectiveness model for MSM vaccination which was 
conducted by PHE[178]. This model concluded that the quadrivalent vaccine was 
likely to be effective and cost-effective at reducing HPV related disease in MSM. 
The results of this model formed part of the evidence which led to the JCVI advising 
that targeted vaccination of MSM aged up to 45 years old attending sexual health 
and HIV clinics should be undertaken if it can be delivered at a cost-effective 
price[179]. As a result of this, a pilot of HPV vaccination was introduced in 2016 in 
42 sexual health and HIV clinics in England. Following the results of this pilot, it was 
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confirmed that a nationwide HPV vaccination programme for MSM will be 
introduced in a phased roll-out from 2018. 
9.3.5. Informing introduction of vaccination in low and middle countries 
It would be remiss to present data on the impact of HPV vaccination without 
touching upon the burden of HPV-related disease in low and middle income 
countries. Whereas cervical cancer is the 13th most common cancer among females 
in the UK[37], worldwide it is the 4th most common and in many low and middle 
income countries it is the most common cancer in females[36]. The variations in the 
incidence of cervical cancer are largely dependent on sexual behaviours and 
attitudes in different countries as well as the provision of secondary prevention (i.e. 
availability of cervical cancer screening). Despite the disproportionately higher 
burden of cervical cancer in low and middle income countries, the vast majority of 
national HPV vaccination programmes have been established in high-income 
countries which will only increase this disparity. It has been estimated that up to 
2014, HPV vaccination programmes had only targeted 12% of young adolescent 
females worldwide, 70% of which were in high-income countries[77]. Clearly those 
at greatest risk of cervical cancer remain the most in need of HPV vaccination.  
There are mechanisms in place to assist with funding of HPV vaccination in lower 
income countries. Firstly, the GAVI Alliance funds vaccines for the poorest countries 
based on their gross national income per capita. There were 54 GAVI eligible 
countries in 2016[180], and by 2016, HPV vaccination had been implemented, or a 
demonstration programme completed, in 23 of these countries. Another mechanism 
is from the Pan American Health Organization (PAHO) who collectively procures 
vaccines for resource-poor countries in the region in order to obtain a much lower 
price than could be obtained if each country procured for smaller amounts of the 
vaccine separately. 
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In the end, the decision of individual countries on whether to vaccinate will depend 
not only on the burden of disease and the cost of procuring and delivering the 
vaccine but also on the safety and potential effectiveness of the vaccines. The 
increasing amount of data on population effectiveness following HPV vaccination in 
other countries can help inform the cost-effectiveness and vaccine strategies in 
these countries. In countries with lower resources, we perhaps need to be more 
inventive; for example, considering the relative benefit of the nonavalent vaccine 
considering the excellent cross-protection from the bivalent vaccine demonstrated in 
this thesis, or considering using only a single dose of vaccine. Whilst this thesis 
explores the impact of HPV vaccination in a high income country with high 
vaccination coverage, there are important lessons that can be learnt. I give two 
examples of prior limitations of the surveillance in England which have been 
addressed in this thesis and which could be of interest to other countries. Firstly, in 
England there are limited data on HPV vaccination status given the lack of a 
national registry. I have demonstrated methods to investigate changes in HPV 
prevalence over time and the association with estimated national coverage in the 
absence of a direct measure of vaccine effectiveness. Secondly, recent analyses 
have focussed on changes in HPV prevalence within the post-vaccination period to 
overcome changes in HPV testing between the pre- and post-vaccination period. 
Similar approaches could be taken in low and middle income countries who 
vaccinate without baseline data on HPV prevalence in target populations.  
9.4. Implications for secondary prevention by cervical 
screening of vaccinated populations 
The decision to screen is often considered against criteria described by Wilson and 
Junger in 1968[181]. The first of these criteria is that “the condition sought should be 
an important health problem”. The results of this thesis have clearly shown that 
national vaccination has reduced HPV infection and will likely have an impact on the 
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incidence of cervical cancer in the future. However, at least in the shorter term, 
cervical cancer will remain an important public health problem in the UK. 
Nevertheless, these substantial declines in HPV16 and 18 and some closely related 
HPV types will have implications for the Cervical Screening Programme in England 
as current screening practices are based on infection and disease rates from before 
the introduction of vaccination. 
Another of Wilson and Junger’s criteria is that “there should be a suitable test or 
examination”. With decreases in HPV infections there will inevitably be a decrease 
in the positive predictive value (PPV) of both HPV testing and cervical cytology. 
Data from women attending for cervical screening in Scotland has shown that the 
PPV of cytology for CIN2+ is reduced by 16% in vaccinated women compared to 
unvaccinated women [182]. In 2016 it was announced that HPV primary screening 
would be implemented into the national cervical screening programme in England. 
The evidence is clear that HPV testing will have a higher PPV for CIN2+ in 
vaccinated populations compared to cytology[183]. However, non-vaccine HPV 
types have been shown to have a lower risk of subsequent disease compared to 
HPV16. One approach may be to triage HPV positive women with type-specific HPV 
testing and only refer based on HPV type-specific PPV for disease  
Finally, I consider how the results of this thesis could potentially influence whether 
different screening intervals are offered for vaccinated and unvaccinated women. A 
recent simulation study concluded that fewer lifetimes screens are needed for 
women vaccinated with the bivalent vaccine and fewer still for those vaccinated with 
the nonavalent vaccine. Any future studies considering screening in the post-
vaccination era should include data from population-based studies such as the one 
included in this thesis to allow incorporation of the protection against vaccine types, 
cross-protection and herd protection of the vaccine. The data from this thesis could 
also inform whether herd protection is sufficient to consider amending screening 
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strategies for all women in a highly vaccinated population regardless of their 
vaccination status. This could be of particular interest in England where vaccination 
status is not necessarily recorded accurately on the NHS call-recall system for 
screening (see Section 5.1.2).   
9.5. Research gaps and implications for future research  
This thesis focusses on the impact of the HPV vaccination programme on HPV 
infection and early disease outcomes. In England, the first vaccinated women 
entered the cervical screening programme in 2015. This offers further opportunities 
to monitor the impact of HPV vaccination in this population. Future surveillance will 
monitor changes in HPV infection in the population attending for cervical screening, 
who are likely to be a lower risk population than those attending for chlamydia 
screening. Furthermore, the surveillance programme will monitor changes in the 
incidence of cervical pre-cancer and cancer in the post-vaccination era. We are 
already conducting HPV testing of cervical cancers diagnosed under the age of 30 
years old in women eligible for vaccination in order to detect changes in the relative 
proportion that are positive for HPV vaccine types and to remain vigilant for potential 
vaccine failures. Looking to the future, similar testing will be considered in non-
cervical cancers which, generally, occur at older ages than cervical cancer. 
Another consideration which, unfortunately, was outside of the timeframe of this 
PhD is the extent of protection of the vaccines against HPV infection over a longer 
time period. Long-term protection is expected against the vaccine types but this is 
less clear for the cross-protection against other HPV types. However, the results of 
this thesis showing such substantial declines in HPV31, 33 and 45 due to direct and 
indirect protection of HPV vaccination may mean that the prevalence of infection 
with these types becomes so low in the population that the duration of direct 
protection is less important.
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I previously mentioned that this thesis has only considered HPV infection in females 
rather than males. The surveillance studies in this thesis make use of a convenient 
source of residual material which can be tested for HPV DNA infection. No 
equivalent source exists for males as chlamydia screening is performed using urine 
specimens for the majority of men. Urine has been shown to lack sensitivity to 
detect HPV infection, particularly in men[116]. Therefore, in this thesis, I have taken 
the approach to infer herd protection in heterosexual males based on the herd 
protection in females. 
Finally, this thesis has only explored the impact of the bivalent HPV vaccine. With 
the change in the national programme to the quadrivalent vaccine in 2012, there will 
be similar questions on the protection of this vaccine against infection. There will 
also be new questions such as the direct impact of the vaccine against genital 
warts. This is already being seen in younger women who would have been eligible 
to receive the quadrivalent vaccine. In 2016 compared to 2009, there was a 72% 
decline in the rate of genital warts diagnoses recorded in GUMCAD among 15 to 17 
year old females, the majority of whom would have been offered the quadrivalent 
vaccine[118]. The impact of the quadrivalent vaccine on infection and disease will 
be complicated by mixing between populations vaccinated with the bivalent vaccine 
and future analyses will need to take this into account.  
9.6. Overall conclusions  
National surveillance of residual specimens has offered a convenient and effective 
approach to provide the first results about the impact of the HPV vaccination 
programme in England. Surveillance using routinely collected samples and data has 
also some limitations which I have discussed above. In this thesis, I have described 
work and analyses to address some of these limitations including collection and 
validation of HPV vaccination records for individual women and the assessment of 
 325 
 
changes in non-vaccine types following an assay change between the pre- and 
post-vaccination periods.  
The high overall vaccination coverage in England has been confirmed with 
serological surveillance although with some variations in uptake among some 
subgroups of the population attending a sexual health clinic. The importance of this 
high coverage should not be underestimated as this affects both direct and indirect 
protection. This is also particularly important for other countries where vaccination 
coverage has been dramatically affected by safety concerns raised by anti-
vaccination campaigns. 
There has been some controversy around the potential protective effect of the 
bivalent vaccine against genital warts. This thesis contradicts ecological analyses 
with results from a case-control study showing no evidence of any effect of this 
vaccine against warts.  
Results in this thesis have also shown dramatic declines in vaccine types with 
consistent evidence that HPV16 and 18 has declined within the post-vaccination 
period and, as expected, is lower in vaccinated women compared to unvaccinated 
women. Furthermore, a relatively unexpected result from this thesis is the 
substantial decline in HPV31, 33 and 45 eight years following the introduction of 
vaccination. This exciting finding supports the theory that non-vaccine HPV types 
are easier to control via herd protection and suggests that direct protection against 
these types may not be necessary. These five types (HPV16, 18, 31, 33 and 45) are 
associated with over 90% of cervical cancers in the UK[131]. Reassuringly, this 
thesis provides no evidence that other non-vaccine types are becoming more 
common following the reductions in HPV16 and 18. The encouraging results in this 
thesis have added to other international data on the benefits of HPV vaccination and 
the expectation that national HPV vaccination programmes will reduce the incidence 
of cervical cancer.
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Appendices 
Appendix A: Systematic review and meta-analysis for 
changes in non-vaccine HPV types  
Table A1: Inclusion and exclusion criteria for systematic review 
Criteria Inclusion  Exclusion  
Study design 
 
 
- Repeat cross-sectional 
studies/surveillance with at 
least one assessment of HPV 
infection pre-vaccine 
introduction and at least one 
assessment post-vaccine 
introduction 
 
- Individually randomised trials 
- Cohort studies comparing HPV 
infection in the same women 
pre- and post-vaccination 
- Post-vaccination studies 
comparing HPV infection in 
vaccinated and unvaccinated 
women 
Study population 
 
- Human participants (females 
and/or males) 
- Population and recruitment 
were the same for pre- and 
post-vaccination periods 
- Populations with very low 
vaccination coverage (<2%) in 
the post-vaccination period 
- Only considering infection in 
populations with HPV-related 
disease (e.g. cervical cancer) 
HPV infection 
outcome 
- Considering HPV DNA 
infection (either prevalence,  
odds or incidence) in relevant 
specimens from population 
 
- Only HPV vaccine types were 
considered 
- Non-vaccine types were 
pooled and type-specific 
results were not available from 
study authors
1
 
1: Authors were not contacted for the updated systematic review conducted in 4
th
 December 
2017 as results were not published. Therefore, publications were included if they considered 
changes of non-vaccine types regardless of whether type-specific results were not 
presented 
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Technical Appendix  
Search Details, Study Details, and Prevalence Ratios   
Database Search Strategies 
Medline Search Strategy: identified 2,410 studies (2016 Feb 19) 
1.   Epidemiologic Studies/ 
2.   exp case-control Studies/ 
3.   (case* and control*).tw 
4.   exp Cohort Studies/ 
5.   cohort*.tw  
6.   Cross-sectional Studies/ 
7.   (cross* and section*).tw 
8.   Seroepidemiologic Studies/ 
9.   Sentinel Surveillance/ 
10. Public Health Surveillance/ 
11. Incidence/ 
12. Prevalence/ 
13. Odds Ratio/ 
14. odds ratio.tw 
15. risk ratio.tw 
16. rate ratio.tw 
17. relative risk.tw 
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18. screening method.tw 
19. effectiveness.tw 
20. observational.tw 
21. (step* and wedge*).tw 
22. Or/1-21 
23. Human Papillomavirus DNA Tests/ 
24. exp Papillomavirus Infections/ 
25. exp Papillomaviridae/ 
26. (HPV or papilloma*).tw  
27. Uterine Cervical Neoplasms/ 
28. Genital Neoplasms, Female/ 
29. Genital Diseases, Female/ 
30. Uterine Cervical Dysplasia/ 
31. (Penile ADJ1 wart).tw 
32. (cervi* or genit*).tw 
33. warts.tw 
34. condyloma*.tw 
35. neoplas*.tw 
36. dysplas*.tw 
37. lesion*.tw 
38. cancer*.tw 
39. carcin*.tw  
40. maligna*.tw  
41. disease*.tw 
42. (carcinoma adj2 situ).tw 
43. Or/33-42  
44. And/32,43 
45. Or/23-30,44 
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46. (Immunis* or immuniz* or vaccin*).tw 
47. Papillomavirus Vaccines/ 
48. Or/46-47 
49. Humans/ 
50. limit to yr=2007-2016 
51. And/22,45,48,49,50 
Embase search strategy: identified 3,843 studies (2016 Feb 19) 
1.   Epidemiology/ 
2.   Cross-sectional study/ 
3.   (cross$ ADJ1 section$).tw 
4.   exp case control study / 
5.   (case$ ADJ1 control$).tw 
6.   cohort analysis/ 
7.   cohort$.tw 
8.   exp Disease surveillance/ 
9.   exp health survey/ 
10. incidence/ 
11. exp prevalence/ 
12. sentinel surveillance/ 
13. seroepidemiology/ 
14. risk/ 
15. infection risk/ 
16. population risk/ 
17. risk reduction/ 
18. observational study/ 
19. (odd$ ADJ1 ratio).tw 
20. (risk ADJ1 ratio).tw 
21. (rate ADJ1 ratio).tw 
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22. (relative ADJ1 risk).tw 
23. (screening ADJ1 method).tw 
24. effectiveness.tw 
25. observational.tw 
26. (step$ ADJ1 wedge$).tw 
27. Or/1-26 
28. exp Papilloma virus / 
29. hpv.tw  
30. Papilloma$.tw 
31. Uterine cervix disease/ 
32. Uterine cervix dysplasia/ 
33. exp Uterine Cervix Tumor/ 
34. urogenital tract tumor/ 
35. genital tract tumor/ 
36. female genital tract tumor/ 
37. female genital tract cancer/ 
38. gynecologic cancer/ 
39. genital tract cancer/ 
40. female genital tract cancer/ 
41. Urogenital tract cancer/ 
42. Female genital tract cancer/ 
43. female genital tumor/ 
44. female genital tract infection/ 
45. genital tract infection/ 
46. gynecologic infection/ 
47. (peni$ ADJ1 wart$).tw 
48. (cervi$ or genit$).tw 
49. wart$.tw 
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50. condyloma$.tw 
51. neoplas$.tw 
52. dysplas$.tw 
53. lesion$.tw 
54. cancer$.tw 
55. carcin$.tw  
56. maligna$.tw  
57. disease$.tw 
58. (carcinoma ADJ2 situ).tw 
59. Or/49-58   
60. And/48,59 
61. Or/28-47,60 
62. (Immunis$ or immuniz$ or vaccin$).tw 
63. Wart virus vaccine/ 
64. Or/62,63  
65. Humans/  
66. limit to yr=2007-2016 
67. And/27,61,64,65,66 
LILACS search strategy: identified 58 studies (2016 Feb 19) 
((cross$ AND section$) OR (case$ AND control$) OR (cohort$) OR (odd$ AND ratio) OR (risk AND 
-
vi$ or genit$) AND (wart$ OR neoplas$ OR dysplas$ 
OR lesion$ OR cancer$ OR carcin$ OR adeno$ OR squamous$ OR disease$ OR (carcinoma AND situ)))) AND 
(Immuni$ or vaccin$) AND (PD 2007 OR PD 2008 OR PD 2009 OR PD 2010 OR PD 2011 OR PD 2012 OR PD 
2013 OR PD 2014 OR PD 2015 OR PD 2016) 
AIM search strategy: identified 17 studies (2016 Feb 19) 
hpv OR Papilloma$ 
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Technical Appendix Table 2.  Prevalence ratios for nonvaccine high-risk HPV types for female adolescents and women in 
systemic review and meta-analysis, by age group and vaccine type* 
  
Age group, y/HPV type 
Bivalent vaccine 
  
Quadrivalent vaccine 
No. of 
 
Heterogeneity 
Prevalence ratio  
(95% CI) 
No. 
 
Heterogeneity 
Prevalence ratio  
(95% CI) I2, % 
p 
value I2,  % 
p 
value 
          
 Nonavlent vaccine HPV types  2     6    
  HPV 31  10.4 0.291 0.54 (0.29 1.03)   8.7 0.36 0.75 (0.60 0.96) 
  HPV 33  0 0.785 1.66 (0.94 2.92)   0 0.687 0.89 (0.64 1.24) 
  HPV 45  75.4 0.044    0 0.716 1.01 (0.76 1.34) 
  HPV 52  0 0.408 1.93 (1.34 2.77)   0 0.627 1.20 (0.99 1.47) 
  HPV 58  0 0.445 1.19 (0.81 1.73)   0 0.742 0.92 (0.69 1.22) 
 Other high-risk HPV types 2     6    
  HPV 35  85.2 0.009    0 0.914 0.91 (0.58 1.42) 
  HPV 39  0 0.755 1.30 (0.89 1.91)   0 0.932 1.26 (1.01 1.58) 
  HPV 51  74.9 0.046    35.2 0.172 1.16 (1.00 1.36) 
  HPV 56  18.3 0.269 2.08 (1.43 3.04)   64.9 0.014  
  HPV 59  51.9 0.149    0 0.478 1.27 (1.03 1.57) 
  HPV 68  0 0.444 1.84 (0.62 5.47)   0 0.601 1.20 (0.82 1.76) 
 Other possibly high-risk types 2     4    
  HPV 26  0 0.873 1.89 (0.84 4.26)   26.8 0.251 1.21 (0.38 3.81) 
  HPV 53  0 0.894 2.22 (1.25 3.94)   0 0.445 1.28 (0.88 1.85) 
  HPV 70  0 0.957 4.07 (1.43 11.55)   0 0.97 0.82 (0.41 1.64) 
  HPV 73  0 0.926 1.39 (0.98 1.98)   0 0.806 1.32 (0.83 2.07) 
  HPV 82  0 0.998 2.00 (0.50 7.95)   65.1 0.035  
20 24           
 Nonavalent vaccine HPV types  3     5    
  HPV 31  57.8 0.094    0 0.889 0.95 (0.81 1.10) 
  HPV 33  55.0 0.108    48.1 0.103  
  HPV 45  74.2 0.021    56.9 0.055  
  HPV 52  65.6 0.055 1.26 (0.87 1.83)   0 0.53 1.28 (1.12 1.46) 
  HPV 58  0 0.499 1.17 (0.94 1.46)   0 0.684 1.12 (0.93 1.34) 
 Other high-risk HPV types 3     5    
  HPV 35  0 0.968 1.22 (0.79 1.87)   43.1 0.134  
  HPV 39  44.8 0.163 1.32 (0.93, 1.88)   0 0.743 1.09 (0.93 1.28) 
  HPV 51  0 0.57 1.37 (1.16 1.62)   47.0 0.11 1.19 (0.88 1.61) 
  HPV 56  75.4 0.017 1.45 (0.82 2.59)   87.5 <0.001  
  HPV 59  86.1 0.001    0 0.604 1.13 (0.94 1.37) 
  HPV 68  67.4 0.046    0 0.842 0.99 (0.72 1.37) 
 Other possibly high-risk types 3     3    
  HPV 26  69.0 0.04    21.1 0.282 1.35 (0.28 6.47) 
  HPV 53  0.3 0.367 1.23 (1.05 1.45)   16.9 0.3 0.90 (0.64 1.25) 
  HPV 70  0 0.382 1.11 (0.81 1.51)   0 0.811 2.47 (1.24 4.94) 
  HPV 73  43.8 0.169    76.3 0.015  
  HPV 82  73.7 0.022     0 0.989 0.94 (0.39 2.26) 
*HPV, human papillomavirus; , prevalence ratios were not calculated because of heterogeneity of data.  
Number of studies were the same for all HPV types within each category.   
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Technical Appendix Table 3. Prevalence ratios for nonvaccine high-risk HPV types for female adolescents and women in systemic 
review and meta-analysis, by age group and potential bias* 
  
Age group, y/HPV type 
 
  
 
No.  
studies§ 
Heterogeneity 
Prevalence ratio 
(95% CI) 
No. 
studies§ 
Heterogeneity 
Prevalence ratio 
(95% CI) I2,% 
p 
value I2,% 
p 
value 
          
 Nonavalent vaccine HPV types  5     3    
  HPV 31  31.2 0.213    0 0.447 0.73 (0.58 0.93) 
  HPV 33  0 0.526 0.79 (0.30 2.06)   34.4 0.218  
  HPV 45  21.5 0.278 0.84 (0.49 1.44)   0.6 0.366 0.99 (0.76 1.31) 
  HPV 52  0 0.681 1.09 (0.77 1.56)   61.9 0.072  
  HPV 58  0 0.672 0.87 (0.58 1.30)   0 0.505 1.08 (0.82 1.42) 
 Other high-risk HPV types 5     3    
  HPV 35  0 0.424 0.85 (0.46 1.58)   60.6 0.079  
  HPV 39  0 0.907 1.21 (0.83 1.78)   0 0.846 1.30 (1.04 1.61) 
  HPV 51  45.3 0.120    0 0.433 1.28 (1.09 1.50) 
  HPV 56  69.3 0.011    79.9 0.007  
  HPV 59  0 0.465 1.29 (0.94 1.76)   85.9 0.001  
  HPV 68  12.6 0.333 1.21 (0.76 1.93)   0 0.948 1.33 (0.75 2.36) 
 Other possibly high-risk types 5     1    
  HPV 26  3.3 0.388 1.27 (0.45 3.58)     1.93 (0.82 4.59) 
  HPV 53  0 0.514 1.32 (0.92 1.90)     2.19 (1.18 4.04) 
  HPV 70  0 0.831 0.90 (0.45 1.76)     4.02 (1.31 12.32) 
  HPV 73  0 0.909 1.33 (0.87 2.05)     1.39 (0.96 2.00) 
  HPV 82  55.0 0.064      2.00 (0.42 9.44) 
20 24           
 Nonavalent vaccine HPV types  5     3    
  HPV 31  27.7 0.237    0 0.670 0.95 (0.81 1.11) 
  HPV 33  0 0.599 0.64 (0.52 0.78)   0 0.424 1.03 (0.83 1.27) 
  HPV 45  78.5 0.001    0 0.948 0.90 (0.74 1.10) 
  HPV 52  0 0.905 1.06 (0.91 1.22)   11.8 0.322 1.37 (1.20 1.56) 
  HPV 58  0 0.859 1.04 (0.85 1.28)   0 0.600 1.23 (1.02 1.50) 
 Other high-risk HPV types 5     3    
  HPV 35  0 0.754 1.42 (0.97 2.08)   10.7 0.326 0.90 (0.67 1.21) 
  HPV 39  8.3 0.359 1.12 (0.94 1.34)   0 0.415 1.14 (0.97 1.34) 
  HPV 51  32.5 0.205    46.9 0.152  
  HPV 56  0 0.914 1.03 (0.89 1.21)   94.5 0.000  
  HPV 59  0 0.443 1.08 (0.91 1.28)   86.4 0.001  
  HPV 68  0 0.692 1.04 (0.72 1.49)   72.5 0.026  
 Other possibly high-risk types 5     1    
  HPV 26  54.8 0.065      1.14 (0.37 3.50) 
  HPV 53  36.3 0.179      1.52 (0.86 2.69) 
  HPV 70  34.5 0.191      1.64 (0.79 3.37) 
  HPV 73  56.0 0.059      1.92 (1.04 3.53) 
  HPV 82  0 0.984 0.75 (0.60 0.94)      0.22 (0.10 0.51) 
*HPV, human papillomavirus; , prevalence ratios were not calculated because of heterogeneity of data.  
Average-low potential bias includes 6 studies (1, 3 5, 8, 9).   
Average-high potential bias includes 3 studies (2,6,7).  
§Number of studies were the same for all HPV types within each category.  
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Technical Appendix Table 4. Prevalence ratio for nonvaccine high-risk HPV types for female adolescents and women in systemic 
review and meta-analysis, by age group and vaccination coverage* 
  
Age group, y/ HPV type 
Low vaccination coverage (<50%) 
  
 
No.  
 
Heterogeneity Prevalence ratio 
(95% CI) 
No. 
 
Heterogeneity Prevalence ratio 
(95% CI) I2, % p value I2, % p value 
          
 Nonavalent HPV types  0     8    
  HPV 31       6.4 0.381 0.73 (0.58 0.91) 
  HPV 33       0 0.471 1.04 (0.78 1.38) 
  HPV 45       5.5 0.387 0.96 (0.75 1.23) 
  HPV 52       24.0 0.238 1.34 (1.13 1.59) 
  HPV 58       0 0.727 1.01 (0.80 1.26) 
 Other high-risk HPV types 0     8    
  HPV 35       25.1 0.229  
  HPV 39       0 0.984 1.27 (1.05 1.54) 
  HPV 51       43.6 0.088  
  HPV 56       74.3 <0.001  
  HPV 59       66.8 0.004  
  HPV 68       0 0.690 1.26 (0.88 1.81) 
 Other possibly high-risk types 0     6    
  HPV 26       0 0.478 1.63 (0.84 3.16) 
  HPV 53       3.6 0.394 1.51 (1.10 2.06) 
  HPV 70       23.6 0.257 1.34 (0.75 2.39) 
  HPV 73       0 0.961 1.36 (1.03 1.80) 
  HPV 82       49.0 0.081  
20 24           
 Nonavalent HPV types  5     3    
  HPV 31  0 0.838 0.96 (0.83 1.12)   25.5 0.261  
  HPV 33  36.3 0.179    0 0.618 0.65 (0.53 0.81) 
  HPV 45  55.9 0.06    62.7 0.068  
  HPV 52  26.1 0.248    0 0.513 1.10 (0.94 1.27) 
  HPV 58  0 0.689 1.21 (1.01 1.45)   0 0.807 1.04 (0.83 1.30) 
 Other high-risk HPV types 5     3    
  HPV 35  30.4 0.219    0 0.590 1.29 (0.80 2.07) 
  HPV 39  5.3 0.377 1.17 (1.00 1.37)   0 0.482 1.08 (0.89 1.30) 
  HPV 51  56.7 0.056    37.8 0.201  
  HPV 56  30.5 0.218    91.7 <0.001  
  HPV 59  73.5 0.004    0 0.673 1.15 (0.96 1.37) 
  HPV 68  61.7 0.034    0 0.810 1.20 (0.78 1.85) 
 Other possibly high-risk types 4     2    
  HPV 26  53.8 0.09    0 0.862 1.76 (1.00 3.12) 
  HPV 53  0 0.522 1.31 (0.95 1.81)   76.6 0.039  
  HPV 70  11.8 0.334 1.72 (1.06 2.79)   0 0.335 1.08 (0.76 1.53) 
  HPV 73  52.5 0.097    0 0.503 1.02 (0.82 1.26) 
  HPV 82  33.7 0.21    0 0.675 0.75 (0.59 0.94) 
*HPV, human papillomavirus; , prevalence ratios were not calculated because of heterogeneity of data.  
Number of studies were the same for all HPV types within each category.   
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Technical Appendix Figure 1. 
Prevalence ratios for meta-analysis of 
changes in other probable high-risk 
human papillomavirus (HPV) types 
(HPV35, HPV39, HPV51, HPV56, 
HPV59, and HPV68) for girls and 
women, by age group (<19 and 20 24 
years of age). Percentages in square 
brackets represent vaccination coverage 
(at least 1 dose) for each study and age 
group. The size of the dark boxes 
around the plot points indicates the 
relative weight given to each study in 
calculation of the summary estimate. The 
study by Cameron et al. (25) is omitted 
from analyses for the younger age group 
because this study included no data for 
those <19 years of age. The study by 
Cummings et al. (21) is omitted from 
analyses for women 20 24 years of age 
because this study included no data for 
this age group. Pre, prevaccination; post, 
postvaccination.  
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Technical Appendix Figure 2. Prevalence 
ratios for meta-analysis of changes in high-
risk human papillomavirus (HPV) types 
(HPV31, HPV33, and HPV45) with evidence 
of cross-protection for girls and women, by 
age group (<19 and 20 24 years of age) and 
vaccine type. Percentages in square brackets 
represent vaccination coverage (at least 1 
dose) for each study and age group. The size 
of the dark boxes around the plot points 
indicates the relative weight given to each 
study in the calculation of the summary 
estimate. The study by Cameron et al. (25) is 
omitted from analyses for the younger age 
group because this study included no data for 
the group <19 years of age. The study by 
Cummings et al. (21) is omitted from analyses 
for women 20 24 years of age because this 
study included no data for this age group. Pre, 
prevaccination; post, postvaccination.  
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Technical Appendix Figure 3. 
Prevalence ratios for meta-analysis of 
changes in other high-risk human 
papillomavirus (HPV) types(HPV52 and 
HPV58)  included in the nonavalent 
vaccine for girls and women, by age 
group (<19 and 20 24 years of age) 
and vaccine type. Percentages in 
square brackets represent vaccination 
coverage (at least 1 dose) for each 
study and age group. The size of the 
dark boxes around the plot points 
indicates the relative weight given to 
each study in the calculation of the 
summary estimate. The study by 
Cameron et al. (25) is omitted from 
analyses for the younger age group 
because this study included no data for 
the group <19 years of age. The study 
by Cummings et al. (21) is omitted from 
analyses for women 20 24 years of 
age because this study included no 
data for this age group. Pre, 
prevaccination; post, postvaccination.  
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Technical Appendix Figure 4. Prevalence 
ratios for meta-analysis of changes in other 
probably high-risk HPV types (HPV35, 
HPV39, HPV51, HPV56, HPV59, and 
HPV68) for girls and women, by age-group 
(<19 and 20 24 years of age) and vaccine 
type. Percentages in square brackets 
represent vaccination coverage (at least 1 
dose) for each study and age group. The size 
of the dark boxes around the plot points 
indicates the relative weight given to each 
study in the calculation of the summary 
estimate. The study by Cameron et al. (25) is 
omitted from analyses for the younger age 
group because this study included no data 
for the group <19 years of age. The study by 
Cummings et al. (21) is omitted from 
analyses for women 20 24 years of age 
because this study included no data for this 
age group. Pre, prevaccination; post, 
postvaccination.  
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Appendix C: Comparison of pre- and post-vaccination HPV 
infection 
C1: Validation study comparing pre- and post-vaccination HPV assays  
(for information only; this study was conducted by VRD at PHE and 
these results do not form part of this PhD).  
 
 
Result of HPV assays 
HPV type 
Both tests 
positive 
HC2/LA
1
 
only 
Luminex
2
 
only 
Both tests 
negative 
Any HPV 239 (55.8%) 3 (0.7%) 73 (17.1%) 113 (26.4%) 
High-risk HPV 185 (43.2%) 11 (2.6%) 36 (8.4%) 196 (45.8%) 
High-risk HPV (not 16/18) 91 (21.3%) 10 (2.3%) 28 (6.5%) 299 (69.9%) 
Vaccine HPV types 
    HPV16 and/or HPV18 84 (19.6%) 11 (2.6%) 18 (4.2%) 315 (73.6%) 
HPV16 62 (14.5%) 7 (1.6%) 16 (3.7%) 343 (80.1%) 
HPV18 29 (6.8%) 11 (2.6%) 5 (1.2%) 383 (89.5%) 
Nonavalent HPV types 
    HPV31/33/45/52/58 81 (18.9%) 10 (2.3%) 18 (4.2%) 319 (74.5%) 
HPV31/33/45 38 (8.9%) 11 (2.6%) 10 (2.3%) 369 (86.2%) 
HPV31 16 (3.7%) 7 (1.6%) 2 (0.5%) 403 (94.2%) 
HPV33 11 (2.6%) 3 (0.7%) 4 (0.9%) 410 (95.8%) 
HPV45 13 (3.0%) 3 (0.7%) 7 (1.6%) 405 (94.6%) 
HPV52 32 (7.5%) 3 (0.7%) 14 (3.3%) 379 (88.6%)    
HPV58 15 (3.5%) 4 (0.9%) 0 (0%) 409 (95.6%)    
HPV6/11 28 (6.5%) 6 (1.4%) 8 (1.9%) 386 (90.2%)    
HPV6 23 (5.4%) 7 (1.6%) 4 (0.9%) 394 (92.1%)    
HPV11 3 (0.7%) 0 (0%) 11 (2.6%) 414 (96.7%)    
Other high-risk HPV types 
    
   
HPV26 1 (0.2%) 2 (0.5%) 2 (0.5%) 423 (98.8%) 
HPV35 2 (0.5%) 1 (0.2%) 3 (0.7%) 422 (98.6%) 
HPV39 18 (4.2%) 6 (1.4%) 4 (0.9%) 400 (93.5%) 
HPV51 30 (7.0%) 13 (3.0%) 5 (1.2%) 380 (88.8%) 
HPV53 17 (4.0%) 13 (3.0%) 8 (1.9%) 390 (91.1%) 
HPV56 20 (4.7%) 2 (0.5%) 9 (2.1%) 397 (92.8%) 
HPV59 12 (2.8%) 22 (5.1%) 2 (0.5%) 392 (91.6%) 
HPV66 19 (4.4%) 27 (6.3%) 0 (0%) 382 (89.3%) 
HPV68 3 (0.7%) 5 (1.2%) 9 (2.1%) 411 (96.0%) 
HPV70 2 (0.5%) 5 (1.2%) 3 (0.7%) 418 (97.7%) 
HPV73 24 (5.6%) 6 (1.4%) 3 (0.7%) 395 (92.3%) 
HPV82 2 (0.5%) 8 (1.9%) 0 (0%) 418 (97.7%) 
1: Hybrid Capture 2 (HC2) and Linear Array testing performed on pre-vaccination 
surveillance specimens  
2: the in-house Luminex assay was performed on post-vaccination surveillance systems        
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C2: Bootstrapping methods for comparing pre- and post-vaccination HPV 
prevalence with estimated sensitivity and specificity 
The below is the Stata code which I wrote to calculate an adjusted odds ratio which 
additionally adjusts for the assay change and the uncertainty in the sensitivity and 
specificity estimates comparing the two assays. This is an example code for HPV31. 
 
* Create sample set for validation study to calculate sensitivity and specificity estimates 
* HPV 31 
clear 
set obs 428 
* tp=tru positives; tn=true negatives; fp=false positives; fn=false negatives 
local tp=16 
local tn=403 
local fp=7 
local fn=2 
local 1=`tp'+`fp' 
local 2=`tp'+`fp'+1 
local 3=`tp'+`fp'+`fn' 
gen hc2=0 
gen luminex=0 
replace hc2=1 in 1/`1' 
replace luminex=1 in 1/`tp' 
replace luminex=1 in `2'/`3' 
save " validation_hpv31.dta", replace 
 
* Create file for Bootstrapping 
use " HPV chlamydia post imms_clean.dta", clear 
gen sensitivity_`type'=1 
gen specificity_`type'=1 
replace sensitivity_31=(16/18) if survey=="pre" 
replace specificity_31=(403/410) if survey=="pre" 
keep hpv31 survey recruit_venue age chlamydia LA_valid age_group sensitivity_31 ///                     
/// specificity_31 year 
gen postpre=1 if survey=="pre" 
replace postpre=2 if survey=="post" 
gen postpre2=1 if survey=="pre" 
replace postpre2=2 if survey=="post" & (year==2010 | year==2011) 
replace postpre2=3 if survey=="post" & (year==2012 | year==2013) 
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save " HPV chlamydia post imms_clean_bootstrap.dta", replace 
 
qui { 
set seed 832015 
forvalues i=1/1000 { 
 use "validation_hpv31.dta", clear 
 bsample 
 diagt luminex hc2 
 local sens=r(sens) 
 local spec=r(spec)  
 use " HPV chlamydia post imms_clean_bootstrap.dta", clear 
 gen sens=1 
 gen spec=1 
 replace sens=(`sens'/100) if survey=="pre" 
 replace spec=(`spec'/100) if survey=="pre" 
 keep if LA_valid & age_group==1 
 bsample 
 logitem hpv31 postpre2 recruit_venue age chlamydia, sens(sens) ///  
/// spec(spec) iterate(100) 
 local or = exp(_b[postpre]) 
 noi di `sens' "," `spec' "," `or' 
} 
 
* Use above 2.5
th
 and 97.5
th
 percentile from above outputs as lower and upper confidence 
intervals 
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Appendix D: Collection and validation of HPV vaccination 
records from CHIS  
D1: Letter to Cornwall GP re validation study 
 
   «GP_Title» «GP_Forename» «GP_Surname» 
   «Practice_Name» 
   «Add_Line_1» 
   «Add_Line_2» «Add_Line_3» 
   «Add_Line_4» «Add_Line_5» 
 
dd/mm/yyyy 
 
Dear «GP_Title» «GP_Surname», 
 
Re: Post-vaccination HPV infection in young women in England 
 
Public Health England (PHE) is responsible for conducting surveillance of HPV to enable 
ongoing evaluation of the HPV Immunisation Programme.  As part of this responsibility, PHE 
have established surveillance of HPV infections in young women, using suitable residual 
samples. PHE has approval from the National Information Governance Board (NIGB) to 
conduct this surveillance (individual patient consent is not required).  
 
The Department of Microbiology at Royal Cornwall Hospital have been providing residual 
samples for this HPV infection surveillance. Before we anonymise and test these samples 
for HPV, we link the samples with HPV vaccination details held at Public Health England.  
The resulting anonymised linked data are used to assess the effectiveness of HPV 
vaccination.  
 
In order to validate the results of this surveillance, we need to verify the accuracy of the data 
on the women’s vaccination status.  We are carrying out this verification for a small number 
of patients in your area. We liaised with the Cornwall LMC and NHS England South (SW) 
Medical Director who are supportive of this work. I am thus contacting you to request any 
information you hold in medical records about the HPV vaccination status of the «NUMBER» 
patients listed on the enclosed form. All we need is information on their vaccination status - 
please could you complete the enclosed form for your patient(s) and return it in the enclosed 
pre-paid, self-addressed envelope? If you prefer, you can send it by encrypted email to 
david.mesher@nhs.net.    
 
All information provided will be treated in strict confidence and held in compliance with PHE 
policies on data security. This is unlinked anonymous surveillance and therefore after linking 
these HPV vaccination data, all patient identifiable information (including the NHS number) 
will be deleted before the HPV testing is performed. 
 
We appreciate the time and effort involved in providing this valuable follow-up information to 
us. If you have any questions regarding this letter or general enquiries regarding the 
surveillance then please contact me on the above email address or by telephone (020 8327 
6807).  
 
Yours sincerely 
                                   
David Mesher,                                                                Alison Mackenzie 
Senior Scientist (HPV Epidemiology)                       Consultant in Public Health Medicine   
                                                                                       Screening and Immunisation Lead  
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In strict medical confidence 
  NHS number   HPV vaccination status (please tick one box for each patient) 
4000000001   No record of patient     □ Unvaccinated □ One-dose received □ Two-doses received □ Three-doses received □ 
4000000002   No record of patient □ Unvaccinated □ One-dose received □ Two-doses received □ Three-doses received □ 
4000000003   No record of patient □ Unvaccinated □ One-dose received □ Two-doses received □ Three-doses received □ 
4000000004   No record of patient □ Unvaccinated □ One-dose received □ Two-doses received □ Three-doses received □ 
4000000005   No record of patient □ Unvaccinated □ One-dose received □ Two-doses received □ Three-doses received □ 
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Appendix E: Supplementary Table for Paper 2: Continuing reductions in HPV16/18 in a population with 
high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study (Section 
6.2) 
Supplementary Table 1: Pre- and post-immunisation prevalence of nonavalent HPV types among women with a non-vaccine  
high-risk HPV type, by age 
HPV type 
Pre-vaccination prevalence 
(%)  
2008 (95% CI) 
n=610 
Post-vaccination prevalence 
(%)  
2010-2011 (95% CI) 
n=1277 
Post-vaccination 
prevalence (%)  
2012-2013 (95% CI) 
n=1332 
p-value for 
trend 
16-18 years     
[Estimated HPV16/18 vaccination coverage] [0%] [60.2%] [73.4%]  
Nonavalent HPV types
1
     
HPV31/HPV33/HPV45/HPV52/HPV58 58.2 (52.2 - 64.3) 51.7 (46.2 - 57.2) 44.8 (39.5 - 50.0) 0.001 
HPV31/HPV33/HPV45 33.7 (27.9 - 39.5) 20.1 (15.6 - 24.5) 17.6 (13.6 - 21.6) <0.001 
HPV31 14.9 (10.6 - 19.3) 1.6 (0.2 - 2.9) 3.7 (1.7 - 5.7) <0.001 
HPV33 9.6 (6.0 - 13.2) 10.3 (7.0 - 13.7) 7.9 (5.1 - 10.8) 0.444 
HPV45 11.5 (7.6 - 15.4) 8.5 (5.4 - 11.5) 6.5 (3.9 - 9.1) 0.031 
HPV52 16.1 (11.6 - 20.6) 25.1 (20.3 - 29.9) 19.3 (15.1 - 23.4) 0.478 
HPV58 14.9 (10.6 - 19.3) 11.6 (8.1 - 15.1) 11.6 (8.3 - 15.0) 0.239 
     
19-21 years     
[Estimated HPV16/18 vaccination coverage] [0%] [21.4%] [41.1%]  
Nonavalent HPV types
1
     
HPV31/HPV33/HPV45/HPV52/HPV58 56.5 (49.8 - 63.1) 54.2 (50.1 - 58.3) 50.4 (46.1 - 54.7) 0.096 
HPV31/HPV33/HPV45 31.0 (24.8 - 37.2) 22.2 (18.8 - 25.6) 21.9 (18.3 - 25.4) 0.019 
HPV31 17.6 (12.5 - 22.7) 5.8 (3.9 - 7.7) 6.7 (4.5 - 8.8) <0.001 
HPV33 7.4 (3.9 - 10.9) 7.3 (5.2 - 9.5) 8.6 (6.2 - 11.0) 0.498 
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HPV45 9.7 (5.7 - 13.7) 9.4 (7.0 - 11.8) 8.0 (5.7 - 10.3) 0.371 
HPV52 15.3 (10.4 - 20.1) 25.7 (22.1 - 29.3) 25.7 (21.9 - 29.4) 0.016 
HPV58 18.5 (13.3 - 23.7) 11.9 (9.2 - 14.5) 9.9 (7.3 - 12.4) 0.002 
     
22-24 years     
[Estimated HPV16/18 vaccination coverage] [0%] [0%] [1.1%]  
Nonavalent HPV types
1
     
HPV31/HPV33/HPV45/HPV52/HPV58 63.2 (54.9 - 71.5) 57.5 (52.6 - 62.5) 62.7 (58.2 - 67.2) 0.571 
HPV31/HPV33/HPV45 33.8 (25.7 - 42.0) 24.6 (20.3 - 28.9) 30.0 (25.8 - 34.3) 0.989 
HPV31 12.0 (6.4 - 17.6) 7.8 (5.1 - 10.5) 8.2 (5.6 - 10.7) 0.296 
HPV33 9.8 (4.7 - 14.9) 6.5 (4.0 - 8.9) 10.4 (7.6 - 13.2) 0.326 
HPV45 15.8 (9.5 - 22.1) 11.4 (8.2 - 14.6) 12.4 (9.3 - 15.4) 0.498 
HPV52 19.5 (12.7 - 26.4) 26.9 (22.5 - 31.4) 28.7 (24.5 - 32.9) 0.065 
HPV58 11.3 (5.8 - 16.7) 9.8 (6.9 - 12.8) 10.2 (7.4 - 12.9) 0.809 
1: defined as the additional HPV types included in the nonavalent vaccine (31, 33, 45, 52 and 58) 
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Appendix F: Changes in HPV prevalence in the post-vaccination period among women negative for 
chlamydia 
Figure F1: Prevalence of HPV infection by year of sample collection (restricted to women who tested negative for chlamydia) 
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Appendix G: Serological surveillance in sexual health clinics  
G1: Laboratory protocol for collection of residual sera at sexual health 
clinics (formerly known as GUM clinics; example version from June 
2014) 
Post-immunisation monitoring of HPV seroprevalence in young women attending  
GUM clinics in England 
PROTOCOL FOR SUBMITTING RESIDUAL SERA SAMPLES 
1. SELECTING SAMPLES 
1.1  Sample Selection 
All samples included in this study are from women aged 16-19 years old. We will request residual 
samples from women who have had a chlamydia, gonorrhoea and syphilis test OR a chlamydia, 
gonorrhoea, syphilis and HIV test. 
Enclosed is a list of randomly selected patients with Patient ID number, clinic ID number/name and 
date of attendance whose samples we would like you to retrieve and submit. These lists will be sent 
quarterly for collection and submission. Please note: Identifiers from GUMCAD should be 
considered patient identifiable information and only accessed by those with relevant 
permissions. 
The clinic ID number/name and patient ID number must match exactly the identifiers on the list 
provided. The date of clinic attendance should be within one week of the clinic attendance date 
provided (if there is a discrepancy between 1-7 days then this should be noted in the space provided 
on the list). 
In addition, samples should be frozen (preferably at below -70
o
C if possible although this is not 
essential): 
2. SUBMITTING SAMPLES 
2.1  Labelling samples 
All sample tubes should be labelled with the clinic identifier, unique patient identifier and date of 
attendance. Please remove any other patient identifiers from the sample tube.   
Details of where to send the sample tube and completed lists are given below. 
2.2 Sample submission 
All serum samples should be frozen in secure, appropriately-labelled packaging including freezer 
packs or dry ice. Serum vials should be rigid polypropylene with a screw-cap with O-ring seal, with a 
capacity of no more than 2 mL. Please ensure a minimum volume of ~250µl. Please ensure that only 
the clinic name/ID number, unique patient ID number and date of attendance are present on the 
sample vial. 
Samples should be sent to the following address (labels are provided for your convenience) as frozen 
samples (details for payment are included below): 
Ezra Linley 
GUM sera for post-immunisation HPV seroprevalence in young women 
PHE Seroepidemiology Unit/ Vaccine Evaluation Unit 
   Public Health England, 
   Public Health Laboratory, Manchester, 
   Manchester Medical Microbiology Partnership 
   2
nd
 Floor, Clinical Sciences Building 2 
Manchester Royal Infirmary, Oxford Road 
Manchester, M13 9WL, UK 
Ideally samples should be sent at the beginning of the week. Please only send samples during 8am to 
4pm Monday-Friday (excluding bank holidays). Please include a fax number so that the receiving 
laboratory can send you a fax to confirm receipt of the samples. 
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2.3 Data submission
Please complete the relevant section of the lists of eligible samples (complete all white sections). 
Please mark which samples have been retrieved and submitted and where appropriate indicate why a 
sample could not be provided, if possible. Completed lists should be sent with the samples to the 
above address. Completed lists should be enclosed in an envelope marked “Private and Confidential” 
which is enclosed in another plain envelope addressed to the above address.
Please retain a copy of the list locally until you receive confirmation from David Mesher at PHE 
Colindale that this can be destroyed (i.e. when all samples have been received and eligibility verified). 
When you have received such confirmation, you must destroy the temporary list as confidential waste. 
3. AFTER SAMPLE AND DATA SUBMISSION
3.1 Payment for samples 
A sum of £4.00 will be paid for each sample submitted with corresponding data (recorded on the 
Temporary List). Sites will be paid on a six-monthly basis (from first sample submission). Please send 
an invoice to David Mesher, Dept HIV/STI, Public Health England, 61 Colindale Avenue, London, NW9 
5EQ every six-months for the total number of samples provided in the specified time-period clearly 
indicating that the invoice is for the collection of GUM sera samples for HPV testing. Any costs incurred 
for delivery of frozen samples should be itemised separately on the invoice.
3.2 HPV testing and storage
Serum specimens will be tested for specific neutralising antibodies to HPV 16 and 18 using enzyme-
linked immunosorbent assay (ELISA). The case definitions will be to assess whether an individual is 
positive due to vaccination against HPV16/18. It may also be possible to determine whether an 
individual has received full vaccination (i.e. 3 doses) based on their titre levels.
4. SAMPLE SELECTION
4.1 Target number of samples
A list of Patient ID number, clinic ID number and date of attendance for selected samples for 2013 
are enclosed. There is no need to send any additional samples for these years.
The table below shows the number of samples we are requesting by age, for 2013 and 2014. These 
numbers are just for your information as we have selected appropriate samples in the enclosed list and 
2014 samples will be requested as data becomes available. These numbers are approximate and may 
vary slightly.
Target number of samples
Age 2013 2014
16y 65 65
17y 95 85
18y 85 85
19y 95 85
Total 340 320
SHHAPT SHHAPT
C6B C5B
C6C D2B
C7 C9
P4A C5A
P4B Pregnant PR1
C1 PR2
C4 PR3
C3 C8
B Sexual assault 40
C15 41
C13 Shigella SG1
C14 SG2
C10A SG3
C10B Syphilis A1
HIV H A2
H1 A3
H1A A4
H1B A5
H2 A6
 LGV C2 A7A
C12 C6A
C16 UTI D2A
C4N Warts (anogenital) C11A
C11D
SHHAPT SHHAPT
P4 Patient type Z
P3 SW
O22 SRH
O20 PEPSE PEPS
O21 Referral type REF1
P2I REF2
P2A REF3
P2B Testing   - HIV HIV antibody test P1A
P2C HIV test offered & declined P1B
P2D HIV test not appropriate P1C
P2E STIs Chlamydia only T1
W1 Chlamydia & gonorrhoea T2
W2 Chlamydia, gonorrhoea & syphliis T3
W3 Chlamydia, gonorrhoea, syphilis & HIV T4
D3 HSV (herpes simples virus) T5
PN Hepatitis A / B / C T6
PNC Syphilis & HIV T7
PNG Self sampling T8
O23 STI tests not required T9
PNH Rapid testing T10
PNN Microscopy TS
PNP 3 site testing TT
PNS
PNT
SHHAPT SHHAPT
O31   PrEP offer & use O41
O32 O42
O33 O43
O51 O44
O52 O45
O53   Patient characteristic O60
SUFFIX SUFFIX NAME SUFFIX
Pharyngeal infection B, C2, C4 O
Quadrivalent HPV vaccine W1, W2, W3 Q
M Rectal infection B, C2, C4, C4N R
*For use in Level 2 (non-GUM) services, optional in Level 3 (GUM) services
DIAGNOSIS, CONDITION OR DISEASE DIAGNOSIS, CONDITION OR DISEASE
BV & anaerobic balanitis
Balanitis / vaginitis / vaginosis (other causes) Other conditions requiring treatment
  Ophthalmia neonatorum
Chancroid 13-28 weeks
Chlamydia 29-40 weeks
Gonorrhoea Acute - within 7 days
Non-acute - more than 7 days
B - 1st diagnosis flexneri
Donovanosis Scabies
Candidosis Pediculosis pubis
PID & epididymitis
Major abnormality 1-12 weeks
New diagnosis Early latent
Cardiovascular
Recurrent episode Primary
Known positive Secondary
C - 1st diagnosis
 Herpes (anogenital) 1st episode Other / unspecified
sonnei
Lymphogranuloma venereum Congenital 
  Trichomoniasis
from home testing / sampling
to GUM (Level 3)*
from NCSP
Post exposure prophylaxis sexual exposure
Neurosyphilis
HIV related care Other late and latent
Sexual reproductive health
SERVICE PROVIDED SERVICE PROVIDED
Cervical cytology done Prisoner
Contraception Sex worker
Mycoplasma genitalium
NSGI (non-specific genital infection) 1st episode
Recurrent episode
Hepatitis A vaccination 1
st
 dose
HPV vaccination
3rd dose
4
th
 dose
Hepatitis B vaccination 1st dose
2nd dose
Medication given B, C4, C10A, C10B, C11A, C11D
Starting or continuing EVENT based regimen
90 tablets
Diagnosed previously 
elsewhere
A1, A2, A3, A4, A5, A6 A7A,
B, C4, C6A, H1, H1A, H1B
X
60 tablets
SUFFIX NAME VALID SHHAPT CODE
Criterion 2: HIV+ partner
Criterion 3: Others at risk
VALID SHHAPT CODE
Starting or continuing DAILY regimen
Transgender
Stopped
Offered & declined
Continued through other source
Initiated*
Chlamydia
Gonorrhoea
Syphilis
30 tablets
PID / epididymitis
Trichomoniasis 
HIV
Criterion 1: MSM / trans womanPrEP eligibility
PrEP prescription
NSGI
SHHAPT Code Look-Up
Sexual Health & HIV Activity Property Types - Summary of Definitions (2017 update)
Hepatitis A immune
Hepatitis B immune
Hepatitis A
Urinary tract infection
Molluscum contagiosum
Cervical cytology Minor abnormality
Hepatitis  A - acute infection
1
st
 dose
2
nd
 dose
3
rd
 dose
Booster
2nd dose
No service and/or no treatment required
Partner notification
